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Abstract: 
There is an extensive amount of epidemiological evidence showing that prenatal 
maternal distress (PNMD) is a risk factor for a wide range of poor obstetric and 
neonatal outcomes, as well as an increased risk for the development of metabolic, 
immune and nervous system disorders in affected children later in life. Whilst many 
epidemiology studies have supported these associations, the biological mechanisms 
linking maternal prenatal distress with adverse outcomes remains understudied, 
particularly in human cohorts. One potential mechanism, known as the 
glucocorticoid hypothesis proposes that fetal overexposure to stress-induced 
maternal cortisol during critical windows of development increases the risk of 
adverse outcomes in the offspring. At the core of this hypothesis is the placenta, 
which expresses the enzyme 11beta hydroxysteroid dehydrogenase type 2 
(HSD11B2), which ultimately controls the amount of cortisol a fetus is exposed to. 
Prenatal stress has been shown to reduce the placental expression of this enzyme; 
however the molecular mechanisms through which this occurs have not been well 
examined. More recently, the transmission of a suboptimal stressed maternal 
microbiota is emerging as an alternative mechanism that may mediate the impact 
of prenatal stress on infant development. However this has not yet been examined 
in a clinical population.  
We first utilized an in vitro placenta model, JEG-3 cells, to examine the 
effects of stress on the placental expression of HSD11B2. JEG-3 cells were cultured 
with exogenous cortisol and interleukin-1 beta (IL-1β), two potential biological 
mediators of prenatal stress. This study showed both cortisol and IL-1β can reduce 
HSD11B2 expression, an effect that could be prevented by co-treatment with a 
histone deacetylase inhibitor.  Having established that cortisol can directly affect 
the expression of HSD11B2, we moved on to our first clinical study to examine this 
question in a clinical population by examining the impact of prenatal distress on 
placental gene expression and infant outcomes. A cohort of 121 pregnant women 
receiving antenatal care at Cork University Maternity Hospital (CUMH) completed 
the Perceived stressed scale (PSS), State Trait Anxiety Inventory (STAI) and 
Edinburgh Postnatal Depression Scale (EPDS) in late pregnancy and donated 
 13 
 
placental biopsies at the time of birth. This study identified a significant reduction in 
HSD11B2 mRNA along with an increase in the glucocorticoid receptor (NR3C1) in 
placentae from high distressed pregnancies. Additionally prenatal distress was 
associated with a number of adverse outcomes including delivering via Caesarean 
section, reduced Apgar scores and reduced birth temperature, supporting a role for 
placental glucocorticoid signalling in the relationship between prenatal distress and 
adverse outcomes.  
Having reported that stress impacts molecular placental signals and birth 
outcomes, we moved on to complete the SMArTI (Stressed Microbial Transfer to 
the Infant) study, a more detailed pregnancy cohort to examine the impact prenatal 
distress on the maternal and infant microbiome. This study yielded a final cohort off 
111 nulliparous pregnant women that were recruited from the IMPROvED 
consortium at CUMH. Women enrolled in SMArTI completed distress 
questionnaires and provided saliva and fecal samples in the second and/or third 
trimester of pregnancy.  Vaginal swabs, placenta samples and newborn hair were 
acquired at birth and infant fecal samples were subsequently collected across the 
first 5 months of life. We first used this cohort to further examine and validate the 
relationship between prenatal distress, placental glucocorticoid genes and infant 
outcomes. We found this relationship to be dependent on the timing of distress, 
type of distress and infant sex. Most notably we observed second trimester 
maternal anxiety correlated with reduced birthweight in female infants, a 
relationship mediated by placental FK506-bind protein 51 (FKBP51) mRNA 
expression.  
We finally used the SMArTI cohort to examine, for the first time, the impact 
of PNMD on the maternal and infant microbiome, using 16S rRNA gene sequencing. 
Reduced diversity of the maternal gut microbiome in the second trimester was 
associated with second trimester distress, most substantially with maternal 
depressive symptoms, an effect that was no longer apparent by the third trimester. 
The third trimester gut microbiome appeared relatively resistant to change with 
only modest alterations observed in women who had high second trimester 
cortisol. Of interest, third trimester distress had no effect on the third trimester gut 
microbiome, highlighting the experience of distress specifically in the second 
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trimester as an important window of vulnerability. Reduced diversity of the vaginal 
microbiome, just prior to delivery, was associated with second trimester cortisol, 
with no alterations linked third trimester distress. When examining the infant gut 
microbiome we found increased diversity across the first 5 months of life to be 
associated with second trimester stress with corresponding decreases to the 
important Bifidobacteriaceae and Lactobacillaceae family.  
In conclusion, this thesis indicates the experience of PNMD influences key 
placental genes involved in glucocorticoid signalling in the placentae. The timing of 
maternal distress and infant sex are important factors in this relationship. Of 
particular interest we find placental FKBP51 to mediate a relationship between 
maternal anxiety and infant birthweight, demonstrating a direct role for placental 
glucocorticoid signalling underlying the relationship between prenatal distress and 
infant outcomes. The work presented in this thesis is the first of its kind to 
prospectively examine the influence of PNMD on the maternal gut, vaginal and 
infant gut microbiome. Stress-induced alterations in the maternal gut microbiome 
may contribute to adverse obstetric and birth outcomes albeit via a mechanism 
other than transmission of a suboptimal maternal microbiota during birth.  Taken 
together, our results identify the second trimester as an especially vulnerable 
period to stress exposures and implicate the placenta and microbiome in mediating 
these effects. Counteracting the impact of stress during this critical time window 
may have important obstetric implications. Additionally understanding the 
consequence of the altered infant gut microbiome as a result of prenatal distress 
warrants further investigation. 
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Chapter 1: 
General Introduction 
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1.0 Introduction: 
The concept that in utero life experiences, such as the emotional state of the 
mother during pregnancy, affects child development has been proposed for 
centuries.  Leonardo Di Vinci wrote in his Quaderni; ‘the same soul governs the two 
bodies the things desired by the mother are often found impressed on the members 
of the child which the mother carries at the time of the desire’. However it was not 
until recent decades that the role of the in utero environment in the development 
of disease became a topic of scientific enquiry. The coining of the term ‘fetal 
programming’ by Professor David Barker in the 1980s led to a new research effort 
aiming to understand how in utero and early-life experiences alter fetal 
developmental trajectories that increases the risk for disease later in life (Barker 
and Osmond, 1986, Barker et al., 1993, Barker et al., 1989).  One factor that has 
received significant attention in this regard is the adverse effects of prenatal 
maternal distress.  
The term ‘prenatal maternal distress’ (PNMD) is broadly used to refer to the 
experience of psychological adversities in the prenatal period, including stress, 
anxiety and depression. There is now an accumulating amount of preclinical and 
clinical evidence showing PNMD influences fetal and/or infant development that 
confers disease risk in childhood and adulthood.  The effects of PNMD are evident 
in both the mother and child and manifests as adverse obstetrical outcomes, 
neonatal outcomes and longer term disease risk.  These include (but are not limited 
to) an increased risk of caesarean delivery, low birthweight (LBW), preterm birth 
(PTB), intrauterine growth restriction (IUGR) and long term disorders of the 
immune, metabolic and nervous systems for affected offspring (Ding et al., 2014a, 
Grote et al., 2010, Dunkel Schetter and Tanner, 2012, Tarabulsy et al., 2014, 
Entringer et al., 2015).  
Whilst the increased risk of adverse obstetric outcomes arising from the 
experience of PNMD is evident, less is known about the biological mechanisms 
underpinning this association. Studies in animals have made substantial progress in 
unravelling these mechanisms, but this has not been well paralleled by clinical 
investigations. The most studied mechanism is the glucocorticoid hypothesis, which 
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proposes that fetal overexposure to maternal cortisol adversely alters fetal 
developmental trajectories to increase disease risk (Reynolds, 2012). At the core of 
this hypothesis lies the placenta, in particular enzymes/expression of genes within 
the placenta involved in glucocorticoid signalling namely 11 beta hydroxysteroid 
dehydrogenase type 2 (HSD11B2). Placental HSD11B2 controls fetal exposure to 
maternal glucocorticoids acting as a protective barrier for the fetus (Togher et al., 
2014). Hence disruptions to this enzyme would be disadvantageous to fetal 
development. Indeed epigenetic dysregulation of placental HSD11B2 is being 
increasingly linked to adverse outcomes (Togher et al., 2014).  
More recently, focus has been placed on the microbiome to explain the 
relationship between PNMD and adverse outcomes. The concept that the 
microbiome is modifiable by stress in not novel (Rea et al., 2016), but little is known 
about the impact that stress induced microbial dysbiosis may have for pregnancy 
outcomes and subsequent infant development. Indeed the maternal gut and 
vaginal microbiome undergoes remodelling throughout the prenatal period to 
support a healthy pregnancy and changes to the maternal vaginal microbiome has 
been linked PTB (Stout et al., 2017, Koren et al., 2012). Alterations in the early 
infant gut microbiome is been increasingly linked to immune disorders in infancy 
and PNMD is beginning to be recognized as one of the factors that may alter the 
infant gut microbiome (Jasarevic et al., 2015b).  It is hypothesised that PNMD alters 
the maternal gut and/or vaginal microbiome and that this stressed microbiome is 
vertically transmitted to the infant during parturition (Jasarevic et al., 2014).  This 
stressed microbial signature then interferes with normal microbial host interactions 
important for infant development, subsequently conferring an increased risk of 
disease. However this has yet to be examined in human populations and needs to 
be considered in the context that the gut microbiome also appears to be a critical 
regulator of the host stress response and that the gut microbiota acquired early in 
life may be involved in priming the Hypothalamic Pituitary Adrenal (HPA) axis for 
appropriate physiological outputs (Clarke et al., 2014a). 
The aim of this review chapter is to provide a comprehensive overview of 
the literature. Firstly I will discuss the current epidemiological evidence linking 
PNMD to adverse outcomes. Next I will give a detailed account of the biological 
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mechanisms that may underlie this relationship, briefly mentioning less studied and 
potentially relevant mechanisms, followed by a detailed account of the 
glucocorticoid hypothesis and placental HSD11B2. Finally I will discuss the 
importance of the maternal and infant microbiome. This will precede the aims of 
the current thesis.  
 
1.1 Evidence from Epidemiological studies: 
A significant proportion of women suffer from psychological disorders in the 
perinatal period and in a systematic review conducted by Bennett and colleagues, 
the prevalence rate of depression during pregnancy was found to be 7.4%, 12.8% 
and 12% in the first, second and third trimester respectively (Bennett et al., 2004). 
Similarly, anxiety is commonly reported during pregnancy with the prevalence 
depending on the type of anxiety experienced (Ross and McLean, 2006). In  a study 
population of 1522 women in the US, 6% of women reported high, 78% reported 
low/moderate and 16% reported no psychological stress during the second and 
third trimester of pregnancy (Woods et al., 2010). Thus, a significant percentage of 
pregnant women experience some form of PNMD during pregnancy that can 
potentially affect the developing fetus. There is a growing body of literature 
available on PNMD, whereby a large number of epidemiological studies have 
confirmed that PNMD is a risk factor for a number of adverse fetal outcomes and 
increases the risk in particular for a number of neuropsychiatric disorders in 
adulthood. Here I discuss the current state-of-the-art of this field with a focus on 
human studies that have identified PNMD as a risk factor for adverse outcomes.  
 
1.1.0 PNMD alters birth outcomes: 
Low Birth Weight, Preterm Birth and Intrauterine Growth Restriction: 
The World Health Organization (WHO) defines LBW as infants born less than 2,500 
grams, which affects ~15.5% of pregnancies (World Health Organisation, 2004). 
LBW often arises as a result of PTB (<37 weeks gestation) or IUGR. PTB affects 10% 
of all births (Beck et al., 2010) and is estimated to account for  35% of all neonatal 
deaths worldwide (Blencowe et al., 2012). IUGR complicates between 10-15% of all 
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pregnancies (Saleem et al., 2011).  Babies born below the 10th percentile for their 
gestational age are referred to as Small for Gestational Age (SGA) and IUGR is a 
common cause of SGA  (Saleem et al., 2011).  In recent years PNMD has been 
identified as a prenatal risk factor for LBW, PTB, SGA and IUGR.  
The relationship between maternal anxiety and these birth outcomes has 
been recently reviewed. In this meta-analysis of 15 studies, women who reported 
anxiety in pregnancy were at a 50% increased risk of PTB and a 76% increased risk 
of LBW, independent of the timing of anxiety measurement (Ding et al., 2014b).  
This risk was heighted for women of lower socioeconomic status and lower prenatal 
care. Additionally Asian women were at an elevated risk as compared to women 
from European countries (Ding et al., 2014a).  
Grote and colleagues undertook a meta-analysis of studies to clarify the risk 
of adverse birth outcomes following maternal prenatal depression (Grote et al., 
2010). This meta-analysis found a relationship between prenatal depression and 
adverse outcomes to be moderated by the type of psychometric measurement 
used. When depression was defined categorically to be clinically significant, there 
was a 39%, 45% and 49% increased risk of PTB, IUGR and LBW respectively. When 
analysed on a continuous scale every 1 unit increase in depression scores was 
associated 3%, 2% and 4% increase risk of PTB, IUGR and LBW respectively. The risk 
of adverse outcomes increased for women who reported depression and were 
living in developing countries or of low socioeconomic class, highlighting 
particularity at risk populations (Grote et al., 2010).  
To our knowledge the relationship between psychological stress and birth 
outcomes has not been systematically reviewed. This is likely a reflection of the 
complex range of psychometric tools used to assess prenatal stress which range 
from environmental exposures, bereavement, biological assessments to a vast array 
of different questionnaire based methods. A summary of current studies 
investigating this relationship between PNMD and birth outcomes can be found 
summarized in Table 1 of this thesis. It is clear that this relationship is complex and 
often reports yield inconstant results with variability arising from differences in 
study design, populations, timing of stress measurement and type of stress 
measurement. None the less the majority of research highlights an increased risk of 
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adverse birth outcomes with heightened maternal psychological stress, although a 
systematic review and meta-analysis of this relationship is warranted.  
 
Other birth outcomes: 
Although the incidence of infant mortality has decreased significantly over 
the past 2 decades, a large portion of infants still die within the neonatal period. In 
2009, 3.3 million babies died in the first month of life and 2.6 were stillborn (World 
Health Organistation, 2014). Whilst there are a wide range of known causes, PNMD 
has recently been identified as a risk factor. In particular maternal bereavement in 
both the preconception and prenatal period, have been linked to an increase risk of 
stillbirth and infant mortality (Class et al., 2013, Laszlo et al., 2013). Additionally in a 
smaller prospective study in a Danish population, PNMD, assessed using the 12-
item general health questionnaire at 16 and 32 weeks’ gestation was associated 
with a 90% increased risk for stillbirth (Wisborg et al., 2008).  Miscarriage occurs in 
10-15% of observed pregnancies and it is thought that environmental factors, such 
as PNMD may play a role. Indeed some studies support and increased risk (Boyles 
et al., 2000, Bashour and Abdul Salam, 2001, Neugebauer et al., 1996), whilst 
others do not (Nelson et al., 2003). PNMD has also been linked to congenital heart 
disease (Carmichael and Shaw, 2000) a major global health problem affecting over 
1.35 million newborns each year (van der Linde et al., 2011). Finally, while some 
studies support a link between PNMD and reduced head circumference at birth 
(Lou et al., 1994, Hansen et al., 2008, Hansen et al., 1996), which is predictor for 
neurodevelopment disorders later in life (Garcia-Alix et al., 2004), others do not, 
and indicate that the effect PNMD on child neurodevelopment may not be 
mediated by an effect on brain size (Obel et al., 2003). However, both studies suffer 
from a small sample size and to our knowledge, there is currently no large cohort 
study that has examined an associated between PNMD and head circumference at 
birth. Until such a study is conducted the association between PNMD and head 
circumference at birth remains unclear. 
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Table 1:  
Author Design 
(N) 
Prenatal 
Stressor 
Timing Outcomes Results 
(Khashan et al., 2009) Prospective 
 (1.3m) 
Maternal 
bereavement 
Preconception PTB 
 
↑ risk PTB 
(Class et al., 2011) Prospective 
 (2.6m) 
Maternal 
bereavement 
Month 5&6 PTB 
LBW 
SGA 
↑ risk PTB & ↓ 
gestations 
↑ risk LBW 
↑ risk SGA 
(Khashan et al., 2008b) Prospective 
 (1.4m) 
Maternal 
bereavement 
Pre-/Post- 
conception 
SGA 
 
↑ risk SGA  
(Barbosa, 2000) Prospective 
 (472) 
Maternal 
bereavement 
During 
pregnancy 
GL ↓ gestational length 
(Pritchard and Teo, 1994) Prospective 
 (393) 
Perceived stress 20 wks. PTB 
LBW 
↑ risk PTB 
↑ risk LBW 
(Hedegaard et al., 1996) Prospective 
 (8719) 
Psychological 30 wks. PTB ↑ risk PTB 
(Nordentoft et al., 1996) Prospective 
 (2432) 
Psychological 20 wks. PTB 
IUGR 
↑ risk PTB 
↔ IUGR 
(Rondo et al., 2003) Prospective 
 (865) 
Psychological 3rd trimester PTB 
LBW 
↑ risk PTB 
↑ risk LBW 
(Nkansah-Amankra et al., 
2010) 
Case control 
(8064) 
Negative life 
Events 
During 
pregnancy 
LBW 
PTB 
↑ risk LBW 
↑ risk PTB 
(Zhu et al., 2010) Prospective 
 (1800) 
Negative life 
Events 
1st trimester 
2nd trimester 
LBW 
PTB 
↑ risk LBW 
↑ risk PTB 
(Copper et al., 1996) Prospective 
 (2593) 
Psychological 25-29 wks. LBW 
PTB 
IUGR 
↑ risk LBW 
↑ risk PTB 
↔ IUGR 
(Roy-Matton et al., 2011) Prospective 
 (303) 
Psychological 10-20 wks. PTB ↑ risk PTB 
(Baibazarova et al., 2013) Prospective 
 (158) 
Psychological 15.3 -18.2 wks. LBW 
GL 
↑ risk LBW 
↓ gestational length 
(Khashan et al., 2014) Prospective 
 (8531) 
Psychological 20 wks. SGA ↑ risk SGA 
(Pagel et al., 1990) Prospective 
 (100) 
Negative life 
Events 
31-36 wks. LBW 
Apgar 
Score 
↑ risk LBW 
↓ Apgar score 
(Sable and Wilkinson, 
2000) 
Case control 
(2378) 
Perceived stress During 
Pregnancy 
LBW 
 
↑ risk  LBW 
 
(Wadhwa et al., 1993) Prospective 
 (90) 
Negative life 
Events 
28-30 wks. LBW ↑ risk LBW 
(Witt et al., 2014b) Population  
(9035) 
Negative life 
Events 
Preconception PTB ↑ risk PTB 
(Witt et al., 2014a) Population  
(9035) 
Negative life 
Events 
Preconception LBW ↑ risk VLBW 
(Mansour and Rees, 
2011) 
Prospective 
 (1391) 
Perceived 
Stress 
28 & 36 wks. LBW 
PTB 
SGA 
↔ 
(Oyarzo et al., 2012) Case Control 
(3609) 
Environmental 1st & 2nd 
Trimester 
PTB 
SGA 
↑ risk PTB 
↑ risk SGA 
 
(Glynn et al., 2001) Case control 
(40) 
Environmental 1st trimester GL ↓ gestational length 
(Torche and Kleinhaus, 
2012) 
Case Control 
(8064) 
Environmental Month 2 & 3 PTB ↑ risk PTB 
Table 1: Maternal prenatal psychological stress and adverse birth outcomes. 
Abbreviations: Preterm birth (PTB), low birth weight (LBW), small for gestational 
age (SGA), gestational length (GL) and intrauterine growth restriction (IUGR). 
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1.1.1 Effects of PNMD on long term outcomes: 
As well as poor obstetric outcomes, there is now an extensive body of literature 
that implicates PNMD in a number of adverse long-term outcomes that affect 
multiple organ systems later in life. These include immune and cardio-metabolic 
disturbances, and altered neurodevelopmental trajectories and increased risk of 
neurodevelopmental and neuropsychiatric disorders in affected infants.  Although a 
large body of pre-clinical evidence supports these findings, which has been 
extensively reviewed elsewhere (Sanchez et al., 2001), here we  briefly summarize 
studies in human populations where maternal exposure to PNMD in the prenatal 
period has been linked to disease in adulthood. 
 
Immune related disorder in infants affected by PNMD: 
PNMD, particularly when experienced in the third trimester, is associated with an 
increased risk of wheezing, coughing and breathlessness in infants (Mathilda Chiu 
et al., 2012, Wright et al., 2013), a major cause of morbidity in preschool children 
(Bisgaard and Szefler, 2007). Additionally, two large prospective cohort studies have 
identified maternal bereavement as a risk factor for immune-related disease in 
adulthood.  In a large cohort of 3.2 million Swedish women, maternal bereavement 
in the first and second trimester was found to be associated with a 48% increase in 
the incidence of hospitalization for asthma (Khashan et al., 2012). In the second 
study, involving 1.6 million Danish women, maternal bereavement during 
pregnancy was associated with a 71% and 39% increased risk for hospitalization 
with severe and less severe infectious disease respectively (Nielsen et al., 2011). 
 
Increased risk of cardio-metabolic disturbances in infants affected by PNMD:  
Fetal exposure to maternal stress is also associated with altered cardiovascular 
function in childhood. In a cohort of 2968 Dutch women, psychological stress 
experienced at 16 weeks’ gestation was associated with increased systolic blood 
pressure, diastolic blood pressure and mean arterial pressure in children at 5 years 
of age (van Dijk et al., 2012a). In the same population, maternal stress at 16 weeks’ 
gestation was not associated with an altered cardiac autonomic nervous system 
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balance (an early indicator of cardiovascular disease) in 5 year old children (van Dijk 
et al., 2012b). Whether PNMD has a long-term effects on cardiovascular disease in 
adulthood remains unknown, as no study to date has examined this relationship in 
a population older than 7 years of age.  
 The prevalence of obesity has increased dramatically over the past 3 
decades, doubling since the 1980s (World Health Organisation, 2014). It has been 
suggested that exposure to maternal stress during fetal life may be a risk factor for 
developing obesity. In a large cohort study in a Danish population maternal 
bereavement during, or up to 6 months before pregnancy was associated with an 
increased risk of childhood overweight in children aged 7-13. Children whose 
mothers experienced bereavement up to six months before pregnancy were at the 
highest risk, being three times more likely to be overweight at 12 years of age (Li et 
al., 2010b).  In a similar cohort study in a Danish population, psychological distress 
assessed by telephone interview at 16 and 30 weeks gestation was not found to be 
associated with weight in 7-year-old children. However when stratified based on 
gender a modest increase of 15% for the risk of overweight was seen in boys, but 
not girls (Ingstrup et al., 2012). More recently a study has been conducted that 
supports the risk for overweight in adulthood. In a cohort study among men aged 
17-31, maternal bereavement up to 6 months before and during pregnancy was 
associated with an increased risk for overweight and obesity. The strongest 
association was seen for men who had a 25% risk of obesity and a 14% risk for 
being overweight if their mothers were in their first trimester at the time of the 
bereavement (Hohwu et al., 2014). 
 PNMD has also been linked to developing other types of metabolic disease. 
Women whose mothers reported psychosocial stress during pregnancy have an 
elevated insulin response to a glucose tolerance test, which is an early indicator of 
insulin resistance (Entringer et al., 2008). Elevated insulin secretion was found in 
women whose mothers reported high levels of stress as a result of the 1988 
Quebec ice storm (Dancause et al., 2013). However, a recent study failed to confirm 
this association and found no relationship between prenatal maternal stress, 
depression and anxiety and glucose metabolism in 5-year-old children (van Dijk et 
al., 2014b). This might be explained by the age difference between the subjects, 
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suggesting that the effects of early life stress on diabetes risk may only present later 
in life. Further, the latter study assessed psychological stress at 16 weeks gestation 
only, a time point that may not represent a window of vulnerability for this effect 
(van Dijk et al., 2014a). Finally, in a large prospective cohort study in a population of 
1.8 million women in Denmark, exposure to maternal bereavement in the second 
trimester was associated with a 15% increased risk of developing type 2 diabetes in 
offspring (Li et al., 2013a).The cumulative data in these studies highlights a role for 
PNMD in the aetiology of cardio-metabolic disorders in affected offspring. 
 
PNMD and disorders of the nervous system:  
The programming effect of PNMD is most widely studied in relation to the nervous 
system. There is a large amount of research linking PNMD to poor 
neurodevelopmental outcomes in infancy, which can be found summarized in Table 
2. A number of studies have found PNMD to confer an increased risk of 
neuropsychiatric conditions including, but not limited to, autism spectrum disorder 
(ASD), attention deficit hyperactivity disorder (ADHD), schizophrenia, effective 
disorders and eating disorders (Table 2). Altered HPA axis activity has been 
associated with many psychiatric disorders (Belvederi Murri et al., 2014, Baumeister 
et al., 2014) and prenatal programming of the HPA axis may contribute to the 
biological mechanism through which PNMD programmes adult psychiatric disease. 
Indeed altered HPA activity, evident by increased cortisol outputs, has been 
observed in offspring born to high stress pregnancies (Table 2).  
 
  
 25 
 
Table 2:  
Author Design 
(N) 
Prenatal Stressor Timing Outcomes Results 
(Huizink et al., 
2003) 
Prospective 
(170) 
(1) Everyday 
problem list 
(2) Salivary cortisol 
(3) PRAQ 
(a)15-17 wks. 
(b)27-28 wks. 
(c)37-38 wks. 
3 & 8 months 
BSID 
  
(1a) ↓ MDI at 8mo 
(2c) ↓ MDI 3mo;  ↓ 
MDI & PDI at 3mo and 
8mo 
(3b) ↓ MDI & PDI at 
8mo,  
(3c) ↓ MDI at 8mo 
(Gutteling et al., 
2005b) 
Prospective 
(172) 
(1) Daily Hassles 
(2) PRAQ 
(3) PSS 
(4) GHQ 
(5) Salivary cortisol 
 
During 
pregnancy 
27 months 
(a) ICQ 
(b) BSID 
(c) CBCL 
(2a) ↑ 
restless/disruptive 
behaviour 
(3a) ↓ 
restless/disruptive 
behaviour 
(2b) ↑ attention 
regulation problems 
(3c) ↑ problem 
behaviour 
(3c) ↑ externalizing 
problems 
(DiPietro et al., 
2006) 
Prospective 
(94) 
(1) POMS-A 
(2) STAI 
(3) DSI 
(4) PSS 
(5) CES-D 
(6) POMS-D 
(7) PES 
24-32 wks. 2 years 
BSID 
(Heartrate) 
(3&4) ↑ PDI 
(1&2) ↑ PDI and MDI 
(5&6) ↑ PDI and MDI 
(7) ↓ PDI 
 
(Bergman et al., 
2007) 
Retrospective 
(123) 
(1) Stressful life 
events  
 
During 
Pregnancy 
14-19 months 
(a) BSID 
(b) Lab-TAB 
(1a) ↓ MDI  
(1b) ↑ fearfulness 
(Bergman et al., 
2010b) 
Prospective 
(125) 
(1) Amniotic fluid 
cortisol  
 (2) Stressful life 
events 
15-20wks 14-19 months 
BSID 
(1) ↓ MDI 
(2) ↓ cognitive 
development (BSID 
total) 
 
(Davis and 
Sandman, 2010) 
Prospective 
(125) 
(1) PSS  
(2) Salivary cortisol 
(3) CES-D 
(4) STAI 
(5) PSA 
(6) PSI 
(a) 15 wks. 
(b) 19 wks. 
(c) 25 wks. 
(d) 30 wks. 
(e) 36 wks. 
3, 6 & 12 
months 
BSID 
(2a) low ↑ MDI 
(2e) high ↑ MDI 
(5a) ↓ MDI 
(Zhu et al., 2014) Case Control 
(38 cases, 
114 controls) 
PLEC (1) 1st trimester 
(2) 2nd trimester 
(3) 3rd trimester 
16-18 months 
(a) BSID-CR 
(b) TTS 
(1a) ↓ MDI 
(1b) ↑ regularity & 
persistence and 
attention span 
(Bhang and Ha, 
2016) 
Prospective 
(648) 
(1) PWI 
(2) CES-D 
 
(a) 1st trimester 
(b) 3rd trimester 
6 months 
BSID 
*ASQ 
(1a) ↓ MDI 
(2a) ↓ MDI 
(Karam et al., 
2016) 
Prospective 
(71) 
PSS 
 
(1) During 
Pregnancy 
(2) 2 months 
postpartum 
1 year 
BSID-III 
(1) ↑ motor scale core 
(2) ↓ motor and socio-
emotional 
development 
 
(Henrichs et al., 
2011) 
Prospective 
(3139) 
Family stress 20 wks. 18 months 
(1) MCDI 
24 months 
(2) PARCA 
37 months 
(3) Snack & gift 
delay task 
(1)↓ word production 
(1) ↓ word 
comprehension 
(2) ↓nonverbal 
cognition 
(3) ↓ snack delay 
performance 
(3) ↓ gift delay 
performance 
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Table 2 continued:  
(Baibazarova et 
al., 2013) 
Prospective 
(158) 
(1) PSS 
(2) PRAQ 
(3) STAI 
(4) Plasma cortisol  
(5) Amniotic fluid 
cortisol 
15-18 wks.  3 months 
IBQ 
(1) ↑ distress to 
limitation 
 
(Pesonen et al., 
2005) 
Retrospective 
(319) 
Psychological Stress During 
Pregnancy 
6 months 
IBQ 
 
↑ Negative 
temperament 
(Davis et al., 
2007) 
Prospective 
(247) 
(1) CES-D 
(2) STAI 
(3) PSS 
(4) Salivary cortisol 
(a) 18-20 wks. 
(b) 24-26 wks. 
(c) 30-32 wks. 
2 months 
IBQ 
 
(4c) ↑ negative 
reactivity 
(1a,b,c) ↑ negative 
reactivity 
(2a,b,c) ↑ negative 
reactivity 
 
(de Weerth et 
al., 2003) 
Prospective 
(17) 
Salivary cortisol 34 wks. 1-20 weeks 
(1) Behavioural 
observations 
7& 18 weeks 
(2) ICQ 
(1) ↑ crying, fussing & 
negative facial 
expression 
(2) ↑ scores at 7 
weeks only (negative 
temperament) 
(Bergman et al., 
2010a) 
Prospective 
(108) 
(1) Amniotic fluid 
cortisol 
(2) Amniotic fluid 
testosterone 
15-20wks 14-19 months 
Lab-TAB 
(1)↔ 
(2) ↑ fear reactivity ♂ 
(Austin et al., 
2005) 
Prospective 
(970) 
(1) Perceived stress 
to life event 
(2) STAI 
(3) EPDS 
3rd trimester 4-6 months 
SITQ 
(2) ↑ scores (worse 
temperament) 
(3) ↑ scores 
(van der Wal et 
al., 2007) 
Prospective 
(8266) 
(1) CES-D 
(2) PRAQ 
(3) PDH 
(4) Work stress 
16 wks. 3-6 months 
Crying 
(1) ↑ crying 
(2) ↑ crying 
(3) ↑ crying 
(4) ↑ crying 
(Sondergaard et 
al., 2003) 
Prospective 
(378) 
(1) General distress 
(2) GHQ 
During 
Pregnancy 
Within month 1 
Infantile colic 
(1) ↑ risk 
 
(Wurmser et al., 
2006) 
Prospective 
(86) 
LES 18 wks. 6 weeks, 3 & 6 
months 
Crying 
Fussing 
↑ crying and fussing 
(Slykerman et 
al., 2005) 
Retrospective 
(539) 
(1) PSS 
(2) Social support 
Late Pregnancy 3.5 years 
SBIS 
(1) ↓ intelligence 
(2) ↑ social support ↑ 
intelligence 
(Laplante et al., 
2008) 
Retrospective 
(89) 
(1) Storm exposure 
(objective) 
(2) IES 
(subjective) 
(3) GHQ 
(4) LES 
During 
Pregnancy 
5.5 years 
(a) WPPSI 
(b) PPCT 
(1a) ↓ scores 
(intellectual) 
(1b) ↓ scores 
(language) 
(Virk et al., 
2014) 
Prospective  
(167,900) 
Maternal 
Bereavement 
12 month prior 
to & during 
pregnancy 
18 years 
BPP (IQ) 
↓ IQ scores in ♂ 
(Rodriguez and 
Bohlin, 2005) 
Prospective 
(290) 
PSS 24 – 32 wks. 
28 wks. 
32 wks. 
ADHD ↑ risk 
(Ronald et al., 
2010) 
Prospective 
(2868) 
Stressful life events During 
pregnancy 
ADHD ↑ risk in 2 year olds 
(Grizenko et al., 
2012) 
Case Control 
(71 case 
71 controls) 
Stressful life events During 
pregnancy 
ADHD ↑ symptom severity in 
children exposed 
(Zhu et al., 2015) Prospective  
(2455) 
-Stressful life events 
-Social support 
-Avoidance coping 
2nd trimester ADHD SLEs, high avoidance 
coping & low social 
support ↑ ADHD 
symptomology in ♂ 
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Table 2 continued:  
(Li et al., 2010a) Prospective  
(1 million) 
Maternal 
bereavement 
(1)Preconceptio
n & (2) 3rd 
trimester 
ADHD ↑ risk in ♂ 
(Class et al., 
2014) 
Prospective  
(2.4 million) 
Maternal 
bereavement 
3rd trimester ADHD ↑ risk 
(Grizenko et al., 
2008) 
Case Control 
(110 cases 
93 controls) 
Stressful life events During 
pregnancy 
ADHD ↑ symptom severity in 
children exposed 
(Motlagh et al., 
2010) 
Case Control 
(222) 
Psychosocial Stress During 
Pregnancy 
ADHD ↑ risk 
(Beversdorf et 
al., 2005) 
Case Control 
(400) 
Psychological 21-32 wks. Autism ↑ risk in PNS at 25-
28wks 
(Kinney et al., 
2008) 
Case Control 
(320,686( 
Environmental Months 5, 6, 9, 
10 
Autism ↑ risk related to 
severity 
(Walder et al., 
2014) 
Prospective  
(89) 
Environmental During 
Pregnancy 
Autism ↑ risk 
(Ronald et al., 
2010) 
Prospective 
(2868) 
Stressful life events During 
pregnancy 
Autism ↑ risk ♂ 
(Class et al., 
2014) 
Prospective  
(2.4 million) 
Maternal 
Bereavement 
Third trimester Autism ↑ risk 
(Li et al., 2009b) Prospective 
(1,492,709) 
Maternal 
Bereavement 
12mt prior to & 
during 
pregnancy 
Autism ↔ risk 
(Rai et al., 2012) Prospective 
(4501 ASD 
54,831 control) 
Psychological During 
Pregnancy 
Autism ↔ risk 
(Spauwen et al., 
2004) 
Prospective  Maternal stress During 
pregnancy 
Childhood 
Psychotic 
Experiences 
↑ risk 
(Dorrington et 
al., 2014) 
Prospective  
(5038) 
Stressful life Events During 
pregnancy 
Childhood 
Psychotic 
Experiences 
↔ risk 
(Betts et al., 
2014) 
Prospective  
(2227) 
Negative life Events During 
pregnancy 
Psychotic 
Experiences 
↔ risk 
(Abel et al., 
2014) 
Prospective  Maternal 
Bereavement 
Preconception 
& postnatal 
Psychosis ↑ risk when exposed 
in postnatal or 
preconception period 
(Khashan et al., 
2008a) 
Prospective  
(1.38 million) 
Maternal 
bereavement 
1st trimester Schizophrenia ↑ risk 
(Malaspina et al., 
2008) 
Prospective  
(88,829) 
Environmental Month 3 Schizophrenia ↑ risk 
(Susser and Lin, 
1992) 
Prospective 
(40,000) 
Environmental 1st trimester Schizophrenia ↑ risk 
(Selten et al., 
2003) 
Retrospective  Environmental During 
pregnancy 
Schizophrenia ↔ risk 
(Fineberg et al., 
2016) 
Case control 
(95 cases 
206 controls) 
Stressful life events During 
pregnancy 
Schizophrenia 
spectrum 
disorders 
↑ risk ♀ only 
(Slykerman et 
al., 2016) 
Retrospective 
(620) 
PSS Late pregnancy 11 years 
(CED-S) 
↑ risk moderate 
depression 
(Van den Bergh 
et al., 2016) 
Prospective 
(86) 
STAI (1) 12-22 wks. 
(2) 23-32 wks. 
(3) 32-40 wks. 
14-15 year 
(a) CDI 
(b) Salivary 
cortisol 
(1b) Trait anxiety ↓ 
daytime cortisol 
(1a) Trait anxiety ↑ 
depression in ♀ 
(Kleinhaus et al., 
2013) 
Case Control 
(92,408) 
Environmental First trimester Affective 
disorder 
↑ risk 
(Khashan et al., 
2011) 
Prospective  
(1.1 million) 
Maternal 
bereavement 
 
2nd trimester Affective 
disorder 
↑ risk 
(Class et al., 
2014) 
Prospective  
(2.4million) 
Maternal 
Bereavement 
12mt before & 
during 
pregnancy 
Bipolar 
Disorder 
↔ risk 
(Li et al., 2008) Prospective  
(1.5 million) 
Maternal 
bereavement 
1st trimester Epilepsy ↔ risk 
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Table 2 continued:  
(Li et al., 2009a) Prospective  
(1.4 million) 
Maternal 
bereavement 
Preconception Febrile 
Seizures 
↔ risk 
(Shang et al., 
2010) 
Case-control 
(120 infants) 
Stressful life events Pregnancy Infantile 
spasms 
↑ risk 
(Cao et al., 2014) Prospective 
(89( 
Environmental During 
Pregnancy 
Motor 
Function 
↓ motor functions 
(Li et al., 2009c) Prospective 
(1.5 million) 
Maternal 
Bereavement 
Pre-/post-
conception 
Cerebral palsy ↑ risk in non-IUGR 
child. 
↑ risk in IUGR child. 
(Su et al., 2015) Prospective  
(5 million) 
Bereavement Preconception Eating Disorder ↑ risk ♂ 
(Liang et al., 
2013) 
Prospective  
(4 million) 
Bereavement Pregnancy Substance 
Abuse 
↔ risk 
(Entringer et al., 
2009) 
Case Control 
(31 case 
30 controls) 
Psychosocial During 
Pregnancy 
HPA activity ↑ ACTH levels 
↑ cortisol response 
(Davis et al., 
2011) 
Prospective  
(116) 
Psychological During 
pregnancy 
HPA Activity ↔ affect 
(Gutteling et al., 
2005a) 
Prospective 
(25) 
Maternal Cortisol During 
pregnancy 
HPA Activity ↑ cortisol response 
(Gutteling et al., 
2004) 
Prospective 
(24) 
Maternal Cortisol During 
pregnancy 
HPA Activity ↑ cortisol response 
Table 2: Prenatal psychological stress and neurological outcomes in offspring. 
Abbreviations: Pregnancy Related Anxiety Questionnaire (PRAQ), Baily Scales of 
Infant Development (BSID), Mental Developmental Index (MDI), Psychomotor 
Developmental Index (PDI), Perceived Stress Scale (PSS), General Health 
Questionnaire (GHQ), Infant Characteristics Questionnaire (ICQ), Child Behavioural 
Checklist (CBCL), Profile of Mood States-Anxiety(POMS-A), State Trait Anxiety 
Inventory (STAI), Daily Stress Inventory (DSI), Centre for Epidemiological Studies-
Depression (CES-D), Profile of Mood States-Depression Subscale(POMS-D), 
Pregnancy Experience Scale (PES), Pregnancy Specific Anxiety (PSA), Parenting 
Stress Index (PSI), Prenatal Life Event Checklist (PLEC), Toddler Temperament Scale 
(TTS), Psychosocial Well-being Index  (PWI), Ages and Stages Questionnaire (ASQ), 
Minnesota Child Development Inventory (MCDI), Parent Report of Children's 
Abilities (PARCA), Infant Behavioural Questionnaire (IBQ), Short Infant 
Temperament Questionnaire (SITQ), Edinburgh Postnatal Depression Scale 
(EPDS),Pregnancy Daily Hassles (PDH), Depression, Anxiety and Stress Scales (DASS), 
Stanford Binet Intelligence Scale (SBIS), Impact of Events Scale (IES), Life Event 
Stress (LES), Wechsler Preschool and Primary Scale of Intelligence (WPPSI), Peabody 
Picture Vocabulary Test (PPCT),  biophysical Profile Score (BPP). 
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1.1.2 Assessing maternal distress in pregnancy: 
Overall the current epidemiological literature outlined above identifies PMND as a 
risk factor for a number of adverse outcomes for both mother and child. However 
there is an overwhelming amount of variability between current reports. This is 
likely a result of the extensive amount of screening tools that researchers use to 
determine maternal experience of PNMD. These range from environmental 
exposures to war or storms (Laplante et al., 2008, Kertes et al., 2016), experience of 
bereavement due to death of a close relative (Class et al., 2014, Khashan et al., 
2011) to a vast array of questionnaire based measurements (Khashan et al., 2014). 
Even within the questionnaire based approach there are a considerable amount of 
tools available that examine different aspects of distress, including, but not limited 
to, objective stress, work stress, perceived stress, stress from daily hassles, financial 
stress, family stress, general anxiety, anxiety specify to pregnancy and depressive 
symptoms  (Lazinski et al., 2008). In a thorough review of psychometric 
instruments, Nast and colleagues have shown the Perceived Stress Scale (PSS), 
State Trait Anxiety Inventory (STAI) and Edinburgh Postnatal Depression Scale 
(EPDS) to be the most reliable indicators of prenatal maternal stress, anxiety and 
depression respectively (Nast et al., 2013). Indeed a further consideration when 
assessing questionnaire-based stress readouts arises when deciding on cut-off 
scores in questionnaires that are clinically relevant to reflect high distress. With 
regards to the EPDS, an EPDS score ≥ 13 has been reported to have the highest 
specificity (97.8%), yet low sensitivity (16.8%) for predicting depressive symptoms 
in pregnancy. Authors have also reported a lower cut off of ≥ 5 for high depression 
kept both specificity and sensitivity to 70%, suggesting an adequate cut off point for 
initial screening (Meijer et al., 2014). In other studies EPDS ≥ 9/10 have been used 
to define clinically relevant depression (Shakeel et al., 2015, Alvarado-Esquivel et 
al., 2014). For the PSS and STAI, no standardized estimates have been reported and 
grouping based on cohort quartiles or means have been used (Khashan et al., 2014, 
Vijayaselvi et al., 2015). In contrast some studies have opted to use the 
questionnaire scores as continuous, rather that categorical variables which can 
yield different outcomes. Single time-point measurements represent another factor 
contributing to variability between studies. It is suggested that when experienced in 
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early pregnancy women perceive events as more stressful that when experienced in 
late pregnancy (Glynn et al., 2001). Additionally studies that have prospectively 
examined stress in pregnancy highlight specific periods of vulnerability (Davis and 
Sandman, 2010). Therefor examining parameters of distress prospectively across 
pregnancy would have greater accuracy.  
Measuring physiological parameters of maternal distress is also important as 
stress induced alterations in maternal physiology is most likely responsible for 
adverse outcomes (Lazinski et al., 2008). Maternal cortisol is most commonly used 
as a physiological indicator of distress. However many studies report no association 
between maternal psychological distress and cortisol levels (Baibazarova et al., 
2013, Harville et al., 2009, Bergman et al., 2010b, Davis and Sandman, 2010). This 
could be a result of cortisol measurements, as assessing human cortisol levels is a 
methodological challenge. Whilst some studies analyse cortisol in maternal serum, 
others use maternal saliva. Measurements in serum samples can be skewed, as 
most serum cortisol is bound to proteins and therefore not biologically active. More 
accurately, cortisol should by analysed in saliva samples as this represents a more 
precise indicator of free, unbound cortisol levels (Aardal-Eriksson et al., 1998). 
Limitations still arise as many cortisol samples rely on the compliance of patients to 
take salivary samples at specific times and slight variations in this compliance can 
alter accuracy of the cortisol circadian profile (Kudielka et al., 2003). Further, many 
environmental factors are known to alter cortisol secretion. For example, salivary 
cortisol concentrations display seasonal variation (Persson et al., 2008). Sleep 
disturbances decrease the salivary cortisol awakening response (Backhaus et al., 
2004). Food intake (Hershberger et al., 2004), caffeine (Lovallo et al., 2005), family 
history of alcoholism (Sorocco et al., 2006), physical activity (Frey, 1982), smoking 
(Rohleder and Kirschbaum, 2006) and alcohol consumption (Kokavec et al., 2009) 
are all known to alter the HPA axis. The maternal HPA is a highly dynamic and 
adaptive system that displays marked intra- and inter-individual variations and 
many studies which utilize single time point cortisol assessments fail to account for 
these variations (Hansen et al., 2008).  Of particular importance for pregnant 
women as there is a natural, yet dramatic increase in circulating cortisol in the third 
trimester (Carr et al., 1981), measuring fluctuations in this period would be 
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particularly difficult. Indeed assessing other biological parameters of maternal 
stress should be considered including analysing maternal catecholamines, cytokine 
profiles and/or placental signalling (Field et al., 2003, Diego et al., 2006, Coussons-
Read et al., 2005).   
 
1.2 Mechanisms of transmission: 
The mechanisms underlying the link between prenatal distress and negative infant 
outcomes are an extensively studied area in preclinical science. Understanding 
these mechanisms is important as it will aid in developing strategies to counteract 
the impact of the stress exposures and prevent poor outcomes. The most 
commonly discussed mechanism is the glucocorticoid hypothesis which suggests 
stress induced increases in maternal HPA activity and subsequently increased fetal 
exposure to glucocorticoids alters fetal development. At the core of this hypothesis 
lies the placenta, which ultimately controls the levels of glucocorticoids the fetus is 
exposed to. More recently attention is being placed on the role of the microbiota in 
mediating this link. In this hypothesis and in addition to the possibility that the gut 
microbiome regulates maternal HPA axis outputs, prenatal distress compromises 
the maternal microbiome and alters the initial seeding and colonisation of the 
infants’ gut, which interferes with postnatal infant development (including 
postnatal HPA axis programming). Other mechanisms included stressed induced 
activation of the sympathoadrenomedullary (SAM) system, activation of the 
maternal immune system and adverse lifestyle behaviours such as increased 
smoking and alcohol use, unhealthy eating, reduced physical activity and sleep 
disturbances (Glover, 2015). Here we review the current literature implicating these 
mechanisms, with focus on the glucocorticoid hypothesis, placenta and 
microbiome.    
 
1.2.0 The glucocorticoid hypothesis: 
The glucocorticoid hypothesis describes how increased fetal exposure to maternal 
glucocorticoids such as cortisol as a result of prenatal stress during pregnancy is 
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associated with a number of poor birth outcomes and increased risk for 
neurological and cardio metabolic syndromes in exposed offspring later in life.  
 As early as the 11-12th week of pregnancy, there are profound changes in 
the activity of the maternal HPA, which leads to increased production of maternal 
cortisol. The levels of cortisol continue to rise during each trimester to reach almost 
three times those of non-pregnant women by the third trimester (D'Anna-
Hernandez et al., 2011, Demey-Ponsart et al., 1982, Jung et al., 2011). The HPA axis 
is regulated by the release of Corticotrophin-releasing hormone (CRH) from the 
hypothalamus, which stimulates the release of adrenocorticotrophin hormone 
(ACTH) from the anterior pituitary gland which in turn stimulates the production of 
cortisol from the adrenal glands.  Normally, cortisol regulates its own secretion 
through a negative feedback loop that inhibits the production of CRH and ACTH 
(Myers et al., 2012). However, during pregnancy, the placenta begins to release 
CRH into the maternal bloodstream and levels reach 1,000 -10,000 times that of a 
non-pregnant woman. This further increases the production of cortisol by the 
adrenals (Duthie and Reynolds, 2013, Petraglia et al., 1987). Although usually 
cortisol negatively regulates the secretion of hypothalamic CRH, in contrast, a rise 
in maternal cortisol actively stimulates the release of placental CRH, which further 
raises the levels of maternal cortisol leading to the progressive increase in maternal 
serum cortisol levels seen during pregnancy (D'Anna-Hernandez et al., 2011, 
Demey-Ponsart et al., 1982, Jung et al., 2011). This increase in maternal 
glucocorticoid levels has been proposed to be required for normal fetal 
organogenesis (Smith and Shearman, 1974) and in keeping with this suggestion, 
antenatal synthetic glucocorticoid administration to pre-term infants has been 
shown to significantly decrease mortality and morbidity in infants born before 34 
weeks of gestation by accelerating lung maturation (Saccone and Berghella, 2016). 
However, excessive fetal exposure to maternal glucocorticoids have been proposed 
as the causative mechanism linking prenatal stress to adverse impacts on birth 
outcomes and result in long-term health consequences in affected infants 
(Barbazanges et al., 1996). Elevated maternal cortisol levels during pregnancy is 
associated with a larger amygdala volume and more affective disorders in girls aged 
7, directly linking maternal cortisol to long term programming effects (Buss et al., 
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2012a). However, no study to date has examined if maternal stress is directly 
associated with elevated fetal cortisol levels during pregnancy or at term.   
Normally the fetus is protected from the high levels of maternal cortisol by 
molecular mechanisms in the placenta that convert active cortisol to its inactive 
metabolite, cortisone and as a consequence, fetal cortisol levels have been shown 
to be ten to thirteen times lower than those found in the maternal circulation 
(Edwards et al., 1993, Gitau et al., 1998). This barrier function of the placenta is 
achieved by the two epithelial layers that cover the chorionic villi of the human 
placenta which serve as the primary barrier between the maternal and fetal 
circulation (Huppertz, 2008). The first of these epithelial layers is the 
syncytiotrophoblast, a large multi-nucleated terminally-differentiated syncytium 
(many nuclei in the same cytoplasmic mass), that is formed by the differentiation 
and fusion of cells derived from second epithelial layer, the underlying 
cytotrophoblast (Huppertz and Borges, 2008). Within these trophoblast layers, there 
is strong expression of the enzyme HSD11B2 which catalyses the conversion of 
active cortisol into inactive cortisone thus protecting the fetus from excessive 
cortisol exposure (Brown et al., 1996, Krozowski et al., 1995, Sun et al., 1997) 
(Figure 1).    
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Figure 1: The placental HSD11B2 shield 
 
 (a): During pregnancy the placenta acts as a critical regulator that limits fetal 
exposure to maternal glucocorticoids. (b): Cross sectional image of the human 
placenta. Blood travels from the fetus through the umbilical arteries (blue) to the 
chorionic villi where exchange of nutrients and waste products with the mother 
occurs. The chorionic villi are made up of two epithelial layers; the 
syncytiotrophoblast and the cytotrophoblast. (c): Longitudinal section of the 
chorionic villi. HSD11B2 is highly expressed in the synctiotrophoblast (+++) and to a 
lesser extent in cytotrophoblast (+).Here HSD11B2 converts cortisol to its inactive 
product cortisone thereby protecting the fetus from glucocorticoid overexposure. 
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Evidence for glucocorticoid overexposure in fetal programming in humans: 
 The glucocorticoid hypothesis has been supported by many studies 
evaluating the relationship between maternal cortisol levels during pregnancy and 
fetal outcome. In a longitudinal study conducted by Bolton et al., high maternal 
cortisol levels in the second and third trimester was associated with reduced 
birthweight and body length, with cortisol accounting for a 19.69% variance in 
bodyweight and a 9% variance in body length (Bolten et al., 2011). Similarly, high 
maternal cortisol levels late in pregnancy was associated with shorter gestations as 
compared to mothers with low cortisol levels (de Weerth et al., 2003)  In contrast, 
maternal cortisol levels in the second trimester were not found to be associated 
with infant birthweight and reduced gestations (Baibazarova et al., 2013), indicating 
the third trimester as window of vulnerability for this effect, a time frame 
coinciding with a critical period for fetal growth and fetal weight gain (Sparks et al., 
1980, Archie et al., 2006).  There is also evidence to suggest that glucocorticoids can 
program cardiovascular disease. Rondo et al. found a positive association between 
maternal cortisol in late pregnancy with low arterial elasticity (Rondó et al., 2010) 
and systemic vascular resistance (Rondo et al., 2010) in children 5-8 years old.  
 In relation to brain function, maternal cortisol levels at 15 weeks gestation 
was positively associated with larger right amygdala volumes and more affective 
symptoms in girls at 7 years of age (Buss et al., 2012a). Large amygdala volumes is a 
characteristic of ASD children (Schumann et al., 2004), suggesting a potential role 
for GC programming of the amygdala be involved in the aetiology ASD. Further, a 
recent study involving a Danish cohort identified elevations in cortisol and ∆4 sex 
steroids in the amniotic fluid of infants who were later diagnosed with ASD (Baron-
Cohen et al., 2014). High maternal cortisol levels in late second and early third 
trimester are associated with an elevated cortisol response to the heel prick test in 
infants and a slower rate of behavioural recovery following the test, indicating HPA 
axis alterations (Davis et al., 2011). Infants whose mothers have high cortisol levels 
late in pregnancy display more crying, fussing, negative facial expressions and no 
vocalization as compared to infants from mothers with low cortisol. These infants, 
from the high cortisol group had a more negative temperament as compared to the 
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low cortisol control (de Weerth et al., 2003).  High cortisol concentrations in late 
but not early or mid-gestation were associated with lower Mental Developmental 
Index (MDI) at 3 months and lower psychomotor developmental Index (PDI) at 3 
and 8 months (Huizink et al., 2003). Discordantly, low cortisol levels at 13 weeks’ 
gestation and high cortisol levels at 38 weeks’ gestation was associated with a 
better MDI scores in infants at 12 months. However the slope of maternal cortisol 
levels across pregnancy was the strongest predictor of infant MDI. This implies that 
the profile of maternal cortisol across gestation, so that adequate amounts are 
available at critical times during development, may be the best predictor of infant 
development (Davis and Sandman, 2010).  
Whilst many studies support a role for elevated maternal cortisol, others do 
not (Bergman et al., 2010a, Baibazarova et al., 2013). However there are 
methodological issues that need to be considered in the assessment of HPA axis 
functions as discussed at the beginning of this chapter. Given these large number of 
potential confounders, perhaps a better measure of fetal cortisol overexposure 
would be to assess fetal cortisol levels directly. In keeping with this, fetal amniotic 
cortisol levels in mid gestation have been associated with decreased birth weight 
(Baibazarova et al., 2013). However performing an invasive procedure during a 
vulnerable time does not represent an optimal collection method for assessing fetal 
glucocorticoid overexposure. Hair cortisol analysis is becoming increasingly used as 
a method to assess HPA activity. Hair growth occurs at an approximate rate of 
1cm/month in adults and is thought to be useful as a retrospective calendar of 
cortisol secretion (Thomson et al., 2010). This highlights the possibility of using 
neonatal hair as a novel methodological approach to evaluate in utero cortisol 
overexposure (Kapoor et al., 2014b).   
An alternative method would be to screen the placenta, given its role as a 
protective barrier for the developing fetus. Within the syncytiotrophoblast of the 
placenta an enzyme HSD11B2 coverts active cortisol to inactive cortisone, 
protecting the fetus from maternal cortisol. Therefore, anything that reduces the 
expression of this enzyme has the potential to allow excess fetal glucocorticoid 
overexposure. In addition to increased cortisol levels, stress is often accompanied 
by elevations in pro-inflammatory cytokines (Coussons-Read et al., 2007), and IL-1β, 
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IL-6, or TNF-α have been shown to reduce HSD11B2 expression and activity in term 
human trophoblast cells (Kossintseva et al., 2006, Chisaka et al., 2005). Both 
noradrenalin and adrenaline, which are secreted as part of a normal stress 
response, have been shown to reduce HSD11B2 activity and expression in vitro 
(Sarkar et al., 2001). Taken together, this indicates that there are multiple 
mechanisms through which PNMD may affect placental HSD11B2, which may not 
be directly related to stress induced elevations in maternal cortisol. Therefore, 
failure to find an association between maternal cortisol levels and fetal outcomes 
would not necessarily eliminate a role for maternal glucocorticoids in the 
programming affect. 
 
1.2.1 Placenta: 
HSD11B2: 
There is increasing preclinical and clinical evidence to suggest that maternal 
stress during pregnancy can lead to alterations in placental HSD11B2 expression. 
For example, direct cortisol infusion into pregnant mice between embryonic day (E) 
12 and E15 resulted in an upregulation of HSD11B2 mRNA and protein expression in 
the placenta at E14.5. However, by E17 placental HSD11B2 mRNA was significantly 
reduced, indicating an adaptive mechanism whereby acute cortisol exposure 
initially upregulates this placental barrier to protect the fetus but chronic cortisol 
exposure reduces its expression resulting in over exposure of the fetus to maternal 
glucocorticoids (Cuffe et al., 2012). In agreement with these findings, it has also 
been shown that pregnant rats subjected to acute restraint stress for one hour on 
gestational day 20, have increased placental HSD11B2 expression (Welberg et al., 
2005). In contrast, chronic restraint stress in pregnant rat dams from gestational 
day 14 to 20 was found to decrease HSD11B2 protein and mRNA expression in the 
placenta (Welberg et al., 2005, Mairesse et al., 2007). This was accompanied by 
reduced fetal birth weight and reductions in circulating ACTH levels and decreased 
adrenal weight (Mairesse et al., 2007). Similarly, pregnant rat dams that were food 
restricted from gestational day 10 to 20, which causes an increase in maternal 
corticosterone levels, have reduced placental HSD11B2 mRNA expression and 
reduced fetal birthweight (Belkacemi et al., 2011b). These offspring display reduced 
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circulating ACTH, adrenal atrophy and decreased mineralocorticoid and 
glucocorticoid mRNA expression in the fetal hippocampus indicating alterations in 
the fetal HPA axis (Lesage et al., 2001). Findings in human pregnancies have been 
less consistent. Amniocentesis in pregnant women, which is associated with 
increased anxiety levels and is a form of acute stress in humans, is associated with 
increased HSD11B2 activity in the placenta (Ghaemmaghami et al., 2014), whereas 
chronic prenatal anxiety and depression in late pregnancy were found to be 
associated with reduced activity and expression of placental HSD11B2 (O'Donnell et 
al., 2012, Seth et al., 2015).  
The precise mechanism(s) linking prenatal stress to reduced placental 
expression of HSD11B2 is unclear, but it has been shown that increased circulating 
glucocorticoid concentrations as a result of stress stimulates the sympathoadrenal 
system causing elevated adrenaline and noradrenaline release from the adrenal 
medulla (Kvetnansky et al., 1995). These stress-induced catecholamines have 
shown to decrease HSD11B2 mRNA in the BeWo human choriocarcinoma cell line 
and in primary trophoblastic cells (Sarkar et al., 2001). Women experiencing high 
levels of stress during pregnancy also have increased circulating levels of pro-
inflammatory cytokines (Coussons-Read et al., 2005). Pro-inflammatory cytokines, 
TNF-α and IL-1β have been shown to decrease the activity and mRNA expression of 
HSD11B2 in vitro (Chisaka et al., 2005, Kossintseva et al., 2006, Suzuki et al., 2005). 
These studies indicate that there are multiple mechanisms through which prenatal 
stress may affect placental HSD11B2 expression and/or activity.  Collectively, these 
data highlight an important point; acute stress during pregnancy may not be 
harmful to the developing fetus due to the ability to upregulate the expression of 
HSD11B2, however, chronic stress can result in a significant decrease in placental 
HSD11B2 expression, meaning that the fetus is exposed to excessive levels of 
maternal cortisol.  Although the precise mechanisms mediating these changes in 
placental HSD11B2 expression remain to be fully elucidated, it has recently 
emerged that epigenetic regulation may play a crucial role. 
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The cell biology of epigenetic regulation of gene expression: 
  The past two decades have been a revolutionary era for the study of 
epigenetics and epigenetic mechanisms. Broadly, epigenetics refers to the study of 
heritable changes in gene function that are not caused by changes to DNA 
sequence (Alikhani-Koopaei et al., 2004). The most intensively studied modes of 
epigenetic regulation are DNA methylation and histone modification. In the 
nucleus, stretches of 140-150 base pairs of DNA are wrapped around proteins call 
histones into structures called nucleosomes (Marsit et al., 2012). The entire 
collection of DNA and associated histone proteins are called chromatin (Marsit et 
al., 2012). Normally DNA is tightly coiled around histone proteins (Alikhani-Koopaei 
et al., 2004). This is a relatively closed structure that restricts transcription factor 
binding and as a result is associated with a reduced level of gene transcription. 
Histone modifications involve the phosphorylation, acetylation and methylation of 
these histone proteins (Lister et al., 2013). Such modifications to histone proteins 
either increase or decrease how tightly the DNA interacts with the histones and 
therefore regulates transcription factor binding(Jensen Pena et al., 2012).For 
example, the addition of an acetyl group by histone acetyl transferase (HAT) 
enzymes to the histone, loosens the electrostatic bonds between it and the DNA, 
resulting in a more open configuration and thus renders DNA more accessible to 
transcription factor binding (Conradt et al., 2013, Nylen et al., 2013, Goffin and 
Eisenhauer, 2002), while histone deacetylases (HDAC) remove them (Santini et al., 
2001a, Santini et al., 2001b). DNA methylation is carried out by enzymes called DNA 
methyltransferase (DMNT) (Wagner et al., 2010), which attach methyl groups to 
cysteine residues that are located in cysteine/guanine rich stretches of DNA located 
in CpG Islands (Cisneros et al., 2003). Methylation of these CpG islands is largely 
associated with gene silencing by inhibition of transcription factor binding and/or 
recruitment of transcriptional repressor complexes (Wagner et al., 2010). It is now 
largely accepted that epigenetics can be modified by environmental exposures – 
‘environmental epigenetics’, particularly during development where the epigenome 
undergoes profound changes (Ding et al., 2012) (Figure 2). 
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Figure 2: Epigenetic regulation of gene expression. 
 
Figure 2: Epigenetic regulation of gene expression. Epigenetic changes are physical 
modifications to DNA structure that change gene expression. Histone acetylation 
and DNA methylation are the most common epigenetic changes. Histone 
acetylation occurs when enzymes called histone acetyltransferases add lysine 
groups to the N terminal tail of histone proteins. This neutralizes the positive 
charge on the histone tail, decreasing their interaction with negatively charged 
DNA. This results in loosening of the DNA around the histones, rendering the DNA 
more accessible to transcription factor binding and enhanced gene transcription. 
Histone deacetylation by histone deacetylases removes these lysine residues 
resulting in reduced gene transcription. DNA methylation is another mode of 
epigenetic modifications. This is carried out by DNA methyltransferases at CpG 
islands. This densely methylated island can directly prevent transcription factor 
binding and therefore reduce gene expression. They can also recruit transcriptional 
repressor complexes with prevent gene transcription by deacetylation.   
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Epigenetic regulation of HSD11B2 expression: 
The human HSD11B2 gene contains four CpG islands, two located in the 
promoter and exon 1 and two in exon 5 and the downstream region (Marsit et al., 
2012, Alikhani-Koopaei et al., 2004). Hypermethylation of normally unmethylated 
CpG islands is indicative of transcriptional repression of the relevant gene (Lister et 
al., 2013). Interestingly, hypermethylation of HSD11B2 CpG islands correlates with 
lower levels of HSD11B2 expression (Alikhani-Koopaei et al., 2004). Low 
methylation levels of HSD11B2 were observed in the placenta (were HSD11B2 
expression is high), whereas in skeletal muscle (low HSD11B2 expression) 
the HSD11B2 promoter was hypermethylated (Alikhani-Koopaei et al., 2004). It has 
been shown that the activity of the HSD11B2 promoter is directly regulated by 
methylation (Alikhani-Koopaei et al., 2004). These data show that exposures that 
change HSD11B2 methylation status in the placenta can result in transcriptional 
repression of the gene, potentially causing the fetus to be exposed to higher levels 
of cortisol that may adversely affect fetal development. In agreement with this 
idea, Marsit and colleagues determined the methylation status of HSD11B2 in 186 
placentae and examined any correlation with fetal birth and neurodevelopmental 
milestones. The methylation status of 4 CpG islands in placental HSD11B2 was 
examined, showing a statistically significant, albeit moderate, negative correlation 
with placental HSD11B2 mRNA expression, indicating that changes in the 
methylation status of placental HSD11B2 can regulate its expression (Marsit et al., 
2012). Intriguingly, a negative correlation was found between infant birth weight 
and ponderal index (ratio of weight for length) and HSD11B2 methylation, 
demonstrating that smaller and leaner/thinner infants showed increased levels 
of HSD11B2 methylation (Marsit et al., 2012). When  the extent of HSD11B2 
methylation was examined in IUGR infants compared with non-IUGR infants, IUGR 
infants showed a significantly greater extent of HSD11B2 methylation than non-
IUGR infants (Marsit et al., 2012). They also examined infant neurobehavioral 
outcomes and found that the extent of HSD11B2 methylation was greatest in 
infants with reduced quality of movement scores as assessed using the NICU 
Network Neurobehavioral Scales (NNNS) examination (Marsit et al., 2012). This 
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study is important as it was the first one to link growth, epigenetic alterations of 
placental genes, and early-life neurobehavioral outcomes in humans. Indeed since 
these work others have confirmed the link between HSD11B2 methylation and 
newborn neurobehavior (Appleton et al., 2015, Paquette et al., 2015). Clearly, 
longer follow-up of infants, beyond the neonatal period is required to determine if 
methylation status of placental HSD11B2 can help identify those children who may 
develop neurobehavioral or learning difficulties later in life (Marsit et al., 
2012). This suggests that the epigenetic status of placental HSD11B2 could also be a 
useful predictor of other adverse outcomes.  
Recent data using a rat model of prenatal stress has now demonstrated that 
prenatal maternal anxiety caused a reduction of HSD11B2 placental expression and, 
importantly, that this was associated with increased CpG methylation of 
placental HSD11B2 (Jensen Pena et al., 2012). This study also attempted to assess 
whether methylation at certain CpG sites within placental HSD11B2 positively 
predicted the methylation status of HSD11B2 in the fetal cortex and hippocampus. 
This raises the intriguing possibility of using the epigenetic status of placenta to 
predict corresponding changes in the fetal brain (Jensen Pena et al., 2012). Prenatal 
maternal anxiety was reported to result in a small but statistically significant 
increase in HSD11B2 methylation at CpG sites 4, 7 and 8, and reduced expression of 
placental HSD11B2. When methylation at these same sites was examined in the 
fetal hypothalamus, significant changes in methylation were observed, but these 
were discordant and in the opposite direction as observed in the placenta, 
apparently causing no effect on HSD11B2 mRNA levels (Jensen Pena et al., 2012). 
However, it should be noted that significant differences in methylation at other CpG 
sites in the placenta were also observed that were not found in the fetal brain, 
suggesting that there may not be a complete direct, inverse relationship between 
both tissues. No differences in DNA methylation were observed in the fetal cortex 
of stressed animals compared with controls (Jensen Pena et al., 2012), suggesting 
that regional differences in the effects of prenatal maternal anxiety on the 
methylation status of HSD11B2 in the fetal brain may exist. This raises the intriguing 
possibility that the epigenetic status of HSD11B2 in the placenta could predict 
changes in the fetal brain. However, it is clear that much work remains to be done 
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to investigate causality, and that the effects of prenatal maternal anxiety on the 
entire epigenome, rather than individual genes, need to be examined. Such studies 
are vital, given the recent demonstration that global epigenomic reconfiguration is 
observed during human brain development, which suggests a key role of DNA 
methylation in brain development and function (Lister et al., 2013).  
Recently, the impact of maternal prenatal anxiety on the placental 
epigenetic status of HSD11B2 has been reported (Conradt et al., 2013). Conradt and 
colleagues used a structured chart review to collect information about whether a 
mother reported depression and/or anxiety during pregnancy. Of the 482 
participants recruited for the study, 13.7% reported depression or anxiety during 
pregnancy, which is consistent with the estimated prevalence rates (Nylen et al., 
2013). In agreement with findings from animal models of prenatal stress (Jensen 
Pena et al., 2012), maternal anxiety during pregnancy resulted in a statistically 
significant increase in methylation of CpG site 4 of the HSD11B2 promoter (Conradt 
et al., 2013). Infants of mothers who were anxious during pregnancy were more 
hypotonic, and placentae from these pregnancies had greater methylation of CpG 
site 4 in HSD11B2 (Conradt et al., 2013). While correlations suggest that the 
epigenetic status of placental HSD11B2 may help identify infants at risk for poor 
neurodevelopmental outcomes, a key challenge that remains is to prove cause and 
effect. Specifically, whether the increase in HSD11B2 methylation in the placenta 
following prenatal anxiety in fact leads to the behavioural changes observed in 
affected infants needs to be further examined. One possible approach could be to 
examine fetal neurobehavioral outcomes following prenatal stress in mice that 
express a drug-inducible, conditional placental-specific knockdown of the 
methyltransferase DNMT3a, whose expression has been shown to be increased in 
the placenta following prenatal stress; (Jensen Pena et al., 2012) or, more 
specifically, the generation of mice carrying methylation resistant CpG sites 
in HSD11B2. It is worth noting here that whilst the methylation status of placental 
HSD11B2 is being increasingly investigated, the potential role of acetylation of 
HSD11B2 is being overlooked. Just like DNA methylation, histone acetylation plays a 
crucial role during fetal development  (Volmar and Wahlestedt, 2015) and histone 
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acetylation has been shown to associated with HSD11B2 expression in the placenta 
(Li et al., 2013b).  
 
The clinical perspective:  extrinsic factors that can modify placental HSD11B2 
expression: 
If epigenetic down regulation of placental HSD11B2 expression is the mechanistic 
link between the experience of maternal stress and the resultant long-term health 
consequences for affected offspring, then strategies that increase placental 
HSD11B2 expression have the potential to improve fetal outcome.  Here we 
highlight two ways that extrinsic factors could modify the expression of placental 
HSD11B2; 1) the use of pharmacological epigenetic modifiers, and 2) dietary 
considerations that may affect placental HSD11B2. 
 
Effects of pharmacological epigenetic modifiers on HSD11B2 expression: 
A defining feature of epigenetic modifications is that they are reversible. Thus, 
drugs that interfere with the enzymes that produce these changes may help 
maintain or restore normal gene expression levels. One class of drugs that alter 
DNA methylation is that of DNMT inhibitors. Many types of DNMT inhibitors have 
been produced and some of these have been used clinically for the treatment of 
leukemias, myelodysplastic syndromes and hemglobinopathies (Goffin and 
Eisenhauer, 2002). These compounds exert their effects by covalently trapping 
methyltransferases, thereby preventing full methylation of a DNA strand (Santini et 
al., 2001a, Santini et al., 2001b). A second class of molecules is that of HDAC 
inhibitors. These compounds inhibit the activity of HDACs, thus preventing histone 
deacetylation of lysine residues on histone tails and, as a consequence, enhancing 
gene transcription. HDAC inhibitors have also been used in epigenetic therapy and 
two of these compounds have recently gained FDA approval as anti-cancer 
therapies (Wagner et al., 2010). 
DNMT inhibitors 5-aza-2′-deoxycytidine (5-AZA) and procainamide have 
been shown to demethylate the HSD11B2 promoter, enhancing both HSD11B2 
expression and activity in the SW620 human colon carcinoma cell line, MCF-7 
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breast adenocarcinoma cell line, and JEG-3 placental carcinoma cell line (Alikhani-
Koopaei et al., 2004). When given orally to rats for seven days, DNMT inhibitors 
were shown to reduce HSD11B2 methylation and to increase HSD11B2 expression 
(Alikhani-Koopaei et al., 2004), which highlights the potential impact of such classes 
of epigenetic pharmacological modifiers on HSD11B2 expression. Similar studies 
have also examined the effects of HDAC inhibition on HSD11B2 expression and 
found that the HDAC inhibitor trichostatin A had no effect by itself on these cell 
lines, but increased HSD211B2 expression in SW620 and MCF-7 cells when added 
only 48 h after 5-AZA treatment, indicating that DNA methylation is the dominant 
form of epigenetic modification on this gene (Alikhani-Koopaei et al., 2004).  
These classes of pharmacological inhibitors have been proposed to be 
potentially useful in reversing placental epigenetic change. However, a major 
challenge with these approaches will be to specifically target the placenta without 
affecting the developing fetus. This is particularly pertinent as recent data shows 
that a global reconfiguration of the fetal neural epigenome occurs during 
development (Lister et al., 2013), suggesting that drugs that interfere with these 
processes may have profound consequences for normal fetal development. These 
drugs have significant detrimental effects on both the mother and fetus. For 
example, intraperitoneal (i.p) injection of pregnant mice with 5-AZA on gestational 
day 10 has been shown to reduce birth weight in affected offspring, an effect that 
persists in males at 5 months of age (Cisneros et al., 2003). This reduced weight is 
also associated with reduced IGF-1 levels in the serum of these offspring (Cisneros 
et al., 2003). Furthermore, males and females who were exposed to 5-AZA in utero 
display a 70% reduction and a 30% reduction in mating capacity and fertility, 
respectively, as measured by the presence of a vaginal plug and viable pregnancy 
(Cisneros et al., 2003). In a recent study by Ding and colleagues, Kunming mice were 
subjected to i.p. injection of 5-AZA or saline on gestational days 1, 2 and 4, followed 
by embryo implantation on day 4. Mice that received 5-AZA showed a significant 
reduction in embryo implantation, as compared with the saline group. This was 
associated with a cell specific reduction in mRNA levels and an increase in the 
methylation levels of many genes involved in endometrial change, as well as a 
decrease in stromal cell proliferation and differentiation (Ding et al., 
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2012).Intravenous infusion of 5-AZA in patients with metastatic lung carcinomas 
induced haematopoiesis toxicity (Momparler et al., 1997), thus limiting their use in 
pregnant women. Given these significant problems and challenges associated with 
their use, the administration of pharmacological epigenetic modifiers to modify the 
placental epigenome is not feasible at the present time. 
 
 Effect of dietary composition on placental HSD11B2 expression: 
The influence of dietary composition as a modifier of placental epigenetic 
machinery is becoming increasingly apparent (Gabory et al., 2012, Gallou-Kabani et 
al., 2010). Mice fed a high fat diet showed reduced placental expression of a 
number of methyltransferases involved in epigenetic modification (Gabory et al., 
2012, Gallou-Kabani et al., 2010). This is a very important finding when one 
considers that, in western societies, 50% of all pregnant women are either 
overweight (BMI of 25–29.9 kg/m2) or obese (BMI of ≥30 kg/m2) (Ogden et al., 
2006), have a dietary caloric excess predominantly derived from fat (Allegri et al., 
2011), or show a higher rate of adverse pregnancy outcomes (Smith et al., 2007, 
Triunfo and Lanzone, 2014).  
DNA methylation is dependent on the availability of methyl group donors 
and cofactors provided by the methionine and folate metabolisms, as well as 
dietary-derived vitamin B6 and B12, suggesting that dietary modifications can affect 
the fetal and placental epigenome (Anderson et al., 2012). This is highlighted by a 
12-wk dose-response choline feeding study conducted in third-trimester pregnant 
women that investigated the effect of a maternal choline intake of 930 mg or 480 
mg per day. Higher maternal choline intake significantly increased the average 
methylation levels in the glucocorticoid receptor gene promoter in placenta and 
fetal leukocytes, with infants showing lower levels of circulating cortisol in the 
higher choline group (Jiang et al., 2012). Although limited data exist regarding the 
impact of dietary composition on the epigenetic modification of placental HSD11B2, 
Takaya et al. examined the methylation of individual CpG dinucleotides in the 
promoter region of hepatic HSD11B2 in offspring of pregnant rats fed a magnesium-
deficient diet from 2wk prior to mating and throughout the gestational period 
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(Takaya et al., 2011). The average methylation of the HSD11B2 promoter in the 
offspring of dams fed a magnesium deficient diet was significantly higher than that 
from controls (Takaya et al., 2011). However, it is important to note that contrary to 
what was expected given previous findings in the placenta (Marsit et al., 2012), 
HSD11B2 methylation was positively correlated with HSD11B2 mRNA expression 
(Takaya et al., 2011). However, responsiveness to environmental exposures in utero 
cannot be generalized across genes and tissues (Loke et al., 2013), suggesting that 
epigenetic modification of the HSD11B2 promoter in different tissues may result in 
different effects on gene expression. Together, these studies show that maternal 
diet can exert gene-specific epigenetic changes that can effect placental mRNA 
expression. The effect of diet on placental epigenetic regulation of HSD11B2 is a key 
question for future research. However, a number of studies have examined the 
effect of both dietary intake and composition on placental HSD11B2. 
A recent study investigating the impact of maternal caloric restriction on 
placental HSD11B2 expression reported that when dietary intake was reduced by 
50% in Sprague Dawley rats from gestational day 10 to 20, these rats showed higher 
maternal corticosterone levels than controls and a reduction in HSD11B2 
expression in the labyrinth zone of the placenta (Belkacemi et al., 2011b, Belkacemi 
et al., 2011a). Furthermore, specific reduction in protein content of the maternal 
diet during early and mid, but not late, gestation in Wistar rats caused a reduction 
of placental HSD11B2 expression (Bertram et al., 2001). These findings have been 
supported by some (Langley-Evans et al., 1996, Whorwood et al., 2001a, 
Whorwood et al., 2001b), though not all (Garbrecht and Schmidt, 2013), studies and 
collectively suggest that adequate protein intake is required to maintain optimal 
expression of placental HSD11B2. However, an excess of calories, predominantly 
derived from high fat and high sugar foods largely define Western dietary habits 
(Allegri et al., 2011). Therefore, an area that demands further investigation is the 
effect of such high calories, high fat/sugar diets on placental HSD11B2 expression. A 
recent study by Sferruzzi-Perri et al. reported altered placental phenotypes in mice 
fed a high fat, high sugar diet that affected placental nutrient handling, which has 
implications for fetal development and pregnancy outcomes (Sferruzzi-Perri et al., 
2013). In addition, the high fat, high sugar diet influenced fetal growth trajectory 
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(initial growth restriction followed by catch-up growth), which may have 
implications for later-life outcomes. However, one potential caveat of this well-
designed study (acknowledged by its authors) was the difference in protein content 
between the two diets (the standard diet consisted of 26% protein compared with 
the high fat, high sugar diet, which consisted of 17% protein) (Sferruzzi-Perri et al., 
2013). It has previously been shown that even mild protein restriction can 
contribute to changes in placental expression of HSD211B2 and development of 
HPA dysfunction and hypertension (Allegri et al., 2011). Therefore, the data from 
Sferruzzi-Perri and colleagues need to be interpreted within the context of 
unmatched maternal protein intakes. However, given that mice and rats fed a high 
fat diet during pregnancy display alterations in the placental transcriptome and 
have dysregulated placental epigenetic machinery (Gabory et al., 2012, Gallou-
Kabani et al., 2010), a much greater understanding of the effects of diet on 
placental HSD11B2 is required. When we analysed the supplementary data 
available in the study by Mao et al. looking at the placental transcriptome at day 
12.5 of gestation in mice fed a high fat diet, robust changes were found in the 
placental transcriptome however HSD11B2 was not in their list of differentially 
expressed genes (Mao et al., 2010). This does not mean that this gene does not 
change in response to a high fat diet, it only means that changes in HSD11B2 gene 
expression were not detected at the particular time at which they did their 
microarray profiling. In addition, transient changes with long-lasting effects cannot 
be ruled out, especially given the data from Sferruzzi-Perri and colleagues 
(Sferruzzi-Perri et al., 2013).  
Future research should focus on addressing the effects of such diets, as well 
as on understanding the correct balance of nutrients that may mitigate the effects 
of increased maternal stress. For instance, could optimal protein levels throughout 
pregnancy protect against the placental morphological and phenotypical changes 
associated with a high fat, high sugar diet. In addition, we know that a reduction in 
total maternal calories downregulates HSD11B2 in the labyrinth zone and 
preliminary evidence suggests that a high fat, high sugar diet influences labyrinth 
zone development; therefore, devising maternal dietary interventions that may 
influence both placental development and ensure optimal fetal outcomes may be 
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an exciting area of research. Could maternal dietary manipulation represent a 
mechanism that could protect or counteract the effect of maternal stress 
(environmental or emotional) on HSD11B2 expression and fetal outcomes? These 
questions warrant further investigation. 
Whether nutritional interventions can specifically prevent or reverse 
prenatal stress-induced epigenetic change in placental HSD11B2 remains to be 
elucidated, but it represents an exciting and, more importantly, feasible approach 
to potentially reverse or prevent the programming effect of prenatal stress on the 
placental and fetal epigenome. 
 
Other placental genes: 
Whilst the majority of the current literature focuses on HSD11B2 as the core 
regulator of fetal glucocorticoid exposure, two other placental genes have recently 
emerged as important contributors; the glucocorticoid receptor (NR3C1) and 
FK506-bind protein 51 (FKBP51). NR3C1 codes for the glucocorticoid receptor (GR) 
which when bound by cortisol, translocates into the nucleus where is regulates 
gene transcription (Clifton et al., 2017). FKPB51, is a chaperone protein which 
regulates nuclear transport of NR3C1, thus reducing the amount of receptor 
available for cortisol binding (Zhang et al., 2008a). Similar to HSD11B2 the placental 
expression of these genes has been linked to prenatal distress and infant neuro-
behaviours (discussed below), with the majority of the literature again focusing on 
the epigenetic regulation.  
A number of studies have now shown that placental NR3C1 can be altered 
by prenatal distress. In cohort of 67 healthy women, low levels of education, a 
potential indicator on elevated prenatal distress was associated with increased 
placental NR3C1 and HSD11B1 mRNA expression, a combination that may increase 
cortisol productivity in the placenta and also increased glucocorticoid sensitivity 
(Raikkonen et al., 2014). Maternal depressive symptoms in the third, but not first or 
second trimester were associated with increased placental NR3C1 mRNA expression 
(Raikkonen et al., 2015). Most interestedly NR3C1 partly mediated the relationship 
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between maternal prenatal depressive symptoms and infants behaviours 
(Raikkonen et al., 2015).  
More often, the methylation status of placental NR3C1 has been linked with 
neurological deficits in newborns. In a cohort of 186 infants increased methylation 
of placental NR3C1, which correlated with reduced mRNA expression, was 
associated with reduced attention in neonates (Bromer et al., 2012). Methylation of 
NR3C1 in the placenta has also been linked with variations in newborn cry, which 
can be an early indicator of poorer neurobehavioral outcome in infancy (Sheinkopf 
et al., 2016). Altered methylation patterns of both placental NR3C1 and HSD11B2 
have been shown to jointly contribute to infant neurobehavior in another study 
cohort (Appleton et al., 2015).  
It has also been shown that placental NR3C1 can mediate a link between 
prenatal mental health and infant neuro-behaviours. Maternal depression, but not 
anxiety (both measured retrospectively after birth) was shown to be related to 
increase CpG2 methylation of placental NR3C1, and this increased methylation was 
associated with hypotonic behaviours, and poor self-regulation in infants assessed 
using the NNNS (Conradt et al., 2013). Condradt et al. observed a significant 
interaction between maternal depression, NR3C1 methylation and poor self-
regulation, hypertonia and lethargy, in that the relationship between NR3C1 
methylation and these behaviours was only evident for infants of depressed 
mothers, and not for infants of non-depressed mothers (Conradt et al., 2013). 
Indeed other studies have shown that the link between increased NR3C1 
methylation and neurobehavioral deficits is still evident in infancy. In a cohort of 
128 infants, Conradt and colleges demonstrated that increased placental NR3C1 
methylation was predictive of increased cortisol reactivity and self-regulation in 
response to stress at 5 months of age (Conradt et al., 2015). 
There is also some evidence to suggest a sex divergent effect of placental 
NR3C1 in response to stress. In mice 60h exposure of corticosterone starting at 
E14.5 is associated with increased expression of NR3C1 in male offspring but not 
females (Cuffe et al., 2012). In humans’, increased maternal cortisol was found to 
be associated with increased NR3C1 mRNA expression in males, but not females 
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(Mina et al., 2015). This suggests cortisol may programme placental NR3C1 
expression is a sex dependant manner with males being more vulnerable to the 
effect.  
FK506 binding proteins are a class of immunophilins that are well known for 
their ability to bind immunosuppressive drugs (Kang et al., 2008). Of particular 
interest is FKBP51 which has been shown to interact with the androgen, 
progesterone and glucocorticoid receptor. Whilst FKBP51 is a positive regulator of 
the androgen receptor, it inhibits the activation of the progesterone and 
glucocorticoid receptors (O’Leary et al., 2013). FKBP51 is emerging as an important 
contributor regulating to the stress response, and mutations in FKBP51 has been 
linked to a number of psychiatric illnesses (O’Leary et al., 2013, Binder et al., 2008, 
Sinclair et al., 2013). FKBP51 has long been known to be abundantly expressed in 
the human placenta (Baughman et al., 1997), however until very recently its role in 
the placenta and in fetal development has not been widely studied.  
One of the first studies to examine the role of FKBP51 in the placenta 
hypothesised that its expression was crucial role for neurodevelopment (Paquette 
et al., 2014). FKBP51 methylation was quantified in 509 placenta samples and 
neurobehavioral outcomes were assessed in newborns using the NNNS. This study 
reported high placenta FKBP51 methylation, and thus reduced mRNA expression 
was associated with poorer neurobehavioral outcomes (Paquette et al., 2014). It 
should be noted however that a follow-up study using a different analytically 
approach reported no association between FKBP51 methylation and newborn 
neurobehavior (Paquette et al., 2015).  
To date only two clinical studies have examined the impact of prenatal 
distress on placental FKBP5, and both of these have focused on methylation levels 
and have not examined FKBP5 placental mRNA expression. The first of these was 
conducted in a cohort of 24 month-infant dyads in the conflicted region of Congo, 
and used war trauma as an indicator of prenatal exposure to stress. This study 
report a positive correlation between placental FKBP5 methylation and exposure to 
war stress (Kertes et al., 2016). More recently perceived stress, anxiety and 
depressive symptoms (but not maternal cortisol) measured in the third trimester 
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were shown to be associated with greater methylation of placental FKBP5, 
HSD11B2 and NR3C1. Indeed increased methylation of HSD11B2 and FKBP5 were 
associated with reduced fetal coupling, which is predictive of neurodevelopmental 
outcomes (DiPietro et al., 2010), and HSD11B2 methylation was found to mediate 
the relationship between prenatal stress and fetal coupling  (Monk et al., 2016). 
This further supports the hypothesis that alterations in the expression of genes in 
the placenta that are involved in glucocorticoid signalling, may underlying the 
adverse effects of prenatal distress on adverse obstetric outcomes.  
 
1.2.2 Focus on the Gut Microbiome: 
The glucocorticoid hypothesis remains the most extensively studied area of 
research linking PNMD with adverse outcomes. However, recently another theory is 
emerging that proposes the experience of PNMD alters the maternal prenatal 
microbiota and that this stressed maternal microbiota is transmitted to the infant 
during parturition which then interferes with postnatal infant development. The 
human body is host to trillions of microorganisms that reside on the skin, oral 
cavity, nasal cavity, reproductive tract and gastrointestinal tract. The number of 
bacterial cells in the human body is estimated to be 3.8x1013, existing at an equal 
ratio to that of human cells (Sender et al., 2016). Over the past few decades our 
knowledge of the human microbiome has expanded with the establishment of 
sequencing technologies (Hooper et al., 2001). There are two primary ways to 
analyse the microbiome; shotgun metagenomics and 16S ribosomal RNA (rRNA) 
gene amplicons, both affording their own weaknesses and strengths (Jovel et al., 
2016). Both technologies require complex bioinformatics that allow the 
classification of bacterial taxa, as well as the diversity of bacteria within (alpha (α) 
diversity) and between samples (beta (β) diversity) (Jovel et al., 2016). During 
taxonomic classification bacteria are first classified into phylotypes (phyla) and then 
clustered into operational taxonomic units (OTUs; family and genus) (Jovel et al., 
2016). The optimization of these sequencing technologies over the past two 
decades has expanded our knowledge of the human microbiome (Hooper et al., 
2001), and it is now clear that the microbiome plays a crucial role in human health, 
with perturbations in the microbiome, or microbial dysbiosis being identified in a 
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vast array of human disease (Sidhu and van der Poorten, 2017, Dinan and Cryan, 
2017). Of particular interest, the gut microbiome has been shown to influence brain 
function, a relationship that is now known to be bidirectional. This has led to the 
coining of the term, microbiota-gut-brain-axis (Dinan and Cryan, 2017, Rogers et al., 
2016). Communication between the gut and the brain occurs through hormonal, 
immunological and neural pathways and disruption to this communication is 
suggested to contribute to the pathophysiology of neurological disorders, 
particularly stress related psychiatric illness, although much of our current 
knowledge comes from preclinical studies (Cryan and Dinan, 2012, Rogers et al., 
2016, Deans, 2017).   
 
Stress and the gut brain axis: 
The idea that the microbiota may play a role in the biology of PNMD comes from 
the extensive literature showing the gut microbiota is important regulators of the 
HPA axis and stress response. Preclinical studies have shown the composition of the 
gut microbiota can be altered by stress (Bailey, 2014, Bailey et al., 2011, De Palma 
et al., 2015, Rea et al., 2016). Additionally in humans, microbial dysbiosis is evident 
in stress related disorders including Irritable Bowel syndrome (Jeffery et al., 2012) 
and depression (Kelly et al., 2016a, Jiang et al., 2015). The relationship between the 
gut bacteria composition and HPA functioning has been demonstrated by studies 
using germ free (GF) animals. GF animal are born and reared in a sterile 
environment and so have no microbiota, therefore are commonly utilized to 
examine the impact of an absent microbiota on host physiology and behaviour. GF 
animals display increased anxiety type behaviour, as well as alterations in brain 
neurochemistry in the amygdala and hippocampus (Neufeld et al., 2011). GF 
animals have an increased ACTH and cortisol response to stressors, an effect that 
can be reversed by reconstituting with Bifidobacteria infantis or by receiving a fecal 
transplant from control mice (Sudo et al., 2004). The most notably effect reported 
in this study was that fecal transplantation was effective at reversing HPA deficits, 
when transplanted in the postnatal period, but not if transplanted later in 
adolescents. This highlights that the early developmental period as a critical 
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window whereby microbial changes may impact physiology (Sudo et al., 2004). 
Despite the extensive literature implicating the gut microbiota as a critical regulator 
of the stress response, the influence of stress on maternal microbial communities in 
pregnancy has hardly been examined. Indeed the increasing evidence highlighting 
the importance of the microbiome in health has triggered interest in understanding 
how the microbiome is acquired, and how it develops and changes throughout the 
lifespan. Establishment of the microbiome in infancy has subsequently emerged as 
a critical period of microbe host interactions, and an increasing body of work is 
attempting to understand how microbial disruptions in early life, may influence 
host physiology and confer disease risk (Mackie et al., 1999, Borre et al., 2014). For 
these reasons there is a need to describe and to understand the functional 
importance of the microbiome during the prenatal and postnatal period in 
determining obstetric and health outcomes. 
 
Prenatal maternal gut microbiome: 
Pregnancy is characterised by a period of substantial physiological changes which 
include weight gain, insulin resistance, increased glucose, hormonal changes and 
immune system modulation which all support the development of a healthy fetus 
(Nuriel-Ohayon et al., 2016). Recently the importance of gut microbial changes 
throughout gestation is being acknowledged and is now accepted to be integral 
part in maintaining a healthy pregnancy. One of the pioneering studies 
demonstrating this, examined the gut microbiota in 91 pregnant women in the first 
and third trimester of pregnancy (Koren et al., 2012). Here β-diversity was found to 
expand with advancing gestation whilst α-diversity indices were reduced. This was 
explained by increasing abundance of Proteobacteria and Actinobacteria and 
changes in the gradient of Bacteroidetes and Firmicutes. When compared to non-
pregnant controls from the Human Microbiome Project Database, the microbiome 
from the first trimester samples was closely related to the controls, whereas the β-
diversity of the third trimester samples was much greater (Koren et al., 2012). 
When transplanted into GF animals, recipients of the third trimester microbiota had 
increase markers of inflammation, gained more weight, had increased blood 
 55 
 
glucose and insulin suggesting the microbiome plays a direct role in contributing to 
the metabolic state that is typical of pregnancy to support the nutritional demands 
of the growing fetus (Koren et al., 2012). Unfortunately the authors did not report 
any correlations between specific bacterial species and physiological symptoms of 
pregnancy. Such information will be important in understanding precisely what 
bacteria are necessary to maintain and support a normal healthy pregnancy. Of 
note one study that thoroughly sampled the gut, vaginal and oral microbiome 
weekly throughout pregnancy reported the gut microbiome to remain stable across 
pregnancy (DiGiulio et al., 2015a). This highlights the need for further studies 
examining the composition and functional role of the microbiome across 
pregnancy, and at different body sites. 
Just like the non-pregnant population, the gut microbiota in pregnancy can 
be influenced by environmental factors. Preclinical studies have shown that 
prenatal stress disrupts bacterial communities in the maternal gut (Jasarevic et al., 
2017), however this has yet to be examined in human populations (Rea et al., 2016, 
Foster et al., 2017). The most well studied factor that has been shown to impact on 
bacteria communities in the maternal prenatal gut is maternal diet and weight. 
When compared to normal weight women, women who are overweight, according 
to their pre-pregnancy body mass index (BMI), have high levels of Bacteroides and 
Staphylococcus. Interestingly the levels of Bacteroides showed a positive correlation 
with weight, BMI and weight gain over pregnancy. Additionally, there was a 
negative correlation observed between weight gain and Bifidobacterium such that 
women who gained less weight had increased Bifidobacterium counts (Collado et 
al., 2008). Women who were classified as obese in pregnancy based on their pre-
pregnancy BMI, were found to have a reduced species richness and evenness along 
with higher abundance of Firmicutes and Actinobacteria and reduced Tenericutes in 
their gut microbiota in early pregnancy (Gomez-Arango et al., 2016).  
Lachnospiraceae and Rikenellaceae were found to positively correlate with 
maternal BMI in these women. Additionally this study found a number of 
correlations between metabolic hormones involved in glucose metabolism and 
energy metabolism to correlate with the maternal gut microbiota. Notably insulin 
and C-peptide levels positively correlated with Coriobacteriaceae of the 
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Actinobacteria phyla and higher abundance of Lachnospiraceae and 
Ruminococcaceae correlated with increased plasma leptin (Gomez-Arango et al., 
2016). It is worth noting that reduced Lachnospiraceae and Ruminococcaceae is a 
microbial signature observed in patients with depression (Jiang et al., 2015), 
suggesting the potential for PNMD to alter important bacteria that interact with 
maternal physiology in pregnancy.  
The impact of prenatal antibiotic use in pregnancy on the maternal gut 
microbiome has not being well studied in humans despite the fact that one in four 
women are prescribed antibiotics in their pregnancy, with antibiotics accounting for 
80% of prescribed medications in pregnancy (Bookstaver et al., 2015). In rodents 
prenatal exposures to commonly administered antibiotics Azithromycin, Amoxicillin 
and Cefaclor altered the maternal gut microbiome, notably reducing species 
diversity, increasing the abundance of Proteobacteria and reducing Firmicutes with 
corresponding alterations at family and genus level including increased growth of 
the pathogenic E.Coli. Antibiotic use was also associated with weight gain over the 
course of the pregnancy (Khan et al., 2016). Use of antibiotics in pregnancy is 
associated with an increased risk of childhood obesity (Mueller et al., 2015b) and 
asthma (Lapin et al., 2015) and the infant gut microbiome is altered by perinatal use 
of antibiotics (Persaud et al., 2014), which could be linked to alterations in maternal 
microbes. This highlights the need for more research to examine the impact of 
antibiotics use on the maternal gut microbiome. 
A growing body of research linking maternal microbial perturbations to 
adverse pregnancy outcomes highlights the importance of the maternal gut 
microbiome in pregnancy. Infection with Helicobacter pylori in pregnant women is 
associated with symptoms of dyspepsia and hyperemesis, two of the most common 
conditions that affect pregnant women (Poveda et al., 2014, Shaban et al., 2014). 
Reduced α-diversity, mainly decreased microbial richness, has been reported in the 
gut of women with gestational diabetes mellitus (GDM) in the first trimester (Koren 
et al., 2012). Although no direct link has been shown between the maternal gut 
bacteria and preterm birth, bacteria abundant in the gastrointestinal tract have 
been isolated from the amniotic fluid of pregnancies complicated by preterm pre-
labour rupture of membranes (DiGiulio et al., 2010). The route by which maternal 
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gut microbes might enter the fetal compartment to influence development is not 
well known. Possible mechanisms include contamination of the maternal vaginal 
canal, which ascends through the birth canal or translocation from the gut into the 
blood stream (Dunlop et al., 2015). This may be particularly important in women 
with heightened stress, as stress can impair intestinal barrier function and integrity 
which could result in greater permeability and escape of bacteria into the 
circulation (Li et al., 2017, Cameron and Perdue, 2005).  
 
Vaginal microbiome: 
The vaginal microbiome plays an important role in protecting against infections, a 
function achieved through the bactericidal activities of the Lactobacilli species 
(Boris et al., 1998, Martin et al., 1999, Nardis et al., 2013, O’Hanlon et al., 2013). 
These bactericidal properties are produced by utilization of glycogen deposited in 
the vaginal epithelium by Lactobacilli to produce lactic acid and maintain a low 
vaginal PH (Vasquez et al., 2002, Mirmonsef et al., 2012). The importance of vaginal 
Lactobacilli is further highlighted by a study showing that greater than 50% of lactic 
acid found in vaginal secretions are of D isoform. As human vaginal epithelial cells 
can only produce the L isoform of lactic acid, and Lactobacilli produce both 
isoforms, this study emphasises the importance of bacteria, particularly Lactobacilli 
in maintaining vaginal health (Boskey et al., 2001). The majority of vaginal 
microbiomes are dominated by a species of Lactobacilli. This has led to the 
grouping of vaginal communities into five ‘community state types’ (CTSs). Four of 
these communities are characterised by their dominance from particular 
Lactobacillus species, L.crispatus, L.gasseri, L.iners or L.jensenii-dominant. The fifth 
CST (CST VI) represents a more even and taxonomically diverse state with low levels 
of Lactobacillus (Romero et al., 2014, DiGiulio et al., 2015b, Charbonneau et al., 
2016) that is more commonly associated with a high vaginal PH and the 
development of bacterial vaginosis (Romero et al., 2014).   
In pregnancy the vaginal microbiome is important, not only protecting the 
developing fetus from infections, but also in the initial seeing of the infant 
microbiome upon rupture of the amniotic membranes. Some studies have reported 
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a substantial change in the vaginal microbiome throughout pregnancy reporting 
reduced species richness and diversity with advancing gestation and predominance 
of Lactobacillales, Clostridiales, Bacteroidales and Actinomycetales (Aagaard et al., 
2012), whilst others do not studies do not identify these changes (DiGiulio et al., 
2015b, Romero et al., 2014). Indeed the latter two studies do report a more stable 
vaginal microbiome in the pregnant population switching between Lactobacillus 
dominant CSTs during pregnancy but rarely to the more diverse CSTs (DiGiulio et al., 
2015b, Romero et al., 2014, Walther-Antonio et al., 2014). The reason why the 
vaginal microbiome undergoes this switching between CSTs in pregnancy is 
unknown, however enhanced vaginal glycogen stores as a results of increased 
estrogen levels in pregnancy, is thought to favour Lactobacilli growth which may 
explain why the vaginal microbiome in pregnant women favours a Lactobacilli 
dominant CST (Prince et al., 2015). Of note, psychological stress in women has been 
linked to reduced estrogen levels (Roney and Simmons, 2015), which may 
consequently, reduce vaginal Lactobacilli growth.  
The vaginal microbiome remains altered in the postpartum. In the study by 
Giulio and colleagues, a noticeable alteration in the vaginal microbiome was found 
in the postpartum period. This involved depletion of Lactobacillus, and the 
introduction of various anaerobic bacteria more common to the gut than the 
vagina, that persist up to one year after birth (DiGiulio et al., 2015b). This change in 
the postpartum vaginal microbiome has also been reported in other studies 
(MacIntyre et al., 2015, Huang et al., 2015). Whether this change in vaginal flora in 
the postpartum period is important for maternal health or is just a mechanical 
disruption from childbirth is unknown. Further studies examining this by assessing 
the vaginal flora in women after Caesarean delivery would help to elucidate this.  
The functional importance of the vaginal microbiome in pregnancy is 
supported by a number of studies linking vaginal microbiome dysbiosis to adverse 
obstetric outcomes. Decreased vaginal richness and diversity of the vaginal 
microbiome in the first and second trimester has been linked to an increased risk of 
PTB (Stout et al., 2017, Nelson et al., 2016). Further women with a Lactobacillus-
poor CST in the first trimester of pregnancy were reported to be more likely to 
delivery PTB (DiGiulio et al., 2015b).  Interestingly the duration and proportion of 
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time a women had this vaginal profile, was predictive of preterm birth (DiGiulio et 
al., 2015a). At taxonomic level, a Lactobacillus depleted microbiota, increased 
abundance of Gardnerella or increased abundance of Ureaplasma increased the risk 
of PTB (DiGiulio et al., 2015b). The influence that PNMD has on vaginal microbial 
communities has yet to be examined clinically, although in rodents prenatal stress 
was found to decreases vaginal Lactobacilli, highlighting the need for research 
examining if stress related changes in the vaginal microbiome occur during 
pregnancy and if so, the consequence that these changes may have for pregnancy 
outcomes (Jasarevic et al., 2015a).  
 
Infant microbiota development: 
The early microbial communities that colonise the gut of an infant are important for 
infant health as this period of first microbial succession overlaps with critical 
periods of immune and nervous system development. Alterations in the 
development of an infant’s microbiome may interfere with developmental 
processes that lay the groundwork for poor health and increased disease risk in 
later in life. Whilst the adult microbiome is stable and ultimately resilient to change, 
the infant microbiome can be altered. Therefore microbiome-based interventions in 
early infancy could be a valuable therapeutic approach to restore aberrant 
microbiome development in order to minimise later disease risk.  
Until recently, the in utero environment was believed to be completely 
sterile, a paradigm referred to has the ‘sterile womb hypothesis’, whereby 
neonates receive their first microbes from the mother by vertical transmission 
during the process of childbirth and then horizontally from the environment after 
birth (Funkhouser and Bordenstein, 2013). Many studies have now reported the 
presence of bacteria in the meconium (Jimenez et al., 2008), placenta (Aagaard et 
al., 2014), amniotic fluid (Collado et al., 2016) and umbilical cord blood (Jimenez et 
al., 2005). These studies have challenged this view, and a new theory has emerged 
proposing colonization of the infant gut begins in utero, which has become known 
as the ‘in utero colonisation hypothesis’ (Perez-Munoz et al., 2017). Despite these 
recent studies, it is still unclear whether bacteria are present in utero, or if the 
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detection of microbes is due to contamination upon specimen collection (Perez-
Munoz et al., 2017, Hornef and Penders, 2017). Additionally, how commensal 
microbes might overcome the structural and immunological barriers of the placenta 
to enter the fetus is unknown. Therefore when and how an infant acquires their 
first microbes remains a topic of scientific debate.  
In the first few years of life, the infant microbiota displays large inter-
individual variation. As time progresses and by the age of one, infants tend to 
converge towards an adult-like level of complexity. Interestingly at this age the 
microbiota of infants is no more similar to their parents than to that of other 
parents, inferring a greater role for environmental over genetic influences on infant 
microbial development (Palmer et al., 2007). A large portion of microbial 
colonization occurs at birth, as babies are exposed to the bacteria present in the 
maternal vagina, fecal matter, skin and associated surroundings. Infant meconium 
samples are often dominated by the facultative anaerobes such as Enterococci and 
Staphylococci (Jimenez et al., 2008). Within the first few days of life these bacteria 
utilize up most oxygen stores, enabling them to be outcompeted by strict 
anaerobes such as Bifidobacteria. The establishment of breastfeeding allows such 
bacteria to thrive as maternal breast milk is a rich source of Bifidobacteria and 
Lactobacillus (Solis et al., 2010), which enables a direct transfer of these bacteria. 
Breast milk also contains human milk oligosaccharides (HMOs) which promote the 
growth of Bifidobacteria (Wickramasinghe et al., 2015). Bifidobacteria are 
important colonisers of the infant gut as they downregulate genes associated with 
inflammation in epithelial cells (Wickramasinghe et al., 2015), inhibit pathogens 
(Simone et al., 2014), modulate intestinal barrier integrity (Chichlowski et al., 2012) 
and ultimately aid in immune system development.  Bifidobacteria remain the 
dominant species in the first year of life but decline with increasing age. Other 
dominant species during this time include Lactobacillus, Streptococcus and 
Lactococcus (Yatsunenko et al., 2012). The cessation of breastfeeding and 
introduction of solid foods marks the next developmental milestone of the infant 
gut bacteria as microbes involved in food degradation start to increase (Backhed et 
al., 2015). By the end of the first year of life the microbial ecosystem starts to 
resemble that of an adult (Palmer et al., 2007), and by age three the microbiome is 
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believed to be stabilized into its adult-like phenotype (Voreades et al., 2014). There 
are now a number of prenatal and postnatal factors that are known to influence 
this early life microbial assembly.  
 
Factors influencing infant microbiome development: 
Mode of Delivery: 
Delivery mode is a key factor influencing the initial microbial assemblage of the 
infant gut. Infants born vaginally (VD) are exposed to the bacteria along the birth 
canal, and so are initially dominated by species resembling that of the maternal 
vaginal and faecal microflora. Conversely, infants born via caesarean section (CS) 
are first exposed to the bacteria on maternal skin and in the environment of the 
theatre, and thus have a different initial colonization. A recent systematic review 
compiled 7 studies that assessed infant microbiota at multiple points over the first 
year of life to show colonization patterns differ based on delivery mode (Rutayisire 
et al., 2016). In the first 7 days of life infants born by CS have lower total diversity, 
with marked reductions of Bifidobacteria, Bacteroides and Enterobacteriaceae 
(Gronlund et al., 1999, Hesla et al., 2014, Mitsou et al., 2008, Dogra et al., 2015, 
Kabeerdoss et al., 2013, Jakobsson et al., 2014). Lactobacilli are observed more 
frequently in VD neonates (Mitsou et al., 2008, Kabeerdoss et al., 2013) whilst CD 
neonates are more often colonized with members of the pathogenic Kliebsiella and 
Veillonella species (Hesla et al., 2014, Dogra et al., 2015). By the end of the first 
month of life, Bifidobacteria are the most dominant microbe regardless of delivery 
mode and at this age both Bifidobacteria and Enterobacteriaceae are no longer 
different between infants (Gronlund et al., 1999, Kabeerdoss et al., 2013, Jakobsson 
et al., 2014). However it should be noted that most studies still report lower 
Bacteroides in CS delivered infants at this time (Gronlund et al., 1999, Hesla et al., 
2014, Kabeerdoss et al., 2013). By the age of 3 months, VD infants still display 
increased levels of Bacteroides (Hesla et al., 2014, Jakobsson et al., 2014, Gronlund 
et al., 1999, Kabeerdoss et al., 2013). By 6 and 12 months of age, delivery mode no 
longer appears to impact microbial colonization (Rutayisire et al., 2016), with only 
one report still identifying increased B.fragilis in VD infants at 6 months  (Gronlund 
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et al., 1999). Further by adulthood, mode of delivery no longer appears to influence 
microbiome composition (Falony et al., 2016). Microbiome alterations specifically in 
the early gut colonization is suggested to be one potential mechanism underlying 
the increased risk of metabolic and immune related disorders in infants born via CD 
(Thavagnanam et al., 2008, Bager et al., 2008, Li et al., 2014, Kuhle et al., 2015).  
 
Mode of feeding: 
The infant diet is another important factor shaping gut colonization patterns. 
Infants who are exclusively breast-fed (BF) at 4 months have increased Lactobacilli 
and Bifidobacteria compared to those that are exclusively formulae-fed (FF). FF 
infants display elevated levels of other bacteria such as Citrobacter spp., C.difficile 
and Enterobacteria cloacae (Backhed et al., 2015). Infants who are still being 
breastfed at 12 months are still dominated by Bifidobacteria and Lactobacillus, 
whereas infants whose breastfeeding has ceased have a shift towards a more adult 
phenotype enriched with Bacteroides and Bilophila, suggesting that cessation of 
breastfeeding rather than introduction of solids is a critical determinant of the shift 
towards a more adult like composition (Backhed et al., 2015). Of interest, BF may 
be a means to compensate for the reduction in Bifidobacteria and Lactobacilli 
associated with CS, as infants who are exclusively breastfed following CS have a 
restoration of B. bifidum and L. gasseri at 3 months that is comparable to VD infants 
(Martin et al., 2016a). Additionally changes in microbiome as a result of the mode 
of feeding in infants, is associated with changes to the host transcriptome. 
Increased microbiome virulent characteristics in BF infants are associated with 
decreases in inflammatory related genes in infant epithelial cells (Schwartz et al., 
2012), inferring a direct consequence of altering the microbiome by mode of 
feeding on the host. Further some bacteria may be directly transferred from breast-
milk to the infant gut as microbes such as Staphylococci, Lactobacilli and 
Bifidobacteria are present in breastmilk (Fernandez et al., 2013). Additionally 
breastmilk contains HMOs which promote Bifidobacteria growth (Asakuma et al., 
2011).  
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Gestational Age and birthweight: 
In a study of 50 LBW infant, α-diversity was initially reduced in LBW infants and 
found to increase over time from one week to one month to two months (Drell et 
al., 2014). The major phyla were Proteobacteria, whose abundance increased from 
one week to one month, Firmicutes which decreased from one week to one month, 
and Bacteroidetes (Drell et al., 2014). Bifidobacterium was undetectable and 
Bacteroides and Lactobacillus were barely detectable in these LBW infants. 
Additionally α-diversity was found to positively correlate with gestational age and 
negatively with the start of enteral feeding (Drell et al., 2014). Further in this study 
infants born to mothers’ with chorioamnionitis had a more diverse gut microbiome, 
which is possibly a reflection of exposure to bacteria in the amniotic fluid (Drell et 
al., 2014). These findings suggest an additive role of maternal infection during 
pregnancy on early infant microbial colonization.  
 
Antibiotics: 
A large portion of fetuses are exposed to antibiotics during pregnancy, usually for 
the treatment of Group B Streptococcus, premature rupture of membranes or to 
reduce infections prior to CS delivery. An estimated 37% of women receive 
antibiotics during pregnancy with 33% receiving antibiotics in the intrapartum 
period (Stokholm et al., 2013). Intrapartum antibiotic prophylaxis (IAP) with 
ampicillin, is associated with increased Enterobacteriaceae and reduced 
Bifidobacteria in both exclusively or partially breastfed infants and lower bacterial 
diversity in bottle fed infants at day 7 of life. By day 30 Bifidobacteria had 
normalized but Enterobacteriaceae remained elevated in antibiotic treated infants 
(Mazzola et al., 2016). Prenatal antibiotic exposure may also interact with mode of 
delivery and feeding to influences the infant gut microbiome composition. 
Neonates delivered vaginally whose mothers received IAP, had reduced richness at 
3 months, whilst those delivered via emergency CS (with IAP) had increased 
diversity at 1 year. Also at 3 months infants exposed to IAP had reduced 
Bacteroidetes, which was 46% in unexposed infants, 24% in exposed delivered 
vaginally and <1% exposed and delivered by CS. Exposed infants delivered via 
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emergency CS had increased Firmicutes and Proteobacteria which persisted at 1 
year, at this time there were no differences in the microbiota of infants exposed 
born vaginally or by elective CS. These relationships were further influences by 
feeding, in that infants who were exclusively breastfed at 3 months were less likely 
to display microbiome alterations at 1 year (Azad et al., 2016). These data suggest 
the potential and usefulness of breastfeeding to counteract the impact of maternal 
adversity on infant gut microbiome composition. 
 
Pregnancy stress: 
Colonization of microbial communities within the infant gut can also be influenced 
by prenatal maternal stress. One of the first studies to demonstrate this, exposed 
pregnant rhesus macaques to an acoustic startle in early and late pregnancy and 
examined the intestinal bacteria in the offspring up to 24 weeks of life.  Exposed 
offspring displayed reductions in Lactobacilli when exposed in early pregnancy, and 
reductions in Lactobacilli and Bifidobacteria when exposed in late pregnancy (Bailey 
et al., 2004). More recently the influence of prenatal stress on offspring microbiota 
has been replicated using an early prenatal stress model in rodents (Jasarevic et al., 
2015a). Here Lactobacilli were again reduced in prenatally stressed offspring, with 
the reduction corresponding to a similar reduction of vaginal Lactobacilli in the 
stressed mothers, implying direct vertical transmission from mother to offspring. 
The authors also identified sex dependent microbial effects with increased 
Bacteroides and Clostridium in exposed males at postnatal day (PD) 2, who overall 
more closely resemble control females than males (Jasarevic et al., 2015a). 
Offspring of prenatally stressed mothers also displayed distinct alterations in 
colonic and plasma metabolites as well as changes in amino acid profiles with the 
hypothalamus, providing a route by which prenatal stress may impact 
developmental outcomes (Jasarevic et al., 2015a). Using the same stress paradigm 
Jasarevic and colleagues further showed sex dependant microbial alterations by 
prenatal distress that persisted up to PD28. They also examined maternal gut 
microbial colonisation and found distinct alterations in bacterial communities, along 
with disruptions to bacterial interactions among prenatally stressed dams (Jasarevic 
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et al., 2017).  Additionally further evidence from preclinical models suggests that 
prenatal stress induced changes in intestinal microbiota can persist into adulthood, 
and that these microbial changes correlate with alterations in HPA axis function 
(Golubeva et al., 2015), providing a direct link between stress-induced microbial 
alterations and offspring physiological functioning.   
Only one study to date has examined the relationship between prenatal 
stress and offspring gut colonization in humans, which largely supports the 
preclinical findings. In this study pregnant women completed psychological distress 
questionnaires and provided salivary samples for cortisol analysis in the third 
trimester of pregnancy, and infant microbial structure was assessed at 7, 14, 28, 80 
and 110 days of life. Infants born from higher stressed pregnancies had high levels 
of pathogenic bacteria including Escherichia and Enterobacter and reduced lactic 
acid bacteria, of which Lactobacilli was included. Bifidobacteria was also reduced in 
these infants. Additionally α-diversity over this time period was elevated in infants 
from high stress pregnancies (Zijlmans et al., 2015a). Further infants born from the 
high stressed pregnancies displayed a high prevalence of adverse gastrointestinal 
symptoms (38%) compared to just 22% of those in the low stressed. Notably infants 
who developed gastrointestinal problems had lower abundances of lactic acid 
bacteria, a microbial phenotype also observed among infants with allergic 
reactions; again directly linking prenatally stressed induced microbial alterations to 
altered infant development (Zijlmans et al., 2015a). To date the impact of prenatal 
stress on the maternal gut and vaginal microbiome has yet to be examined in 
humans. As such if vertical transmission of a ‘stressed microbial signature’ during 
parturition accounts for the altered microbial structure in infants, or if other 
mechanisms are involved in this process remains to be determined.  
 
Altered microbiome development and disease risk: 
Early establishment of the infant microbiome coincides with critical periods of 
immune, metabolic and nervous system development (Borre et al., 2014), thus 
forming the rationale behind the extensive body of literature examining factors that 
might interfere with this process.  
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Infant Microbiome and disorders of the Metabolic System: 
In support of this concept, one longitudinal study has examined the association 
between infant microbial development and the development of type 1 diabetes 
(T1D) in a cohort of 33 children. In this study infants who went on to develop T1D 
displayed a flattening of α-diversity before 2 years of age, a time when the diversity 
of non-convertors and semi-convertors continued to rise. At the compositional 
level, these infants were overrepresented by potentially pathogenic bacteria 
Ruminococcus and Streptococcus and had reductions in the dominant 
Lachnospiraceae (Kostic et al., 2015).   
 
Infant  microbiome and Immune System development: 
The link between infant microbial colonization and immune system disorders has 
been prospectively studied in clinical populations, and is mechanistically paralleled 
by preclinical work strongly supporting a role for bacteria is regulating immune 
system development (Kelly et al., 2007).  In two longitudinally designed cohorts, 
infants with greater amounts of Lactobacillaceae and Bifidobacterium species in 
their gut during the first 2 months of life were less likely to develop allergic 
symptoms by the age of 5 (Sjogren et al., 2009, Johansson et al., 2011). Early 
colonization with Bifidobacteria can influence systemic immune responses. Infants 
with higher numbers of Bifidobacteria species in the first two months of life have 
higher levels of secretory IgA (SlgA) at 6 months of age. Additionally Bacteroides 
fragilis has been shown to negatively correlated with toll like receptor 4 in 
peripheral blood mononuclear cells (PBMCs) at 12 months of age, which are 
important in pathogen recognition and immunity (Sjogren et al., 2009). 
Bifidobacteria have been shown to play a significant role in immune system 
development in young rats including promoting maturation of dendritic cells, 
influencing T-cell development and increasing IL-10 production from PBMCs (Dong 
et al., 2010). Of note, manipulating the gut microbiota by supplementation with 
probiotics during pregnancy and in infants 6 months postnatally, increases 
Lactobacilli and Bifidobacteria in the infant gut at 2 years of age and significantly 
reduces the risk of eczema (Kukkonen et al., 2007). Importantly, prenatal stress-
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induced alterations in the infant microbiome have been linked to allergic symptoms 
in infants (Zijlmans et al., 2015a). Further the current evidence demonstrates a 
predominant role for Lactobacilli and Bifidobacterium species in immune system 
development, and these bacterial species are the ones that are most commonly 
reduced in offspring exposed to prenatal stress (Jasarevic et al., 2015a, Bailey et al., 
2004, Zijlmans et al., 2015a). This provides further evidence that microbial dysbiosis 
may underlie the link between prenatal stress and immune system disorders.   
 
Infant Microbiome and the Nervous System: 
The relationship between early microbial colonization and neurodevelopmental 
outcomes has not been extensively studied in humans, and much of our knowledge 
comes from preclinical studies using GF animal models (sterile animals that have 
never been exposed to microbes). One of the earliest studies examining this 
demonstrated an exaggerated HPA response in GF animals when compared to 
specific pathogen free (SPF) mice, a phenotype that was reversed when the 
mothers of the GF animals were fed a single Bifidobacterium infantis strain. 
Importantly reconstitution of the GF mice with faeces from the SPF mice could also 
rescue the exaggerated HPA response, but only when reconstituted in early life 
(Sudo et al. 2004). This highlights an important window during which gut microbes 
can impact on nervous system functioning (Sudo et al., 2004). This exaggerated HPA 
phenotype has also been demonstrated by another study, where the GF animals 
also displayed reduced anxiety like behaviours along with altered neurochemistry in 
the brain that was specific to male offspring including reduced BDNF and increased 
tryptophan and serotonin. Again early colonization, immediately post weaning, 
could restore the behavioural deficits in GF animals but not the altered 
neurochemistry (Cryan et al., 2012).  Alterations in the gut microbiome in children 
with ASD adds clinical support to the idea that the gut microbiome plays a role in 
neurodevelopment (Mulle et al., 2013). Indeed a recent exploratory trial has shown 
promise for fecal microbiota transplant in improving ASD behaviours and associated 
gastrointestinal function in a cohort of 18 ASD children (Kang et al., 2017). Delivery 
via CS, which is known to produce profound alterations early microbial colonization, 
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increases the risk of ASD (Curran et al., 2015). Recently the first report directly 
linking the infant microbiome to neurological outcomes was published. In this study 
the microbiota was characterised from fecal samples from 89 infants at 1 years old 
and cognitive testing was performed at 1 and 2 years old as well as structural MRI 
(Carlson et al., 2017). Infants were clustered into three groups based on their 
microbiome; high abundance of Faecalibacterium (C1), high abundance of 
Bacteroides (C2) and high abundance of Ruminococcaceae (C3). At 2 years old 
infants from C2 has the highest cognitive performance with infants from C1 
showing the lowest. Alterations in grey matter volume were also observed based on 
microbiome clustering. Further higher α-diversity was associated with poorer 
cognition at 2 years of age (Carlson et al., 2017). This work highlights the need for 
more longitudinal studies directly examining early infant microbial colonization and 
its association with neurobehavioral outcomes in childhood and adulthood. This will 
elucidate the importance of early gut colonization on neurodevelopmental 
disorders.  
These reports raise the issue of how infant gut microbiota affect the 
developing brain. Microbial communication via the vagus nerve represents one 
mechanism by which the gut bacteria can communicate with the brain. Indeed 
when the vagus nerve is severed, the antidepressant and anxiolytic effects of 
Lactobacillus rhamnosus in rodents are prevented (Bravo et al., 2011). Further the 
same bacterial strain was found to increase firing and activity of vagal afferents ex 
vivo (Perez-Burgos et al., 2013). Conversely behavioural alterations induced in mice 
by antibiotic depletion of the gut microbiota occurred regardless of vagotomy 
(Bercik et al., 2011), highlighting other methods of communication also exist 
between the gut bacteria and the brain.  
Microorganisms produce and secrete a variety of metabolites and 
neurotransmitters that can enter the blood stream and in some case, cross the 
blood brain barrier to gain access to the brain (Sharon et al., 2014). Of particular 
interest short chain fatty acids (SCFAs), produced by the microbiome have 
widespread effects on the brain (Oleskin and Shenderov, 2016). Of note, SCFAs, 
butyrate and propionate have potent HDAC inhibitory activity (Waldecker et al., 
2008, Stilling et al., 2016), which could have significant impacts on brain 
 69 
 
development, as HDACs are import regulators of brain development (Volmar and 
Wahlestedt, 2015).  
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1.3 Aims and Objectives of Thesis  
This thesis aims to investigate the biological mechanisms by which prenatal 
maternal distress can influence fetal development.  In particular this work focuses 
on two key mechanisms: 1. placenta mechanisms, and 2. the maternal-infant 
microbiome. Currently, literature regarding the effect of prenatal distress on 
placental glucocorticoid signalling has produced conflicting findings and the 
molecular mechanisms that are involved in this effect have not been well studied. 
The concept that the microbiome may play a role in the programming effects of 
prenatal distress is novel and has only been investigated a handful of times in 
studies that have primarily focused on the effect on the infant microbiome in 
rodents. The impact that prenatal mental health has on the maternal microbiome 
has not been investigated in humans. Therefore the overall objective of this thesis 
was to establish a longitudinal study cohort that would allow a thorough 
investigation into the biological underpinnings linking prenatal distress to adverse 
outcomes.  
 
1.3.0 Investigate the biological and molecular mechanisms by which prenatal 
stress alters placental HSD11B2 expression 
Over the past decade placental HSD11B2 has emerged as a critical regulator of fetal 
development. There has been an explosion of descriptive clinical studies suggesting 
prenatal distress may influence the regulation of HSD11B2, however, the precise 
molecular mechanisms that regulate HSD11B2 under conditions of stress have not 
been studied.  This chapter used an in vitro model of placental cells to examine the 
biological mechanism by which prenatal distress might influence placental HSD11B2 
expression, with particular focus on cortisol, and IL-1β. Both compounds have been 
found to be elevated in the serum of pregnant women experiencing stress and may 
have the potential directly influence HSD11B2 expression. Additionally, whilst many 
studies are focusing primarily in the role of DNA methylation in HSD11B2 
regulation, this chapter explored the part that histone acetylation plays in 
controlling HSD11B2 placental expression.    
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1.3.1 Examine the effects of prenatal distress on birth outcomes and placental 
gene expression in a preliminary human cohort 
To date most studies have examined the effect of prenatal distress on the 
methylation status of HSD11B2, with limited studies investigating the effect at level 
of mRNA expression.  This goal of this work was to examine the prevalence and 
impact of prenatal distress on birth outcomes and placental gene expression in 
women receiving antenatal care at Cork University Maternity Hospital (CUMH).  
 
1.3.2 Establish a comprehensive study cohort to examine the multiple influences 
of prenatal distress  
In order to examine the effect of prenatal distress on the microbiome we aimed to 
establish a longitudinal study cohort of nulliparous healthy pregnant women at 
CUMH. We aimed to measure multiple variables of psychological distress and 
collect and biobank maternal stool and saliva samples at multiple times throughout 
pregnancy. Additionally we intended to acquire vaginal swabs, placental samples 
and newborn hair at birth and collect and biobank infant stool samples across the 
first 5 months of life. Data and samples collected from this cohort would provide a 
comprehensive database to examine the biological underpinnings of PNMD.  
 
1.3.3 Use this cohort to further understand how prenatal distress influences 
placental gene expression 
The current thesis will first use this second cohort to further examine the influence 
of PNMD on genes involved in glucocorticoid signalling in the placenta. This cohort 
will address previous limitations by exploring both psychological and physiological 
measures of stress at multiple time-points throughout pregnancy. 
 
1.3.4 Investigate the influence of prenatal distress on maternal gut, vaginal and 
infant gut microbiome development 
As the microbiome is emerging as important determinant of maternal and infant 
health we next sought to examine the influence of psychological and physiological 
readouts of stress on the maternal and infant gut microbiome. The current 
hypothesis from preclinical work suggests PNMD impairs the maternal gut and 
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vaginal microbiota and this stressed microbial signature is then transferred to the 
infant at birth. With this in mind the current thesis aims to explore this hypothesis 
in humans by examining the impact of PNMD on the maternal gut microbiome 
across pregnancy, the vaginal microbiome just prior to parturition and the infant 
microbiome as it is seeded and develops over the first 5 months of life.   
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Chapter 2:  
Materials and Methods 
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2.1.0 Cell culture   
All experiments involving cell culture were performed in a sterile laminar-flow Class 
II Microflow Biological Safety Cabinet under aseptic conditions. Materials used were 
purchased sterile or sterilized by autoclaving. Liquids were sterilized by passing 
them through a 0.20 µM polyethersulfone filter (Sigma). For all cell culture 
experiments JEG-3 cells (ATCC) were used as an in vitro model of placental 
trophoblast cells (Orendi et al., 2011). JEG-3 cells were stored in Dulbecco’s 
modified Eagle Medium Nutrient Mixture F-12 (DMEM F-12; Sigma), with 20% fetal 
calf serum (FCS; Sigma) and 10% dimethyl sulfoxide (DMSO; Sigma) in liquid 
nitrogen. Prior to use, cells were thawed and centrifuged at 500 rpm for 5 min. The 
supernatant was removed and the cells were resuspended in ‘growth media’ 
consisting of DMEM F-12 containing 100nM L-Glutamine (Sigma), 100U/ml 
penicillin (Sigma), 10µg/ml streptomycin (Sigma) and 10% FCS. The cells were then 
added to a T75 flask (VWR) with 20 ml of pre-warmed growth media and incubated 
at 37°C in a humidified atmosphere of 5% CO2 (ThermoForma Series II, Thermo 
Electron Corporation). Growth media was removed and replaced with fresh growth 
media every 48 h until 80-90% confluency was reached. 
 Once cells reached confluency, growth media was removed from the flask 
and the cells were washed in Hank’s Balanced Salt Solution (HBSS; Sigma) to 
remove any residual media. The cells were enzymatically dissociated by adding 2 ml 
of 0.2 % Trypsin (Sigma) to the cells and incubating for 5 min at 37°C. 2 ml of growth 
media was then added to the flask to neutralize the trypsin. The cell suspension was 
removed from the flask and placed in a 15ml conical flask (Sigma) and centrifuged 
at 500 rpm for 5 min. The supernatant was removed and the remaining cell pellet 
was resuspended in 1 ml of growth media. Mechanical dissociation was performed 
by triturating the cell suspension with a plugged flame polished Pasteur pipette 
(Sarstedt). A 1:10 dilution was made using growth media for cell counting. 10 µl of 
the diluted cell suspension was added to a haemocytometer (Marenfield Superior) 
and 5 grids were counted using the following formula:  
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Cells per ml =  
Number of cells counted x dilution factor (10) x haemocytometer constant (10000) 
Number of squares counted (5) 
 
Cells were then added to a T75 flask at a density of 1 x 106 cells with 20ml of 
growth media. For the thiazolyl blue tetrazolium bromide (MTT) assay, 
immunocytochemistry and RNA extraction, cells were seeded into 24-well tissue 
culture plates (VWR) at a density of 1 x 105, 3 x 104 or 1 x 105 cells/well respectively 
along with 500 µl of growth media. Plated cells were incubated at 37°C and 5% CO2 
for 24 h prior to treatment. On the day of treatment the growth media was 
removed and replaced with 500 µl of fresh pre-warmed growth media. Cells were 
treated with 1, 5 or 10 µM of MC1568, MS275 or SAHA (Selleckchem) for 24 h. 
Where indicated, 10ng/ml IL-1β (Promokine) or 2µM Cortisol (Santa Cruz) were 
added to the cells for 24 h prior to the HDAC inhibitor. 
 
2.1.1 MTT Assay   
To assess cell viability, MTT solution was made by dissolving MTT (Sigma) in HBSS to 
a final concentration of 0.5 mg/ml. The media was removed from the cells and 300 
µl of MTT solution was added per well. Following a 2 h incubation at 37°C and 5% 
CO2, the MTT solution was removed and 100 µl of DMSO was added to each well to 
lyse the cells. 75 µl of the DMSO solution was pipetted into a 96 well plate (VWR) 
and the absorbance of each sample was determined using a plate reader (Tecan 
sunrise) at a wavelength of 595nm with a reference wavelength of 630nm. 
 
2.1.2 Fixation, blocking and Immunocytochemistry   
At the experimental end point, the 24 well plates were removed from the incubator 
and the media was aspirated. 500 µl of ice-cold 4% paraformaldehyde (PFA) 
dissolved in 10mM phosphate buffered solution (PBS) was added to the cells and 
the plates were incubated at -20°C for 10 min. Following fixation, the PFA was 
removed and the cells were washed three times in 10mM PBS containing 0.02% 
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Triton X-100 (PBS-T) for 5 min. Cultures were incubated in a blocking solution of 5% 
bovine serum albumin (BSA; Sigma) in PBS-T for 1 h at room temperature. After 
blocking, the BSA solution was removed and the cells were incubated with 200 µl of 
the desired primary antibodies, which were diluted in 1% BSA in PBS-T at 4°C 
overnight. The following primary antibodies were used: rabbit HSD11B2 (1:250; 
Santa Cruz), rabbit AcH3 (1:250; Santa Cruz), rabbit GR (1:250; Santa Cruz) or rabbit 
IL1R1 (1:250; Invitrogen). Following primary antibody application the primary 
antibodies were removed and the cells were washed three times in PBS-T for 5 min. 
The cells were then incubated in 250 µl of Alexa Fluor 488 or 594, conjugated 
secondary antibodies (1:1000, Invitrogen) reactive to the species of the primary 
antibodies and diluted in 1% BSA in PBS, at room temperature for 2 h in the dark. 
The secondary antibodies were removed, and three 5 min PBS-T washes were 
carried out before cultures were counterstained with DAPI (1:3000; Sigma) diluted 
in PBS for 5 min at room temperature. The cells received a final three 5 min washes 
in PBS, and were stored in PBS at 4°C in the dark until imaged on an inverted 
fluorescent microscope (FV1000, Olympus) with AnalysisD™ software. Negative 
controls in which the primary antibody was omitted were also prepared. The 
fluorescence intensity of individual cells was measured using Image J analysis 
software (Rasband, WJ, http://rsb.info.nih.gov/ij/). The relative fluorescence 
intensity was calculated as the intensity of each individual cell after subtraction of 
the background noise. 
 
2.1.3 RNA Extraction  
RNA was extracted from JEG-3 cells or term human placental tissue (for placental 
tissue see collection and detailed extraction protocol below) using Trizol Reagent 
(Life Technologies). For RNA extraction from JEG-3 cells, media was removed and 
cells were washed in PBS. 50 µl of Trizol was added to each well and cells were 
incubated on ice for 10 min. Cells were removed from the plate by scraping and 
transferred into Eppendorf tubes (Sarstedt). 10 µl of chloroform (Sigma) was added 
to each sample at left at room temperature for 5 min, followed by centrifugation at 
12,000 rpm for 15 min at 4°C. The upper aqueous phase was transferred into fresh 
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Eppendorf tubes and 25 µl of propanol (Sigma) was added to each tube and were 
left at room temperature for 10 min. Samples were then centrifuged at 12,000 rpm 
for 10 min at 4°C. The supernatant was removed and the RNA pellet was washed in 
50 µl of ice-cold 70% ethanol. The sample was vortexed and centrifuged for a final 
time at 7,500 rpm for 5 min at 4°C. The supernatant was removed and the RNA 
pellet was left to air-dry for 15 min. The pellet was resuspended in 15 µl of RNAse 
free water (Sigma). RNA concentration in ng/µl was determined by using a 
Spectrophotometer (ND1000; NanoDrop Technologies, Inc). 
  
2.1.4 cDNA synthesis and real time Polymerase Chain Reaction (PCR) 
500 ng of RNA was reverse transcribed using a high capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) in a 20μl reaction mixture consisting of 2.0μl 
10× RT Buffer, 0.8μl 25× dNTP mix (100mM), 2.0μl 10× RT Random Primers, 1.0μl 
Reverse Transcriptase, and 4.2μl Nuclease-free H2O, using the following 
parameters: 25 °C for 10 min; 37 °C for 120 min; 85 °C for 5 min; 4 °C for at least 
10 min. The cDNA was stored at −80 °C prior to use. For real-time PCR, samples 
were run in triplicate using the following parameters 50 °C for 2 min; 95 °C for 
10 min; 50 repetitions of 95 °C for 15 s and annealing/elongating at 60 °C for 1 min. 
 
2.1.5 Immunohistochemistry   
Histological placental sections (6µM) were incubated in blocking solution (5% 
bovine serum albumin (BSA)) for 1 h at room temperature. Sections were treated 
with 10% H2O2 for 5 min, washed in 10 mM Phosphate Buffered Saline (PBS) and 
blocked for 1 h in 10% normal goat serum in 10 mM in PBS-T. Sections were 
incubated in primary antibody to HSD11B2 (1:250; Santa Cruz) in 1% normal goat 
serum in 10 mM PBS with 0.4% Triton-X overnight at 4°C. Following a 3 × 10 min 
wash in 10 mM PBS, sections were incubated with a biotinylated secondary 
antibody (1:200; Vector Labs) for 2 h at room temperature. Following another 
3 × 10 min wash in 10 mM PBS, sections were incubated in ABC solution (1:200; 
Vector Labs) for 45 min at room temperature followed by immersion in 
diaminobenzidine substrate/chromogen reagent for 2–3 min at room temperature. 
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Sections were dehydrated, cleared, mounted and imaged using an Olympus AX70 
Provis upright microscope.  
 
2.2.0 Participant recruitment (chapter 4) 
This study was carried out with full ethical approval from the Research Ethics 
Committee of Cork Teaching Hospital. Participants attending antenatal care at Cork 
University Maternity Hospital (CUMH), Cork, Ireland between July 2015 and 
September 2016 were invited to participate in this study.  The inclusion criteria 
were; 1) 18 years of age or older, 2) English speaking, 3) having a current singleton 
pregnancy and 4) plans to give birth in in the maternity hospital. The participants 
were recruited when they were greater than 28 weeks’ gestation. Written informed 
consent was obtained from all women who agreed to take part and participants 
were asked to complete a combination of questionnaires used to assess maternal 
distress (Khashan et al., 2014) and donate a small biopsy of their placenta following 
delivery. For placental collection a kit was inserted into the patients’ medical chart 
with written instructions for the midwives on the delivery ward. Detailed clinical 
and demographic data were collected from the medical notes of patients once the 
entire cohort had given birth. This data included information on maternal age, BMI, 
previous obstetric complications, previous psychiatric history, medical conditions, 
current obstetric complications, birthweight, gender, gestational age, Apgar score, 
birth temperature, neonatal resuscitation (if any), admissions to the Neonatal 
Intensive Care Unit (NICU) and mode of feeding on discharge from the hospital.  
 
2.2.1 Questionnaires 
This study used the 10-item Perceived Stress Scale (PSS). The PSS is a popular tool 
used to measure psychological stress and how individuals appraise stressful life 
events. Higher Scores on the PSS are indicative of a higher level of perceived stress. 
In this study, a score of greater than or equal to 20 was used as the cut-off for the 
‘high stress’ group. Maternal anxiety was measured using the 6-item version of 
State Trait Anxiety Inventory (STAI). The 6 item STAI is a frequently used brief 
psychological measure of anxiety and the 6 item version which has been validated 
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for use during pregnancy (Marteau and Bekker, 1992). As there are currently no 
recommended cut off scores for the STAI during pregnancy, women were deemed 
anxious if they scored in the top 25% of the cohort. Depressive symptoms were 
assessed using the Edinburgh Postnatal Depression Scale (EPDS). Consistent with 
previous studies, we used a score of 13 or greater to indicate a high probability of 
depression (Rubertsson et al., 2011, Cohen et al., 1983). These self-reported 
questionnaires are marked by a 4-point Likert Scale. In this study, the Cronbach’s 
alpha of the PSS, STAI and EPDS were 0.867, 0.838 and 0.894 respectively.  
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Figure 1: Timeline of recruitment for cohort 1 
 
 
Figure 1: Recruitment of third trimester pregnant women from Cork University 
Maternity Hospital proceeded through July 2015 to September 2015. The inclusion 
criteria were; 1) 18 years of age or older, 2) English speaking, 3) having a current 
singleton pregnancy and 4) plans to give birth in in the maternity hospital. Placental 
samples were collected and bio-banked until November 2015 when the final 
women in the cohort gave birth. Data collection from storage medical records and 
then commenced and finished in December 2015 closing the study collection phase.   
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2.2.2 Placental Collection 
Participants agreeing to donate their placenta had a ‘placental collection kit’ 
(Appendix A) inserted into their medical records. Midwives on the delivery ward 
were asked to place the placenta into a yellow biohazard bag (supplied) 
immediately after delivery and label this bag with a patient identifier.  The bag 
containing the placenta was placed into a collection bucket located on the delivery 
ward at room temperature. Midwives were then asked to contact Katie as soon as 
possible. All placental samples were collected from the delivery ward within 2 hours 
of delivery. The placenta was brought to the lab and placed on a sterile aluminium 
bench. The placenta was cleaned with sterile water and the membranes and 
umbilical cord were removed.  Placental weight was measured in kg. 5 cross-
sectional samples were randomly excised from each placenta to incorporate both 
the maternal and fetal sides. The samples were washed in dH2O and immediately 
stored at -80 °C for further analysis.  
 
2.2.3 RNA extraction, cDNA synthesis and PCR 
RNA was extracted from placental samples using the Trizol method as per the 
manufacturer’s instructions. Briefly, placental sample was homogenised in 3 ml of 
Trizol reagent and left on ice for 10 minutes. Samples were centrifuges at 4°C from 
5 minutes and 1 ml of the supernatant was transferred into a new Eppendorf. 200ul 
of chloroform was added, mixed and left at room temperature for 3 minutes. The 
sample was centrifuged at 4°C 12000g for 15 min. The upper clear aqueous phase 
was removed and placed in a new 1.5ml Eppendorf, 500ul of isopropanol was 
added and left at room temperature for 10 min. The sample was centrifuged at 4°C 
12000g for 10 min. The supernatant was removed and the pellet was washed in 1 
ml of 70% ethanol. The sample was centrifuged, supernatant removed and the 
pellet was left to air dry and re-suspended in 70ul of RNase free H20. RNA 
concentration and quality was assessed using the Nanodrop 8000.  500 ng of 
placental RNA was reversed transcribed using the high capacity cDNA reverse 
transcription kit (Applied Biosystems) using the following parameters 25 °C for 
10 min; 37 °C for 120 min; 85 °C for 5 min; and held at 4 °C until storage at 80 °C. 
Real time PCR was performed for HSD11B2 under the following cycling parameters; 
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50 °C for 2 min; 95 °C for 10 min; 50 repetitions of 95 °C for 15 s and 
annealing/elongating at 60 °C for 1 min. All samples were run in duplicate, cycle 
threshold values were recorded and analysis was performed using the 2−ΔΔcycle 
threshold method (Livak and Schmittgen, 2002).  
 
2.3.0 Participant recruitment for the SMArTI Study 
The SMArTI (stress microbial transfer to the Infant) study was carried out with full 
ethical approval from the Research Ethics Committee of Cork Teaching Hospital 
(Appendix A). Patients participating in the IMPROvED study at CUMH between 
October 2014 and August 2015 were invited to take part in SMArTI.  Exclusion 
criteria for the IMPROvED study can be found at (Navaratnam et al., 2013). Women 
were referred to SMArTI from midwives working on the IMPROvED study or 
through posters and advertisements (Appendix A). Women who were approached 
to participate but declined were noted to produce recruitment estimates. All 
patients participating must agree to provide 1) questionnaires for at least one visit 
2) saliva samples for at least one visit, 3) vaginal swab at birth (if vaginal delivery) 
and 4) fecal samples from their infant for as many time points as possible (see 
Figure 2 for breakdown of visits). Maternal fecal specimens, placenta and newborn 
hair samples were optional. For full study protocol see Appendix A. Detailed clinical 
and demographic data were collected from the IMPROvED database once the entire 
cohort had given birth. Additionally participants were asked about the mode of 
feeding of their infant when providing infant fecal samples. Details on postnatal 
maternal and infant antibiotic use and diagnosis of colic was also collected.  
 83 
 
Figure 2: Flowchart of SMArTI visits 
 
Figure 2: Flowchart of participant visits for the SMArTI study 
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Figure 3: Timeline of SMArTI study 
 
Figure 3: Timeline and overview data collected during the SMArTI study. This study 
began in August 2014 with the final sample collected in July 2016. Analysis of data 
and samples began thereafter.  
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2.3.1 Questionnaires 
Questionnaires were completed by participants online using Survey Monkey 
(https://www.surveymonkey.com/). As well as the PSS, STAI and EPDS as used in the 
pilot study participants completed the Pregnancy Distress Questionnaire (PDQ), 
Pittsburgh Sleep Quality Index (PSQI), Childhood Trauma Questionnaire (CTQ), an 
IBS Severity Questionnaire, Food Frequency Questionnaire (FFQ) and a Food 
Knowledge Questionnaire (FKQ) (Appendix A). The mean gestational age at which 
the surveys were completed were 15.62 ± 0.136, 20.30 ± 0.087 and 32.67 ± 0.125.  
 
Perceived Stress Scale 
This study used the 10-item PSS. The PSS is a popular tool used to measure 
psychological stress and how individuals appraise stressful life events. Higher Scores 
on the PSS are indicative of a higher level of perceived stress (Cohen et al., 1983). In 
the SMArTI cohort a PSS score below or above the cohort mean was used to 
indicate low and high stress respectively. For both the second and third trimester 
PSS < 13 indicated low stress and PSS > 14 indicated high stress (Appendix A).  
 
State Trait Anxiety Inventory 
Maternal anxiety was measured using the 6-item version of STAI. The 6 item STAI is 
a frequently used brief psychological measure of anxiety and the 6 item version 
which has been validated for use during pregnancy (Marteau and Bekker, 1992). In 
the SMArTI cohort a STAI score below or above the cohort mean was used to 
indicate low and high anxiety respectively. . For both the second and third trimester 
STAI < 4 indicated low anxiety and STAI > 5 indicated high anxiety (Appendix A). 
 
Edinburgh Postnatal Depression Scale 
Depressive symptoms were assessed using the EPDS. For both the second and third 
trimester EPDS < 8 was used to indicated low depressive symptomology and EPDS > 
9 was used to indicate high depressive symptomology (Appendix A). 
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Pregnancy Distress Questionnaire (PDQ) 
The PDQ is a short questionnaire that measures any stress and anxiety specific to 
pregnancy (Alderdice et al., 2013) (Appendix A). 
 
Pittsburgh Sleep Quality Index (PSQI) 
The present study used the PSQI to assess sleep quality across pregnancy. The PSQI 
consists of 19 items which are then grouped into seven components; subjective 
sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep 
disturbances, sleep medications and daytime dysfunction (Buysse et al., 1989). Each 
score is weighted on a 0-3 scale and summed to form a global PSQI score. A PSQI 
global score < 5 is indicative of good sleep quality, whereas a global PSQI score of ≥ 
5 indicates poor sleep quality (Tsai et al., 2016) (Appendix A). 
 
Childhood Trauma Questionnaire (CTQ) 
114 participants completed the 28-item version of CTQ during their pregnancy. The 
CTQ assesses 5 scales of childhood maltreatment; physical abuse, emotional abuse, 
sexual abuse, physical neglect and emotional neglect (Bernstein et al., 2003).  The 
measure includes a three-item Minimization/Denial scale indicating the potential 
underreporting of maltreatment. Participants respond to each item in the context 
of “when you were growing up” and answer according to a five-point Likert scale 
ranging from “never” = 1 to “very often” = 5, producing scores of 5 to 25 for each 
trauma subscale. The three items comprising the Minimization/Denial scale are 
dichotomized (“never” = 0, all other responses = 1) and summed; a total of one or 
greater suggests the possible underreporting of maltreatment (Appendix A). 
 
IBS Severity Questionnaire 
To measure gastrointestinal function we used the Rome III criteria for assessing 
gastrointestinal function (Ford et al., 2014) (Appendix A). 
 
Food Frequency Questionnaire (FFQ) and Food Knowledge Questionnaire (FKQ) 
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Food intake over the course of pregnancy was measured using the FFQ. Additionally 
participants’ knowledge on their food intake was assess by the FKQ (Appendix A). 
 
2.3.2 Sample Collection and Storage  
Maternal fecal samples 
Participants were provided with ‘at home’ sample collection kits (Appendix A) and 
asked to collect the fecal samples at home, as close as possible to the time of their 
next SMArTI study appointment. The collection kits contained disposable gloves, a 
plastic container with an AnaeroGen sachet (Thermo Fisher Scientific) attached to 
the inside lid, disposable gloves, a zip lock bag and an envelope (Appendix A). 
Participants were instructed to put on the gloves, place the opened plastic 
container inside the toilet bowl and preform a bowel movement into the container. 
Participants were asked to tear the top of the AnaeroGen sachet open and firmly 
secure the lid of the container. The container was then placed into the zip lock bag 
and sealed in the envelope. The date and time of sample collection was noted on 
the envelope and participants were ask to keep the samples as cool as possible until 
bringing it with them to their SMArTI appointment at CUMH. Once acquired, 
samples were immediately aliquoted into five Eppendorf tubes in a Microflow 
Biological Safety Cabinet and stored at -80°C.  
 
Maternal saliva samples  
Participants were provided with ‘at home’ saliva collection kits (Appendix A) and 
asked to collect the saliva samples at home, the morning of, or before their SMArTI 
study appointment. To avoid contamination, participants were asked to abstain 
from brushing their teeth until all samples had been collected, and to abstain from 
eating for at least 30 minutes prior to collecting the samples. Participants were 
instructed to keep the saliva samples as cool as possible until bringing them to their 
appointment. Saliva collection kits consisted of 4 Salivettes (Sarstedt) in a zip-lock 
bag. Saliva samples were collected 1) immediately upon waking, 2) 30 min after 
waking, 3) 1 h after waking and 4) 3 h after waking. For each sample participants 
were asked to remove the lid of the Salivette tube and tip the ‘bud’ into their 
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mouth without using their hands. Participants were asked to chew the bud for 1-2 
min and transfer the bud directly back into the Salivette tube without touching. The 
Salivette tube was labelled with the time and date, placed in the zip lock bag and 
kept cool until their appointment at CUMH. Once acquire, Salivette tubes were 
centrifuged for at 5000 rpm for 5 min at 4°C and each sample was aliquoted into 2x 
Cryovials and stored at -80°C.   
 
Vaginal Swab and placental samples 
Participants agreeing to these samples had a collection kit containing sterile swabs 
(Epicentre) and a biohazard bag inserted into their medical notes (Appendix A). 
Midwives in the delivery ward were asked to collect these samples. Vaginal swabs 
were collected after the patients consent when admitted to the delivery ward. A 
sterile swab was inserted into the vagina and turned a couple of times before being 
removed and sealed into its plastic tube. The tube containing the swab was then 
sealed in a zip lock bag and labelled with a patient identifier before being stored at 
4°C. Vaginal swabs were collected from the delivery ward every day and stored at -
80°C. Placental collection proceeded as per section 2.2.2.  
 
Newborn hair 
All participants were visited in CUMH within 24 hours after birth. Mothers were 
asked to donate a small sample of newborn hair from their infant. For infants 
whose mothers consented, a small section of hair was cut from the newborns head, 
as close to the scalp as possible and immediately placed in aluminium foil. Hair was 
stored at room temperature until processing. 
 
Infant fecal samples 
All women in the study were provided with collection kits containing sterile 
collection tubes with scoops (Sarstedt), zip lock bags and envelopes (Appendix A). 
Participants were asked to collect infant fecal samples at 1 week (w), 2 w, 2w, 3 
months (m) and 5 m. Participants received a SMS reminder the evening before and 
morning of sample collection.  When a dirty nappy was produced mothers were 
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asked to collected fecal matter with the scoop and seal in the sterile tube. The 
tubes were labelled with time and date, placed into the zip lock bag and kept as 
cool as possible. Participants were asked to contact Katie as soon as possible once 
the sample was collected and collection from the participants home was arranged 
immediately. Samples were transported on ice to CUMH. Samples were aliquoted 
into Eppendorf tubes in a Microflow Biological Safety Cabinet and stored at -80°C. 
Sample collection and freezing time were noted.  
 
2.4 Cortisol Concentration 
On the day of processing, samples were thawed on ice and cortisol concentration 
was determined by Enzyme linked immunosorbent Assay (ELISA) according to the 
manufactures instructions (Enzo Life Sciences). Prior to use reagents were brought 
to room temperature.  Assay buffer solution was prepared by pipetting 5 ml of 
assay buffer 45 ml of dH2O (1:10). Wash buffer solution was made by pipetting 
10ml of wash buffer into 190 ml of dH2O (1:20).  The cortisol standard (100, 00 
pg/ml) was diluted in assay buffer to produce a standard curves of concentrations 
0, 156, 313, 625, 1250, 2500, 5000, 10 000 pg/ml. Once fully thawed saliva samples 
were vortexed and diluted in Assay buffer solution (1:3) to a final volume of 240 µl. 
100 µl of assay buffer was pipetted into the NSB and B0 wells. Samples were 
vortexed and 100 µl of each sample was pipetted into the appropriate wells of the 
plate. 100 µl of standards was pipetted into the appropriate wells. All samples and 
standards were run in duplicate. 50 µl of blue conjugate was added to each well 
except the TA and Blank wells. 50 µl of yellow conjugate was pipetted into each 
well except the blank, TA and NSB well. The plate was sealed and incubated at room 
temperature for 2 h on a shaker at 500 rpm. After the incubation, the contents of 
the wells was emptied and the wells were washed with 400 µl of wash solution 
three times. The wells were emptied and dried. 5 ml of blue conjugate was added 
to the TA wells. 200 µl of pNpp substrate was pipetted into each well. The plate was 
covered with aluminium foil and left at room temperature. After 1 h, 50 µl of stop 
solution was added to each well and the plate was immediately read at 405 nm 
using the Varioskan Flash Instrument 4.00.51. Blank measurements were 
 90 
 
subtracted and a four parameter logistic calibrator curve was constructed of the 
standards to determine cortisol concentration in each sample using the SkanIt 
Software (2.4.3 RE for Varioskan Flash). CV values were also recorder (%).  
 
2.5 DNA Extraction from Maternal Fecal Samples 
DNA was extracted from the maternal fecal samples using the Qiagen DNA stool 
Mini Kit in a sterile laminar-flow Class II Microflow Biological Safety Cabinet. Prior to 
use AW1 and AW2 buffer was prepared by adding 25 ml and 30ml of 100% 
molecular grade EtOH (Sigma) to each buffer respectively. Fecal samples were 
thawed on ice and 0.2 g of faeces was added to 1 ml Qiagen Lysis Buffer in a 2 ml 
screw cap tube containing a mix of 0.1 mm, 2.0 mm, 2.3 mm and 3.5 mm sterile 
zirconia beads (Thistle Scientific). The sample was homogenised for 90 seconds 
using the MagnaLyser Instrument (Roche) and incubated at 90 °C for 5 min. 
Samples were centrifuged at 16,000 g for 2 min and the supernatant was removed 
and transferred to a fresh 2 ml Eppendorf tube and placed on ice.  500 µl of Qiagen 
lysis buffer was added to the 2 ml screw cap tubes containing the pellet and the 
sample was homogenised again for a further 90 seconds using the MagnaLyser, 
followed by a 5 minute incubation at 90°C and centrifugation . The supernatants 
were then pooled and an InhibitEX tablet was added and vortexed until completely 
dissolved.  Samples were centrifuged at 16,000 g for 2 min and the supernatant was 
removed.  200 µl of the supernatant was added to a new 1.5 ml Eppendorf 
containing 15 µl of Proteinase K and 200 µl of Buffer AL. The samples were vortexed 
briefly and incubated at 70 °C for 10 minutes. Following incubation the complete 
lysate was removed and placed in a QIAamp spin column. The column was 
centrifuged at 16 000 f for 1 min. The supernatant was discarded and the column 
was placed in a new 2 ml collection tube. 500 µl of AW1 buffer was added and the 
column was centrifuged at 16 000 g for 2 min. The supernatant was discarded and 
the column was again placed in a new 2 ml collection tube and 500 µl of AW2 buffer 
was added before centrifugation for 3 min at 16 000 g. The column was placed in a 
new collection tube and centrifuged for a further 1 min at 16 000g to remove any 
buffer carryover. The collection tube was discarded and the column was placed into 
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a new 1.5 ml Eppendorf tube. 200 µl of AE buffer was added and the sample was 
left the sit at room temperature for 2 min. The column underwent a final 
centrifugation at 16 000 g for 1 min to elute the DNA. Extracted DNA quantity 
(ng/ml) and quality (280/280) was determined using the Nanodrop 1000 and elutes 
were stored at -80 °C.  
 
2.6 DNA Extraction from Infant Samples 
Microbial DNA was extracted from 0.2 g stool samples using the Repeat Bead 
Beating method described by Yu and Morrison (Yu and Morrison, 2004), with some 
modifications. Lysis buffer was prepared to a desired concentration of 1M Sodium 
Chloride (NaCl), 500mM Tris hydrochloride (Tris-HCL), 500mM 
Ethylenediaminetetraacetic acid and 13% SDS in dH2O. Infant fecal samples were 
thawed on ice and 0.2 g of faeces was added to 1 ml Qiagen Lysis Buffer in a 2 ml 
screw cap tube containing a mix of sterile zirconia beads (described section 2.6). 
The tubes were sealed and homogenised for 90 seconds (MagnaLyser). Samples 
were removed and cooled on ice for 60 seconds before another 90 seconds of 
homogenisation. Samples were incubated at 70 °C for 15 minutes. Samples were 
centrifuged at 16,000 g for 2 min, the supernatant was removed and placed in an 
Eppendorf on ice. 200 µl of lysis buffer was added to the remaining pellet. The 
tubes were homogenised again for 90 s in the MagnaLyser, followed by a 60 s 
incubation on ice and another 90 s in the MagnaLyser. Samples were heated at 70 
°C for 15 min and centrifuged for 2 min at 16,000 g. The supernatant was removed 
and pooled with the supernatant form the first homogenisation. 260 µl of 10M 
ammonium acetate (Sigma) was added to the pooled supernatant and placed on ice 
for 5 min. The samples were centrifuged at 16,000 g for 10 min at 4°C. The 
supernatant was pipetted into 2 x 1.5 ml Eppendorf tubes and 250 µl of isopropanol 
(Sigma; molecular grade) was added to precipitate the nucleic acids and left on ice 
for a further 30 min. The sample was centrifuged for 10 min at 16,000g at 4°C. The 
supernatant was removed and the nucleic acid pellet was washed in 350 µl of 70% 
EtOH. Sample were vortexed and centrifuged for 5 min at 16,000 g at 4 °C. The 
supernatant was removed and discarded at the pellet was allowed to air-dry for 10 
min followed by resuspension in 100 µl of TE buffer (Sigma). For purification, 1.5 µl 
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of DNase free RNase was added to each sample and left at 37 °C for 15 min. The 
duplicate samples were pooled and 15 µl of proteinase K (Qiagen) and 200 µl of AL 
buffer (Qiagen) were added. The mix was vortexed and incubated at 70 °C for 10 
min.  The samples were incubated wit 200 µl of 100 % EtOH, vortexed and 
transferred to a QIAamp spin column. Samples were cleaned with AW1 and AW2 
(Qiagen) buffer as described in section 2.6. DNA was dissolved in 150 µl of AW 
buffer. Extracted DNA quantity (ng/ml) and quality (280/280) was determined using 
the Nanodrop 1000. DNA was separated into two 75 µl aliquots and stored at -80 
°C.  
 
2.7 DNA extraction from vaginal Samples 
Collected swabs were removed from -80°C and immediately placed in a 2ml screw 
cap tube containing zirconia beads (as described above) with 1 ml of lysis buffer 
(described in Section 2.7). Samples were left at room temperature for 20min. A 
spatula was used to drain residual liquid from the swab and the swab was 
discarded. The tubes were sealed and homogenised for 90 seconds (MagnaLyser). 
Samples were removed and cooled on ice for 60 seconds before another 90 
seconds of homogenisation. Samples were incubated at 70 °C for 15 minutes. 
Samples were centrifuged at 16,000 g for 2 min, the supernatant was removed and 
placed in an Eppendorf on ice. 200 µl of lysis buffer was added to the remaining 
pellet. The tubes were homogenised again for 90 s in the MagnaLyser, followed by a 
60 s incubation on ice and another 90 s in the MagnaLyser. Samples were heated at 
70 °C for 15 min and centrifuged for 2 min at 16 000 g. The supernatant was 
removed and pooled with the supernatant form the first homogenisation. DNA 
extraction proceeded as outlined above in Section 2.6.  
 
2.8 16S rRNA Sequencing Library Preparation  
Extracted DNA samples were quantified using the Nanodrop 1000TM and stored at -
80 °C until amplification. Preparation of samples for 16S Metagenomics Sequencing 
was done according to the manufactures instructions (Illumina). DNA was amplified 
to the V4 region of the bacterial 16S rRNA under the following parameters; 95°C for 
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3 min, 25 cycles of 95°C for 30 sec, 55°C for 30 sec and 72°C for 30 sec and finally 
72°C for 5 min before being held at 4°C. The PCR product was cleaned using 
AMPure XP beads and 5µl of supernatant was transferred to a new PCR plate where 
PCR was performed with Nextera XT index primers under the same conditions as 
mentioned above. The product was cleaned again using AMPure XP beads and the 
final product was analysed on a Bioanalyser DNA 1000 chip for quality assurance 
(size ~630bp). Samples were diluted and sequenced by the Miseq Illumina System 
(See Figure 4).  
 
2.9 Newborn hair sample Preparation 
1mg of hair was suspended in 1 ml of methanol in a 2ml Eppendorf tube. The hair 
was incubated at 50°C for 24 h. Following incubation samples were placed on the 
sonicator for 30 min at 37 °C followed by another 24 h at 50°C. After incubation the 
supernatant was removed and placed in a clean 2 ml Eppendorf. The supernatant 
was evaporated under nitrogen until completely dry and the pellet was 
resuspended in 220ul of PBS. Cortisol concentration was determined using the 
ENZO ELISA kit as described in section 2.5, without diluting the samples.  
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Figure 4: Process from fecal sample collection to microbiome bioinformatics.  
 
Figure 4: Microbiome work-package form stool sample to data analysis. DNA is extracted 
from stool samples, amplified against the V4 region of the 16S gene followed by Miseq 
Illumina sequencing. Bioinformatics preformed to determine the impact of the composition 
and diversity of microbiome on health. 
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2.10 Statistical analysis 
For chapter 3, where appropriate, unpaired students t-test and one-way ANOVAs 
with Tukey post-hoc were used for statistical analysis. Data were deemed 
significant when p < 0.05. Data analysis was performed using Graphpad prism 5. For 
chapter 4, data analysis was performed using Graphpad prism 5 and SPSS version 
22. Participants with greater than 3 missing values in their questionnaire were 
removed. Participants were also removed when medical records were unavailable. 
Kolmogorov-Smirnov tests were used to test for normality. Birthweight, birthweight 
centiles and placental weight ratios were normally distributed and analysed using 
an unpaired student t-tests or one-way ANOVA with Tukey's post hoc testing. 
Placental weight, Apgar scores and birth temperature displayed a non-normal 
distribution, therefore non parametric tests were used. Binary logistics regression 
with 95% confidence intervals were used to analysis nominal data. Multivariate 
data was analysis by ordinal logistic regression. Analysis was adjusted for maternal 
age, social class and BMI where indicated. Data were deemed significant if p < 0.05. 
For chapter 5 data analysis was performed using SPSS v22 and RStudio 3.4.1. 
Normality was tested using Kolmogorov-Smirnov tests. Data were deemed not 
normal when p < 0.05.  Outliers were identified using a Grubbs test. Relationships 
were determined using linear regression analysis and were adjusted for maternal 
BMI where indicated. For chapter 6, data analysis was performed using RStudio 
3.4.1 and SPSS v22. Kolmogorov-Smirnov tests were used to test for normality. α-
diversity was normally distributed and was analysed using unpaired Student’s t-
tests. Phyla, Family and Genus measures were not normal and were subsequently 
analysed by Mann Whitney U-tests. As scoring in maternal distress questionnaires 
did not correlated with maternal salivary cortisol we treated these as independent 
variables. This resulted in a total of 8 predictor variables, stress (PSS), anxiety (STAI), 
depressive symptoms (EPDS), and maternal cortisol measurements from the second 
and third trimester. Only vaginally delivered infants were included in analysis 
involving infant samples. Newborn cortisol levels were not normally distributed and 
were therefore log transformed prior to analysis. The relationship between 
newborn cortisol and α-diversity of the infant gut was subsequently determined by 
linear regression analysis.  Data were significant if p < 0.05.   
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3.1 Abstract: 
Exposure to maternal cortisol plays a crucial role in fetal organogenesis. However, 
fetal overexposure to cortisol has been linked to a range of short- and long-term 
adverse outcomes. Normally, this is prevented by the expression of an enzyme in 
the placenta called 11-beta hydroxysteroid dehydrogenase type 2 (HSD11B2) which 
converts active cortisol to its inactive metabolite cortisone. Placental HSD11B2 is 
known to be reduced in a number of adverse pregnancy complications, possibly 
through an epigenetic mechanism. As a result, a number of pan-HDAC inhibitors 
have been examined for their ability to promote HSD11B2 expression. However, it 
is not known if the effects of pan-HDAC inhibition are a general phenomenon or if 
the effects are dependent upon a specific class of HDACs. Here, we examined the 
ability of pan- and class-specific HDAC inhibitors to regulate HSD11B2 expression in 
JEG3 cells. We find that pan-, class I, or class IIa HDAC inhibition promoted HSD11B2 
expression and prevented cortisol or interleukin-1β-induced decrease in its 
expression. These results demonstrate that targeting a specific class of HDACs can 
promote HSD11B2 expression in JEG3 cells. This adds to the growing body of 
evidence suggesting that HDACs may be crucial in maintaining normal fetal 
development. 
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3.2 Introduction: 
The glucocorticoid hypothesis proposes that overexposure of the fetus to 
glucocorticoids may produce long lasting effects on fetal development that 
subsequently increase disease risk later in life (Reynolds, 2013). The glucocorticoid 
hypothesis is affirmed by studies that have shown that elevated maternal cortisol is 
associated with heightened HPA activity (Davis et al., 2011) and alterations in brain 
structure (Buss et al., 2012a) in affected offspring. At the core of this process is the 
placental enzyme 11β-hydroxysteroid dehydrogenase type 2 (HSD11B2), an enzyme 
that is expressed primarily within the syncytiotrophoblast of the placenta where it 
catalyses the conversion of active cortisol into its inactive product cortisone 
thereby controlling the levels of cortisol that reach the fetus (Chapman et al., 2013). 
A number of preclinical and clinical studies have demonstrated a reduction in the 
placental expression of HSD11B2 following exposure to prenatal stress (Jensen 
Pena et al., 2012), anxiety (Conradt et al., 2013) and following maternal infection 
(Straley et al., 2014). In addition to this, placental HSD11B2 mRNA levels are 
reduced in pregnancy complications such as preeclampsia, (Hu et al., 2014) 
intrauterine growth restriction (IUGR), (Dy et al., 2008) preterm birth (PTB) 
(Kajantie et al., 2003) and low birth weight (LBW) (Mericq et al., 2009). 
A complex repertoire of molecular pathways has been shown to be involved 
in regulating placental HSD11B2 expression. Inhibition of the mitogen-activated 
protein kinases (MAPK), ERK1/2 increases HSD11B2 expression (Guan et al., 2013), 
whilst supressing p38 reduces HSD11B2 activity (Sharma et al., 2009). HSD11B2 is 
increased by activation of peroxisome proliferator-activated receptor delta (PPARδ) 
(Julan et al., 2005) through recruitment of the SP1 transcription factor (TF) (He et 
al., 2014). Similarly, activation of the hedgehog signalling (Zhu et al., 2016) and 
forskolin-induced activation of the cyclic AMP (cAMP) pathway increases HSD11B2 
expression (Ni et al., 2009). More recently epigenetic mechanism have been linked 
to HSD11B2 regulation. The most widely studied epigenetic mechanisms are DNA 
methylation and histone acetylation. Histone acetylation is regulated by histone 
acetyl transferase (HATs) and histone deacetylase (HDACs) enzymes. HATs add 
acetyl groups onto the N-terminal tail of histone proteins which increases gene 
expression (Yang, 2004). HDACs remove them thereby repressing transcription 
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(Murakami, 2013). In humans 18 HDACs have been discovered and they are classed 
into four main families; class I (HDAC 1, 2, 3 and 8), class II (HDAC 4, 5, 6, 7, 9 and 
10), class III (SIRT1, 2, 3, 4, 5, 6 and 7) and class IV (HDAC 11) (Brandl et al., 2009).  
Recently a significant emphasis has been placed on in vitro studies to tease 
apart the precise epigenetic mechanisms involved in regulating placental HSD11B2 
expression.  Global knock down of DNA methylation using the demethylating agent 
5-aza-2'-deoxycytidine (5-aza) in JEG-3 cells has been shown to increase the 
expression of a number steroidogenic genes including HSD11B2, indicating a direct 
link for regulation of HSD11B2 expression by methylation (Hogg et al., 2014). 
Despite advancements being made in understanding the role of methylation in 
HSD11B2 expression, little focus has been placed on examining the role that HDACs 
play in regulating HSD11B2. The present study aimed to investigate the role of 
histone acetylation in regulating basal and stressor-induced changes in HSD11B2 
protein expression in an in vitro placenta model using small molecule 
pharmacological inhibitors.  
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3.3 Methods: 
3.3.0 Cell Culture and Treatment 
JEG-3 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM):F12 
(Sigma), with 10% foetal calf serum (FCS), 100nM L-Glutamine, 100U/ml penicillin 
and 10µg/ml streptomycin (Sigma). Cells were maintained at 37°C in a humidified 
atmosphere of 5% CO2. 50,000 cells per well were plated on a 24 well plate and 
were treated with 1, 5 or 10 µM of MC1568, MS275 or SAHA (Selleckchem). Where 
indicated, 10ng/ml interleukin-1β (IL-1β; Promokine) or 2µM Cortisol (Cort; Santa 
Cruz) were added for 24 h before HDAC inhibitor (HDI). 
 
3.3.1 MTT Assay 
To assess cell viability, a thiazolyl blue tetrazolium bromide (MTT) solution was 
added to the cells at a concentration of 1mg/ml in HBSS (Sigma). Following a 2 hour 
(h) incubation at 37°C, the cells were lysed in DMSO (Sigma). Absorbance was 
measured at a wavelength of 540nm with a reference wavelength of 630nm. 
 
3.3.2 Immunocytochemistry 
At the experimental end point, cultures were fixed in 4% paraformaldehyde (PFA) in 
PBS for 10 min. Following 3 × 5min washes in 10mM PBS containing 0.02% Triton X-
100 (PBS-T), cultures were incubated in blocking solution (5% BSA in PBS-T) for 1 h 
at room temperature. Where indicated cultures were incubated in the following 
primary antibodies; HSD11B2 (1:250; Santa Cruz), AcH3 (1:250; Santa Cruz), GR 
(1:250; Santa Cruz) or IL1R1 (1:250; Invitrogen) diluted in 1% BSA in 10mM PBS at 4 
°C for 16h. Following 3 × 5min washes in PBS-T, cells were incubated in the 
appropriate Alexa Fluor 488- or 594-conjugated secondary antibodies (1:1000; 
Invitrogen) diluted in 1% BSA in 10mM PBS at room temperature for 2 h. Cultures 
were counterstained with DAPI (1:3000; Sigma). Cells were imaged under an 
Olympus IX70 inverted microscope with Olympus DP70 camera and AnalysisD™ 
software.  
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3.3.3 RNA Extraction and Real-Time PCR 
RNA was extracted from JEG-3 cells 24 hours after seeding and term human 
placental tissue using Trizol Reagent (Life Technologies). Placental tissue was 
homogenised with a pestle and mortar and JEG-3 cells were removed from flasks by 
scraping, and incubated in Trizol for 10 min and RNA extraction proceeded 
according to the manufacturers’ instructions.  500 ng of RNA was reverse 
transcribed using a high capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) in a 20μl reaction mixture consisting of 2.0μl 10× RT Buffer, 0.8μl 25× 
dNTP mix (100mM), 2.0μl 10× RT Random Primers, 1.0μl Reverse Transcriptase, and 
4.2μl Nuclease-free H2O, using the following parameters: 25 °C for 10 min; 37 °C for 
120 min; 85 °C for 5 min; 4 °C for at least 10 min. The cDNA was stored at −80 °C 
prior to use. For real-time PCR, samples were run in duplicate using TaqMan® Gene 
Expression Assay (Applied Biosystems) for HSD11B2 using 18S as a reference gene 
under the following parameters; 50 °C for 2 min; 95 °C for 10 min; 40 repetitions of 
95 °C for 15 s and annealing/elongating at 60 °C for 1 min. 
 
3.3.4 Immunohistochemistry 
Histological placental sections (6µM) were incubated in blocking solution (5% 
bovine serum albumin (BSA)) for 1 h at room temperature. Sections were treated 
with 10% H2O2 for 5 min, washed in 10mM Phosphate Buffered Saline (PBS) and 
blocked for 1 h in 10% normal goat serum in 10mM PBS with 0.4% Triton-X. 
Sections were incubated in primary antibody to HSD11B2 (1:250; Santa Cruz) in 1% 
normal goat serum in 10mM PBS with 0.4% Triton-X overnight at 4°C. Following a 
3 × 10 min wash in 10mM PBS, sections were incubated with a biotinylated 
secondary antibody (1:200; Vector Labs) for 2 h at room temperature. Following 
another 3 × 10 min wash in 10mM PBS, sections were incubated in ABC solution 
(1:200; Vector Labs) for 45 min at room temperature followed by immersion in 
diaminobenzidine substrate/chromogen reagent for 2–3 min at room temperature. 
Sections were dehydrated, cleared, mounted and imaged using an Olympus AX70 
Provis upright microscope.  
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3.3.5 Statistical Analysis 
For real time PCR, expression levels were calculated using the 2 delta Ct threshold 
method (Schmittgen and Livak, 2008). For immunocytochemistry the fluorescence 
intensity of individual cells that were immunopositive for HSD11B2 or AcH3 were 
measured by densitometry using Image J analysis software (Rasband, WJ, 
http://rsb.info.nih.gov/ij/). The relative fluorescence intensity of HSD11B2 or AcH3 
was calculated as the average fluorescence intensity after subtraction of the 
background noise. Data was analysed using GraphPad Prism v 5 (GraphPad 
Software Inc, San Diego, California). Where indicated data was analysed (as per 
section 2.3) with unpaired Student’s t-test or one-way ANOVA with Tukey’s post-
hoc testing. Values of p < 0.05 were considered statistically significant.   
 103 
 
3.4 Results: 
3.4.0 Distribution of HSD11B2 in the Human Placenta and JEG-3 Cells 
We utilized the BioGPS database, an online platform that enables the examination 
of relative levels of gene expression across multiple human tissues (Wu et al., 
2009).  Using this directory we confirmed the highest levels of HSD11B2 in the 
placenta, followed by the kidneys, with very little expression seen in other tissues 
(Fig. 1a), which was confirmed by immunohistochemistry on human term placental 
samples (Fig. 1c). We next aimed to validate the use of the human choriocarcinoma 
cell line, JEG-3 cells. JEG-3 cells are a widely used in vitro model of placental 
trophoblast cells and have previously been demonstrated to be an abundant source 
of endogenous HSD11B2 (Alikhani-Koopaei et al., 2004, Tremblay et al., 1999). In 
agreement with this, real-time PCR confirmed the expression of HSD11B2 mRNA in 
JEG-3 cells, with placental RNA used as positive control (Fig. 1b). 
Immunohistochemical staining preformed 24 hours after seeding also confirmed 
abundant expression of expression of HSD11B2 protein in JEG-3 cells (Fig. 1d).   
 
3.4.1 Pan-HDAC Inhibition Increases HSD11B2 Expression in JEG-3 Cells 
HDACs can be divided into four distinct families, of particular interest are class I 
(HDAC1, 2, 5, 8) and class II (HDAC5, 6, 7, 9 and 10) HDACs (Haberland et al., 2009). 
We used the BioGPS database to examine the relative expression levels of these 
different HDACs in the human placenta. Class I and class II HDACs were widely 
expressed in the placenta (Appendix B, Supplementary Fig. 1), however HDAC1 
(Class I) and HDAC5 (Class IIa) had the highest relative levels of expression in the 
placenta compared to other tissues (Fig. 3a, e).  Given the widespread expression of 
HDACs, we next sought to determine the effect of global HDAC inhibition on 
placenta HSD11B2 protein expression. We treated JEG-3 cells with SAHA, a 
competitive inhibitor of both class I and class II HDACs (Xu et al., 2007). An initial 
dose response experiment was carried out 24 hours after seeding where JEG-3 cells 
were treated with concentrations of SAHA ranging from 1-10µM for 24h, followed 
by immunocytochemical staining for HSD11B2. The relative expression of HSD11B2 
protein was quantified using densitometry. A one-way ANOVA revealed a significant 
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overall effect of SAHA treatment on HSD11B2 expression (F(3,8)=5.5, p=0.02).  
Tukey’s post-hoc test revealed a significance difference between the vehicle- and 
10µM SAHA group (p<0.05) (Fig. 2a).  As the effects of SAHA were significant at 
10µM, we also immunocytochemically stained for p-Ac-histone H3 (S11/K15) 
(pAcH3) in this group and found a significant increase in the levels of pAcH3 in cells 
treated with 10µM SAHA for 24h (p<0.001) (Fig. 2b).  Overall these data indicate 
that pan-HDAC inhibition increases the levels of pAcH3 (which has been shown to 
correlate with gene expression) and HSD11B2 expression in JEG-3 cells.  
 
3.4.2 Class-Specific HDAC Inhibitors (HDI) Promote HSD11B2 Expression in JEG-3 
Cells 
We next investigated if the effects of pan-HDAC inhibition on HSD11B2 expression 
was class specific using a class I-specific HDI (MS275) (Bracker et al., 2009), and a 
class IIa-specific HDI (MC1568) (Collins et al., 2014). JEG-3 cells were treated with 
increasing concentrations (0-10µM) of MS275 or MC1568 for 24 h before being 
immunocytochemically stained for HSD11B2 and quantified using densitometry. A 
one-way ANOVA revealed a significant overall effect of both MS275 (F(3,8)=95.89, 
p<0.0001) and MC1568 (F(3,8)=53.69, p<0.0001) treatment. Tukey’s post-hoc test 
showed that MS275 or MC1568 promoted a significant increase in HSD11B2 protein 
expression with a significant difference observed between the control and HDI-
treated groups at concentrations of 1µM  (p<0.05), 5µM (p<0.0001) and 10µM 
(p<0.0001) (Fig. 3b, f).  We also examined pAcH3 levels using densitometry and 
found a significant increase in the levels of pAcH3 in cells treated with 10µM 
MC1568 or MS275 for 24h (p<0.001) (Fig 3c, g).  These data show that class-I and 
class-IIa inhibition can promote HSD11B2 protein expression in JEG-3 cells. 
 
3.4.3 Cortisol and IL-1β Decrease HSD11B2 Expression Which Is Prevented by 
MC1568 
Given that alterations in placental HSD11B2 expression are seen in pregnancies 
complicated with stress or infection (Straley et al., 2014, Jensen Pena et al., 2012), 
we next sought to determine if the biological mediators of stress (Cort) and 
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infection (IL-1β) altered HSD11B2 protein expression at the cellular level. Having 
confirmed using immunocytochemistry that the glucocorticoid receptor (GR) and 
interleukin 1 receptor, type I (IL1R1) were expressed in JEG-3 cells (Fig. 4a),  we 
carried out an MTT assay to establish a concentration of Cort and IL-1β that did not 
affect cell viability. JEG-3 cells were treated with Cort (0-10µM) or IL-1β (0-
100ng/ml) for 24h and MTT assays were performed. An ANOVA showed an overall 
effect of Cort and IL-1β treatment on cell viability, with a difference observed with 
10µM Cort (Fig. 4b) and 100ng/ml IL-1β (Fig. 4c) groups (P<0.05).  JEG-3 cells were 
then treated with 2µM of Cort or 10ng/ml IL-1β (concentrations that did not affect 
cell viability) for 24h before being fixed and immunocytochemically stained for 
HSD11B2. Using densitometry, we observed a reduction in HSD11B2 protein 
expression following exposure to Cort and IL-1β (Fig. 4d).  
 
3.4.4 HDIs Can Restore HSD11B2 Expression in an Environment of Stress and 
Inflammation 
After identifying Cort and IL-1β as potential biological mediators causing a decrease 
in HSD11B2 protein expression we next aimed to determine if HDIs could 
counteract these effects of cortisol and IL-1β on HSD11B2 protein expression. After 
plating for 24 hours, JEG-3 cells were treated with 10µM of SAHA, MC1568 or 
MS275 followed by cortisol or IL-1β before being fixed and immunocytochemically 
stained for HSD11B2 protein. Densitometry revealed that pre-treatment of JEG-3 
cells with non-specific inhibitor SAHA attenuated the effect of IL-1β and Cort (SAHA: 
2.8±0.15; SAHA+ IL-1β: 3.0±0.2; SAHA + Cort: 3.350±0.19) (Fig. 5a, e) on HSD11B2 
expression.  Similarly treatment of JEG-3 cells with either class I- specific HDI, 
MS275 (MS275: 2.2±0.06; MS275+ IL-1β: 3.18±0.06; MS275 + Cort: 2.2±0.09) (Fig. 
5b, f) or class II a-specific HDI MC1568 (MC1568: 1.8±0.08; MC1568+ IL-1β: 2.3±0.1; 
MC1568 + Cort: 1.4±0.07) (Fig. 5c, g) was sufficient to attenuate the effect of both 
Cort and IL-1β on HSD11B2 expression. These data show that exposure to 
heightened levels of Cort and IL-1β can reduce the levels of HSD11B2 protein in 
JEG-3 cells, and that this effect that can be prevented by HDAC inhibition.  
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3.5 Figures and Figure Legends: 
Figure 1: 
 
 
 
Figure 1: (A) Expression of data derived from the BioGPS database showing relative 
HSD11B2 expression across multiple human tissues. (B) Real-time PCR showing 
HSD11B2 expression in the term human placenta and in JEG-3 cells using the 2 
delta-Ct method (N=3, p > 0.05, Unpaired Student’s t-test; Housekeeping gene 18S).  
Representative photomicrographs of (C) a term human placenta and (D) JEG-3 cells 
immunocytochemically stained for HSD11B2. Scale bar = 50μm.  
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Figure 2: 
 
 
 
Figure 2: Epigenetic regulation of HSD11B2 expression. Graphical representation of 
(A) HSD11B2 and (B) AcH3 expression in JEG-3 cells treated with 0-10µM of SAHA 
for 24h. Data are expressed as mean ± SEM. (C) Representative photomicrographs 
of JEG-3 cells immunocytochemically stained for HSD11B2 (* p < 0.05, *** p < 0.001 
compared to 0µM. (A) One-way ANOVA with post hoc Tukey’s and (B) Unpaired 
Student’s t-test; 25 cells per group per experiment; N=3). Scale bar = 50μm.  
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Figure 3: 
 
 
Figure 3: Class-specific HDACs on HSD11B2 regulation in the placenta.  (A) 
Expression data from the BioGPS database showing the relative expression of a 
Class-I HDAC, HDAC 1 in the placenta relative to multiple human tissues. Graphical 
representation of (B) HSD11B2 and (C) AcH3 expression in JEG-3 cells treated with 
Class-I HDAC inhibitor MS275 for 24 h. (D) Representative photomicrographs of JEG-
3 cells immunocytochemically stained for HSD11B2 and AcH3 after treatment with 
MS275 for 24 h.  (E) Expression data from the BioGPS database showing the relative 
expression of a Class- II a HDAC, HDAC 5 in the placenta relative to multiple human 
tissues. Graphical representation of (F) HSD11B2 and (G) AcH3 expression in JEG-3 
cells treated with Class- II a HDAC inhibitor MC1568 for 24 h. Data are expressed as 
mean ± SEM (H) Representative photomicrographs of JEG-3 cells 
immunocytochemically stained for HSD11B2 and AcH3 after treatment with 
MC1568 for 24 h.  Data are expressed as mean ± SEM (*** p < 0.001 compared to 
0µM; (B, F) one-way ANOVA with post hoc Tukey’s and (C, G) Unpaired Student’s t-
test; 25 cells per group per experiment; N=3). Scale bar = 50μm.  
 109 
 
Figure 4: 
 
 
Figure 4: Cortisol and IL-1β response in JEG-3 cells.  (A) Representative 
photomicrographs of JEG-3 cells immunocytochemically stained for the 
Glucocorticoid receptor (GR; green) and (C) the Interleukin 1 Receptor, Type I (IL-
1R1; red).  The second panel shows the corresponding DAPI stained image. (B, C) 
MTT assay examining the viability of JEG3 cells treated with either 0-10µM Cortisol 
(B) or 0-100ng/ml IL-1β (C) for 24 h in vitro. (D) Graphical representation showing 
the levels HSD11B2 in JEG-3 cells exposed to a vehicle (control), 10ng/ml IL-1β or 
2µM cortisol for 24 h. Data are expressed as mean ± SEM (* p  < 0.05 compared to 
0µM, *** p < 0.001 compared to control ; one-way ANOVA with post hoc Tukey’s; 
(D) 100 cells per group per experiment; N=3). Scale bar = 50μm.  
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Figure 5: 
 
 
 
Figure 5: SAHA, MS275 and MC1568 prevent Cortisol and IL1β-induced decreases in 
HSD11B2 expression. Graphical representation and HSD11B2 expression in JEG-3 
cells treated with 2µM Cort or 10ng/ml IL-1β in the presence or absence of 10µM 
SAHA (A, D), MS275 (B, E) or MC1568 (C, F) for 24 h. Data are expressed as 
mean ± SEM.  (*** p < 0.001 compared to DMSO; one-way ANOVA with post hoc 
Tukey’s; 25 cells per group per experiment; N=3).  
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3.6 Discussion: 
The aim of this study was to examine the role of epigenetic regulators in the control 
of HSD11B2 protein expression in placental cells. We used the in vitro placental 
model JEG-3 cells, as despite their limitations, they are a well-established cell line 
commonly used to mimic placental trophoblast cells (Orendi et al., 2011). We 
employed pharmacological inhibitors of HDACs to modulate histone acetylation and 
examined the impact of this on HSD11B2 protein expression. Finally, to assess the 
potential of these compounds to regulate HSD11B2 expression under conditions of 
stress and inflammation, cells were exposed to biological mediators of these 
conditions, namely exogenous cortisol and IL-1β.   
HSD11B2 has previously been shown to localise to trophoblast cells, with 
highest expression observed in the syncytiotrophoblast (Krozowski et al., 1989, 
Chen et al., 2015). In line with these studies we demonstrated HSD11B2 protein is 
strongly expressed in the term human placenta. To model trophoblast cells in vitro, 
we used the human choriocarcinoma cell line, JEG-3 cells. We found that these cells 
express HSD11B2 mRNA making them a useful and convenient model to examine 
the molecular mechanisms that regulate HSD11B2 expression.  
Using the BioGPS database we demonstrated high expression of class 1 
HDACs 1, 2, 3 and 8 and class 2 HDACs 5, 4, 7 and 9, suggesting a role for HDAC 
proteins in the placenta. Based on these findings, we used a SAHA, a pan-HDAC 
inhibitor and demonstrated a dose dependant increase in HSD11B2 protein 
expression. To confirm the increased in HSD11B2 protein expression was paralleled 
by an increase in histone acetylation, we immunocytochemically stained the cells 
for AcH3 and showed a similar dose dependant increase AcH3. This is in 
contradiction to previous studies, where HSD11B2 expression was reported to be 
unchanged in JEG-3 cells following treatment with broad spectrum class-I and class-
II inhibitor trichostatin A (Alikhani-Koopaei et al., 2004). However the dose of TSA 
(300nm) used in these studies was much smaller than the dose at which we 
observed an effect (10uM) and we have identified that the effect of HDAC inhibition 
on HSD11B2 expression is dose dependant. 
HDACs play a diverse role during fetal development (Haberland et al., 2009). 
Global knockdown of HDAC3 (Montgomery et al., 2008) HDAC1 (Montgomery et al., 
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2007) and HDAC7 (Montgomery et al., 2007) results in fetal lethality, however mice 
lacking HDAC6 develop normally (Zhang et al., 2008b). HDACs have also been 
shown to be important regulators of placental development as inhibition of class-II 
HDACs has been shown to impair trophoblast differentiation through interactions 
with Hypoxia-inducible factor (Maltepe et al., 2005). Additionally interaction of 
HDACs with the STAT-1 TF may contribute to inhibition of IFN-γ-inducible gene 
expression in trophoblast cells thereby protecting the placenta cells from maternal 
immune rejection and contributing to a successful pregnancy (Choi et al., 2009). 
This broad range of functions of HDACs suggests that global inhibition could result 
in detrimental effects, therefore a more specific inhibition could represent an 
optimal method for modifying HSD11B2 expression. To determine if HDAC 
regulation of HSD11B2 protein expression is class specific we used class specific 
pharmacological HDAC inhibitors. We observed a similar increase in HSD11B2 
protein expression with class specific inhibition of either class I or class IIa HDACs, 
suggesting many HDACS are likely involved in regulating HSD11B2 protein 
expression. Whilst this is the first study to examine the effects of class specific 
inhibitors on HSD11B2 expression, it is interesting to note that previous studies 
have demonstrated a class specific effect of HDACs on regulation of other placental 
genes. Specifically, matrix metalloproteinase 9 has been shown to be regulated by 
class-II but not class-I HDACs (Poljak et al., 2014).  
Placental HSD11B2 has been shown to be reduced in a number of adverse 
pregnancy conditions including anxiety, stress and infection (Jensen Pena et al., 
2012, Conradt et al., 2013, Straley et al., 2014). As elevations in pro-inflammatory 
cytokines and steroids are observed in these conditions (Coussons-Read et al., 
2007, Baibazarova et al., 2013), we used cortisol and IL-1β to mimic an environment 
of stress and inflammation. We have previously demonstrated a reduction in 
HSD11B2 protein expression in JEG-3 cells following administration of IL-1β (Straley 
et al., 2014). In this study we also report a decrease in HSD11B2 expression 
following cortisol administration. In contrast Ni and colleagues have previously 
shown an increase in HSD11B2 expression in primary human trophoblast cells 
exposed to Cort (Ni et al., 2009). However this study used a number of different 
methodological approaches to the work presented here. Firstly the work conducted 
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by Ni and colleagues used primary cell cultures and we used a cell line. This 
highlights the need for further study of these questions in primary trophoblast cells. 
Additionally the maximum dose of cortisol used was 1µM, whereby we observed a 
decrease at 2µM. It is possible that cortisol may act in an adaptive way to induce 
HSD11B2, thereby protecting the fetus from high maternal glucocorticoids, but at a 
certain threshold cortisol may begin to negatively impact on HSD11B2 expression. 
Finally, Ni and colleagues quantified HSD11B2 mRNA expression and we focused 
primarily on protein levels (Ni et al., 2009).Further examination of the role of 
HDACs and HSD11B2 gene expression will uncover if this regulation occurs at a 
transcriptional, translational and/or posttranslational level. 
Interestingly broad or either class specific HDAC inhibitors were sufficient to 
prevent the cortisol and IL-1β-induced decreases in HSD11B2 expression. This raises 
the possibility of targeting key epigenetics modulators to protect the fetal 
glucocorticoid barrier and untimely fetal glucocorticoid overexposure.  However 
given the critical role of epigenetic marks in fetal development, non-specific 
inhibition of HDACs, even at class level, could produce detrimental effects on fetal 
development, therefore identifying more specifically the precise epigenetic 
mechanism mediating HSD11B2 regulation using knockdown or overexpression of 
individual HDACs would allow the development of a more targeted approach. The 
advancement of targeted nanoparticles to deliver chemotherapeutic agents directly 
to the placenta represents an exciting new avenue to alter placental epigenetic 
mediators without inferring with the fetus (Kaitu'u-Lino et al., 2013). Notably we 
also observe a potentiation of the effects of SAHA on HSD11B2 expression when 
administered with cortisol. Once activated the GR can bind to many coactivator 
proteins with known HAT activity (Ito et al., 2005). The combined inhibition of 
HDACs by SAHA with the potential increase in HAT activity cause by GR activation 
from exogenous cortisol may explain this enhanced HSD11B2 protein expression. 
This relationship further highlights the complexity of HSD11B2 regulation and the 
epigenetic landscape and confirms the need for more studies examining how 
placental HSD11B2 protein is controlled under both basal and pathological 
conditions. 
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A limitation to this work is the use of commercially available antibodies, 
which have the potential to produce false positive results due to non-specific 
protein binding. The antibody we used in this study, acquired from Santa Cruz, has 
been frequently used to quantify HSD11B2 expression in placental cells and 
therefore we are confident that we have accurately measured HSD11B2 protein 
expression (Li et al., 2011, Ma et al., 2012, Ni et al., 2009). Although we 
acknowledge the sensitivity and specificity of this, and other commercially available 
antibodies for HSD11B2, warrants further investigation (Herrera et al., 2013). By 
quantifying protein expression via immunocytochemistry (versus western blotting) 
we were able to improve the specificity of our results by measuring protein levels in 
distinct cellular localizations (Kurien et al., 2011). For HSD11B2, cytoplasmic 
expression was quantified and for AcH3 nuclear levels were measured.  
Here we provide evidence of a role for histone acetylation in the regulation 
of HSD11B2 in the placenta; a limitation is that the present study used JEG-3 cells. 
Although we confirmed HSD11B2 to be abundantly expressed in this cell line and 
that HSD11B2 levels are comparable between JEG-3 cells and the human placenta, 
there are potential caveats associated with using JEG-3 cells (Sokolov et al., 2015).  
As such replicating the current study in primary trophoblasts will help to clarify the 
functional role of HDACs in the regulation of HSD11B2 protein expression in the 
placenta. However the present study demonstrates a role for HDACs in the 
regulation of a key enzyme that maintains the fetal glucocorticoid barrier under 
basal and pathological conditions. It is likely that combinations of different 
epigenetic modifiers including HDACs are involved in regulating HSD11B2 
expression. As HDACs have a broad role in regulating fetal development, inhibition 
of all HDACs could be detrimental to the developing fetus. Therefore unravelling 
the role of individual HDACs in HSD11B2 regulation, using more specific 
pharmacological inhibitors or targeted knockdown of HDACs will be crucial to 
understand the epigenetic mechanisms that regulate HSD11B2 expression, and for 
developing novel protective pharmacotherapies for the human placenta. 
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4.1 Abstract: 
The experience of maternal distress in pregnancy is often linked with poorer 
obstetric outcomes for women as well as adverse short and long term outcomes for 
affected offspring. Alterations in placental glucocorticoid signalling and subsequent 
increased fetal exposure to cortisol during development have been suggested to 
underlie this relationship. In the current study 121 pregnant women receiving 
antenatal care at Cork University Maternity hospital completed the Perceived Stress 
Scale, State Trait Anxiety Inventory and Edinburgh Postnatal Depression Scale in the 
third trimester of pregnancy. Placental samples were collected immediately after 
delivery. Maternal history of psychiatric illness and miscarriage were significant 
predictors of poorer mental health in pregnancy. Higher levels of anxiety were 
associated with an increase in women delivering via elective Caesarean Section, and 
an increase in women bottle-feeding their infant. Birth temperature was mildly 
reduced among infants of women who reported high levels of depressive 
symptomology. Similarly babies of mothers who scored high in all stress measures 
(cumulative distress) had mildly reduced 5-minute Apgar scores. High cumulative 
distress reduced the expression of placental HSD11B2 and increased the expression 
of placental NR3C1 mRNA. This data supports a role for a relationship between 
prenatal distress and adverse obstetric outcomes. The alterations in placental gene 
expression support a potential role for altered placental glucocorticoid signalling in 
mediating this relationship. This highlights the importance of addressing mental 
health during pregnancy to promote healthier obstetric and infant outcomes.  
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4.2 Introduction:  
There is now an extensive body of evidence showing that the in utero experience is 
a critical determinant of fetal outcome (Langley-Evans, 2006).  One factor that has 
been extensively studied in this regard is the adverse effect of maternal prenatal 
distress on birth outcomes (Bussières et al., 2015). This is important, as 
understanding the relationship between prenatal distress and unfavourable births 
outcomes may allow for targeted maternal or fetal surveillance in high-risk 
pregnancies, or timely intervention to decrease the risk of an adverse outcome. The 
term prenatal distress is often used to collectively refer to negative psychological 
wellbeing and encompasses, stress, anxiety and depression. The prevalence of 
prenatal distress is estimated to be 31%, 28% and 12% for stress, anxiety and 
depression respectively (McDonald et al., 2013).  Thus, a significant proportion of 
women experience clinically significant levels of maternal distress during 
pregnancy, highlighting the need to study its impact on birth outcomes.   
A number of epidemiological studies have shown that fetal exposure to 
maternal prenatal distress can alter fetal development and increase short and long 
term disease risk. Prenatal stress and anxiety increases the risk of preterm birth 
(PTM) and low birth weight (LBW) (Ding et al., 2014b, Bussières et al., 2015). 
Prenatal depression has been found to increase the risk of operative deliveries (Hu 
et al., 2015), PTB and LBW (Grote et al., 2010). However in a more recent meta-
analysis, Accortt and colleagues reported significant variability in existing studies 
(Accortt et al., 2015), highlighting the need for further studies examining the 
association between prenatal depression and birth outcomes.  
While the clinical outcomes have been the subject of intensive investigation, 
the molecular and biological parallels of these changes in human population are not 
well known. Given the well-known effect of stress on glucocorticoid signalling, one 
proposed hypothesis is that alterations in placental glucocorticoid signalling, leads 
to overexposure of the fetus to maternal cortisol (Cottrell et al., 2013). This has 
been proposed as a key biological mechanism underpinning the programming 
effect of prenatal distress on poor outcomes (Cottrell et al., 2013). In particular 
prenatal distress has been shown to alter the expression of three important genes 
in the placenta; 11-beta hydroxysteroid dehydrogenase type 2 (HSD11B2) (Jensen 
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Pena et al., 2012, Seth et al., 2015, O'Donnell et al., 2012), the glucocorticoid 
receptor (NR3C1) (Palma-Gudiel et al., 2015) and FK506 binding protein (FKBP5) 
(Monk et al., 2016). Expression of these genes have been shown to correlate with 
infant birthweight (Green et al., 2015, Mulligan et al., 2012) and growth restriction 
(Zhao et al., 2014), suggesting an that altered placental glucocorticoid signalling 
may play a role in determining newborn outcome.   Further alterations in the 
epigenetic expression of HSD11B2 (Appleton et al., 2015), NR3C1 (Sheinkopf et al., 
2016), and FKBP5 (Paquette et al., 2014) may be predictive of neurobehavioral 
problems in infancy.  
The primary objective of this study was to evaluate the link between 
prenatal stress, depression and/or anxiety in late pregnancy on neonatal and 
obstetric outcomes in pregnant women receiving antenatal care at Cork University 
Hospital. The secondary goal was to examine any changes in key genes involved in 
placental glucocorticoid signalling that have previously been linked to unfavourable 
birth outcomes and poorer neurodevelopment in infancy. 
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4.3 Methods:  
4.3.0 Participant recruitment 
This study was carried out with full ethical approval from the Research Ethics 
Committee of Cork Teaching Hospital. Participants attending antenatal care at Cork 
University Maternity Hospital (CUMH), Cork, Ireland between July 2015 and 
September 2016 were invited to participate in this study.  The inclusion criteria 
were; 1. 18 years of age or older, 2. English speaking, 3. having a current singleton 
pregnancy and 4. plans to give birth in in the maternity hospital. The participants 
were recruited when they were greater than 28 weeks’ gestation to time of 
delivery. Participants were recruited in late pregnancy as  this time corresponds to a 
period where the prevalence of prenatal distress is heightened (Lee et al., 2007).  
Written informed consent was obtained from all women who agreed to take part 
and participants were asked to complete a combination of questionnaires used to 
assess maternal distress (Khashan et al., 2014) and donate a small biopsy of their 
placenta following delivery. Detailed clinical and demographic data were collected 
from the medical notes of patients once the entire cohort had given birth. This data 
included information on maternal age, body mass index (BMI), previous obstetric 
complications, previous psychiatric history, medical conditions, current obstetric 
complications, birthweight, gender, gestational age, Apgar score, birth 
temperature, neonatal resuscitation (if any), admissions to the Neonatal Intensive 
Care Unit (NICU) and mode of feeding on discharge from the hospital.  
 
4.3.1 Questionnaires 
This study used the 10-item Perceived Stress Scale (PSS). The PSS is a popular tool 
used to measure psychological stress and how individuals appraise stressful life 
events. Higher Scores on the PSS are indicative of a higher level of perceived stress. 
In this study, a score of greater than or equal to 20 was used as the cut-off for the 
‘high stress’ group. Maternal anxiety was measured using the 6-item version of 
State Trait Anxiety Inventory (STAI). The 6 item STAI is a frequently used brief 
psychological measure of anxiety and the 6 item version which has been validated 
for use during pregnancy (Marteau and Bekker, 1992). As there are currently no 
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recommended cut off scores for the STAI during pregnancy, women were deemed 
anxious if they scored in the top 25% of the cohort. Depressive symptoms were 
assessed using the Edinburgh Postnatal Depression Scale (EPDS). Consistent with 
previous studies, we used a score of 13 or greater to indicate a high probability of 
depression (Rubertsson et al., 2011, Cohen et al., 1983). These self-reported 
questionnaires are marked by a 4-point Likert Scale. In this study, the Cronbach’s 
alpha of the PSS, STAI and EPDS were 0.867, 0.838 and 0.894 respectively.  
 
4.3.2 Placenta collection 
Placental samples were collected within 3 hours of delivery. Placental weight was 
measured after the cord and membranes had been removed. 5 cross-sectional 
samples were randomly excised from each placenta to incorporate both the 
maternal and fetal sides. The samples were washed in dH2O and immediately 
stored at -80 °C for further analysis.  
 
4.3.3 RNA extraction, cDNA synthesis and PCR 
RNA was extracted from placental samples using the Trizol method as per the 
manufacturers instructions. Briefly, placental sample was homogenised in 3 ml of 
Trizol reagent and left on ice for 10 minutes. Samples were centrifuges at 4°C from 
5 minutes and 1 ml of the supernatant was transferred into a new Eppendorf. 200ul 
of chloroform was added, mixed and left at room temperature for 3 minutes. The 
sample was centrifuged at 4°C 12000g for 15 min. The upper clear aqueous phase 
was removed and placed in a new 1.5ml Eppendorf, 500ul of isopropanol was 
added and left at room temperature for 10 min. The sample was centrifuged at 4°C 
12000g for 10 min. The supernatant was removed and the pellet was washed in 1 
ml of 70% ethanol. The sample was centrifuged, supernatant removed and the 
pellet was left to air dry and re-suspended in 70ul of RNase free H20. RNA 
concentration and quality was assessed using the Nanodrop 8000.  500 ng of 
placental RNA was reversed transcribed using the high capacity cDNA reverse 
transcription kit (Applied Biosystems) using the following parameters 25 °C for 
10 min; 37 °C for 120 min; 85 °C for 5 min; and held at 4 °C until storage at 80 °C. 
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Real time PCR was performed for HSD11B2, FKBP5, NC3R1 under the following 
cycling parameters; 50 °C for 2 min; 95 °C for 10 min; 50 repetitions of 95 °C for 15 s 
and annealing/elongating at 60 °C for 1 min. All samples were run in duplicate, cycle 
threshold values were recorded and analysis was performed using the 2−ΔΔcycle 
threshold method (Livak and Schmittgen, 2002).  
 
4.3.4 Data analysis 
Data was collected and analysed on SPSS version 22 and Graphpad prism 5. Missing 
values were checked for and any questionnaire responses with greater than 3 
missing values were removed. Where medical records were unavailable, 
participants’ questionnaire scores were also removed from the cohort. Normality 
was tested for using the Kolmogorov-Smirnov tests prior to beginning inferential 
statistics. Birthweight, birthweight centiles and placental weight ratios were 
normally distributed and were analysed using an unpaired student t-tests or one-
way ANOVA with Tukey’s post hoc. Placental weight, Apgar scores and birth 
temperature displayed a non-normal distribution; therefore non parametric tests 
were used. For nominal data, binary logistic regression analyses with 95% 
confidence intervals were used. Multivariate data were evaluated with ordinal 
logistic regression analysis. Values of P < 0.05 were considered statistically 
significant. All analyses were adjusted for maternal age, body mass index (BMI) and 
social class.  
 In our analyses we grouped mode of delivery into 3 models. In model 1, 
mode of delivery was grouped as either spontaneous vaginal delivery (SVD) or 
operative. Model 2 included vaginal delivery versus Caesarean section (CS) delivery.  
In model 3, mode of delivery was grouped as SVD, emergency CS (EMCS), elective 
CS (ELCS), vacuum (VD) or Forceps delivery (FD). Additionally newborns were 
grouped into number of adverse birth outcomes based on six parameters; (a) 
Admission to the NICU (b) Newborn Resuscitation received (c) Delivered before 37 
weeks gestation (d) 5 minute Apgar score ≤ 7 (e) Birth Temperature < 36.5°C and (f) 
Birth Centile ≤ 10 or ≥ 90. 
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4.4 Results: 
4.4.0 Descriptive statistics 
159 pregnant women were initially recruited into the study and completed the 
questionnaires. Participants were removed from the study if they were less than 28 
weeks’ gestation when they completed the questionnaires (13%), had incomplete 
survey information (3%) or if medical records were unavailable (7.5%) (Fig. 1). The 
final analysis included 121 participants. The mean age of the participants was 31.75 
years (SD = 4.54, range 17 – 41). The average BMI was 26.33 (SD = 4.60, range 18.6 
– 38.8). The mean gestational age at which the surveys were completed was 35.55 
weeks’ (SD 3.541, range 28 -41). The majority of the women in this study where 
multigravida (67.8%) or primigravida (26.4%). 2.5% of participants had delivered 
greater than 5 infants and 3.3% had greater than 7 previous deliveries. 23.1% of this 
population had a history of having one or more miscarriages (n = 28). Only 2 
participants (1.7%) had a history of ectopic pregnancies and therefore no further 
analysis was conducted in relation to ectopic pregnancy history. 21.5% of the study 
population had a history of psychiatric illness (n = 26). Depression was the most 
common psychiatric illness in this population (9.9%, n=12), followed by anxiety 
(7.4%, n=9), postnatal depression (5%, n=6) and bipolar disorder (0.8%, n=1) (Table 
1 & 2).  
 
4.4.1 Perceived Stress Scale 
The mean PSS score in the entire study cohort was 16.36 ± 0.591 (Appendix C, Fig. 
1). This number is comparable to other studies that have used the 10-item PSS to 
assess prenatal stress in the third trimester (Liou et al., 2013).   High levels of 
perceived psychological stress was determined by a PSS score of greater than or 
equal to 20 (33.1%, n = 40). Participants with a score of less than or equal to 19 
were deemed ‘low stress’ (66.9%, n=81). Women with high levels of stress during 
pregnancy were 2 times more likely to have a history of psychiatric illness (OR 
2.519; 95% CI=1.036–6.125). This relationship remained significant after controlling 
for maternal age, BMI and social class (aOR 2.591; 95% CI=1.033 – 6.499). When 
grouped based on type of psychiatric illness, maternal stress was not associated 
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with depression, anxiety or PND individually (Table 3). Prenatal stress had no effect 
neonatal outcome (Fig. 2), mode of delivery, gestational age at delivery or infant 
feeding (Table 3). Additionally scoring on the PSS was not related to neonatal 
resuscitations, admission to the NICU, birth centiles (Appendix C, Table 1) or 
number of neonatal adversities (Appendix C, Table 3). 
  
4.4.2 State Trait Anxiety Inventory 
The mean Score in the STAI was 6.17 ± 0.347. As there are currently no guidelines 
to indicate high anxiety in the perinatal period using the STAI, we defined highly 
anxious of as the top quartile of scores in the cohort (27.3%, n=33). Previous 
depression, anxiety or PND alone was not associated with scoring in the STAI. 
However, when grouped by any psychiatric illness there was an association with 
scoring high in the STAI and having a history of psychiatric illness (OR 3.020; 95% 
CI=1.215–7.509). This relationship remained significant after including maternal age 
and BMI into the model (aOR3.299; 95% CI=1.270-8.572) (Table 1). A history of 
miscarriage was associated with a 3 fold increased risk of scoring high in STAI (aOR 
3.071; 95% CI=1.165-8.095) (Table 2), indicating previous pregnancy loss as a 
contributing factor to anxiety during pregnancy.  
 
4.4.3 Edinburgh Postnatal Depression Scale 
The mean EPDS was 9.07 ± 0.512 (Appendix C, Fig. 1 & Table 2). An EPDS score 
greater than or equal to 13 was used to mark participants as being ‘highly likely 
depressed’ (25.6%, n=31). Concordantly, participants who scored 12 or less were 
grouped in the ‘not likely depressed’ category (74.4%, n = 90).  Participants who 
scored in the ‘highly likely depressed’ group were greater than 3 time more likely to 
have had a history of psychiatric illness (aOR 3.566; 95% CI=1.348-9.434). When 
stratified based on type of psychiatric illness (depression, stress or anxiety), women 
with a history of depression were 4 times more likely to be in the ‘highly likely 
depressed’ group after adjusting for maternal age, BMI and social class (aOR 4.451; 
95% CI=1.198-16.538) (Table 1). Maternal history of miscarriage was associated 
with a three-fold increased risk of scoring high in the EPDS (aOR 3.878; 95% 
CI=1.420-10.590) (Table 5). Babies of women who were ranked in the ‘highly likely 
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depressed’ group on the EPDS had a reduced temperature at birth (P < 0.05 *) (Fig. 
4D). Maternal depressive symptomology did not affect mode of delivery, 
gestational age at delivery or infant feeding (Table 5). Additionally scoring on the 
EPDS was related to neonatal resuscitations, admission to the NICU, birth centiles 
(Appendix C, Table 1) or number of neonatal adversities (Appendix C, Table 3).  
 
4.4.4 Cumulative group 
As prenatal stress, anxiety and depression are highly correlated (Appendix C, Fig. 2), 
a new group was created for participants who scored in the high category on all 
three questionnaires (14.9%, n= 18). Participants in this group were up to 3 times 
more likely to have a history of miscarriage (aOR = 3.903; 95% CI=1.224-12.446) 
(Table 6). The risk of having a history of psychiatric illness in this group rose to 
greater than 6 times (aOR = 6.229; 95% CI = 1.947-19.926). Similar to participants 
who ranked high in the EPDS, participants in this category were more likely to have 
a history of depression (aOR = 4.504; 95% CI=1.073-18.897) (Table 6). Infants born 
to women in the cumulative high stress group had a lower 5 minute Apgar score 
than other infants. Further, unlike babies from the low group, babies born to 
mothers in this group did not have a significant increase in their Apgar score from 1 
to 5 minutes (Fig.4E).  Maternal cumulative distress had no effect on mode of 
delivery, gestational age at delivery or infant feeding (Table 6).  
 
4.4.7 Placental gene expression 
To determine the relationship between prenatal distress and placental 
glucocorticoid gene expression, we performed real time PCR on placental samples 
for three key genes; HSD11B2, FKBP1, NR3C1. Placentae were available for 16 of 
the high cumulative distress participants and 9 of the low scoring participants. 
Scoring in the high group was associated with a significant decrease in HSD11B2 (p 
= 0.0296) and an increase in NR3C1 (p=0.048) mRNA in the placenta (Fig 6). 
Additionally placental NR3C1 was negatively correlated with placental weight (r2 = 
0.159; p=0.025) and birthweight centiles (r2 = 0.412; p=0.036) (Appendix C, Table 5). 
There was no effect of prenatal cumulative distress on the expression of FKBP5 
(p=0.101) (Fig 6).  Placental FKBP5 expression positively correlated with maternal 
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BMI (r2 = 0.185; p=0.025) (Appendix C, Table 6). Placental gene expression was not 
related to infant sex or obstetric outcomes (Appendix C, Fig. 3). 
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4.5 Figures and Figure Legends: 
Figure 1:  
 
 
 
Figure 1: Flowchart of participants. 159 questionnaires were completed with 21 
(13.2%) removed from the dataset for being less than 28 weeks gestation and a 
further 5 (3.1%) removed for incomplete filling of the questionnaire. Medical 
records were unavailable for 12 (7.5%) of the participants. Placental samples were 
collected,  frozen and biobanked for 100  of the remaining participants (82.6%).  
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Table 1:  
Demographics N (%) 
Age (years) 
≤ 18  
19 – 24  
25 – 29  
30 – 35  
≥ 35  
 
1 (0.8%) 
8 (6.7%) 
26 (21.8%) 
48 (40.3%) 
36 (30.3%) 
BMI (kg/m
2
) 
Underweight (< 18.50) 
Normal (18.5 – 24.99) 
Overweight (25 – 29.9) 
Obese (> 30.0) 
 
0 
50 (41.7%) 
44 (36.4%) 
26 (21.5%) 
Social class 
1. Professional workers 
2. Managerial and technical 
3. Non-manual 
4. Skilled manual 
5. Semi-skilled 
6. Unskilled 
7. Unemployed 
 
14 (11.6%) 
37 (30.6%) 
8 (6.6%) 
28 (23.1%) 
9 (7.4%) 
8 (6.6%) 
6 (5%) 
Medical History 
History of miscarriage 
Yes 
No 
History of ectopic pregnancy 
Yes 
No 
 
 
28 (23.1%) 
93 (76.9%) 
 
2 (1.7%) 
119 (98.3%) 
Psychiatric history 
History of  any psychiatric illness 
Yes 
No 
History of depression 
Yes 
No 
History of anxiety 
Yes 
No 
 
 
26 (21.5%) 
95 (78.5%) 
 
12 (9.9%) 
109 (90.1%) 
 
9 (7.4%) 
112 (92.6%) 
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Table 1 continued:  
History of postnatal depression 
Yes 
No 
6 (5%) 
115 (95%) 
Onset of delivery 
Spontaneous 
Induction 
 
51 (50.5%) 
50 (49.5%) 
Rupture of membranes 
SROM 
PROM 
AROM 
 
35 (34%) 
3 (2.9%) 
65 (63.1%) 
Mode of delivery 
Spontaneous vaginal delivery (SVD) 
Forceps delivery (FD) 
Vacuum delivery (KVD) 
Emergency Caesarean section (EMCS) 
Elective Caesarean section (ELCS) 
 
67 (55.8%) 
4 (3.3%) 
19 (15.8%) 
10 (8.3%) 
20 (16.7%) 
Resuscitation at birth 
Yes 
No 
 
17 (14.4%) 
101 (85.6%) 
Admission to the Neonatal Unit 
Yes 
No 
 
5 (4.2%) 
115 (95.8%) 
Mode of Feeding on discharge 
Exclusive breast fed 
Mixed feeding 
Bottle fed 
 
56 (46.3%) 
7 (5.8%) 
58 (47.9%) 
Table 1: Descriptive statistics of categorical variables.   
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Table 2:  
Measure Mean (N) SEM SD Range 
Maternal age 31.75 0.41 4.54 17 - 41 
Maternal BMI 26.33 0.42 4.60 19 - 40 
Birthweight 3654.67 40.66 445.49 2690 - 4800 
Placental weight 558.33 10.84 106.29 300 - 900 
Placental weight ratio 0.157 0.006 0.06 0.09 – 0.70 
Birth Temperature 36.80 0.09 1.01 35 - 39 
1 minute Apgar Score 8.54 0.10 1.19 3 - 10 
5 minute Apgar Score 9.53 0.06 0.73 6 - 10 
Gestational Age at delivery 39.58 0.09 1.04 37 - 41 
Birthweight Centiles 47.58 2.46 26.87 1 - 98 
Table 2: Descriptive statistics of continuous variables. 
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Figure 2:  
 
 
 
Figure 2: Prenatal stress and neonatal outcomes. Graphical representation of 
birthweight (A), placental weight (B), placental weight ratio (C), birth temperature 
(D) and Apgar score (E) in neonates whose mothers were ranked in the high and 
low stress category. Unpaired students t-test between low and high on birth weight 
(A) and placental weight ratio (C) show no significant difference between groups P > 
0.05. Mann Whitney test between low and high on placental weight (B) and birth 
temperature (D) show no significant difference between groups P > 0.05. Mann 
Whitney test show increased Apgar score from 1 to 5 minute (E) in low and high 
stress group (P < 0.0001 ***).  
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Table 3:  
Perceived Stress Scale 
 OR (CI; p-value) aOR (CI; p-value) 
Psychiatric history 
Psychiatric Illness 2.519 (1.036 – 6.125 ; 0.042) * 2.591 (1.033 – 6.499 ; 0.042) * 
Depression 2.203 (0.663 – 7.338 ; 0.197) 2.648 (0.747 – 9.382 ; 0.131) 
Anxiety 2.082 (0.696 – 10.867 – 0.149) 2.592 (0.622 – 10.796 ; 0.191) 
Postnatal Depression 1.013 (0.178 – 5.780 ; 0.988) 0.837 (0.135 – 5.206 ; 0.849) 
Miscarriage history 
Miscarriage 1.741 (0.730 – 4.155 ; 0.211) 2.278 (0.878 – 5.911 ; 0.091) 
Mode of delivery 
Model 1 
 
SVD 1 (Reference) 1 (Reference) 
Operative 1.023 (0.478 – 2.190 ; 0.954) 1.014 (0.466 – 2.204 ; 0.972) 
Model 2 Vaginal 1 (Reference) 1 (Reference) 
CS 1.017 (0.423 – 2.441 ; 0.97) 1.178 (0.467 – 2.970 ; 0.729) 
Model 3 SVD 1 (Reference) 1 (Reference) 
EMCS 0.511 (-2.302 – 0.961 ; 0.420) 0.503 (-2.345 – 0.969 ; 0.416) 
ELCS 1.364 (-0.720 – 1.340 ; 0.555) 1.706 (-0.556 – 1.625 ; 0.337) 
KVD 1.193 (-0.886 – 1.239 ; 0.745) 1.046 (-1.043 – 1.133 ; 0.935) 
FD 0.682 (-2.703 – 1.937 ; 0.746) 0.492 (-3.062 – 1.645 ; 0.555) 
Gestational Age at delivery 
< 39 weeks gestation 0.673 (0.284 – 2.252 ; 0.673) 0.758 (0.266 – 2.157 ; 0.603) 
Mode of Feeding 
Breastfed 1 (Reference) 1 (Reference) 
Bottle-fed 1.111 (-0.674-0.885; 0.791) 1.059 (-0.737 – 0.852 ; 0.887) 
Mixed 0.844 (-1.902-1.564; 0.848) 1.094 (-1.710 – 1.890 ; 0.922) 
Table 3: Women with a history of psychiatric illness more likely to report prenatal 
stress. Odds ratios assessing the relationship between prenatal stress, history of 
psychiatric illness, history of miscarriage, mode of delivery, gestational age at 
delivery and mode of feeding.  Binary logistic regression analysis revealed 
participants with a history of psychiatric illness were more likely to score high on 
the PSS (P < 0.05 *). Adjusted for maternal age, BMI and social class.  
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Figure 3:  
  
 
 
Figure 3: Prenatal anxiety and neonatal outcomes. Graphical representation of 
birthweight (A), placental weight (B), placental weight ratio (C), birth temperature 
(D) and Apgar score (E) in neonates whose mothers were ranked in the high and 
low anxiety category. Unpaired students t-test between low and high on birth 
weight (A) and placental weight ratio (C) show no significant difference between 
groups P > 0.05. Mann Whitney test between low and high on placental weight (B) 
and and birth temperature (D) show no significant difference between groups P > 
0.05. Mann Whitney test show increased Apgar score from 1 to 5 minute in low and 
high anxiety group (P < 0.0001 ***).  
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Table 4:  
State Trait Anxiety Inventory 
 OR (CI; p-value) aOR (CI; p-value) 
Psychiatric history 
Psychiatric Illness 3.020 (1.215 – 7.509 ; 0.017) * 3.532 (1.322 – 9.389 ; 0.012) * 
Depression 2.066 (0.607 – 7.037 ; 0.246) 2.579 (0.699 – 9.515 ; 0.155) 
Anxiety 1.367 (0.321 – 5.812 ; 0.672) 1.322 (0.275 – 6.358 ; 0.727) 
Postnatal Depression 2.833 (0.542 – 14.806 ; 0.217) 2.509 (0.432 – 14.583 ; 0.306) 
Miscarriage history 
Miscarriage 3.163 (1.296 – 7.721 ; 0.011) * 3.807 (1.384 – 10.473 ; 0.010) * 
Mode of delivery 
Model 1 
 
SVD 1 (Reference) 1 (Reference) 
Operative 2.443 (1.077 – 5.545 ; 0.033) * 2.264 (0.977 – 5.246 ; 0.057) 
Model 2 Vaginal 1 (Reference) 1 (Reference) 
CS 2.222 (0.923 – 5.348 ; 0.075) 2.306 (0.895 – 5.937 ; 0.083) 
Model 3 SVD 1 (Reference) 1 (Reference) 
EMCS 1.038 (-1.626 – 1.701 ; 0.965) 0.817 (-1.917 – 1.513 ; 0.817) 
ELCS 4.154 (0.359 – 2.489 ; 0.009) ** 5.411 (0.509 – 2.868 ; 0.005) ** 
KVD 2.423 (-0.227 – 1.997 ; 0.119) 2.235 (-0.345 – 1.954 ; 0.170) 
FD 1.385 (-2.017 – 2.668 ; 0.785) 1.013 (-2.424 – 2.451 ; 0.992) 
Gestational Age at delivery 
< 39 weeks gestation 3.182 (1.196 – 8.467 ; 0.020) * 3.235 (1.182 – 8.855 ; 0.022) * 
Mode of Feeding 
Breastfed 1 (Reference) 1 (Reference) 
Bottle-fed 2.964 (0.195 –1.978; 0.017)* 2.710 (0.086 – 1.908 ; 0.032) * 
Mixed 3.917 
(-0.293 – 3.023; 0.107) 
5.189 (-0.148 – 3.441 ; 0.072) 
Table 4: Prenatal anxiety, maternal history and obstetric outcomes. Odds ratios 
assessing the relationship between prenatal anxiety, history of psychiatric illness, 
history of miscarriage, mode of delivery, gestational age at delivery and mode of 
feeding.  Binary logistic regression analysis revealed participants with a history of 
psychiatric illness or specifically depression and miscarriage were more likely to 
score high on the STAI (P < 0.05 *). High anxiety was associated with an increased 
risk of delivery by ELCS (P < 0.01 **). Prenatal anxiety related to increased risk of 
delivery before 39 weeks gestation (P < 0.05 *). Women in the high anxiety group 
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were more likely to be bottle feeding on hospital discharge (P < 0.05 *).  Adjusted 
for maternal age, BMI and social class. 
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Figure 4:  
 
 
Figure 4: Prenatal depressive symptoms and neonatal outcomes. Graphical 
representation of birthweight (A), placental weight (B), placental weight ratio (C), 
birth temperature (D) and Apgar score (E) in neonates whose mothers were ranked 
in the high and low depressive category. Unpaired students t-test between low and 
high on birth weight (A) and placental weight ratio (C) show no significant 
difference between groups P > 0.05. Mann Whitney test between low and high on 
placental weight (B)  show no significant difference between groups P > 0.05. Mann 
Whitney test shows decreased birth temperature (D) among the high depressive 
symptoms group (P < 0.05 *). Mann Whitney test show increased Apgar score from 
1 to 5 minute in low and high depressive symptom group (P < 0.0001 ***).  
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Table 5:  
Edinburgh Postnatal Depression Scale 
 OR (CI; p-value) aOR (CI; p-value) 
Psychiatric history 
Psychiatric Illness 3.429 (1.366 – 8.607 ; 0.009) ** 3.566 (1.348 – 9.434 ; 0.010) * 
Depression 3.360 (0.995 – 11.341 ; 0.051) 4.451 (1.198 – 16.539 ; 0.026) * 
Anxiety 2.519 (0.631 – 10.053 ; 0.191) 2.042 (0.475 – 8.776 ; 0.337) 
Postnatal Depression 1.483 (0.258 – 8.522 ; 0.659) 1.111 (0.149 – 8.312 ; 0.918) 
Miscarriage history 
Miscarriage 3.611 (1.463 – 8.913 ; 0.005) ** 3.878 (1.420 – 10.590 ; 0.008) 
** 
Mode of delivery 
Model 1 
 
SVD 1 (Reference) 1 (Reference) 
Operative 1.739 (0.764 – 3.960 ; 0.187) 1.751 (0.743 – 4.128 ; 0.200) 
Model 2 Vaginal 1 (Reference) 1 (Reference) 
CS 1.344 (0.538 – 3.361 ; 0.527) 1.618 (0.592 – 4.419 ; 0.348) 
Model 3 SVD 1 (Reference) 1 (Reference) 
EMCS 0.946 (-1.713 – 1.603 ; 0.948) 0.950 (-1.755 – 1.652 ; 0.953) 
ELCS 2.038 (-0.379 – 1.804 ; 0.201) 2.456 (-0.275 – 2.072 ; 0.133) 
KVD 1.747 (-0.574 – 1.691 ; 0.334) 1.521 (-0.777 – 1.617 ; 0.492) 
FD 3.786 (-0.715 – 3.378 ; 0.202) 3.485 (-0.869 – 3.366 ; 0.248) 
Gestational Age at delivery 
< 39 weeks gestation 2.154 (0.792 – 5.855 ; 0.133) 2.391 (0.841 – 6.796 ; 0.102) 
Mode of Feeding 
Breastfed 1 (Reference) 1 (Reference) 
Bottle-fed 1.520 
(-0.433-1.272; 0.336) 
1.301 (-1.621 – 2.147 ; 0.784) 
Mixed 1.467 
(-1.377-2.143; 0.670) 
1.337 (-0.594 – 1.175 ; 0.520) 
Table 5: Prenatal depressive symptoms, maternal history and obstetric outcomes. 
Odds ratios assessing the relationship between prenatal depressive symptoms, 
history of psychiatric illness, history of miscarriage, mode of delivery, gestational 
age at delivery and mode of feeding.  Binary logistic regression analysis revealed 
participants with a history of psychiatric illness or specifically depression and 
miscarriage were more likely to score high on the EPDS (P < 0.05 *, P < 0.01 **). 
Adjusted for maternal age, BMI and social class.  
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Figure 5:  
 
 
Figure 5: Prenatal cumulative distress and neonatal outcomes. Graphical 
representation of birthweight (A), placental weight (B), placental weight ratio (C), 
birth temperature (D) and Apgar score () in neonates whose mothers were ranked 
in the high and low cumulative distress category. Unpaired students t-test between 
low and high on birth weight (A) and placental weight ratio (C) show no significant 
difference between groups P > 0.05. Mann Whitney test between low and high on 
placental weight (B), and birth temperature (D) show no significant difference 
between groups P > 0.05. Mann Whitney test show increased Apgar score from 1 to 
5 minute in low cumulative distress group (P < 0.0001 ***) but not in high group (P 
> 0.05). There was a significant reduction in 5 minute Apgar score among high 
cumulative distress group (F; Mann Whitney test; P < 0.05 *).  
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Table 6:  
Cumulative distress 
 OR (CI; p-value) aOR (CI; p-value) 
Psychiatric history 
Psychiatric Illness 5.059 (1.752 – 14.606 ; 0.003) ** 6.229 (1.947 – 19.926 ; 0.002) ** 
Depression 3.393 (0.902 – 12.763 ; 0.071) 4.504 (1.073 – 18.897 ; 0.040) * 
Anxiety 3.233 (0.730 – 14.329 ; 0.122) 3.411 (0.649 – 17.916 ; 0.147) 
Postnatal Depression 3.094 (0.523 – 18.302 ; 0.213) 3.136 (0.427 – 23.036 ; 0.261) 
Miscarriage history 
Miscarriage 3.320 (1.162 – 9.488 ; 0.025) * 3.903 (1.224 – 12.446 ; 0.021) * 
Mode of delivery 
Model 1 
 
SVD 1 (Reference) 1 (Reference) 
Operative 2.193 (0.786 – 6.113 ; 0.133) 1.982 (0.684 – 5.739 ; 0.207) 
Model 2 Vaginal 1 (Reference) 1 (Reference) 
CS 1.646 (0.558 – 4.852 ; 0.366) 1.758 (0.545 – 5.672 ; 0.345) 
Model 3 SVD 1 (Reference) 1 (Reference) 
EMCS 0.952 (-2.258 – 2.161 ; 0.965) 0.704 (-2.647 – 1.945 ; 0.765) 
ELCS 2.857 (-0.230 – 2.329 ; 0.108) 4.375 (0.005 – 2.947 ; 0.049) * 
KVD 2.286 (-0.526 – 2.179 ; 0.231) 2.307 (-0.596 – 2.267 ; 0.252) 
FD 2.857 (-1.345 – 3.445 ; 0.390) 2.121 (-1.843 – 3.346 ; 0.570) 
Gestational Age at delivery 
< 39 weeks gestation 1.557 (0.452 – 5.355 ; 0.483) 1.548 (0.431 – 5.558 ; 0.503) 
Mode of Feeding 
Breastfed 1 (Reference) 1 (Reference) 
Bottle-fed 1.638 (-0.535 – 1.522 ; 0.347) 1.409 (-0.730 – 1.415 ; 0.531) 
Mixed - - 
Table 6: Prenatal cumulative distress, maternal history and obstetric outcomes. 
Odds ratios assessing the relationship between prenatal cumulative distress, history 
of psychiatric illness, history of miscarriage, mode of delivery, gestational age at 
delivery and mode of feeding.  Binary logistic regression analysis revealed 
participants with a history of psychiatric illness or specifically depression and 
miscarriage were more likely to be in high cumulative distress group (P < 0.05 *, P < 
0.01 **). Prenatal cumulative distress was associated with increased delivery by 
ELCS (Ordinal regression; P < 0.05 *). Adjusted for maternal age, BMI and social 
class.  
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Figure 6:  
 
 
Figure 6: Placental gene expression. Real time PCR showing (A) HSD11B2, (B) NR3C1 
and (C) FKBP5 expression in the term human placenta between participants in the 
low and high cumulative stress group using the 2-delta-Ct method (Low n=9, High 
n=15; Unpaired Student’s t-test P < 0.05 *). 
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4.6 Discussion: 
The present study adds to the existing literature highlighting a negative role for 
prenatal distress in mediating adverse pregnancy and birth outcomes. Prenatal 
stress is commonly reported during pregnancy and varies in its definition. 
Psychological wellbeing encompasses a broad area of health that expands beyond 
diagnosable mental health disorders such as depression, anxiety and posttraumatic 
stress disorder.  There are a wide range of screening tools used to identify women 
who may be at risk of stress, anxiety and depression that are commonly used to 
measure psychological status in pregnancy. The extensive tools available means 
prenatal stress is commonly defined and assessed in multiple ways which has led to 
significant inconsistencies between studies. To characterise psychological distress in 
this study, we used the Perceived stress scale, State Trait Anxiety Inventory and 
Edinburgh Postnatal Depression. A large meta-analysis demonstrated these 
questionnaires to have excellent reliability and to currently be the best available 
tools to measure stress, anxiety and depressive symptomology during pregnancy 
(Nast et al., 2013).  
The current study does not support a strong association between maternal 
prenatal distress and neonatal outcomes. Although we identified a significant 
reduction in birth temperature among neonates from women with high depressive 
symptoms, and reduced new-born temperature is related to increased infant 
mortality (Soll, 2008), we recommend this result be interpreted with caution as 
infants of mothers who report depression had an average temperature of 36.43 °C, 
and infants are only considered clinically hypothermic when temperature drops 
below 36°C. Additionally the reduced birth temperature observed here may be 
reflective of a slightly higher incidence of caesarean deliveries among the higher 
depressive group, as low operating room temperatures may contribute to reduced 
body temperatures at birth (Duryea et al., 2016). We also found a reduction in the 
five minute Apgar score among babies from the high cumulative stress group. 
Further these babies did not display an increase in Apgar scores from 1 to 5 
minutes. A low 5-minute Apgar score is associated with infant mortality (Thorngren-
Jerneck and Herbst, 2001) and is predictive of poor neurological function later in life 
(Lie et al., 2010) (Moster et al., 2001, Seidman et al., 1991).  
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We also found prenatal anxiety increased the risk of women delivering via 
elective C-Section and delivering before 39 weeks gestation. The reduced gestations 
observed among these women are likely a reflection of the increased rates of 
elective CS in this highly anxious group, which are often scheduled for 39 weeks’ 
gestation (Laye and Dellinger, 2006).  In line with previous studies (Fairlie et al., 
2009), we show that women with high levels of anxiety in late pregnancy were 
more likely to bottle feed their infants prior to hospital discharge. This highlights a 
central role for anxiety in late pregnancy to mediate adverse obstetric outcomes, 
and may have implications for mode of feeding in the post-partum period.  
Fetal over-exposure to maternal cortisol as a mediator of adverse fetal 
outcomes is well described in the literature (Reynolds, 2013). In the placenta, the 
fetus is protected from high levels of maternal cortisol by the actions of the enzyme 
HSD11B2. This enzyme cleaves cortisol into its inactive product cortisone and in 
doing so prevents fetal overexposure to maternal cortisol. Scientific enquires are 
now focusing on this enzyme to be a mediator of prenatal distress (Jensen Pena et 
al., 2012, Seth et al., 2015, Togher et al., 2014, Appleton et al., 2013). Here 
consistent with these studies we demonstrate a significant reduction in the 
expression of placental HSD11B2 in women who were in the high cumulative stress 
group. Additionally we find this group to have elevated levels of the NR3C1 
receptor in the placenta. Maternal distress has previously been shown to increase 
the glucocorticoid receptor, NR3C1 in the placenta (Raikkonen et al., 2014, 
Reynolds et al., 2015). It is worth noting that increased placental NR3C1 may result 
in increased CRF production from the placenta (Bronson and Bale, 2015). Increased 
CRF entry into the fetal compartment may contribute to altered development 
(Cratty et al., 1995). Taken together this data suggests the placenta of women who 
experience distress may not only have a reduced capacity to break down cortisol 
but may also be increasingly sensitive to maternal glucocorticoids.  Further the 
correlation that we observe between NR3C1 expression, placental weight and 
birthweight centiles suggests placental glucocorticoid signalling could lie at the core 
of mediating the adverse effects of maternal distress on birth outcomes.  
Additionally the well described association between these placental genes with 
infant neurodevelopment (Conradt et al., 2013, Sheinkopf et al., 2016) suggests 
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altered placental HSD11B2 and/or NR3C1 expression may be a biomarker for, or 
indicative of, altered neurodevelopment in infancy.   
We identified maternal history of psychiatric illness or miscarriage as 
significant predictors of poorer mental health in pregnancy. This is in line with 
previous studies where women with a history of early pregnancy loss have elevated 
levels of stress, anxiety and depression in subsequent pregnancies (Woods-
Giscombé et al., 2010, McCarthy et al., 2015). Identifying these women and offering 
support measures to reduce the risk of mood disturbance in their current 
pregnancy may be beneficial in reducing neonatal and obstetric complications. Of 
interest prenatal yoga has been shown to enhance positive mood, reduce 
depressive and anxiety symptoms (Davis et al., 2015), and decrease salivary cortisol 
and alpha amylase levels (Kusaka et al., 2016) in pregnancy. Additionally, a 
preliminary trial showed significant improvement in anxiety and depressive 
symptoms in women receiving an antenatal mindfulness intervention (Woolhouse 
et al., 2014). The  ‘Centering Pregnancy’ trial which promotes group prenatal care 
has been shown to reduce rates of preterm birth and enhance breastfeeding 
initiation and is widely implemented across the United States (Ickovics et al., 2007). 
Examining the effectiveness of such strategies in a country specific manner will be 
crucial in progressing clinical practise and promoting interventions to manage 
maternal distress in pregnancy to ultimately improve maternal and birth outcomes 
in this high risk population.   
 
Study limitations 
The current study has several limitations. First the relatively limited sample size in 
this cohort may explain why we do not find an effect with prenatal distress and 
birth and placental weight. Additionally enrolling women after 28 weeks gestation 
precludes our ability to measure any association with extremely PTB. Further the 
earliest age at delivery in this cohort was 37 weeks’ gestation which prevented us 
from investigating an association with pre-term delivery which has a background 
incidence in our population of 4%, lower than the global estimated of 5-10% (Zeitlin 
et al., 2013). The limited ethnicity of our cohort did not allow us to examine any 
ethnic differences, which is an important factor when considering prenatal distress 
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(Borders et al., 2015), however this limitation resulted in a relatively homogenous 
study cohort that reduced the influence of confounding.  Measuring maternal 
distress in late pregnancy only, underscores the importance of other vulnerable 
periods during gestation. It is worth noting however, that the third trimester 
represents a particularity vulnerable developmental period whereby the fetus can 
be affected by maternal perturbations. Finally we were unable to assess or control 
for maternal antidepressant use or lifestyle factors such as exercise, diet, smoking 
or alcohol intake which may mediate the relationship between prenatal distress 
and adverse outcomes (Shapiro et al., 2013).  
 
Conclusions: 
Despite these limitations the current study is important as it identifies prenatal 
anxiety in late pregnancy as a significant factor leading to increased opting for C-
section delivery and increased bottle feeding of infants. Additionally the changes in 
placental HSD11B2 and NR3C1 expression further confirms a role for placental 
glucocorticoid signalling at the core of the programming effects of prenatal distress.   
Further studies conducted longitudinally throughout pregnancy and including both 
psychological and physiological measures of distress in larger and more ethnically 
diverse populations will help to clarify specifically at risk vulnerable individuals. 
Translating these results into prenatal clinics and establishing interventions to 
manage distress in pregnancy will be crucial in reducing morbidities in pregnancy 
and neonates.  
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Chapter 5:  
Placental FKBP51 mediates a link 
between second trimester maternal 
anxiety and birthweight in female 
infants 
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5.1 Abstract: 
Prenatal distress is associated with adverse short and long-term outcomes in 
offspring. Alterations in placental glucocorticoid signalling and fetal overexposure 
to excessive glucocorticoids have been implicated as an underlying mechanism. 
Infant sex is emerging as an important factor in disease susceptibility following 
exposure to prenatal distress and the placental responses of one sex over the other 
is suggested to underlie these differences. This study aimed to examine the effects 
of maternal distress across pregnancy on birth outcomes and placental 
glucocorticoid genes in a sex dependant manner. Nulliparous pregnant women 
completed the Perceived Stress Scale, State Trait Anxiety Inventory and Edinburgh 
Postnatal Depression Scale throughout pregnancy. Glucocorticoid regulating genes 
in the placenta, HSD11B2, NR3C1 and FKBP51 were analysed by real time PCR and 
cortisol was measured in newborn hair as an indicator of fetal exposure. Second 
trimester stress was negatively correlated with birthweight in males and positively 
correlated with NR3C1 in female placenta.  Second trimester anxiety was negatively 
correlated with birthweight and FKBP51 in females only. In mediation analysis, 
placental FKBP51 expression was found to mediate the link between prenatal 
anxiety and birthweight. Newborn cortisol was negatively correlated with second 
trimester anxiety and positively correlated with female placental FKBP51. Again 
FKBP51 mediated the link between anxiety and newborn cortisol. These results 
highlight an important role for FKBP51 in the placental response to prenatal distress 
in females. The precise role that placental FKBP51 has in infant development has 
not been extensively studied and warrants further investigations.  
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5.2 Introduction: 
There is now a large body of evidence showing that the in utero experience is a 
critical determinant of future health (Langley-Evans, 2006, Cao-Lei et al., 2016, 
Todd et al., 2017). One factor that has been extensively studied in this regard is the 
adverse effects of prenatal maternal psychological distress, which we define as the 
experience of significant levels of psychological stress, depression, and/or anxiety 
during pregnancy (Togher et al., 2017) (Khashan et al., 2014). We have previously 
reported the incidence of this in pregnancy using the SCOPE (Screening for 
Pregnancy Endpoints) pregnancy cohort of nulliparous healthy pregnant women 
(Kenny et al., 2014, Larsen et al., 2013). All participants completed a combination of 
validated questionnaires used to assess maternal psychological distress (Khashan et 
al., 2014). These included the 10-item Perceived Stress Scale (PSS) to measure 
psychological stress (Cohen et al., 1983), the 6-item version of State Trait Anxiety 
Inventory (STAI) to measure maternal anxiety (Marteau and Bekker, 1992), and the 
Edinburgh Postnatal Depression Scale (EPDS) to measure maternal depressive 
symptoms in pregnancy (Rubertsson et al., 2011, Cohen et al., 1983). We found that 
15% of women experienced ‘very high levels of perceived psychological stress 
(≥90th percentile score), 18% were classified as being as ‘very highly anxious’ (≥90th 
percentile score), while 15% were classified as being ‘highly likely depressed’ (EPDS 
score >9) (Khashan et al., 2014). Collectively these data have shown that 
approximately one in seven women experience clinically significant levels of 
prenatal maternal psychological distress during pregnancy.  
This is important as numerous epidemiological studies have reported that 
exposure to prenatal maternal psychological distress is a risk factor for a range of 
adverse short and long-term outcomes in affected offspring. These include an 
increased risk of adverse obstetric outcomes including Caesarean delivery, preterm 
birth, low birth weight and babies who are small for gestational age (Liou et al., 
2016, Grote et al., 2010, Ding et al., 2014a, Rose et al., 2016, Togher et al., 2017, 
Khashan et al., 2014). Moreover prenatal maternal psychological distress has been 
proposed to be a risk factor for the development of immune (Flanigan et al., 2016, 
Khashan et al., 2012), metabolic (Entringer, 2013, Entringer et al., 2008) and 
neuropsychiatric disorders (Class et al., 2014, Khashan et al., 2011, Khashan et al., 
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2008a) later in life, with the relative risk varying by offspring sex (Khashan et al., 
2011, Quarini et al., 2016, Mueller and Bale, 2008, Weinstock, 2007). These studies 
highlight the importance of prenatal maternal psychological distress as a risk factor 
for adverse outcomes in exposed offspring; however the causal pathways mediating 
these associations are unclear.  
The glucocorticoid hypothesis is the most widely studied biological 
mechanism proposed to mediate the association between prenatal maternal 
psychological distress and adverse outcomes (Reynolds, 2013).  During pregnancy, 
changes in the maternal hypothalamic-pituitary-adrenal (HPA) axis, leads to an 
exponential rise in cortisol in the maternal circulation (Nolten et al., 1980, Goland 
et al., 1988). This cortisol stimulates the release of corticotrophin releasing 
hormone (CRH) from the placenta that enters the maternal circulation and further 
increases the production of cortisol forming a feed forward loop. As a result 
maternal cortisol levels are up to ten-fold higher than fetal levels  (Riley and Challis, 
1991). This progressive increase in maternal cortisol is necessary for fetal 
organogenesis, however excessive fetal exposure may alter developmental 
trajectories (Togher et al., 2014). The maternal-fetal cortisol gradient is maintained 
by the expression of 11β-hydroxysteroid dehydrogenase type 2 (HSD11B2) in the 
placental trophoblast which converts active cortisol into inactive cortisone (Togher 
et al., 2014).  Additionally, the glucocorticoid receptor (NR3C1) and FKPB51, a 
chaperone protein which regulates nuclear transport of NR3C1 (Zhang et al., 
2008a), play an important role in the fetal response to cortisol. We and others have 
shown that maternal distress particularly in late pregnancy reduces placental 
HSD11B2 expression (Togher et al., 2017, Seth et al., 2015, O'Donnell et al., 2012). 
We also found that glucocorticoid receptor NR3C1 is upregulated by third trimester 
distress (Togher et al., 2017). Increased methylation of placental FKBP51 has been 
reported following early third trimester stress (Monk et al., 2016), however we 
previously observed no change in FKBP51 expression following distress in the third 
trimester (Togher KL, 2017), indicating the need to examine other trimesters. 
Collectively these data suggest that prenatal maternal psychological distress may 
alter molecular mechanisms that regulate fetal exposure to maternal cortisol. 
Importantly alterations in the expression and regulation of HSD11B2, NR3C1 and/or 
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FKBP51 has been linked to poor birth outcomes (Dy et al., 2008, Causevic and 
Mohaupt, 2007, Filiberto et al., 2011) as well as neurobehavioral problems in 
infants (Conradt et al., 2013, Appleton et al., 2015, Marsit et al., 2012, Paquette et 
al., 2014), suggesting that these may play a causal role in mediating the association 
between maternal distress and adverse outcomes.  
In this study we sought to examine the relationships between psychological 
prenatal distress across pregnancy with birth outcomes and placental HSD11B2, 
NR3C1 and FKBP51 expression, as three key mediators of placental cortisol 
signalling. Moreover we undertook causal mediation analysis to determine whether 
any changes in the placental expression of these genes were associated with birth 
outcomes using gender-sensitive methodology.  
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5.3 Methods: 
5.3.0 Participants 
This study received full ethical approval from the Clinical Research Ethics 
Committee of Cork Teaching Hospitals. Nulliparous pregnant women enrolled in the 
IMPROvED study (Navaratnam et al., 2013) at Cork University Maternity Hospital 
were invited to participate in this study. Participants completed the PSS, STAI, and 
EPDS in the second and/or third trimesters of pregnancy. Detailed demographic and 
medical information was acquired from the participants’ medical records. 
 
5.3.1 Newborn Hair Collection and Processing 
Newborn hair was acquired from the posterior vortex of the newborns head within 
24h of birth and stored at room temperature until processing. 1mg of hair was 
incubated in 1 ml of methanol at 50°C for 24 h. Samples were sonicated for 30 min 
at 37 °C followed by another incubation for 24 h 50°C. The supernatant was 
removed and evaporated under nitrogen and the pellet was resuspended in 
Phosphate Buffered Solution. Cortisol concentration was determined by ELISA as 
per the manufacturer’s instructions (Enzo life Sciences). 
 
5.3.2 Placental collection and real-time PCR 
Placenta biopsies were collected from 56 participants within 2h of delivery, washed 
in dH2O and immediately stored at -80°C. RNA was extracted from placental 
samples using Trizol reagent as previously described (Togher KL, 2017). Briefly, 
placental samples were homogenised in Trizol and left on ice for 10 min. Samples 
were centrifuged and the supernatant was incubated in chloroform at room 
temperature for 5min followed by centrifugation for 15min at 4°C to remove the 
aqueous phase. RNA was isolated by incubation of the aqueous phase with 
propanol at room temperature for 10min. Samples were centrifuged and the pellet 
washed in 70% ethanol before resuspension in RNAse free H2O (Sigma). RNA quality 
and quantity were determined by the Nanodrop 1000. RNA was reverse transcribed 
into cDNA (400 ng/ml) using the high capacity cDNA reverse transcription kit 
(Applied Biosystems) under the following parameters: 25 °C for 10 min; 37 °C for 
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120 min; 85 °C for 5 min; 4 °C for at least 10 min. Real time PCR was performed for 
using the following targets; GAPDH, YWAZ, HSD11B2, NR3C1, FKBP51 and IL1B 
(Integrated DNA Technologies; IDT) using the following parameters 50 °C for 2 min; 
95 °C for 10 min; 50 repetitions of 95 °C for 15 s and annealing/elongating at 60 °C, 
as previously described (Togher KL, 2017). All samples were run in triplicate and 
gene expression determined the 2−ΔΔcycle threshold (2dCT) method (Livak and 
Schmittgen, 2002). 
 
5.3.3 Statistical Analysis 
Data analysis was performed on SPSS v22. Normality of predictor and outcome 
variables was tested for using Kolmogorov-Smirnov tests. All questionnaire scores 
were normally distributed. Relationships were determined using linear regression 
analysis. Outliers were determined using a Grubbs test and removed if p < 0.05.  
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5.4: Results: 
5.4.0 Exposure to second trimester maternal anxiety negatively affects female 
birth weight 
We first sought to determine whether maternal psychological distress scores 
affected infant birth weight. To do this we examined the associations between PSS, 
STAI and EPDS scores in the second and third trimester with birth weight (mean = 
3623 ± 460.3 g) (n=55). We found that PSS scores in the second trimester were 
negatively correlated with male (p < 0.05), but not female birth weight (Figure 1a, 
b).  We found no associations between PSS scores in the third trimester and male or 
female birth weight (Table 1). In contrast, second trimester STAI scores were 
negatively correlated with female (p < 0.05) but not male birth weight (Figure 1c, 
d). We found no associations between STAI scores in the third trimester and birth 
weight in male or female infants (Table 1). Similarly, we found no association 
between EPDS scores in the second or third trimester with birth-weight of infants of 
either sex (Table 1). As infant birth weight was significantly altered by maternal BMI 
(β = .31, t (54) = 2.41, p = 0.019) we adjusted our regression model to examine the 
potential confounding effects of maternal BMI. When BMI was included in the 
analyses, the relationship between second trimester PSS scores and male birth 
weight disappeared (aβ = -.32, t (23) = -1.72, p = 0.099). In contrast, second 
trimester anxiety remained correlated with female birth weight when BMI was 
included in the regression model (aβ = -.46, t (26) = -2.71, p = 0.012). These data 
revealed a gender specific effect of maternal anxiety on birth weight in female 
infants. 
 
5.4.1 Placental FKBP51 mediates the association between second trimester 
maternal anxiety and female birth weight 
As second trimester anxiety was associated with female birth weight, we next 
examined the relationship between second trimester STAI scores and three key 
genes involved in glucocorticoid signalling in the placenta, HSD11B2, NR3C1 and 
FKBP51. In agreement with our findings on female birth weight (Figure 1), we found 
a significant negative correlation between second, but not third, trimester STAI 
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scores and placental FKBP51 expression in females (β= -.64, t (25) = -4.10, p < 
0.0001), but not males (β= -.53, t(23) = -1.78, p = 0.09). We found no significant 
associations between STAI scores in the second or third trimester and HSD11B2 or 
NR3C1 expression in males or females. We also found no associations between PSS 
and EPDS scores in the second or third trimester and placental expression of 
HSD11B2, NR3C1 and FKBP51, indicating that this effect appears specific to 
heightened anxiety levels. We subsequently examined if placental FKBP51 
expression was an independent predictor of infant birth weight. There was a 
significant association between placental FKBP51 with birth weight in female (β= 
.54, t (29) = 3.38, p = 0.002) but not male (β= -.16, t (24) = -0.78, p = 0.44) infants. 
These data show that second trimester anxiety (STAI scores) negatively correlated 
with both birth weight and placental FKBP51 in females, and that FKBP51 positively 
correlates with birth weight in females. Given these findings, we hypothesised that 
placental FKBP51 may be mediating the relationship between maternal anxiety and 
female birth weight. In support of this hypothesis when FKBP51 was included into 
the regression model the association between maternal anxiety and female birth 
weight disappeared (β = .19, t (25) = -0.816, p = 0.423) (Figure 2a). These data show 
that the association between second trimester maternal anxiety and female birth 
weight is mediated by placental FKBP51. 
 
5.4.2 Alterations in second trimester maternal anxiety and placental FKBP51 are 
associated with newborn cortisol levels 
The placental and fetal response to glucocorticoids is crucial in determining fetal 
growth outcomes. This is highlighted by studies showing that eexposure to 
synthetic glucocorticoids during pregnancy is associated with reductions in birth 
weight (Khan et al., 2011), with some sex-specific outcomes also observed 
(Stevenson et al., 2000). As FKBP51, negative regulates nuclear transport of NR3C1 
(Zhang et al., 2008a), we hypothesized that this may result in alterations in cortisol 
levels in infants. In an exploratory technique we measured cortisol levels in 
newborn hair as a potential retrospective measure of cortisol exposure in utero. We 
next examined the relationship between maternal distress and infant cortisol levels. 
Maternal PSS or EPDS scores in the second or third trimester did not correlate with 
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infant cortisol levels (Table 4). Surprisingly however, second trimester maternal 
anxiety (STAI) was negatively associated with infant hair cortisol levels (β= -.43, t 
(25) = -2.33, p = 0.028). We next went on to examine the relationship between 
placental genes and birth outcomes with infant cortisol. Placental HSD11B2 (β= -
.02, t (28) = -0.10, p = 0.920) and NR3C1 (β= -.19, t (28) = -1.00, p = 0.325) were not 
related to newborn cortisol. Intriguingly however, FKBP51 expression was positively 
correlated with infant cortisol levels in females only (β= .54, t (13) = 2.23, p = 
0.045). As both maternal anxiety and FKBP51 were related to newborn cortisol 
levels, when we included both in the mediation, the relationship between second 
trimester anxiety (aβ= -.27, t (11) = -0.62, p = 0.550) and FKBP51 (aβ= .30, t (11) = 
0.68, p = 0.510) with newborn cortisol levels disappeared. These data suggest that 
FKBP51 mediates the relationship between second trimester anxiety and newborn 
cortisol levels (Figure 2b). However, there was no correlation observed between 
newborn cortisol levels and infant birth weight. 
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5.5 Tables and Figures: 
Figure 1: 
 
 
 
Figure 1: Scatter plots of birthweight and (A-B) second trimester stress (PSS) and (C-
D) second trimester anxiety (STAI) in males (blue) and females (red). Statistical 
analysis: Univariate linear regression *p < 0.05.  
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Table 1:  
Linear Regression Analysis 
PSS (2
nd
 trimester)  Both Males Females 
Birthweight β=-.18, t50=-1.32, p=0.19 β=-.40, t23=-2.08, p=0.04 β=-.05, t26=-0.25, p=0.79 
Birthweight Centiles β=-.18, t50 =-1.29, p=0.20 β=-.30, t23=-1.50, p=0.14 β=-.16, t26=-0.82, p=0.41 
Gestational Age β=-.18, t50=-1.31, p=0.19 β=-.18, t23=-0.90, p=0.37 β=-.16, t26=-0.16, p=0.41 
PSS (3
rd
 trimester)    
Birthweight β=-.10, t45=-0.71, p=0.47 β=-.24, t20= -1.08, p=0.29 β=-.05, t24=0.25, p=0.80 
Birthweight Centiles β=-.05, t45=-0.37, p=0.70 β=-.15, t20=-0.67, p=0.50 β=.00, t24=0.01, p=0.99 
Gestational Age β=-.15, t45=-1.00, p=0.32 β= -.18, t20=-0.82, p=0.42 β=-.23, t26=-0.85, p=0.39 
STAI (2
nd
 trimester)    
Birthweight β=-.25, t50=-1.85, p=0.07 β=.08, t23=0.39, p=0.69 β=-.43, t26=-2.42, p=0.02 
Birthweight Centiles β=-.19, t50=-1.41, p=0.16 β=-.00, t23=-0.02, p=0.97 β=-.34, t26=-1.80, p=0.08 
Gestational Age β=-.13, t50=-0.91, p=0.36 β=.06, t23=0.30, p=0.764 β=-.23, t26=-1.22, p=0.23 
STAI (3
rd
 trimester)    
Birthweight β=-.28, t45=-1.95, p=0.05 β=-.18, t20=-0.81, p=0.42 β=-.33, t24=-1.70, p=0.10 
Birthweight Centiles β=-.19, t45=-1.33, p=0.18 β=-.19, t20=-0.84, p=0.40 β=-.23, t24=-1.17, p=0.25 
Gestational Age β=-.29, t45=-2.02, p=0.04 β=-.13, t20=-0.59, p=0.56 β=-.36, t24=-1.88, p=0.07 
EPDS (2
nd
 trimester)    
Birthweight β=-.13, t50=-0.95, p=0.34 β=-.15, t23=-0.72, p=0.47 β=-.13, t26=-0.69, p=0.49 
Birthweight Centiles β=-.09, t50=-0.69, p=0.49 β=-.22, t23=-1.06, p=0.29 β=-.10, t26=-0.51, p=0.60 
Gestational Age β=-.20, t50=-1.46, p=0.15 β=-.13, t23=-0.65, p=0.51 β=-.20, t26=-1.04, p=0.30 
EPDS (3
rd
 trimester)    
Birthweight β=-.12, t45=-0.85, p=0.39 β=-.08, t20=-0.37, p=0.70 β=-.14, t24=-0.72, p=0.47 
Birthweight Centiles β=-.06, t45=-0.39, p=0.69 β=-.08, t20=-0.35, p=0.73 β=-.03, t24=-0.15, p=0.87 
Gestational Age β=-16, t45=-1.13, p=0.26 β=-.22, t20=-0.99, p=0.33 β=-.18, t24=-0.90, p=0.37 
Table 1: Prenatal distress and birth outcomes. Linear regression analysis of 
maternal distress across pregnancy and birth outcomes. 
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Table 2:  
Linear Regression Analysis 
HSD11B2  Both Males Females 
2
nd
 trimester    
PSS β=.26, t49=1.88, p=0.06 β=.39, t22=1.99, p=0.06 β=.09, t26=0.47, p=0.63 
STAI β=-.11, t49=-0.80, p=0.42 β=-.11, t22=-0.54, p=0.59 β=-.11, t26=-0.55, p=0.58 
EPDS β=.09, t49=0.67, p=0.50 β=.05, t22= 0.27, p=0.78 β=.07, t26=0.39, p=0.69 
3
rd
 trimester    
PSS β=-.10, t45=-0.70, p=0.48 β=-.20, t20=-0.90, p=0.37 β=-.02 t24=-0.10, p=0.91 
STAI β=-.00, t45=-0.02, p=0.98 β=-.00, t20=-0.02, p=0.97 β=-.01, t24=-0.06, p=0.95 
EPDS β=-.05, t45=-0.34, p=0.73 β=.07, t20=0.33, p=0.74 β=-.14, t24=-0.71, p=0.48 
NR3C1    
2
nd
 trimester    
PSS β=.11, t50=0.80, p=0.42 β=-.14, t23=-0.14, p=0.48 β=.42, t26=2.32, p=0.02 
STAI β=.14, t50=1.03, p=0.30 β=.16, t23=0.78, p=0.44 β=.13, t26=0.66, p=0.51 
EPDS β=.02, t50=0.19, p=0.84 β=-.13, t23=-0.63, p=0.53 β=.16, t26=0.16, p=0.42 
3
rd
 trimester    
PSS β=-.20, t45=-1.39, p=0.17 β=-.31, t20=-1.44, p=0.16 β=-.12, t24=-0.59, p=0.55 
STAI β=-.02, t45=-0.14, p=0.89 β=-.01, t20=-0.07, p=0.94 β=-.02, t24=-0.09, p=0.92 
EPDS β=-.18, t45=-1.25, p=0.21 β=-.24, t20=-1.07, p=0.29 β=-.15, t24=-0.75, p=0.45 
FKBP51    
2
nd
 trimester    
PSS β=-.04, t49=-0.32, p=0.75 β=-.03, t23=-0.17, p=0.86 β=-.08, t25=-0.42, p=0.67 
STAI β=-.46, t49=-3.59, p=0.001 β=-.53, t23=-1.78, p=0.088 β=-.64, t25=-4.10, p=0.000 
EPDS β=-.25, t49=-1.82, p=0.07 β=-.24, t23=-1.15, p=0.25 β=-.33, t25=-1.74, p=0.09 
3
rd
 trimester    
PSS β=-.15, t44=-1.05, p=0.29 β=-.12, t20=-0.53, p=0.60 β=-.21, t23=-1.03, p=0.31 
STAI β=-.21, t44=-1.40, p=0.16 β=-.13, t20=-0.61, p=0.54 β=-.30, t23=-1.50, p=0.14 
EPDS β=-.13, t44=-0.92, p=0.36 β=.07, t20=0.34, p=0.73 Β=-.40, t23=-2.06, p=0.05 
Table 2: Maternal distress across pregnancy and placental gene expression. Linear 
regression analysis of maternal distress across pregnancy and placental HSD11B2, 
NR3C1 and FKBP51 expression. 
  
 157 
 
Table 3:  
Linear Regression Analysis 
HSD11B2 Both Males Females 
Birthweight β=.05, t53=0.36, p=0.72 β=-.17, t23=-0.81, p=0.42 β=.14, t29=0.76, p=0.45 
Birthweight Centiles β=.14, t53=1.04, p=0.30 β=-.07, t23=-0.36, p=0.71 β=.21, t29=1.17, p=0.24 
Gestational Age β=-.01, t53=-0.07, p=0.94 β=-.05, t23=-0.25, p=0.79 β=.05, t29=0.27, p=0.78 
NR3C1    
Birthweight β=-.07, t54=-0.55, p=0.58 β=-.05, t24=-0.24, p=0.80 β=.09, t29=-0.47, p=0.63 
Birthweight Centiles β=-.16, t54=-1.24, p=0.21 β=-.03, t24=-0.15, p=0.87 β=-.26, t29=-1.43, p=0.16 
Gestational Age β=.27, t54=2.09, p=0.04 β=.27, t24=1.36, p=0.18 β=.29, t29=1.64, p=0.11 
FKBP51    
Birthweight β=.21, t53=1.58, p=0.11 β=-.16, t24=-0.78, p=0.44 β=.54, t29=3.38, p=0.002 
Birthweight Centiles β=.21, t53=1.57, p=0.122 β=-.09, t24=-0.43, p=0.67 β=.56, t29=3.51, p=0.002 
Gestational Age β=.02, t53=0.16, p=0.87 β=-.22, t24=-1.11, p=0.27 β=.20, t29=1.06, p=0.29 
Table 3: Placental gene expression and birth outcomes. Linear regression analysis of 
placental HSD11B2, NR3C1 and FKBP51 expression with infant gestational age and 
birthweight.  
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Figure 2:  
 
 
Figure 2: Placental FKBP51 mediates the relationship between prenatal anxiety and 
birthweight in females. Mediation Plots (A) Placental FKBP51 mediates the 
relationship between second trimester maternal anxiety and infant birthweight in 
females. (B) Placental FKBP51 mediates the relationship between second trimester 
maternal anxiety and newborn hair cortisol in females. Statistical Analysis: Linear 
regression analysis.   
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Table 4:  
Linear Regression Analysis 
Newborn Cortisol Both Males Females 
PSS  
(2
nd
 trimester) 
β=-.13, t25= -0.68, p=0.49 β=.12, t13= 0.42, p=0.68 β=-.41, t25= -1.44, p=0.17 
PSS  
(3
rd
 trimester) 
β=-.10, t26= -0.53, p=0.59 β=.01, t13= 0.03, p=0.97 β=-.17, t12= -0.60, p=0.55 
STAI  
(2
nd
 trimester) 
β=-.43, t25= -2.33, p=0.028 β=-.51, t13= -2.06, p=0.06 β=-.51, t11= -1.91, p=0.08 
STAI  
(3
rd
 trimester) 
β=-.16, t26= -0.81, p=0.42 β=-.23, t13= -0.83, p=0.42 β=-.10, t12= -0.36, p=0.72 
EPDS  
(2
nd
 trimester) 
β=-.36, t25= -1.91, p=0.067 β=-.15, t13= -0.54, p=0.59 β=-.42, t11= -1.46, p=0.17 
EPDS  
(3
rd
 trimester) 
β=-.15, t26= -0.80, p=0.42 β=-.04, t13= -0.15, p=0.87 β=-.24, t12= -0.84, p=0.41 
Table 4: Maternal stress across pregnancy and newborn cortisol. Linear regression 
analysis of maternal distress across pregnancy and newborn cortisol levels.  
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Figure 3:  
 
 
 
 
Figure 3: Summary figure. Second trimester maternal anxiety decreases infant 
birthweight in female offspring by inhibiting placental FKBP51. Similarly second 
trimester maternal anxiety reduced fetal cortisol exposure by inhibiting FKBP51 in 
female offspring.   
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5.6: Discussion: 
A large number of women report experiencing psychological distress in their 
pregnancy (Khashan et al., 2014, O'Donnell et al., 2012). This is important as 
prenatal distress has been linked to a wide range of poor obstetric and neonatal 
outcomes as well as an increased risk of disease in childhood and adulthood. Of 
particular importance prenatal distress is commonly linked to birthweight and birth 
size (Bussières et al., 2015). Reduced birthweight remains a significant clinical 
challenge as it is often associated with increased mortality and morbidity (Jeschke 
et al., 2016). Additionally infants of lower birthweights are at an increased risk of 
developmental impairments in childhood, particularity in relation to 
neurodevelopment (Walhovd et al., 2012, Howe et al., 2016). Whilst the poor 
outcomes associated with being born low birthweight are well documented, the 
prenatal determinants linking psychological distress and birthweight are not very 
well understood.  
Here we find the effect of maternal distress on birth outcomes to depend on 
the type of distress, timing of distress and sex of the infant. We initially observed a 
significant relationship between second trimester stress and reduced infant 
birthweight in males. However this association disappeared after adjustment for 
maternal BMI. Most notably we observe a significant negative correlation between 
birthweight and second trimester anxiety specifically, consistent with a recent 
report (Pinto et al., 2017). When stratified based on sex, this relationship was only 
observed in females. This sex difference in relation to birthweight and prenatal 
anxiety has previously being reported where males born from anxious pregnancies 
has increased birthweight compared to male controls, and females born from 
anxious mothers had reduced birthweights compared to female controls (Kaitz et 
al., 2015). Additionally anxious mothers of females are also more likely to develop 
obstetric complications, whereas anxious mothers of males are not (Kaitz et al., 
2014). Male fetuses are generally more vulnerable to the effects of maternal 
distress (Stormer, 2011). It has been postulated that under conditions of adversities 
the male fetus favours growth at the expense of other developmental processes, 
whereas the female fetus conserves growth, thus being born at lower weights but 
with fewer morbidities in late life (Kaitz et al., 2014). In support of this, mid 
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pregnancy exposure to dexamethasone, a synthetic glucocorticoid, was found to 
decrease maternal blood in sinusoids of the female but not male placenta, 
restricted blood flow may mechanistically explain restricted growth in female 
fetuses  (O'Connell et al., 2017). 
At a biological level, sex specific responses in the placenta to maternal 
perturbations may explain why one sex is more vulnerable over the other (Clifton, 
2010). In particular sex specific responses to maternal glucocorticoids, or more 
specifically how the placenta regulates glucocorticoids differentially may play a role 
(Hodyl et al., 2010, Cuffe et al., 2017). In this study we focused on three genes in 
the placenta involved in glucocorticoid regulation; HSD11B2, NR3C1 and FKBP51. 
Inconsistent with our previous work (Togher et al., 2017) and work of others (Seth 
et al., 2015), we do not observe a reduction in HSD11B2 following prenatal distress, 
however the mean stress score in this population was relatively low and the effect 
of maternal stress on HSD11B2 expression has been shown to be dependent on 
severity (Welberg et al., 2005). Second trimester maternal stress increased NR3C1 
expression in female placentae. Additionally we find increased placental NR3C1 to 
be related to increased gestational age irrespective of sex. This increase in NR3C1 
we observe among females but not males could again represent an adaptive 
response of the female placenta in response to maternal distress.  
FKBP51 is a chaperone protein that stimulates translocation of the 
glucocorticoid receptor into the nucleus, resulting is less available receptor for 
glucocorticoid binding and subsequently reduced glucocorticoid response (Zhang et 
al., 2008a). Consistent with previous reports (Monk et al., 2016, Kertes et al., 2016) 
we find prenatal distress to reduce placental FKBP51 expression. Importantly we 
find placental FKBP51 to mediate a relationship between second trimester anxiety 
and infant birth weight in females only, suggesting a critical role for this chaperone 
protein in the female fetal response to maternal anxiety. As FKBP51 regulates the 
glucocorticoid receptor, reduced expression my result in increased receptor 
availability for cortisol binding and subsequently increased placental production of 
Cortisol releasing factor (CRF). Increased CRF may in turn alter fetal developmental 
trajectories (Glover, 2015). As such, a retrospective examination of maternal, 
placental and/or fetal CRF would be of interest. 
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We hypothesised that placental changes in FKBP51 would result in 
alterations in fetal cortisol. Indeed we observed a positive correlation between 
placental FKBP51 and newborn cortisol in females only. Of particular interested 
second trimester anxiety was the only distress variable that influences newborn 
cortisol levels. Following our mediation we show second trimester maternal anxiety 
decreases newborn cortisol levels by reducing FKBP51 in female placenta. Although 
newborn cortisol exposure was not related to birth outcomes this may be another 
mechanism by which the placenta protects the female fetus from maternal distress.  
The current study has a number of limitations. We first acknowledge the 
small sample size and suggest this research be carried out in a larger scale, although 
appreciate the difficulties in running large scale placental collection studies (Burton 
et al., 2014). However even with this limited sample we observe clinically significant 
observations. Although we report significant associations with prenatal distress and 
birthweight we would like to highlight that only one (1.8%) infant in this cohort was 
born <2500g, the WHO estimate for clinically defined low birthweight (World 
Health Organisation, 2004).  
Overall this study is important as it identifies a crucial role for the timing of 
distress, the type of distress and fetal sex in the relationship between prenatal 
distress and placental gene expression. This adds to the existing literature 
supporting a role for alterations in placental glucocorticoid signalling following 
prenatal distress. To our knowledge this is the first study to identify an association 
between placental FKBP51 and infant birthweight. Importantly we identify this gene 
to be a key mediator underlying a relationship between prenatal anxiety and 
birthweight in females, which highlights the crucial role placental signalling, has, in 
terms of exposure to maternal distress and infant development. The identification 
of this relationship warrants further investigation into the precise role that FKBP51 
has in fetal development. 
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6.1 Abstract: 
The experience of prenatal maternal stress is associated with high rates of adverse 
obstetric outcomes and altered infant development. The mechanisms underpinning 
this may be linked to inappropriate remodelling of the maternal microbiome during 
pregnancy and subsequent vertical transmission of a suboptimal microbiome at 
birth. The current study aimed to assess the association between prenatal maternal 
stress and the maternal gut, vaginal and infant microbiome in a clinical population. 
Nulliparous pregnant women completed stress, anxiety and depression 
questionnaires and provided saliva and fecal samples in the second and third 
trimester of pregnancy. Vaginal swabs were collected at the time of delivery. Infant 
fecal samples were obtained at 1wk, 2wks, 3wks, 3mo and 5mo. Microbial 
community structure was analysed by 16S rRNA gene sequencing. Second 
trimester stress and depressive symptoms were associated with a reduced 
diversity of the second trimester maternal gut microbiota.  Second trimester 
cortisol was associated with increased diversity of the third trimester gut 
microbiota and reduced diversity of the vaginal microbiota. Infants born from 
pregnancies experiencing higher stress in the second trimester had increased 
alpha diversity and reduced relative abundance of fecal Bifidobacteria and 
Lactobacilli. Conversely, third trimester depressive symptomology was related to 
reduced alpha diversity in the infant gut microbiota. Infant gut colonization was 
also influenced by newborn cortisol levels.  Further studies are required to clarify 
the implications of these stress-induced microbial alterations for obstetric 
outcomes and infant development.   
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6.2: Introduction: 
The experience of maternal psychological stress (stress, anxiety and/or depressive 
symptomology) during pregnancy is associated with the development of a number 
of obstetric complications including preterm birth (Shapiro et al., 2013, Staneva et 
al., 2015, Khashan et al., 2009), growth restriction (Khashan et al., 2014) and low 
birth weight (Khashan et al., 2008b, Hasanjanzadeh and Faramarzi, 2017). Infants 
exposed prenatally to high maternal psychological distress are at an increased risk 
of developing diseases of metabolic (Ingstrup et al., 2012, Hohwu et al., 2014, Li et 
al., 2013a), immune (Khashan et al., 2012, Chiu et al., 2012, Suh et al., 2017) and 
nervous systems (Khashan et al., 2011, Class et al., 2014) in childhood and 
adulthood. The underlying biological mechanisms linking maternal distress to 
adverse outcomes particularly in humans are unclear, but fetal overexposures to 
stress-induced elevations in maternal glucocorticoids have been a primary focus 
(Reynolds, 2013). However, it is now known that stress and the associated activity 
of the hypothalamus–pituitary–adrenal axis can influence the composition of the 
gut microbiota in a bidirectional fashion, however the functional consequences of 
this have only begun to emerge (Clarke et al., 2013, Clarke et al., 2014b). Most 
recently, pre-clinical studies have proposed that stress-related alterations in 
maternal microbiota during pregnancy and subsequently vertical transmission of 
this stressed microbiota to the infant during parturition is a potential mechanism 
linking prenatal maternal stress to infant neurodevelopment (Jasarevic et al., 2014).  
Bacterial colonization of the infant gastrointestinal tract largely begins at 
birth as the baby ingests its mother’s vaginal microbes during passage through the 
birth canal (Milani et al., 2015). Over the first weeks/months of a newborn’s life, 
the microbial populations continue to be established with influences from birth 
mode and environmental sources playing a major role in the developmental 
trajectory of the infant gut microbiota. This establishment of the infant gut 
microbiota in early life overlaps with critical periods of immune (Dimmitt et al., 
2010), metabolic (Backhed, 2011) and nervous system (Borre et al., 2014, Sudo et 
al., 2004) development and as such, alterations to the developmental trajectory of 
the infant microbiota may increase disease risk.  Gestational age (Cong et al., 2016), 
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antibiotic use (Azad et al., 2016), mode of delivery (Hill et al., 2017)  and mode of 
feeding (Thompson et al., 2015) are critical determinants of the infant microbiome.  
Recently prenatal stress has been associated with altered seeding and 
development of the infant gut microbiota. In rodents, a chronic stress paradigm in 
early pregnancy was found to disrupt the vaginal and infant gut microbiome, 
notably a reduction in lactobacilli in both, suggesting direct transmission during 
birth (Jasarevic et al., 2015a). Additionally, stressed-induced microbial changes 
were related to alterations in gut metabolic profiles and amino acid availability in 
the hypothalamus (Jasarevic et al., 2015a). Most recently, pregnancy stress has 
been shown to disrupt the maternal gut, in addition to vaginal and infant microbial 
communities in rodents (Jasarevic et al., 2017, Golubeva et al., 2015). In rhesus 
monkeys, stress in late pregnancy was found to reduce the abundance of 
bifidobacteria and lactobacilli in the infants gut (Bailey et al., 2004). Only one study, 
to our knowledge, has examined this relationship in a clinical cohort, whereby 
maternal anxiety and cortisol levels in late pregnancy were related to reduced 
lactobacilli and bifidobacteria and increased pathogenic bacteria in infants gut. 
Furthermore, this stress-associated microbial signature was related to allergic 
symptoms at 3 months of age. However, in this study maternal distress was only 
assessed in late pregnancy and focused primarily on measures of anxiety without 
concurrent maternal microbiota assessments (Zijlmans et al., 2015b).  
To our knowledge, no previous clinical study, has prospectively examined 
the impact of pregnancy stress on the prenatal maternal gut and vaginal microbiota 
and subsequently infant gut microbiota seeding and assembly. Additionally, 
whether a trimester specific effects exists has not yet been explored. The current 
study aims to address this limitation using a well phenotyped clinical sample 
population, assessing both psychological and physiological measures of maternal 
stress in the second and third trimesters of pregnancy and using high throughput 
16S gene sequencing to analyse microbial community structure in the maternal gut, 
vagina and infant gut microbiota.  
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6.3: Methods: 
6.3.0 Subject Recruitment, samples and data collection  
This study received full ethical approval from the Clinical Research Ethics 
Committee of Cork Teaching Hospitals. For detailed protocol see Appendix A. 
Nulliparous healthy pregnant women enrolled in the IMPROvED study at Cork 
University Maternity hospital (CUMH) between September 2015 and August 2016 
were invited to participate in this study (Navaratnam et al., 2013). 111 pregnant 
mothers and subsequently their offspring participated in this study. Inclusion 
criteria for this study included being enrolled in the IMPROvED study (Navaratnam 
et al., 2013) Provide details of inclusion and exclusion criteria. Participants were 
asked to complete the Perceived stress Scale (PSS; stress), State Trait Anxiety 
Inventory (STAI; anxiety) and Edinburgh Postnatal Depression Scale (EPDS; 
depressive) in the second and/or third trimesters of pregnancy. In both trimesters, 
participants were asked to collect saliva and fecal samples at home and store at 4°C 
until transport to CUMH within 24h of collection. Saliva samples were collected 
using Salivettes (Sarstedt) at four time points; upon waking, 30min after waking, 60 
min after waking and 180min after waking. Fecal samples were collected in plastic 
containers containing Anaerobic Sachets (Fisher Scientific). Vaginal swabs were 
acquired when participants where admitted to CUMH just prior to delivery. Parents 
collected fecal samples from their infants at home and stored them at 4°C until 
transport to CUMH in coolers within 24h. All samples were stored at -80°C until 
processing.  
 
6.3.1 Maternal cortisol concentration 
Saliva samples were thawed on ice and cortisol concentration was determined by 
Enzyme Linked Immunosorbent Assay (ELISA; Enzo life Sciences) according to the 
manufacturer’s instructions. The cortisol awakening response (CAR) was 
determined by calculating the area under the curve with respect to ground (AUCG) 
(Pruessner et al., 2003).  
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6.3.2 Newborn cortisol concentration 
A hair sample was collected from the newborn infant’s head within 24h of birth. 
1mg of hair was incubated in 1 ml of methanol at 50°C for 24 h. Samples were 
sonicated for 30 min at 37 °C followed by another incubation for 24 h at 50°C. The 
supernatant was removed and evaporated under nitrogen and the pellet was 
resuspended in phosphate buffered solution. Cortisol concentration was 
determined by ELISA as per the manufacturer’s instructions (Enzo life Sciences).  
 
6.3.3 DNA extraction from fecal samples 
Prior to extraction, fecal samples were thawed on ice. Maternal fecal samples were 
added to a tube containing Qiagen Lysis Buffer and a mix of sterile zirconia beads 
(Thistle Scientific). The sample was homogenised for 90 sec using the MagnaLyser 
Instrument (Roche) and incubated at 90 °C for 5 min. Samples were centrifuged and 
the supernatant transferred to a clean tube.  DNA extraction proceeded according 
to the manufacturer’s instructions (Qiagen DNA stool Mini Kit). DNA was extracted 
from vaginal swabs and infant fecal samples in a slightly adapted method to 
improve DNA yield as previously described (Yu and Morrison, 2004).  
 
6.3.4 Sequencing 
Preparation of DNA samples for 16S sequencing was performed according to the 
manufacturer’s instructions (Illumina). DNA was amplified to the V4 region of the 
bacterial 16S rRNA under the following parameters; 95°C for 3 min, 25 cycles of 
95°C for 30 sec, 55°C for 30 sec and 72°C for 30 sec and finally 72°C for 5 min before 
being held at 4°C. The PCR product was cleaned using AMPure XP beads and 5µl of 
supernatant was transferred to a new PCR plate where PCR was performed with 
Nextera XT index primers under the same conditions as mentioned above. The 
product was cleaned again using AMPure XP beads and the final product was 
analysed on a Bioanalyser DNA 1000 chip for quality assurance (size ~630bp). 
Samples were diluted and sequenced by the Miseq Illumina System. 
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6.3.5 Outcome measures 
We analysed the maternal gut microbiome in the second and third trimester of 
pregnancy, the vaginal microbiome prior to delivery and the infant gut microbiome 
at 1, 2 and 3 weeks and 3 and 5 months. Chao1 Index, Shannon Index, Simpson 
Index, Phylogenetic diversity and number of species were used as indicators of 
alpha diversity. Bacterial OTUs were analysed at phylum, family and genus levels.  
 
6.3.6 Statistical Analysis 
For the EPDS, we ranked women scoring equal to and above 9 as exhibiting high 
depressive symptoms and those scoring below 9 as exhibiting low depressive 
symptoms as previously described (Navaratne et al., 2016). For the PSS, STAI and 
CAR women were ranked as scoring high or low if they scored above or below the 
mean respectively. As scoring in maternal distress questionnaires was not 
significantly correlated with salivary cortisol levels we treated maternal cortisol 
concentration as an independent variable.  As the infant gut differs based on mode 
of delivery (Hill et al., 2017), we examined the infant gut in vaginally and caesarean 
delivered infants separately. Here we report the results for vaginally delivered 
infants only. Distribution was tested using Kolmogorov-Smirnov tests; p < 0.05 non-
normal distribution and p > 0.05 normal distribution.  Following normality testing, 
unpaired student t-tests were used to calculate differences between alpha diversity 
indices. Phylum, family and genus levels were analysed by Mann Whitney U-tests. 
Results were deemed significant if p < 0.05. Statistical analysis was performed using 
R and SPSS.  
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6.4: Results: 
6.4.0 Maternal Demographics and descriptive statistics 
The final cohort consisted of 111 nulliparous pregnant women. 95 (85.5%) women 
completed the questionnaires in the second trimester (Mean Gestational Age (GA): 
20 ± 0.92) and 79 (71.1%) women completed the questionnaires in the third 
trimester (Mean GA: 32 ± 3.62). The cortisol awakening response was available for 
79 (71.1%) and 75 (67.5%) women in the second and third trimesters, respectively. 
The mean (± SD) age and BMI of this cohort were 30.6 ± 4.4 and 25.4 ± 3.8 
respectively. Maternal demographics and descriptive statistics can be found in 
(Appendix D, Table 1 & 2).The mean PSS, STAI, and EPDS were 13.88 ± 5.32, 4.61 ± 
3.63 5.77 ± 4.40 in the second trimester and 11.22 ± 5.87, 4.94 ± 3.40 and 5.66 ± 
4.64 in the third trimester, respectively.  
 
6.4.1 Correlations between psychological and physiological stress  
We first sought to identify any correlations between the four measures of maternal 
stress. Maternal stress (β=.03, t76=.25, p=0.79), anxiety (β=.00, t76=.06, p=0.94) or 
depressive (β=-.09, t76=-.08, p=0.41), scores in the second trimester did not 
correlate with second trimester maternal cortisol (AUCg). Similarly maternal stress 
(β=.17, t64=1.39, p=0.16), anxiety (β=.15, t64=1.27, p=0.20) or depressive (β=.15, 
t76=1.23, p=0.22) scores in the third trimester did not correlate with third trimester 
maternal cortisol (AUCg). There was a positive correlation between second 
trimester anxiety and third trimester maternal cortisol (β=.28, t64=2.36, p=0.02). As 
there were no strong correlations observed between maternal psychological and 
physiological stress, we treated these as four independent distress variables. 
 
6.4.2 Second trimester stress and depressive symptomology shapes the diversity 
and composition of the bacterial communities in the maternal gut 
We next examined the effect of maternal distress in the second trimester on the 
maternal gut microbiome in the second trimester. High stress was associated with 
reduced species richness of the maternal gut in the second trimester (p < 0.05). At 
family level, women with high stress had a reduction in the dominant 
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Ruminococcaceae (p < 0.05). High depressive symptoms was associated with 
reductions in species richness and diversity (Figure 1a-c), increased 
Faecalibacterium (p < 0.05) and reduced Ruminococcaceae uncultured (Figure 1j). 
Second trimester anxiety or cortisol had little effect on the second trimester 
maternal gut microbiome with only a few alterations observed in non-dominant 
genus (Appendix D). We examined if second trimester distress altered the maternal 
gut microbiome in the third trimester. Second trimester stress, anxiety and 
depressive symptoms did not impact the maternal gut in the third trimester (Figure 
1d-f, k; Appendix D).  High cortisol in the second trimester was associated with 
increased alpha diversity (p < 0.05), Erysipelotrichaceae and Peptostreptococcaceae 
uncultured and decreased Alcaligenaceae (p < 0.05) in the third trimester gut 
(Appendix D). Third trimester distress measures had minimal effect on the maternal 
gut microbiome (Figure 1g-i, l, Appendix D). This suggests that second, but not third 
trimester maternal distress, markedly disrupts the composition of the maternal gut 
microbiota.  
 
6.4.3 Second trimester maternal cortisol correlated with reduced diversity of the 
vaginal microbiome 
Research from rodents suggests that stress induced changes in the maternal vaginal 
microbiome are vertically transmitted to the infant during parturition (Jasarevic et 
al., 2015a).  To test this, we acquired vaginal samples from women just prior to 
giving birth. We found a significant association between second trimester anxiety 
and reduced abundance of the dominant Streptococcaceae (p < 0.01) in the 
maternal vagina. Second trimester stress and depressive symptoms had no effect 
on the vaginal microbiota ((Figure 2a-i).). The vaginal microbiome of women who 
had elevated cortisol in the second trimester displayed reduced species richness 
and diversity compared to non-stressed controls (Figure 2j-l). Third trimester stress 
did not alter the diversity or composition of dominant bacteria in the maternal 
vagina. Of note, there was a trend towards reduced richness of vaginal 
communities by both second and third trimester maternal stress (p < 0.1) (Appendix 
D).  
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6.4.4 The development of the infant gut microbiota is influenced by the timing 
and nature of the prenatal distress exposure 
Second trimester distress: 
The diversity of the infant gut microbiota was increased when women were 
exposed to high second trimester stress at 3wk, 3mo and 5mo (Figure 3a-e). At a 
compositional level, prenatal stress was associated with a number of alterations:  
increased Firmicutes and Veillonellaceae and reduced Bifidobacteriaceae, 
Bacteroidaceae and Porphyromonadaceae at 3wks (p < 0.05), increased Firmicutes 
(p < 0.05) and Erysipelotrichaceae (p < 0.01) and decreased Bifidobacteriaceae (p < 
0.05) and Lactobacillaceae (p < 0.01) at 3mo and increased Clostridiaceae and 
decreased Lactobacillaceae at 5mo (p < 0.05) (Figure 3f, g). Maternal anxiety was 
associated with reduced Actinobacteria (p < 0.01) and Nocardiaceae and increased 
Lactobacillaceae at 1wk (p < 0.05), reduced Nocardiaceae and decreased 
Clostridiaceae 1 at 3mo (p < 0.05) and decreased Clostridiaceae 1 at 5mo (p < 0.05).  
Veillonellaceae was increased at 1wk in infants of mothers who had high depressive 
symptoms (p < 0.05). The diversity of the infant gut at 2wks was reduced in the 
group with high maternal cortisol (Shannon & Simpson Index; p < 0.05). High 
cortisol was also related to reduced Bacteroidetes (p < 0.05), Coriobacteriaceae (p < 
0.001) and Porphyromonadaceae (p < 0.05) at 2wk, reduced Enterococcaceae at 
3wks (p < 0.05), reduced Coriobacteriaceae at 3mo (p < 0.05) and reduced 
Coriobacteriaceae and Veillonellaceae at 5mo (p < 0.05) (Appendix D). 
 
Third trimester distress: 
Coriobacteriaceae was reduced in infant gut microbiota at 2wks by high third 
trimester stress (p < 0.05). At 3wk and 3mo, Nocardiaceae was reduced by high 
maternal stress (p < 0.05). At 1wk old Clostridiaceae was elevated in the high 
maternal anxiety group (p < 0.05) while at 2wks, Nocardiaceae was reduced by high 
anxiety (p < 0.05) and at 5mo of age, Lachnospiraceae was reduced (p < 0.05) by 
maternal anxiety. The diversity of the infant gut was reduced at 1wk and 2wks 
following high depressive symptomology in the third trimester (p < 0.05). At 1wk, 
Clostridiaceae 1 was increased (p < 0.05), at 2wks Nocardiaceae was reduced and at 
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5mo Erysipelotrichaceae was reduced (p < 0.05) by maternal depressive symptoms. 
High maternal cortisol in the third trimester was associated with reduced 
Coriobacteriaceae at 2wks and increased Actinobacteria and Bifidobacteriaceae at 
3mo (p < 0.05) (Appendix D).  
 
6.4.5 Infant cortisol 
We finally examined if the infant gut microbiome development could be influenced 
by in utero stress exposure. In an exploratory analysis we used new born hair as a 
retrospective indicator of fetal exposure to cortisol in the last month of pregnancy.  
New born hair cortisol was available for 49 infants with a mean concentration of 
2579.28 ± 1072.32 ng/ml. There was a positive correlation between infant hair 
cortisol levels and the diversity of the infant gut at 3wks ((β= .27, t (62) = 
2.23, p =0.029) and 5mo (PD; β= .37, t (32) = 2.24, p =0.032 & Species; β= .36, t (32) 
= 2.17, p =0.037) (Figure 4). For compositional analysis, infants were grouped as 
having high or low hair cortisol levels if they scored above (high) or below (low) the 
mean.  At 2wks, high cortisol was related to reduced abundance of Collinsella (p < 
0.05). At 3mo old, there was a reduction in Coriobacteriaceae and Enterococcaceae 
(p < 0.05) with high cortisol, whilst Collinsella and Lachnospiraceae uncultured were 
reduced at 5mo (p < 0.05).  
 
6.4.6 Potential Confounders 
There was a positive correlation between maternal age and Chao1 Index at 1wk (p < 
0.05).  As none of our predictor variables correlated with Chao1 Index at 1wk, no 
further adjustments were performed including maternal age. Maternal BMI across 
pregnancy was negatively correlated with maternal cortisol in the third trimester 
(p < 0.01) and the diversity of the infant gut at 1wk (p < 0.01). BMI in the third 
trimester also positively correlated with the diversity of the vaginal microbiome. 
We subsequently adjusted our analysis of the vaginal microbiome and second 
trimester cortisol for maternal BMI, which did not influence this relationship (aβ=-
.40, p =0.021), suggesting the effect of maternal cortisol on the vaginal microbiome 
is independent of BMI.  
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6.5: Figures and Figure Legends: 
Figure 1: 
 
Figure 1: Maternal depressive symptoms in the second trimester alters the diversity 
and composition of the second trimester maternal gut: (A-I) Box-whisker plots 
showing the alpha diversity of the maternal gut by depressive symptoms. The top 
and bottom of each box are the 25th and 75th percentiles of the samples, 
respectively. The line in the middle of each box is the sample median. Whiskers 
extend to the upper and lower 95% confidence interval of the median.  (J-K) Heat 
maps show the relative abundance of dominant genus in the maternal gut by 
maternal depressive symptoms. (A-C, J) maternal second trimester gut by second 
trimester depressive symptoms (EPDS < 8 low N=36, EPDS > 9 high N=10), (D-F, K) 
maternal third trimester gut by second trimester depressive symptoms (EPDS < 8 
low N=23, EPDS > 9 high N=8), (G-I, L) maternal third trimester gut by third 
trimester depressive symptoms (EPDS < 8 low N=25, EPDS > 9 high N=8). (A-I) 
Unpaired Student t-test *p < 0.05, (J-L) Mann Whitney U-tests *p < 0.05. 
Abbreviations: Edinburgh Postnatal Depression Scale (EPDS). 
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Figure 2: 
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Figure 2: Second trimester maternal cortisol reduces the diversity and richness of 
the vaginal microbiome. Box-whisker plots showing the diversity of the maternal 
vaginal microbiome by second trimester maternal stress. The top and bottom of 
each box are the 25th and 75th percentiles of the samples, respectively. The line in 
the middle of each box is the sample median. Whiskers extend to the upper and 
lower 95% confidence interval of the median. Bar graph demonstrating the relative 
abundance of dominant phyla (abundance greater than 1%) in the maternal vagina 
by second trimester distress. (A-C) Vaginal microbiome by second trimester stress 
(PSS < 13 low N=21, PSS > 14 high N=31), (D-F) vaginal microbiome by second 
trimester anxiety (STAI < 4 low N=31, STAI > 5 high N=21), (G-I) vaginal microbiome 
by second trimester depressive symptoms (EPDS < 8 low N=39, EPDS > 9 high 
N=13), (J-L) vaginal microbiome by second trimester cortisol (CAR < 545131 low 
N=29, CAR > 545132 high N=19). Unpaired Student’s t-test; * p < 0.05. 
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Figure 3: 
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Figure 3: Infant gut colonization is altered by second trimester maternal stress: 
Diversity and composition of the infant gut at 1wk, 2wks, 3wks, 3mo and 5mo by 
the experience of maternal stress (PSS) in the second trimester. (A) Chao1 index, 
unpaired students t-test p < 0.05 *, (B) Simpson index, unpaired students t-test  < 
0.01 **, p < 0.05 * (C) Shannon index, unpaired students t-test p < 0.05 *, (D) 
Phylogenetic diversity, unpaired students t-test p < 0.05 *, (E) Number of species, 
unpaired students t-test p < 0.05 *, (F) Bar charts of dominant phyla in the infant 
gut by maternal stress in the second trimester. Each colour represent a different 
phyla. Mann Whitney U-tests p < 0.05 *. (G) Heat map showing the relative 
abundance of dominant families in the infant gut by second trimester maternal 
stress. Lowest abundance blue and highest abundance red.  Mann Whitney U-tests; 
p < 0.01 **; p < 0.05 *.  
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Figure 4: 
 
 
Figure 4: Diversity of the infant gut differs based on newborn hair cortisol levels: 
alters the Correlation bubble plot of newborn cortisol levels with alpha diversity of 
the infant gut. Bubble colour corresponds to standardized beta coefficient. Size of 
bubble is equal for all variables. Univariate linear regression analysis; * p <0.05. 
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6.6: Discussion: 
The establishment of the infant gut microbiome is a key developmental process 
that contributes to postnatal maturation of the immune, metabolic and nervous 
systems (Borre et al., 2014, Mueller et al., 2015a). This is evident by a number of 
studies showing disruption to microbiome development in early life precedes the 
onset of a number of disorders in childhood including diabetes, eczema, and 
asthma (Abrahamsson et al., 2014, Fujimura et al., 2016, Kostic et al., 2015, Wang 
et al., 2008). Understanding factors that might influence early bacterial colonization 
of an infant’s gut is therefore important. Indeed delivery mode (caesarean versus 
vaginal), gestational age at delivery, pre-/post-natal antibiotic exposure and mode 
of feeding (formulae versus breast) have emerged as key regulators of infant 
microbiome development (Hill et al., 2017, Fallani et al., 2010, Mueller et al., 2015a, 
Yassour et al., 2016, Groer et al., 2014, Smith and Morin, 2005, Zijlmans et al., 
2015a, Jasarevic et al., 2015b). More recently prenatal maternal stress is emerging 
an important contributor influencing the development of infant microbiome 
(Jasarevic et al., 2017, Jasarevic et al., 2015a), however this has only been examined 
once in a human cohort, with limited measures of prenatal maternal stress 
(Zijlmans et al., 2015b).   
To explore the impact of prenatal stress on infant microbiome development 
we collected fecal samples form infants a 1wk, 2wks, 3wks, 3mo and 5mo old. As 
mode of delivery is considered an important contributor to microbiome 
development (Hill et al., 2017), we examined vaginal delivered infants only. We 
found a main effect for maternal stress in the second trimester, infants whose 
mothers had high PSS scores had increased diversity of the infant gut at 3wks, 3mo 
and 5mo. This is consistent with one other study in a human population where 
prenatal distress was also found to be associated with increased overall diversity of 
the infant gut across the first 115 days of life (Zijlmans et al., 2015a), although 
distress here was measured in very late pregnancy and we find this effect specific to 
second trimester stress. The consequence of increased bacterial diversity this early 
on in life is unclear in contrast to during adulthood where higher diversity is 
associated with health. Infants born by C-section typically have a microbial 
signature characterised by reduced diversity (Hill et al., 2017). Conversely, formula 
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feeding is associated with increased diversity, in comparison to exclusive 
breastfeeding (O’Sullivan et al., 2015, Gritz and Bhandari, 2015). Typically reduced 
alpha diversity in infancy has been suggestive of an adverse microbial environment 
as reduced diversity has been linked to the development of eczema, asthma and 
type-1 diabetes in childhood (Abrahamsson et al., 2014, Abrahamsson et al., 2012, 
Kostic et al., 2015). However, most recently increased alpha diversity measured at 1 
year of age was found to correlate with poorer cognition and changes to grey 
matter volumes in infants by the age of 2 (Carlson et al., 2017), suggesting 
physiological systems may respond differently to the degree of diversity of the 
infant gut that is likely dependant on infant age. Indeed the increased diversity we 
observed here among the infants from high stressed pregnancies corresponds to a 
period of increased Clostridiaceae and decreased Bifidobacteriaceae and 
Lactobacillaceae, which could be suggestive of an adverse microbial ecosystem. 
Bifidobacteria are known to be master colonizers of the infant gut, which feed on 
human milk oligosaccharides in breastmilk, have anti-inflammatory properties and 
decrease intestinal permeability (Underwood et al., 2015). Reduced abundance of 
Lactobacilli and Bifidobacteria have been observed in infants with colic (de Weerth 
et al., 2013b, de Weerth et al., 2013a) and enrichment of Bifidobacteria is generally 
associated with healthier infants (Zheng et al., 2016). The importance of 
Bifidobacteria is highlighted by its use as a probiotic to treat disorders in neonates 
including colic and necrotizing enterocolitis (Di Gioia et al., 2014). The reductions of 
these beneficial bacteria appears to be a hallmark of prenatal stress as a number of 
preclinical and clinical studies have reported similar reductions in Bifidobacteria and 
Lactobacilli (Zijlmans et al., 2015a, Bailey et al., 2004). Interestingly, Zijlmans and 
colleagues show that a reduction in lactic acid bacteria, including Lactobacilli, was 
associated with the development of allergic and gastrointestinal symptoms at 3 
months of age (Zijlmans et al., 2015a). Although we did not measure physiological 
parameters of disease in these infants, the stressed microbial signature we 
observed suggests these infants may be at an increased risk of developing certain 
disorders. Indeed a further follow-up of these infants to examine immune and 
nervous system function would be of interest.  
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It is largely accepted that the fetus develops in a sterile environment in 
utero and receive their first microbes at birth when the amniotic membranes 
rupture and as they pass through the birth canal.  During this process the microbes 
of the maternal vagina are vertically transmitted to the infant (Milani et al., 2015, 
Asnicar et al., 2017b). In rodents it has been shown that a stress-induced microbial 
signature is vertically transmitted from mother to infant at birth (Jasarevic et al., 
2015a). Although we were unable to directly correlate stress-induced vaginal 
microbe changes with that of the infant gut, our results do not strongly support the 
transmission of a stressed microbiome at birth. Indeed, we found that the vaginal 
microbiome was most notably influenced by maternal cortisol levels in pregnancy, 
whereas the infant gut was not. Similarly, second trimester perceived stress (and 
third trimester depressive symptoms) which we have linked to alterations in the 
infant gut microbiome, did not impact the vaginal microbiome. This suggests there 
may be other mechanisms by which maternal stress could influence the 
development of the infant gut microbiome.  
Fetal overexposure to glucocorticoids during development may be one such 
mechanism. Examining fetal stress exposures in utero remains a methodological 
challenge. Analysis of newborn hair after birth is a novel approach to explore fetal 
exposures in the final months of gestation (Kapoor et al., 2014a). Here, we 
measured cortisol in hair samples from newborns acquired within 24h of birth. We 
found newborn cortisol levels to positively correlate with the diversity of the infant 
gut at 3wks and 5mo old and segregate infants into a number of compositional 
changes at varying ages. To our knowledge, this is the first attempt to examine the 
impact of in utero cortisol exposure of infant microbiome development. The 
alterations we observe suggest that fetal exposure to glucocorticoids during 
development may also play a role in establishment of the infant microbiome, 
suggesting another mechanism independent of vertical transmission, which may be 
important to microbial succession.  
To date, most studies have examined the role of environmental factors that 
primarily alter infant gut colonization, with very little focus being placed on 
maternal bacterial communities. To characterize the impact of prenatal distress on 
the maternal gut microbiome throughout pregnancy, we collected fecal samples 
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from healthy nulliparous pregnant women in the second and/or third trimester of 
pregnancy. We observed a number of changes in the maternal gut of women with 
high perceived stress in the second trimester including reduced species richness 
and reduced abundance of the dominant family Ruminococcaceae, a family with an 
important role in energy metabolism (Gosalbes et al., 2011). The maternal gut was 
most profoundly influenced by depressive symptoms in the second trimester with 
reduced species richness and diversity of the second, but not third trimester 
maternal gut microbiome. This decrease in alpha diversity indices of the gut 
microbiome has recently been demonstrated in a cohort of clinically depressed 
patients (Kelly et al., 2016a). The consequence of this reduced microbial diversity in 
the maternal gut warrants further investigations.  Among the general population 
reduced diversity has been link to metabolic type symptoms including insulin 
resistance, increased adiposity and increased inflammation (Le Chatelier et al., 
2013). Further reduced alpha diversity of the gut in first trimester of pregnancy has 
been linked to high serum zonulin, a marker for intestinal permeability (Mokkala et 
al., 2016). Of interest increased intestinal permeability has been observed among 
pregnant women with intrahepatic cholestasis (Reyes et al., 2006). At the 
compositional level, maternal depressive symptoms were associated with reduced 
Ruminococcaceae uncultured and increased abundance of Faecalibacterium of the 
Clostridiaceae family. Whether the changes we observed here have implications for 
obstetric or neonatal outcomes remains to be determined.  
The current study has a number of limitations. Firstly the cut-off scores we 
used to define high and low stress, anxiety and cortisol were based on group means 
which may or may-not be clinically meaningful. Further we grouped women as 
having high depressive symptomology with EPDS scores greater than 9. Typically, an 
EPDS score greater than 13 is used to detect depressive symptomology in 
pregnancy (Su et al., 2007) although generating more accurate and specific scoring 
of the EPDS is currently a topic of scientific enquiry (Thombs et al., 2015). None the 
less we observed significant alterations in the maternal microbiome even with this 
low EPDS cut-off. We did not measure physiological parameters in the infants 
therefore we do not yet know the consequences, if any, of these microbial changes 
for infant health. As the current study had a number of predictor variables we 
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acknowledge the limitation of using multiple testing in this cohort. However we 
highlight this research as exploratory and descriptive but an important starting 
point in examining the impact of prenatal distress on the maternal and infant 
microbiome. 
Overall, this study supports a role for maternal stress as an important 
contributor to the development of the infant gut microbiome, although most likely 
independent from direct vertical transmission from the mother at birth. The 
concept that maternal mental health may influence infant microbial succession is 
relatively new and the consequences that these changes could have for infant 
health needs to be further investigated. Indeed alterations in early gut colonization 
may be another biological mechanism by which prenatal maternal stress 
programmes adverse infant development. Additionally, we observed substantial 
alterations in the maternal gut microbiome by second trimester stress, particularly 
depressive symptomology. Such alterations could have an impact on maternal 
prenatal health, and as such, the role that these changes may have on pregnancy 
and neonatal outcomes should be further examined. Our study may have 
implications for both the mother and the infant with second trimester prenatal 
distress in particular associated with marked alterations in both the maternal and 
infant microbiome. Lower prenatal distress is associated with benefits for both the 
maternal microbiome, in terms of increased diversity, and the infant microbiome in 
terms of increased relative abundance of beneficial bacteria such as Bifidobacteria. 
Further studies are required to tease apart the mechanisms underpinning these 
effects and to provide an evidence base for beneficial preventative stress-reduction 
or microbiota-based interventions during pregnancy that will improve both 
maternal and offspring health. 
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Chapter 7: 
General Discussion 
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Summary of results: 
The present thesis focused on exploring the biological factors that may underlie the 
relationship between maternal prenatal distress and adverse pregnancy and infant 
outcomes. The current literature positions fetal overexposure to glucocorticoids 
during critical periods of development as the primary link. More recently, 
alterations in the infant gut microbiome are emerging as another potential 
component in this complex relationship. Though this is a topic that is being 
extensively studied in preclinical environments, its translation into clinical cohorts 
has not been well examined. Understanding the mechanisms that underlie the link 
between maternal exposure to prenatal distress and the risk of adverse offspring 
outcomes is a major healthcare objective. Not only will this further our 
understanding of this relationship at a biological level, but it will enable the 
development and implementation of appropriate therapeutic strategies to manage 
or reduce the impact of maternal distress in pregnancy, with an ultimate objective 
to reduce adverse pregnancy and infant outcomes.  
 In the first phase of this thesis I undertook an in vitro experiment to explore 
the impact of potential biological stress mediators on the placental expression of 
HSD11B2, a critical regulator of fetal glucocorticoid exposure (Togher et al., 2014).  
This study found that high dose cortisol and the pro-inflammatory cytokine, IL-1β 
downregulated the expression of placental HSD11B2 following 24h of exposure. 
Previous work has shown HSD11B2 to be downregulated in the placenta of women 
who report high distress in pregnancy, particularly in the third trimester (O'Donnell 
et al., 2012, Seth et al., 2015). As cortisol and IL-1β are elevated in the plasma of 
stressed women (Coussons-Read et al., 2007, Davis and Sandman, 2010, Seth et al., 
2015), our results suggest psychological stress-induced increases in these 
compounds may be the biological mechanism by which prenatal distress alters 
placental HSD11B2 expression. Epigenetic regulation is emerging as the key 
molecular mechanism through which prenatal distress alters HSD11B2 expression, 
with many studies focusing primarily on DNA methylation (Monk et al., 2016). Using 
an in vitro approach, my work confirms a role for DNA methylation in HSD11B2 
regulation (Appendix B, Supplementary Fig. 2), but more specifically identifies 
HDACs as important directors of HSD11B2 expression. I found that pharmacological 
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inhibition of these HDACs prevented cortisol and IL-1β induced reductions in 
HSD11B2 expression, highlighting the potential of targeting epigenetic modifiers to 
prevent HSD11B2 alterations in pregnancy. Of particular interest for interventions 
in the prenatal period, the epigenome can be influenced and modified by dietary 
components as well as the gut microbiome (Pham and Lee, 2012, Stilling et al., 
2014).  
 In my next study (Chapter 4), I moved to a clinical cohort to explore the 
influence of prenatal distress on pregnancy and birth outcomes and further 
examine the interaction between prenatal distress and placental gene expression. 
Although the role that maternal prenatal distress plays in contributing to an 
increased risk of adverse outcomes has been extensively studied (Ding et al., 2014a, 
Grote et al., 2010, Accortt et al., 2015), significant variation exists largely due to the 
extensive range of tools used to assess and define maternal distress, which 
incorporates environmental exposures, ranging from subjective reports of daily life 
stress using questionnaires to major life events such as exposure to bereavement, 
war and famine.  In this study, I focused on three well-validated psychological 
screening tools that measure different aspects of distress; the Perceived Stress 
Scale (PSS; stress), the State Trait Anxiety Inventory (STAI; anxiety) and the 
Edinburgh Postnatal Depression Scale (EPDS; depressive symptoms). These well-
validated questionnaires have previously been used to capture the maternal 
experience of distress in a similar cohort in Cork (Khashan et al., 2014, Larsen et al., 
2013). A recent systematic review identified these questionnaires as the most 
accurate psychometric instruments to examine distress in pregnancy (Nast et al., 
2013). Using these questionnaires (in the late third trimester), I identified that 
women with a history of psychiatric illness and/or miscarriage are at an increased 
risk of experiencing distress in their pregnancy. Identifying at risk individuals is 
important as it will allow increased surveillance of these women in the prenatal 
period. Moreover, I found that women who report high anxiety were up to five 
times more likely to deliver via elective caesarean section (CS) and two times less 
likely to breastfeed their infant. Formulae feeding is linked with an increased risk of 
illness in childhood (Martin et al., 2016b). The long-term effects of delivery by CS 
are the subject of intense scrutiny (Stevens et al., 2009, Curran et al., 2016, Curran 
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et al., 2015). I analysed the placentae of the women who scored high in all three 
distress questionnaires and those who scored low in all three distress 
questionnaires to create a cumulative distress group. I found, consistent with 
previous reports (Seth et al., 2015, O'Donnell et al., 2012), a reduction in placental 
HSD11B2 mRNA expression among the high distress group. Additionally, I observed 
an increase in the expression of the glucocorticoid receptor (NR3C1) in the 
placentae from the high distress women. The decrease in HSD11B2 with a 
corresponding increase in NR3C1 suggests that the fetus may have been exposed to 
increased levels of cortisol throughout their pregnancy, although an assessment of 
fetal cortisol would be required to confirm this assumption. 
 For the next part of this thesis I recruited a second cohort of pregnant 
women (SMArTI cohort) from the IMPROvED study (Navaratnam et al., 2013) at 
Cork University Maternity Hospital. This cohort yielded a final population of 111 
healthy nulliparous pregnant women who completed the PSS, STAI, EPDS, 
Pregnancy Distress Questionnaire (PDQ), Pittsburgh Sleep Quality Index (PSQI), 
Childhood Trauma Questionnaire (CTQ), Food Frequency Questionnaire (FFQ) and 
questionnaires relating to gastrointestinal function in the second and/or third 
trimesters of pregnancy. Women provided corresponding saliva samples for cortisol 
analysis and fecal samples for 16S rRNA gene sequencing. At the time of delivery, 
vaginal swabs for 16S rRNA sequencing, newborn hair for cortisol analysis and 
placental samples were acquired. Infant fecal samples were subsequently collected 
over the first 5 months of life for 16S rRNA sequencing. Biological samples were 
collected in excess and bio-banked for future studies (subject to ethical approval). 
Final numbers of data and samples collected can be found in Appendix A. 
 From this cohort, I went on to further study the relationship between 
prenatal distress and placental genes involved in glucocorticoid signalling. This 
cohort allowed us to assess distress in both the second and third trimester of 
pregnancy, where I found an association between second trimester anxiety and 
placental gene expression that was dependant on fetal sex.  Most notably, I found 
anxiety in the second trimester to negatively correlate with infant birthweight and 
birthweight centiles in female infants only. I also observed a positive correlation 
between second trimester maternal anxiety and the expression of FKBP51 in the 
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placentae of female infants. Of particular interest, the relationship between second 
trimester maternal anxiety and infant birthweight in females was found to be 
mediated by placental FKBP51. FKBP51 is a chaperone protein that regulates NR3C1 
(Stechschulte and Sanchez, 2011). The precise role of FKBP51 in the placenta 
remains understudied; however, FKBP5 methylation levels have recently been 
linked to poorer neurodevelopment (Paquette et al., 2014). In a novel and 
exploratory technique, I used newborn hair to measure newborn cortisol levels as a 
potential indicator of fetal cortisol exposure in utero (Kapoor et al., 2016). I found 
second trimester maternal anxiety to negatively correlate with newborn cortisol 
levels, a relationship again found to be mediated by placental FKBP51 in female 
infants. Although newborn cortisol levels were not related to infant birthweight, it 
may be possible that cortisol may influence developmental processes that could 
influence disease risk later in life. This study highlights an important role for 
placental FKBP51 in the placental response to prenatal distress in female infants. 
 In the final stage of this thesis I explored the microbiome as an alternative 
biological mechanism potentially linking prenatal distress to adverse outcomes. I 
first examined if the maternal gut microbiome in the second and third trimester 
differed based on maternal distress (PSS, STAI, EPDS and cortisol). An association 
between second trimester depressive symptoms and the second trimester maternal 
gut microbiome was observed. Women who were ranked as having higher 
depressive symptoms in the second trimester had gut microbiomes characterised 
by reduced species richness and diversity. This microbial phenotype has previously 
been observed among a cohort of depressed patients (Kelly et al., 2016b). The 
consequence that this may have for pregnancy and neonatal outcomes warrants 
further investigation.  
 Preclinical studies suggest that stress induced alterations in the vaginal 
microbiome are transmitted to the infant at birth (Jasarevic et al., 2015b, Jasarevic 
et al., 2015a); therefore I examined the vaginal microbiome just prior to delivery. 
The vaginal microbiome remained largely unchanged by second and third trimester 
psychological distress (PSS, STAI and EPDS), however the diversity of the vaginal 
microbiome was reduced in women with a high second trimester cortisol 
awakening response. I subsequently analysed the infant gut microbiome of 
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vaginally delivered infants at 1wk, 2wks, 3wks, 3mo and 5mo old.  I found that 
vaginally delivered infants born to women who reported high second trimester 
perceived stress had an increased alpha diversity of their gut microbiome at 3wk, 
3mo and 5mo along with corresponding decreases in the beneficial 
Bifidobacteriaceae and Lactobacillaceae and increased Clostridiaceae, suggestive of 
an adverse microbial environment. As the maternal vaginal microbiome remained 
unchanged by second trimester stress and the emergence of the infant microbial 
phenotype was evident from 3wks and not at earlier ages, this work does not 
support vertical transmission of a stressed microbiome during birth. Conversely 
infants born to women with high depressive symptomology in the third trimester 
displayed reduced alpha diversity at 1wk and 2wks but not at later ages.   
 
Placental HSD11B2  
The most commonly proposed biological mechanism to be mediating the effects of 
prenatal distress on adverse pregnancy outcome is the glucocorticoid hypothesis. 
This hypothesis proposes that fetal overexpose to glucocorticoids alters fetal 
developmental trajectories that confers disease risk in later life (Reynolds, 2013). 
The glucocorticoid hypothesis is supported by many studies that have linked 
maternal cortisol levels in pregnancy to adverse outcomes in affected children 
(Rondo et al., 2010, Rondó et al., 2010, Bolten et al., 2011, Baibazarova et al., 2013, 
Buss et al., 2012a, Davis and Sandman, 2010). However, some studies do not 
support this relationship (Bergman et al., 2010a, Baibazarova et al., 2013) and the 
work presented in this thesis, consistent with other reports, demonstrates maternal 
psychological distress is not always accompanied by elevations in maternal cortisol 
(Baibazarova et al., 2013, Hompes et al., 2012, Davis and Sandman, 2010, Bergman 
et al., 2010b). Failure to find a correlation between psychological and physiological 
stress in pregnancy could be reflective of the difficulties in accurately assessing 
cortisol levels as described in the introduction of this thesis.  In light of this, 
placental HSD11B2 is an integral part of the glucocorticoid hypothesis. In the 
placenta HSD11B2 converts cortisol into its inactive cortisone, thereby controlling 
the amount of cortisol the fetus is exposed to (Togher et al., 2014). Anything that 
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therefore reduces placental HSD11B2 has the potential to allow glucocorticoid 
overexposure. Of note, prenatal distress is often accompanied by elevations in 
maternal cytokines and noradrenaline, both of which have been shown to 
downregulate placental HSD11B2 (supported by the work presented in Chapter 3 of 
this thesis) (Kossintseva et al., 2006, Sarkar et al., 2001).  Therefore, stress induced 
increase in maternal cortisol is not the only mechanism by which maternal stress 
may induce increased fetal glucocorticoid exposure and examination of placental 
HSD11B2 levels may be a more accurate barometer of the glucocorticoid 
hypothesis.  
In chapter 4 of this thesis I found that maternal distress in late pregnancy 
was associated with reduced placental expression of HSD11B2. This is consistent 
with previous reports (Seth et al., 2015, O'Donnell et al., 2012). However, in our 
second cohort, described in chapter 5, maternal distress was not associated with 
the same decrease. Of note, the mean stress score in the SMArTI cohort was slightly 
lower than the cohort from chapter 4 and the effect of maternal stress on HSD11B2 
expression has been shown to be dependent on the severity of the stress exposure, 
with acute stress upregulating its expression and chronic stress causing a 
downregulation (Welberg et al., 2005).  Notably in the SMArTI cohort, I observed a 
trend towards a significant increase in HSD11B2 mRNA expression in placenta from 
male infants with high second trimester stress. This result is consistent with another 
study demonstrating socioeconomic adversity in pregnant women to be related to 
reduced methylation, and thus increased expression of placental HSD11B2 
(Appleton et al., 2013) and when stratified by sex this effect was only seen in males 
(Appleton et al., 2013).  This upregulation of HSD11B2 in the male placenta could 
result in the fetus not being exposed to sufficient amounts of cortisol at a critical 
window of organ development. Alternatively, this stress induced increase could be 
an adaptive mechanism whereby the placenta is attempting to protect the fetus 
from maternal cortisol. Indeed fetal exposure to elevated maternal cortisol in mid-
pregnancy decreases infant physical and neuromuscular maturation in male 
offspring only (Ellman et al., 2008), suggesting males may be particularity 
vulnerable to fluctuations in maternal hormones at this time.  
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FKBP51: a novel player in fetal programming 
Mutations in FKBP51 are commonly associated with stress reliance, depressive 
behaviour and anxiety type disorders (O'Leary et al., 2013) and in mice, 
pharmacological inhibition of FKBP51 can reduce anxiety like behaviours (Hartmann 
et al., 2015). The relationship I observe here between maternal anxiety and 
placental FKBP51 is striking and the increase in FKBP51 could be reflective of a 
genetic increase in the mother which then appears in the placenta, it would be of 
interest to examine FKBP51 in maternal circulation. FKBP51 interacts with steroid 
hormones receptors through chaperone heat shock protein 90 (HsP90), inhibiting 
the activation of the glucocorticoid receptor and the progesterone receptor (PR) 
and increasing the activation of androgen receptor (Stechschulte and Sanchez, 
2011). The precise role of FKBP51 in the placenta and fetal development has not yet 
been examined; therefore it is difficult to frame the biology underlying the 
association between maternal anxiety, placental FKBP51 and birthweight. It would 
be plausible to speculate a role for fetal cortisol exposure, as I found placental 
FKBP51 to positively correlate with newborn cortisol levels; however I identified no 
association between newborn cortisol and birthweight. Alternatively, the inhibitory 
action of FKBP51 on the progesterone receptor may underlie this relationship. 
Progesterone supplementation is commonly administered to women at risk of PTB 
and women who receive progesterone are less likely to deliver a preterm or LBW 
infant (Dodd et al., 2005). As the relationship I observed between placental FKBP51 
and birthweight was specific to females, it is of particular interest that increased 
maternal serum placental progesterone in the first trimester was found to be 
associated with increased birthweight in females, with no significant effect on 
males (Hartwig et al., 2013). Therefore, it may be possible that the inhibitory 
actions of FKBP51 on the PR may underlie the link between maternal anxiety and 
female birthweight. None the less our finding, together with the previously 
reported relationship between placental FKBP51 methylation and neurobehavioral 
problems in infants (Paquette et al., 2014), suggests placental FKBP51 as a novel 
player in fetal programming. 
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Prenatal depressive symptoms influence the maternal gut microbiome.   
The prenatal maternal microbiome is emerging as an important contributor to 
maternal and infant health (Dunlop et al., 2015, Solt, 2015). In particular, 
alterations to the vaginal microbiome in pregnancy is now commonly linked to 
adverse pregnancy outcomes (Hyman et al., 2014, Jayaprakash et al., 2016, Kwak et 
al., 2014, Dunlop et al., 2015). Very little research has focused on the impact that 
the maternal gut microbiome may have for pregnancy health despite studies that 
have shown gut microbial communities to be important in physiological parameters 
in pregnancy (Koren et al., 2012). One study that examined the effect of the 
maternal gut and vaginal microbiome in relation to PTB found the maternal gut but 
not vaginal microbiome was predictive of PTB. In particular, women that went on to 
deliver preterm had a great abundance of Clostridium, Lactobacillus and 
Bacteroides (Shiozaki et al., 2014). The maternal gut microbiome has been shown to 
be influenced by maternal factors such as gestational diabetes, weight gain and BMI 
(Singh et al., 2017). This thesis identifies maternal depressive symptoms to be 
another potential contributor to maternal gut bacterial communities. This may have 
important consequences for pregnancy health. When the microbiome from 
depressed patients was transplanted into germ free animals, the depressed 
phenotype also appeared to be transplanted suggesting the microbiome is a driving 
force contributing to depressive symptoms (Kelly et al., 2016b). This is exciting as it 
highlights the potential of targeting the microbiome to improve depressive 
symptoms, which would be of particular importance in the pregnant population to 
move away from or avoid pharmacotherapies. The impact that the depressive-
associated microbial changes I observed in this thesis have for obstetric and 
neonatal outcomes remains to be determined. The extensive database collected as 
part of the SMArTI cohort will allow us to examine such associations in the future.  
 
Questioning vertical transmission? 
According to the sterile womb hypothesis, a fetus develops in a sterile environment 
and is only exposed to its first microbes at birth through vertical transmission, when 
the baby ingests its mothers’ vaginal microbes as it travels through the birth canal 
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(Mueller et al., 2015a, Asnicar et al., 2017a). Preclinical studies have shown that 
maternal prenatal stress alters the composition of the maternal microbiome, and 
this stressed microbiome is then vertically transmitted to the infant at birth 
(Jasarevic et al., 2015a, Jasarevic et al., 2017). The work presented in this thesis is 
the first time, to my knowledge; this has been examined in a clinical population and 
does not directly support this hypothesis. Here I find the vaginal microbiome, but 
not the infant microbiome, is altered by second trimester maternal cortisol. 
Conversely the infant microbiome, but not the vaginal microbiome is altered by 
second trimester maternal psychological stress. This suggests an alternative 
mechanism of action may play a role; potential mechanisms are proposed below.  
 Maternal prenatal distress can impair the development of the fetal HPA axis, 
which may result in permanent changes in HPA functioning in the postnatal period. 
This has been shown in both human and animal models (Emack et al., 2008, Kapoor 
and Matthews, 2005, Diego et al., 2004, Oberlander et al., 2008, Brennan et al., 
2008, Grant et al., 2009, Yehuda et al., 2005). The microbiome can influence the 
HPA axis, likewise the HPA axis can influence the microbiome, and this is one of the 
mechanisms behind the bidirectional communication between gut microbes with 
the brain (Foster et al., 2017). Therefore alterations to the developing HPA by 
PNMD might impact the microbial communities in the infant gut postnatally. In this 
thesis, I measured cortisol in newborn hair which may be more reflective of cortisol 
exposure in utero as opposed to  HPA axis functioning in the newborn (Kapoor et 
al., 2014b). It would have been beneficial to examine HPA axis functioning in these 
infants through blood or salivary cortisol measures at corresponding time points to 
fecal sample acquisition.  
 Although I did not examine maternal care in the postpartum, it may be 
possible that maternal behaviours in the postnatal period could contribute to the 
alterations I observed in the infant gut in relation to the second trimester maternal 
stress. Indeed the experience of stress in pregnancy is associated with an increased 
risk of depression in the postpartum period as well as poor mother-infant bonding 
(Robertson et al., 2004, Rossen et al., 2016) and maternal cortisol levels in the 
postpartum have been shown to influence maternal behaviours (Fleming et al., 
1987, Fleming et al., 1997).  Although the influence that maternal care may have on 
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infant microbiome development has not been examined in clinical populations, in 
rodents maternal separation has been shown to be associated with perturbations in 
the early gut microbiota (O'Mahony et al., 2009). Additionally in preterm infants, 
maternal skin-to-skin care has been shown to influence oral microbial communities 
in the neonate (Hendricks-Munoz et al., 2015) suggesting the potential of maternal 
behaviours in the early postnatal period to influence the infant microbiome. 
 Infant feeding practises is a major determinant of the composition of the gut 
microbiome (O’Sullivan et al., 2015, Guaraldi and Salvatori, 2012). Bifidobacteria 
and Lactobacilli are abundantly expressed in breast milk and are directly 
transmitted to the infant during feeding (Soto et al., 2014, Solis et al., 2010). 
Additionally human milk oligosaccharides found in breast milk provide a food 
source which allows Bifidobacteria to flourish (Wickramasinghe et al., 2015, 
Underwood et al., 2015). As a result, breastfed infants are dominant in 
Bifidobacteria, whereas bottle fed infants have higher amounts of Bacteroides and 
Clostridium (Fallani et al., 2010, Penders et al., 2006). Additionally, breastfed infants 
typically have reduced alpha diversity compared to infants that are formulae fed 
(O’Sullivan et al., 2015, Backhed et al., 2015). In this thesis, I show infants born from 
high stressed pregnancies have increased alpha diversity with reduced abundance 
of Bifidobacteria and Lactobacilli, similar to the profile of bottle fed infants. Indeed 
in our cohort infants born from women with high second trimester stress have a 
higher percentage of bottle-feeding than breastfeeding (albeit not statistically 
significant) (Appendix D). Therefore, an increased preference of formulae feeding in 
the high stressed pregnancies may contribute to the alterations I observe in the 
infant microbiome. Although this cohort was not designed to and does not have the 
power to analyse such an association, it would be of interest to examine any 
potential mediating effect of feeding mode on the relationship between maternal 
stress and the infant microbiome in future studies.  
 Another mechanism by which prenatal stress might impact infant 
microbiome development could be through altering the composition of breast milk. 
Although to our knowledge the composition of the milk microbiome in stressed 
women has not been examined, the milk microbiome is susceptible to modification 
by maternal factors as both maternal weight in pregnancy and mode of delivery has 
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been shown to influence the microbial composition of breastmilk (Cabrera-Rubio et 
al., 2012, Gomez-Gallego et al., 2016). As well as having its own microbiome, 
human breastmilk contains many bioactive substances including immune 
cells/molecules and steroids which are transferred to the infant by feeding (Gomez-
Gallego et al., 2016). Of particular interest, cortisol has been detected in breastmilk 
and levels of cortisol in breastmilk have been shown to be related to temperament 
in infants (Grey et al., 2013, Sullivan et al., 2011). Additionally, maternal distress in 
the postpartum was found to correlate with immune markers in breastmilk 
(Kawano and Emori, 2015). Collectively, this data suggests the potential for a 
stressed microbiome to be vertically transmitted from mother to infant through 
breastmilk as oppose to, or in addition to, vaginally during parturition. 
 In rodents, prenatal and early life stress have been associated with impaired 
intestinal barrier function (Soderholm et al., 2002, Gareau et al., 2006, Golubeva et 
al., 2015) and the microbiome plays a role in modulating the integrity and structure 
of the gastrointestinal tract (Jandhyala et al., 2015). It may therefore be possible 
that maternal perturbations in this period could influence the development of the 
gastrointestinal tract that may have consequences for microbial assembly in the 
postnatal period. Of interest, I found an association between second, but not third, 
trimester stress and the infant gut microbiome and the second trimester is a period 
whereby the fetal gastrointestinal system undergoes substantial growth 
(Marnerides et al., 2012, Zalel et al., 2003). 
   
Second trimester window of vulnerability: 
This work presented from the SMArTI cohort in chapters 5 and 6 identifies the 
second trimester as a critical developmental window whereby the fetus may be 
most vulnerable to the effects of maternal experience of distress. Indeed, the 
importance of second trimester adversities is well documented in the literature. 
Maternal use of cocaine primarily in the second trimester is associated with poorer 
infant development (Richardson et al., 2008). Second trimester maternal distress 
using the same psychological assessments I used increased the risk of SGA (Khashan 
et al., 2014). Similarly, Class and colleagues identified mid-gestation exposure to 
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severe life events, particularly in months 5 and 6 of pregnancy, heightened the risk 
for PTB, LBW and SGA (Class et al., 2011). The vulnerability of the second trimester 
is further evident by a number of studies identify second trimester stress 
specifically to predict poorer neurodevelopment in infants (King and Laplante, 
2005, Glynn et al., 2001, Buss et al., 2010, Buss et al., 2011). The second trimester is 
a period of rapid fetal growth, particularly for the fetal brain (Buss et al., 2012b). 
Further, the fetal HPA response becomes active from 20 weeks of pregnancy (Gitau 
et al., 2001), therefore maternal stress arising in this period may have a more 
detrimental impact on fetal HPA axis functioning. Additionally, it has been 
suggested that by the third trimester of pregnancy the maternal HPA no longer 
responds to stressors, due to the natural surge of maternal cortisol and it has been 
postulated that as pregnancy advances women become more resistant to the effect 
of psychological stress (Kammerer et al., 2002, Glynn et al., 2008).  In line with this 
the natural increases in placental HSD11B2 with advancing pregnancy may further 
protect the fetus from the effects of maternal stress in the third trimester (Schoof 
et al., 2001). 
 
Therapeutic Implications: 
This thesis adds further support to the adverse role that prenatal distress can have 
for pregnancy and infant outcomes. Whilst there are no standardized estimates for 
the prevalence of distress in pregnancy, there is sufficient evidence to conclude a 
significant proportion of women will experience some form of distress throughout 
their pregnancy (Khashan et al., 2014). Therefore, it is important to understand 
more about the biology of prenatal distress to optimize intervention strategies, in 
the hope of improving psychological symptoms among pregnant women and 
reducing the risk of adverse outcomes for both mother and baby. 
Placental HSD11B2 is the first line of defence protecting the developing 
fetus from excessive glucocorticoid exposure. I, along with others (Seth et al., 2015, 
Appleton et al., 2013) have shown this enzyme to be downregulated by third 
trimester maternal distress which could suggest fetal overexposure to maternal 
cortisol. Therefore, preventing downregulation of HSD11B2 by maternal distress 
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would be of interest for the fetus. This thesis has identified HDACs as important 
regulators of HSD11B2, and found HDAC inhibition could prevent decreases in 
HSD11B2 under condition of stress and inflammation, therefor targeting HDACs to 
increase HSD11B2 expression may be of therapeutic benefit. Excitingly, HDACs can 
be modified by diet which represents an optimal intervention strategy for pregnant 
women (Togher et al., 2014). 
In chapter 4 I identified that maternal anxiety in late pregnancy was 
associated with increased risk of delivery by elective CS. CS without medical 
indication is associated with an increased risk of adverse outcomes for both the 
mother and infant (Souza et al., 2010, Steer and Modi, 2009, Finn et al., 2016). The 
prevalence of caesarean delivery is on the rise (Betrán et al., 2016). The WHO 
estimates indicate that in the year 2008, 3.18 million CS were necessary whilst 6.20 
were performed with a total excess cost of 2.32 billion (Gibbons et al., 2010) 
therefore elective CS delivery not only represents a significant health problem for 
mom and child but also a global economic burden. Based on our results reducing 
anxiety among pregnant women may be one potential strategy to reduce the rates 
of CS deliveries. 
In chapter 6, I found that the maternal gut microbiome was altered by 
maternal depressive symptoms. The consequence of this alteration for pregnancy 
outcomes needs to be determined; however it highlights the potential of targeting 
the gut microbiome to potentially reduce depressive symptoms in pregnancy. 
Indeed probiotics have been suggested to be safe for use in pregnancy (Elias et al., 
2011) and a recent meta-analysis among the general population concluded 
probiotics to be effective at alleviating depressive symptoms (Wallace and Milev, 
2017).  Therefore probiotics and/or prebiotics have the potential to be an exciting 
new therapeutic avenue used to managing mental health in pregnancy. Exploring 
new means to manage depression in pregnancy is particularly important given the 
potential adverse effects antidepressants may have for infant development 
(Oberlander et al., 2006). 
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Strengths and limitations:  
The main strength of this work is the prospective longitudinal cohort study design 
employed in the SMArTI cohort with high quality phenotyping and accompanying 
bio-samples. Recently the first human study to examine the impact on PNMD on 
infant microbiome development was published (Zijlmans et al., 2015a). This first 
limitation to this study was the measurement of PNMD in the third trimester only 
and using questionnaires very specific to anxiety as oppose to stress and 
depression. I have overcome this in the SMArTI cohort by prospectively examining 
multiple aspect of PNMD in both the second and third trimester of pregnancy. The 
cohort would have been further strengthened if I were also able to capture these 
parameters in the first trimester, however this was not a possibility for my work 
having recruited from the IMPROvED cohort where compulsory visits only began in 
the early second trimester (Navaratnam et al., 2013).The second, and largest 
restriction to the study published by Zijlmans and colleagues was not assessing the 
maternal microbiome and focusing primarily on the microbiome of infants (Zijlmans 
et al., 2015a). This means the SMArTI cohort, that I have collected here, is the very 
first time the microbiome has been looked at in pregnancy in relation to maternal 
mental health. This study will therefore have important implications for novel 
approaches to how we manage mental health in pregnancy. The final advantage of 
the SMArTI study, over that of the study conducted by Zijlmans, is the longer 
assessment of the infant microbiome. The final infant sample time point I collected 
was at 5 months of age, as compared to 3 months in the Zijlmans study (Zijlmans et 
al., 2015a). 
 The next advantage of the SMArTI cohort is the clinical phenotyping of 
PNMD. In addition to the in-depth analysis of trimester specific effects, I employed 
both psychological and physiological measurements of maternal distress. I 
measured maternal HPA activity by collecting saliva samples from the participants 
over 4 time-points across the morning, allowing me to assess the cortisol 
awakening response (CAR). Measuring the CAR overcomes many of the 
methodological challenges and downfalls of other studies utilizing single time point 
measures (Stewart et al., 2015) and/or measuring cortisol levels in serum samples 
(Aardal-Eriksson et al., 1998, LeWinn et al., 2009, Baibazarova et al., 2013). 
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Additionally the psychometric instruments I used to assess psychological distress 
(PSS, STAI and EPDS) have been shown to be the most reliable questionnaire based 
approach to examine PNMD in pregnancy (Nast et al., 2013). 
 The quality of the biobank I produced from the SMArTI study will allow for 
many more investigations that will further our knowledge of the biological 
underpinnings linking PNMD to adverse outcomes. Every biological sample acquired 
for SMArTI was collected with very strict Standard Operating Procedures (SOPs) 
that I created before commencing recruitment for this study. These SOPs allowed 
every sample to be collected and bio-banked in the exact same manner, thereby 
limiting any collection error. Most importantly, for infant fecal samples I arranged 
collection from the participants’ home within the first few hours of the sample 
being acquired. The infant microbiome is less stable than that of children and adults 
and therefore storing fecal samples for longer periods disrupts the microbiome 
composition (Guo et al., 2016). The collection method I used therefore allowed for 
accurate analysis of the infant gut microbiome. Additionally every placental sample 
collected in this thesis was done so within two hours of delivery, a tiresome task 
that ensured accuracy of our gene expression analysis (Wolfe et al., 2014). 
Additionally to determine microbial composition, I used the 16S gene rRNA 
sequencing approach as opposed to shotgun metagenomics. Both technologies are 
much superior to culture based techniques employed in the past. Whilst the 16S 
approach is subject to greater bias, it allows for a deeper analysis than that of 
shotgun metagenomics with a greater ability to detect less abundant and rare 
bacterial species (Shah et al., 2011). 
 By limiting the inclusion of SMArTI participants to women enrolled in the 
IMPROvED study (Navaratnam et al., 2013), SMArTI was able to produce a 
homogenous cohort of healthy nulliparous pregnant women which reduces the 
influence of confounding. Additionally the array of maternal data collected, which 
included measurements of early childhood trauma, sleep quality, pregnancy specific 
anxiety, food intake and gastrointestinal function will allow us to further examine 
how the maternal environment can alter the microbiome in pregnancy and any 
potential contributing effects to the depressive microbial phenotype I presented in 
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this thesis. Lastly, this cohort provides an excellent database to continue to unravel 
the complex biological underpinnings of PNMD in a clinical population. 
 The present thesis also has a number of limitations. The primary constraint 
to the cohort I recruited in chapter 4 was analysis of distress in the third trimester 
only with no physiological measurements of distress. However, I overcame this 
limitation in the SMArTI cohort. In both cohorts, I did not measure maternal 
behaviour in the postpartum period. Psychological disturbances in the prenatal 
period is a significant predictor of developing postpartum depression (O'Hara and 
Swain, 1996). It is possible that alterations in maternal behaviours in the 
postpartum period may have an impact on infant microbiome composition and 
infant development. Indeed, in preclinical models prenatal stress has been shown 
to influence infant development by altering postpartum maternal care (Champagne 
and Meaney, 2006). As this was an exploratory and descriptive cohort, I kept the 
experience of stress, anxiety, depression and maternal cortisol as independent 
predictor variables. As a result, a limitation to the present work is the use of 
multiple testing. However, analysing the data in this way allowed us to examine 
specifically which psychological experience was most detrimental to outcomes and 
whilst stress, anxiety and depression are often comorbid with some overlaps in 
their pathophysiology their clinical presentation and thus management often differ 
(Hirschfeld, 2001, Itoi and Sugimoto, 2010). As discussed in the introduction of this 
thesis there is currently a large amount of variability in relation to scoring on 
questionnaires to define PNMD. In particular, I used a cut-off of greater than or 
equal to 9 to indicate high depressive symptomology in pregnancy and I 
acknowledge that this is a relatively low score to imply clinically relevant depressive 
symptoms. However, it is important to note that even at this subclinical level of 
depressive symptoms I observed significant alterations in the maternal gut 
microbiota. The current work did not identify any strong association between 
maternal psychological distresses with maternal salivary cortisol; however this is 
not uncommon in the prenatal population (Davis and Sandman, 2010). Another 
limitation to this work was the complexity and demanding nature of this study 
resulted in a relatively high percentage of loss-to-follow-up. Finally, I were unable 
to measure physiological parameters in these infants, therefore the consequence, if 
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any, that the stressed induced microbial changes may have for infant physiology 
has yet to be determined. 
  
Future perspectives: 
The work presented in the current thesis has identified several possibilities for 
future research. Firstly we have shown that HSD11B2 is epigenetically regulated by 
histone acetylation in a relatively broad manner. As HDACs are critical for normal 
fetal and placental development, understanding specific individual HDACs that can 
regulate HSD11B2 would be of interest when devising therapeutic strategies. A 
targeted knock down approach using short interfering RNAs of individuals HDACs in 
vitro would allow the identification of specific HDACs involved in HSD11B2 
regulation. Additionally the ability of HDACs in regulating NR3C1 and particularly 
FKBP51 should be examined using a similar approach. Once individual HDAC have 
been identified, examining there expression in our placental samples and 
correlating the expression with HSD11B2, NR3C1 and FKBP51 should be performed.       
In chapter 6 of this thesis I report that the second trimester maternal gut 
microbiome undergoes is altered by maternal depressive symptoms. It will be 
important to determine the functional consequence that these changes may have 
for pregnancy health and subsequently outcomes. As part of the SMArTI cohort I 
have acquired a detailed account of medical data from each participant’s pregnancy 
as well as detailed information pertaining to pregnancy and neonatal outcomes, 
including onset of labour, mode of delivery, gestational age at delivery, birthweight, 
gestational size and Apgar scores. A thorough analysis of the influence of the 
maternal gut microbiome on these outcomes should be examined. Subsequently if 
any maternal bacteria may influence or mediate the relationship between PNMD 
and birth outcomes warrants investigation.  
I have recruited a comprehensive cohort of mother infant-dyads where I 
have demonstrated that second trimester maternal stress has significant impacts 
on the establishment of the infant gut microbiome. It is critical that the infants in 
this cohort be further studied to examine developmental outcomes particularity in 
relation to immune system dysfunction and neurodevelopment. The recent report 
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demonstrating increased diversity of the infant gut to be related to poorer 
cognition highlights the need to do neurodevelopmental assessments on these 
infants (Carlson et al., 2017). The microbial profile of infants born from high stress 
pregnancies also displayed increased diversity, highlighting the importance for 
neurodevelopmental assessment, in particular, of these infants. The first infant in 
the SMArTI cohort turned two years old in January 2017, and the 
neurodevelopmental alteration observed by Carlson and colleagues was evident 
from two years old, therefore following up these infants in the coming year will be 
of utmost importance.   
Production of metabolites by the microbes is one of the primary 
mechanisms by which the microbiome interacts with host physiology (Al-Asmakh et 
al., 2012). Of particular interest are short chain fatty acids butyrate, propionate and 
acetate which due to their ability to readily cross the blood brain barrier could have 
consequences for infant neurodevelopment (Al-Asmakh et al., 2012). Therefore, 
examining the corresponding metabolomics profiles accompanying the microbiome 
alterations I observe would help elucidate potential microbial consequences. I have 
extracted fecal water from maternal and infant fecal samples that will allow me to 
examine the impact of the microbial changes on the metabolome in the future.   
I have observed significant alterations in both the maternal and infant gut by 
PNMD, albeit by different aspects of distress (maternal gut influenced by depressive 
symptoms and the infant gut by stress). Potential strategies to reverse these 
microbial changes should be examined. Firstly, can the depressed microbial 
signature in pregnant women be reversed by probiotics, prebiotics and/or diet? 
And if so can this improve the experience of depressive symptoms in pregnant 
women? Probiotics have been shown to reduce stress in the non-pregnant 
population (Allen et al., 2016) and a randomized controlled trial found a 
Mediterranean diet intervention to be effective at reducing depressive symptoms in 
a cohort of patients with major depression (Jacka et al., 2017), showing the 
potential of microbiome targeted interventions to improve psychological wellbeing. 
Based on the work presented in this thesis such interventions should start to be 
considered for the prenatal population in an effort to move away from 
pharmacotherapies in pregnancy.  
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Finally, it appears that changes in the infant gut microbiome as a result of 
PNMD are independent of the maternal gut microbiome. The functional 
consequences of this alteration in the infant gut microbiome need further 
investigation but if they are shown to be linked with adverse neonatal development 
or other health consequences, future work should focus on microbial interventions 
applied directly to infants.  
 
Conclusion: 
Maternal prenatal stress leaves an imprint across pregnancy, the signs of which are 
often visible in the developing infant.  This thesis suggests these effects appear to 
be mediated via a number of different mechanisms and confirms that prenatal 
stress produces a number of effects over and above overexposure to maternal 
cortisol alone. Regulation of glucocorticoids in the placenta and subsequent fetal 
exposure is an incredibly complex system. I have attempted to unravel this process 
by examining three key placental genes that have been linked to poorer infant 
outcomes. Our results highlight the intricacy of placental glucocorticoid signalling, 
with differential responses based on timing of maternal distress, type of distress, 
severity of distress and infant sex.  Most notably this thesis identifies an important 
role for placental FKBP51 in mediating the effect of maternal anxiety on infant 
birthweight in female infants. This highlights the need for future studies to examine 
the precise role of FKBP51 in placental and infant development. This is the first 
study to show the maternal gut microbiome is altered by maternal mental health. 
Furthermore, I found evidence to support a role for maternal prenatal distress in 
altering the development of the infant gut microbiome. Examining the 
consequences of these changes for maternal and infant health is warranted to 
devise future therapeutic strategies targeting placental gene expression and 
microbial changes in the gastrointestinal tract to counteract the adverse impacts of 
prenatal stress. 
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Figure 1:  
 
 
 
Figure 1: Summary figure of the potential biological underpinnings linking prenatal 
maternal distress to adverse outcomes, a complex relationship that involves a 
multitude of biological mediators. One potential mechanism includes stress-
induced elevations in maternal cortisol, pro-inflammatory cytokines, catecholamine 
among other mediators which alter placental glucocorticoid signalling ultimately 
overexposing the fetus to cortisol. Cortisol overexposure alters fetal developmental 
processes during critical widows of fetal development that confers an increased risk 
to disease later in life. An alternative or contributory mechanism involves stressed 
induced alterations in the infant gut microbiome. These microbial alterations 
interfere with postnatal infant development, also conferring an increased risk of 
disease in later life.   
 207 
 
Acknowledgements: 
 I would first like to thank my supervisors Dr Gerard O Keeffe, Prof 
Louise Kenny, Dr Ali Khashan and Dr Gerard Clarke for affording 
me the opportunity to undertake this PhD and offering your 
guidance throughout the completion of this programme. 
Additionally I am grateful to have had the input of Prof. John 
Cryan, Prof. Ted Dinan and Prof. Tony Ryan as advisors on this 
work.  
 
 I would like to thank the staff at Cork University Maternity 
Hospital, particularly the nursing and midwifery staff of the 
delivery ward, who despite being constantly rushed of their feet 
made time to enable me carry out this research.  
 
 The work in this thesis was in the most part funded by the 
Science Foundation Ireland (SFI) research centres, INFANT and 
APC Microbiome Institute through the APC Innovation Platform. 
As such I would like to thank the people in both organizations for 
their ongoing support.  
 
 A project of this magnitude required the collaboration of multiple 
research labs and so I would like to thank the people and labs of 
the Department of Anatomy and Neuroscience, Obstetrics and 
Gynaecology, Psychiatry, Neurogastroenterology and Teagasc for 
their technical support. In particular Tara Foley from the 
Department of Anatomy and Neuroscience has been a massive 
support over the past 4 years.  
 
 I am incredibly grateful to the amazing women who participated 
in this research. Without the time and dedication of these 
women and their children this work would not have been 
possible. The extensive commitment these families gave to a 
 208 
 
research project, that was far more demanding than rewarding, 
was admirable.  
 
 Finally I would like to thank my family and friends for their 
support and encouragement over the past four years. In 
particular my aunt Caroline, without whom I would have never 
had the opportunity to enter into third level education. As such I 
owe all of my academic achievement to her and I will be forever 
grateful. Throughout this journey my partner Gary has stuck by 
my side, in what I can imagine was a horrendous undertaking 
with the strenuous amount of hours I spent in the lab/office 
every day. I could not, and would not have been able to complete 
this journey without him and I am incredibly thankful for his 
ongoing support.  
  
 209 
 
Abbreviations: 
PNMD   Prenatal Maternal Distress 
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IL-   Interleukin- 
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PTB   Preterm Birth 
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WHO   World Health Organization 
SGA   Small for Gestational Age 
GL   Gestational Length 
OR   Odds Ratio 
RR   Risk Ratio 
ASD   Autism Spectrum Disorders 
ADHD   Attention deficit Hyperactivity Disorder 
SAM   Sympatho-Adrenomedullary  
CRH   Corticotrophin-releasing hormone 
ACTH   Adrenocorticotrophin hormone 
MDI   Mental Developmental Index  
PDI   Psychomotor developmental Index 
TNF-α   Tumor necrosis factor-alpha 
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E   Embryonic day 
HAT   Histone Acetyl Transferase 
HDAC   Histone Deacetylases 
DNMT   DNA Methyltransferase 
NNNS   NICU Network Neurobehavioral Scales 
5-AZA   5-Aza-2′-Deoxycytidine 
IP   Intraperitoneal 
rRNA   Ribosomal RNA 
OTU   Operational Taxonomic Units 
GF   Germ Free 
BMI   Body Mass Index 
GDM   Gestational Diabetes Mellitus 
CSTs   Community State Types 
HMOs   Human Milk Oligosaccharides 
VD   Vaginal Delivery 
CS   Caesarean Section 
BF   Breast-fed 
FF   Formulae-fed 
IAP   Intra-partum antibiotic prophylaxis 
PD   Postnatal day 
T1D   Type 1 diabetes 
SlgA   Secretory IgA 
GF   Germ Free 
CUMH   Cork University Maternity Hospital 
DMEM   Dulbecco’s modified Eagle Medium Nutrient Mixture 
FCS   Fetal Calf Serum 
DMSO   Dimethyl Sulfoxide 
HBSS   Hanks Balanced Salt Solution 
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MTT   Thiazolyl Blue Tetrazolium Bromide 
PFA   Paraformaldehyde 
PBS   Phosphate Buffer Solution  
PBS-T   PBS Triton X 
NICU   Neonatal Intensive Care Unit 
PDQ   Pregnancy Distress Questionnaire 
PSQI   Pittsburgh Sleep Quality Index 
CTQ   Childhood Trauma Questionnaire 
FFQ   Food Frequency Questionnaire 
FKQ   Food Knowledge Questionnaire 
Cort   Cortisol 
HDI   HDAC Inhibitors 
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Detailed Protocol for the SMArTI Study: 
Recruitment: 
The IMPROvED consortium which is an FP-7-funded program lead by Professor 
Kenny, the Director of the Irish Centre for Fetal and Neonatal Translational 
Research (INFANT), UCC. This recently launched program is recruiting 5000 first 
time low risk pregnant women from six European centres at a cost of €6 million 
(http://www.fp7-improved.eu). It is expected that 1,500 women will be recruited in 
Cork University Maternity Hospital and the first baby is expected to be born in 
August 2014 and the final baby in August 2016. The added value of this cohort 
cannot be overestimated. In addition to a well-curated maternal biobank, 
pregnancies are extensively phenotyped with detailed maternal and paternal social, 
demographic and life-style data. The data are stored on a purpose built Internet-
based database developed by MedSciNet. Therefore this is a unique and timely 
opportunity. We aim to recruit 150 women from the IMPROvED participants for the 
present study divided as follows: 50 women reporting low stress score (<the 25% 
percentile), 50 women reporting high stress score (>75% percentile) and 50 women 
with irritable bowel syndrome. 
 
During Pregnancy: 
Participating women in IMPROvED will complete the Perceived Stress Questionnaire 
(PSS), State Trait Anxiety Questionnaire and Edinburgh Postnatal Depression Scale 
(EPDS) at 3-4 time points during pregnancy to cover the three trimesters of 
pregnancy.  We will recruit all women enrolled in IMPROvED until we have a quota 
of 50 women who rank as having high stress and 50 women who rank as having low 
stress as determined by these questionnaires. From the IMPROvED consortium we 
also aim to recruit 50 women who have been clinically diagnosed with IBS. We will 
ask these women to fill out a Gastrointestinal Symptom Severity form and the IBS 
Module Survey 3 times for the duration of the pregnancy.  In addition to this, all 
women recruited to this study will be asked to complete a food frequency and food 
knowledge questionnaire in each trimester. This will allow us to assess how 
nutrition in pregnancy can influence short- and long-term outcomes in both the 
mother and offspring. Further, we will ask women to complete the Pittsburgh Sleep 
Quality Index in each trimester. Chronic Sleep loss in Pregnancy is associated with 
elevated stress in pregnancy and adverse pregnancy outcomes, further women who 
have sleep problems are more likely to identify as being stressed  (Palagini et al., 
2014), this will allow us to evaluate the association between sleep loss and adverse 
fetal outcomes. Finally, we will invite each participant to complete the Childhood 
Trauma Questionnaire, in an attempt to look at early life stress in these women. 
Participants will be given the option to fill out these questionnaires by hand on the 
day of their visit or online via Survey Monkey the day of or the day before their 
expected visit. If participants opt for the online version, we will acquire an email 
address from them and they will be sent the links to the surveys via email. 
Alternatively, if women opt for handwritten surveys and are unable to complete 
them on the day of their visit we will supply stamped envelopes for them to be 
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returned here to CUMH. We will also collect salivary cortisol at these time points 
for analysis of the cortisol awakening response (CAR), a physiological index of stress 
and a reliable marker of hypothalamic-pituitary-adrenal axis (HPA) activity. To get 
an accurate measure of HPA activity in relation to perceived stress women will be 
asked to donate their salivary sample within 24hours of completing the 
questionnaire. Each participant will be given a take home kit containing 4 salivettes 
(sarsedt) along with instructions on how to obtain the sample (attached). Women 
will be asked to take the sample on the morning of their IMPROvED visit and bring it 
with them to their appointment. Cortisol levels will be analysed using a 
commercially available ELISA assay from Enzo Life Sciences. On each visit 
participating women will be given the option to donate three stool and vaginal 
samples. Stool samples will be self-taken by the women via a home stool collection 
kit. Each kit comes with a detailed set of instructions (attached). Again participants 
will be asked to bring the sample on the day of their appointment.  On the day of 
their appointment each participant will be asked to provide swabs from the oral 
cavity. Swabs will be collected by the study personnel at the time of appointment 
(See protocol ‘Sampling of the Oral Cavity for SMarTI). DNA and RNA will be 
extracted from each sample using specialised DNA and RNA extraction kits and 
stored in the secure ‘biobank’ facility on the 5th floor of CUMH.  
 
Upon Delivery: 
An additional vaginal swab and stool sample will be collected prior to delivery along 
with a maternal faecal sample. Similar to above, DNA will be extracted at stored in 
the biobank facility on the 5th floor of CUMH. After delivery we will collect a small 
sample of the placenta (1cm x 1cm x 1cm). The sample will be snap frozen in liquid 
nitrogen and stored the INFANT biobank. We potentially could be able use this 
sample for future research that at the moment cannot be foreseen. Further we will 
collect a hair sample from each infant at birth from the posterior vertex of the 
head. This sample will be used to assess cortisol levels in the infant. As cortisol 
present in the hair is believed to be a representation of long term HPA activity, we 
will use these samples to measure fetal cortisol exposure in utero. At birth we will 
take additional fetal characteristics such as gestational age, sex, weight, apgar score 
and head circumference. This data will be stored in a secure location of the 5th floor 
of CUMH. Only Chief- and co investigators on this study will have access to this 
information. We will use this date to determine an association (if any) between 
maternal stress/cortisol levels/IBS and birth outcome. 
 
Follow up: 
We will ask each participant to complete the EPDS postnatally to evaluate the 
relationship between postnatal depression and infant flora and behaviour. Each 
participant will be given the option to complete this survey by hand or online. 
Babies born by vaginal delivery will be followed up and stool samples will be 
collected at 1, 2 and 3 weeks, 3 and 5 months. Along with the stool sample, parents 
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will be asked to provide a urine sample from their infant at the 5 month collection. 
DNA and RNA will be extracted from each sample using specialised DNA and RNA 
extraction kits and stored in the secure ‘biobank’ facility on the 5th floor of CUMH. 
Once all samples are collected they will be shipped to an external sequencing 
company for determination of the metabogenomic composition of each individual’s 
microbiota.   This will allow us to examine the temporal changes in the gut and 
vaginal microbiome in relation to pregnancy only (low stress group) and in relation 
to exposure to high stress and IBS. In addition to very detailed data on the mothers 
and their partners and obstetric variables, data on breastfeeding and antibiotic use 
during pregnancy/delivery and in early life of the offspring will be available. 
Breastfeeding and antibiotics are known to alter the gut microbiota of the newborn 
therefore it is important to examine whether these factors play a role in any 
observed associations between stress and IBS and altered gut microbiota in the 
child. Finally we will use the revised version of the Infant Behavioural Questionnaire 
(IBQ-R) to assess infant temperament at 5 months of age. Parents will be asked to 
complete this questionnaire when their infant is 5 months of age ( a time 
corresponding to our last infant stool collection). The IBQ-R will enable us detect if 
maternal stress and IBS affects infant temperament at 5 months of age. Further it 
will enable us to elucidate the role for the gut flora in this relationship. 
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Flowchart of SMArTI final numbers: 
 
 
 
Description: Final cohort numbers from the SMArTI study.     
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SMArTI patient Information Leaflet: 
 
 
 
Description: The information leaflet given to patients and placed in antenatal clinics 
during recruitment of the SMArTI study.  
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SMArTI poster: 
 
Description: The poster given to patients and placed in antenatal clinics during 
recruitment of the SMArTI study.  
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SMArTI consent form: 
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Biological Sample Collection: 
Saliva collection: 
 
 
Contents: 
(a) Detailed Instructions 
(b) Salivettes (x4) 
(c) Zip-lock bag (x1) 
Description: Instructions and home collection kit given to SMArTI participants for 
collection of saliva samples at home.  
Maternal fecal sample collection kit: 
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Contents: 
(d) Detailed Instructions 
(e) Latex gloves 
(f) Plastic container contain AnaeroGen Sachet 
(g) Zip-lock bag (x2) 
(h) Envelope 
 
Description: Kit given to SMArTI participants for home collection of fecal samples at 
home.  
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Vaginal swab and Placenta Collection: 
  
 
Contents: 
(i) Detailed Instructions 
(j) Yellow Placenta Bag 
(k) Epicentre Sterile Swabs (x2) 
(l) Zip-lock bag 
(m) Short Instructions 
 
Description: This kit was inserted into participants chart so staff on the delivery 
ward knew they were enrolled in the SMArTI study and could collect the samples.   
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Infant stool sample Collection: 
 
Description: Instructions given to participants for collection of infant fecal samples.   
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Questionnaires:  
Perceived Stress Scale: 
These questions ask about your feelings and thoughts during THE LAST MONTH. 
In each case, you will be asked to indicate how often you felt or thought a certain 
way.  Although some of the questions are similar, there are differences between 
them and you should treat each one as a separate question. The best approach is to 
answer each question fairly quickly.  Don’t try to count up the number of times you 
felt a particular way, but rather circle the answer that you think best fits for you. 
 Never Almost  
Never 
Some-
times  
Fairly 
Often 
Very  
Often 
In the last month, how often have you been upset 
because of something that happened 
unexpectedly? 
0 1 2 3 4 
In the last month, how often have you felt that you 
were unable to control the important things in 
your life? 
4 3 2 1 0 
In the last month, how often have you felt nervous 
and stressed? 
0 1 2 3 4 
In the last month, how often have you felt 
confident about your ability to handle your 
personal problems? 
4 3 2 1 0 
In the last month, how often have you felt that 
things were going your way? 
4 3 2 1 0 
In the last month, how often have you found that 
you could not cope with all the things you had to 
do? 
0 1 2 3 4 
In the last month, how often have you been able to 
control irritations in your life? 
4 3 2 1 0 
In the last month, how often have you felt that you 
were on top of things? 
4 3 2 1 0 
In the last month, how often have you been 
angered because of things that happened that 
were outside of your control? 
0 1 2 3 4 
In the last month, how often have you felt 
difficulties were piling up so high that you could 
not overcome them?  
0 1 2 3 4 
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State Trait Anxiety Inventory 
Please read each of the following statements and circle the most appropriate 
number to the right of the statement to indicate how you feel right now, at this 
moment. Do not spend too much time on any one statement but circle the answer 
which seems to describe your present feelings best.  
 
 Not at all Somewhat Moderately Very Much 
I feel calm 3 2 1 0 
I feel tense 0 1 2 3 
I feel upset 0 1 2 3 
I feel relaxed 3 2 1 0 
I feel content 3 2 1 0 
I feel worried 0 1 2 3 
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Edinburgh Postnatal Depression Scale: 
These questions ask about your mood.  
Please circle the answer that best describes to how you have felt in THE PAST 
WEEK. 
(1)  I have been able to laugh and see the funny side of things: 
 As much as I always could (0) 
 Not quite so much now (1) 
 Definitely not so much now (2) 
 Not at all (3) 
 
(2) I have looked forward with enjoyment to things: 
 As much as I ever did (0) 
 Rather less than I used to (1) 
 Definitely less than I used to (2) 
 Hardly at all (3) 
 
(3) I have blamed myself unnecessarily when things went wrong: 
 No not at all (0) 
 Hardly ever (1) 
 Yes, sometimes (2) 
 Yes, very often (3) 
 
(4)  I have felt anxious or worried for no very good reason: 
 Yes, quite a lot (3) 
 Yes, sometimes (2) 
 No, not much (1) 
 No, not at all (0) 
 
(5) I have felt scared or panicky for no very good reason: 
 Yes, quite a lot (3) 
 Yes, sometimes (2) 
 No, not much (1) 
 No, not at all (0) 
 
(6) Things have been getting on top of me: 
 Yes, most of the time I haven’t been able to cope at all (3) 
 Yes, sometimes I haven’t been coping as well as usual (2) 
 No, Most of the time I have coped quite well (1) 
 No, I have been coping as well as ever (0) 
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(7) I have been so unhappy that I have had difficulty sleeping: 
 Yes, most of the time (3) 
 Yes, sometimes (2) 
 Not very often (1) 
 No, not at all (0) 
 
(8) I have felt sad or miserable: 
 Yes, most of the time (3) 
 Yes, sometimes (2) 
 Not very often (1) 
 No, not at all (0) 
 
(9) I have been so unhappy that I have been crying: 
 Yes, most of the time (3) 
 Yes, sometimes (2) 
 Not very often (1) 
 No, not at all (0) 
 
(10) The thought of harming myself has occurred to me: 
 Yes, quite often (3) 
 Sometimes (2) 
 Hardly ever (1) 
 Never (0) 
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Pregnancy Distress Questionnaire 
(1)  I find weight gain during pregnancy troubling 
 Not at all worried (0) 
 Slightly worried (1) 
 Moderately worried (2) 
 Quite worried (3) 
 Extremely worried (4) 
 
(2)  Physical symptoms of pregnancy, such as nausea, vomiting, swollen feet or backache, 
irritate me 
 Not at all (0) 
 Slightly (1) 
 Moderately (2) 
 Quite (3) 
 Extremely (4) 
 
(3)  I am worried about handling the infant when I first come home from the hospital 
 Not at all worried (0) 
 Slightly worried (1) 
 Moderately worried (2) 
 Quite worried (3) 
 Extremely worried (4) 
 
(4)  Emotional ups and downs during pregnancy annoy me 
 Not at all (0) 
 Slightly (1) 
 Moderately (2) 
 Quite (3) 
 Extremely (4) 
 
(5)  I am troubled that my relationships with other people important to me are changing due to 
my pregnancy 
 Not at all worried (0) 
 Slightly worried (1) 
 Moderately worried (2) 
 Quite worried (3) 
 Extremely worried (4) 
 
 
(6)  I am worried about eating healthy foods and a balanced diet for the infant 
 Not at all worried (0) 
 Slightly worried (1) 
 Moderately worried (2) 
 Quite worried (3) 
 Extremely worried (4) 
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(7)  Overall, the changes in my body shape and size during pregnancy bothers me 
 Not at all (0) 
 Slightly (1) 
 Moderately (2) 
 Quite (3) 
 Extremely (4) 
 
(8)  I am concerned that having a new infant will alter my relationship with the infants’ father 
 Not at all worried (0) 
 Slightly worried (1) 
 Moderately worried (2) 
 Quite worried (3) 
 Extremely worried (4) 
 
(9)  I worry about having an unhealthy infant 
 Not at all worried (0) 
 Slightly worried (1) 
 Moderately worried (2) 
 Quite worried (3) 
 Extremely worried (4) 
 
(10)  I am anxious about labour and childbirth 
 Not at all worried (0) 
 Slightly worried (1) 
 Moderately worried (2) 
 Quite worried (3) 
 Extremely worried (4) 
 
(11)  The possibility or premature childbirth frightens me 
 Not at all worried (0) 
 Slightly worried (1) 
 Moderately worried (2) 
 Quite worried (3) 
 Extremely worried (4) 
 
(12)  I am worried that i might not become emotionally attached to the infant 
 Not at all worried (0) 
 Slightly worried (1) 
 Moderately worried (2) 
 Quite worried (3) 
 Extremely worried (4) 
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Pittsburgh Sleep Quality Index 
The following questions relate to your usual sleep habits during the past month 
only. Your answers should indicate the most accurate reply for the majority of days 
and nights in the past month. Please answer all questions. 
 
During the past month, 
 
(1) When have you usually gone to bed?      
 
(2)   How long (in minutes) has it taken you to fall asleep each night?   
 
(3) When have you usually gotten up in the morning?     
 
(4) How many hours of actual sleep do you get at night? (This may be different than the 
number of hours you spend in bed)        
 
(5)     During the past month, how often have you had trouble sleeping because you… 
 
(a) Cannot get to sleep within 30 minutes 
 Not during the past month (0) 
 Less than once a week (1) 
 Once or twice a week (2) 
 Three or more times a week (3) 
 
(b) Wake up in the middle of the night or early morning 
 Not during the past month (0) 
 Less than once a week (1) 
 Once or twice a week (2) 
 Three or more times a week (3) 
 
(c) Have to get up to use the bathroom 
 Not during the past month (0) 
 Less than once a week (1) 
 Once or twice a week (2) 
 Three or more times a week (3) 
 
(d) Cannot breathe comfortably 
 Not during the past month (0) 
 Less than once a week (1) 
 Once or twice a week (2) 
 Three or more times a week (3) 
 
(e) Cough or snore loudly 
 Not during the past month (0) 
 Less than once a week (1) 
 Once or twice a week (2) 
 Three or more times a week (3) 
 
(f) Feel too cold 
 Not during the past month (0) 
 Less than once a week (1) 
 Once or twice a week (2) 
 Three or more times a week (3) 
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(g) Feel too hot 
 Not during the past month (0) 
 Less than once a week (1) 
 Once or twice a week (2) 
 Three or more times a week (3) 
 
(h) Have bad dreams 
 Not during the past month (0) 
 Less than once a week (1) 
 Once or twice a week (2) 
 Three or more times a week (3) 
 
(i) Have pain 
 Not during the past month (0) 
 Less than once a week (1) 
 Once or twice a week (2) 
 Three or more times a week (3) 
 
(j) Other reason(s), please describe, including how often you 
 Not during the past month (0) 
 Less than once a week (1) 
 Once or twice a week (2) 
 Three or more times a week (3) 
 
(6) During the past month, how often have you taken medicine (prescribed or “over the counter”) to 
help you sleep? 
 Not during the past month (0) 
 Less than once a week (1) 
 Once or twice a week (2) 
 Three or more times a week (3) 
 
(7) During the past month, how often have you had trouble staying awake while driving, eating 
meals, or engaging in social activity? 
 Not during the past month (0) 
 Less than once a week (1) 
 Once or twice a week (2) 
 Three or more times a week (3) 
 
(8) During the past month, how much of a problem has it been for you to keep up enthusiasm to get 
things done? 
 Not during the past month (0) 
 Less than once a week (1) 
 Once or twice a week (2) 
 Three or more times a week (3) 
 
(9) During the past month, how would you rate your sleep quality overall? 
 Very good (0) 
 Fairly good (1) 
 Fairly bad (2) 
 Very bad (3) 
  
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Scoring PSQI 
 
 Component 1: #9 Score      
 C1______ 
 
 Component 2: #2 Score (<15min=0; 16-30 min=1; 31-60 min=2, 
 >60 min=3) + #5a Score (if sum is equal 0=0; 1-2=1; 3-4=2; 5-6=3) 
 C2______  
 Component 3 #4 Score (>7=0; 6-7=1; 5-6=2; <5=3)    
 C3______ 
 
 Component 4 (total # of hours asleep)/(total # of hours in bed) x 100 
(>85%=0, 75%-84%=1, 65%-74%=2, <65%=3)    
  C4_______ 
 
 Component 5 Sum of Scores #5b to #5j (0=0; 1-9=1; 10-18=2; 19-27=3)
 C5_______ 
 
 Component 6 #6 Score      
 C6_______ 
 
 Component 7 #7 Score + #8 Score (0=0; 1-2=1; 3-4=2; 5-6=3) 
 C7_______ 
 
 
Add the seven component scores together ________ Global PSQI Score ________  
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Childhood Trauma Questionnaire 
This questionnaire studies different aspects of your childhood. 
Please circle one answer per question which most accurately represents your 
experience 
Please answer every question as accurate as possible. 
When I was growing up…….. 
 
Never 
true 
Rarely 
true 
Some-
times  
true 
Often 
true 
Very  
Often 
true 
1. I didn’t have enough to eat 
0 1 2 3 4 
2. I knew that there was someone to take 
care of me and protect me 4 3 2 1 0 
3. People in my family called me things like 
stupid, lazy or ugly. 0 1 2 3 4 
4. My parents were too drunk or high to take 
care of the family 0 1 2 3 4 
5. There was somebody in my family who 
helped me feel like I was important or special 4 3 2 1 0 
6. I had to wear dirty clothes 
0 1 2 3 4 
7. I felt loved 
4 3 2 1 0 
8. I thought that my parents wished that I 
had never been born 0 1 2 3 4 
9. I got hit so hard by someone in my family 
that I had to see a doctor or go to the 
hospital 
0 1 2 3 4 
10. There was nothing I wanted to change 
about my family 4 3 2 1 0 
11. People in my family hit me so hard that it 
left me with bruises or marks 0 1 2 3 4 
12. I was punished with a belt, a cord or 
some other hard object 0 1 2 3 4 
13. People in my family looked out for each 
other 4 3 2 1 0 
14. People in my family said hurtful or 
insulting things to me 0 1 2 3 4 
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15. I believe that I was physically abused 
0 1 2 3 4 
16. I had the perfect childhood 
4 3 2 1 0 
17. I got hit or beaten so badly that it was 
noticed by someone like a teacher, neighbour 
or doctor 
0 1 2 3 4 
18. I felt that someone in my family hated me 
0 1 2 3 4 
19. People in my family felt close to each 
other 4 3 2 1 0 
20. Someone tried to touch me in a sexual 
way, or tried to make me touch them 0 1 2 3 4 
21. Someone threatened to hurt me or tell 
lies about me unless I did something sexual 
with them 
0 1 2 3 4 
22. I had the best family in the world 
4 3 2 1 0 
23. Someone tried to make me do sexual 
things or watch sexual things 0 1 2 3 4 
24. Someone molested me 
0 1 2 3 4 
25. I believe that I was emotionally abused 
0 1 2 3 4 
26. There was someone to take me to the 
doctor if I needed it 4 3 2 1 0 
27. I believe that I was sexually abused 
0 1 2 3 4 
28. My Family was a source of strength and 
support 4 3 2 1 0 
 
 
CTQ subscales 
 
 Physical neglect:   Q 1, 2, 4, 6 & 26 
 Emotional abuse:   Q 3, 8, 14, 18 & 25 
 Emotional neglect:  Q 5, 7, 13, 19 & 28 
 Physical abuse:  Q 9, 11, 12, 15 & 17 
 Sexual abuse:   Q 20, 21, 23, 24 & 27 
 Minimalizing/denial scale: Q 10,  16 & 22 
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IBS severity Questionnaire: 
In the past month, how often did you have discomfort or pain anywhere in your abdomen? 
 Never (0; skip remaining questions) 
 Less than one day a month (1) 
 One day a month (2) 
 Two to three days a month (3) 
 One day a week (4) 
 More than one day a week (5) 
 Every day (6) 
 
Have you had this discomfort or pain for 6 months or longer? 
 No (0) 
 Yes (1) 
 
How often did this discomfort or pain get better or stop after you had a bowel movement? 
 Never or rarely (0) 
 Sometimes (1) 
 Often (2) 
 Most of the time (3) 
 Always (4) 
 
When this discomfort or pain started, did you have more frequent bowel movements? 
 Never or rarely (0) 
 Sometimes (1) 
 Often (2) 
 Most of the time (3) 
 Always (4) 
 
When this discomfort or pain started, were your stools (bowel movements) looser? 
 Never or rarely (0) 
 Sometimes (1) 
 Often (2) 
 Most of the time (3) 
 Always (4) 
 
When this discomfort or pain started, how often did you have harder stools? 
 Never or rarely (0) 
 Sometimes (1) 
 Often (2) 
 Most of the time (3) 
 Always (4) 
 
In the past month, how often did you have hard or lumpy stools? 
 Never or rarely (0) 
 Sometimes (1) 
 Often (2) 
 Most of the time (3) 
 Always (4) 
 
In the past month, how often did you have loose, mushy or watery stools? 
 Never or rarely (0) 
 Sometimes (1) 
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 Often (2) 
 Most of the time (3) 
 Always (4) 
 
Do you have abdominal pain at this time? 
 No (0) 
 Yes (1) 
 
If yes, how severe in your abdominal pain? 
 No pain (0) 
 Mild (1) 
 Moderately (2) 
 Severe (3) 
 Very severe (4) 
 
Do you currently have abdominal fullness, bloating or swelling? 
 No (0) 
 Yes (1) 
 
If yes, how severe is your abdominal fullness, bloating or swelling?  
 None (0) 
 Mild (1) 
 Moderately (2) 
 Severe (3) 
 Very severe (4) 
 
How satisfied are you with your bowel habit? 
 Very unhappy (0) 
 Unhappy (1) 
 Quite happy (2) 
 Happy (3) 
 Very happy (4) 
 
How much do your Gastrointestinal Symptoms affect or interfere with your life in general? 
 Not at all (0) 
 Not much (1) 
 Quite a lot (2) 
 
How much do you currently feel the urge to have a bowel movement? 
 Not at all (0) 
 Not much (1) 
 Quite a lot (2) 
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Food Frequency Questionnaire 
The questionnaire is organised into 9 different food categories and you will be 
asked to record your average frequency of consumption of each food item over the 
last year. 
 
 YOUR DIET OVER THE LAST YEAR  
For each food there is an amount shown, either what we think is a “medium serving” or a 
common household unit such as a slice or teaspoon. Please put a tick in the box to indicate 
how often, on average, you have eaten the specified amount of each food, to the nearest 
whole number during the past year i.e. from when you receive this questionnaire to the 
same month the previous year. Please estimate your average food use as best you can. 
Please answer every question, do not leave ANY lines blank.  
 
Please read the questions and instructions carefully and complete each section to 
the best of your ability. 
 
MEAT, FISH & 
POULTRY 
(Medium 
serving – the 
size of a deck 
of cards) 
Never 
or less 
than 
once 
per 
month 
1-3 per 
month 
Once a 
week 
2-4 
per 
week 
5-6 
per 
week 
Once 
a day 
2-3 
per 
day 
4-5 
per 
day 
6+ 
per 
day 
Beef: roast          
Beef: steak          
Beef: mince          
Beef: stew          
Beef burger (1 
burger) 
         
Pork: roast          
Pork: chops          
Pork: slices/ 
escalope 
         
Lamb: roast          
Lamb: chops          
Lamb: stew          
Chicken 
portion or 
other  
poultry e.g. 
turkey:  
Roast 
         
Breaded 
chicken,  
chicken 
nuggets,  
chicken burger 
         
Bacon          
Ham          
Corned beef, 
Spam,  
Luncheon 
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meats 
Sausages, 
Frankfurters  
(1 sausage) 
         
Savoury pies 
(e.g. meat  
pie, pork pie, 
steak &  
kidney pie, 
sausage  
rolls) 
         
Liver, heart, 
kidney 
         
Liver paté          
Fish fried in 
batter, as in  
fish and chips 
         
Fish fried in  
breadcrumbs 
         
Oven 
baked/grilled 
fish  
(in 
breadcrumbs 
or  
batter) 
         
Fish 
fingers/fish 
cakes 
         
Other white 
fish, fresh or  
frozen (e.g. 
cod,  
haddock, 
plaice, sole,  
halibut, coli) 
         
Oily fish, fresh 
or  
canned (e.g. 
mackerel,  
kippers, tuna, 
salmon,  
sardines, 
herring) 
         
Shellfish (e.g. 
crab,  
prawns, 
mussels) 
         
 
BREAD AND  
SAVOURY 
BISCUITS  
(One slice or 
one  
biscuit) 
Never 
or less 
than 
once 
per 
month 
1-3 per 
month 
Once a 
week 
2-4 
per 
week 
5-6 
per 
week 
Once 
a day 
2-3 
per 
day 
4-5 
per 
day 
6+ 
per 
day 
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White bread 
and rolls  
(including 
ciabatta and  
panini bread) 
         
Brown bread 
and rolls 
         
Wholemeal 
bread and  
rolls 
         
Cream 
crackers,  
cheese biscuits 
         
Crisp bread, 
e.g. Ryvita 
         
Pancakes, 
muffins,  
oatcakes 
         
 
CEREALS (One  
medium sized 
bowl) 
Never 
or less 
than 
once 
per 
month 
1-3 per 
month 
Once a 
week 
2-4 
per 
week 
5-6 
per 
week 
Once 
a day 
2-3 
per 
day 
4-5 
per 
day 
6+ 
per 
day 
Porridge, 
Readybrek 
         
All Bran, 
Weetabix,  
Shredded 
Wheat 
         
Branflakes, 
Bran Buds 
         
Cornflakes, 
Rice  
Krispies 
         
Muesli (e.g. 
Country  
Store, Alpen, 
sugar  
coated 
         
Sugar Coated 
Cereals  
(e.g. Frosties, 
Crunchy  
Nut 
Cornflakes,  
Crunchy Sugar 
Coated  
Muesli) 
         
 
POTATOES, 
RICE  
AND PASTA 
Never 
or less 
than 
1-3 per 
month 
Once a 
week 
2-4 
per 
week 
5-6 
per 
week 
Once 
a day 
2-3 
per 
day 
4-5 
per 
day 
6+ 
per 
day 
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(Medium  
serving – 
about a  
cupful) 
once 
per 
month 
Boiled, instant 
or jacket  
potatoes 
         
Mashed 
potatoes 
         
Chips          
Roast potatoes          
Potato salad          
White rice          
Brown rice          
White/yellow 
or green  
pastas (e.g. 
spaghetti,  
macaroni, 
noodles) 
         
Wholemeal 
pasta 
         
Lasagne (meat 
based) 
         
Lasagne 
(vegetarian) 
         
Moussaka          
Pizza          
Macaroni 
Cheese 
         
 
DAIRY 
PRODUCTS  
AND FATS 
Never 
or less 
than 
once 
per 
month 
1-3 per 
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per 
week 
Once 
a day 
2-3 
per 
day 
4-5 
per 
day 
6+ 
per 
day 
Cream 
(Tablespoon) 
         
Full-fat yoghurt 
or  
Greek-style 
yoghurt  
(125g carton) 
         
Low-fat yoghurt,  
fromage frais 
(125g  
carton) 
         
Dairy desserts 
(125g  
carton) 
         
Cheddar cheese  
(medium 
serving) 
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Brie, Edam type 
cheese  
(medium 
serving) 
         
Low-fat cheddar 
cheese  
(medium 
serving) 
         
Cottage cheese, 
cream  
cheese, low-fat 
soft  
cheese (medium  
serving) 
         
Eggs as boiled, 
fried,  
scrambled, 
poached  
(one) 
         
Quiche 
(medium  
serving) 
         
Light salad 
cream or  
light 
mayonnaise  
(tablespoon) 
         
Salad cream,  
mayonnaise  
(Tablespoon) 
         
French dressing  
(tablespoon) 
         
Other salad 
dressing  
(Tablespoon) 
         
 
THE FOLLOWING 
ON  
BREAD OR  
VEGETABLES 
Never 
or less 
than 
once 
per 
month 
1-3 per 
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per 
week 
Once 
a day 
2-3 
per 
day 
4-5 
per 
day 
6+ 
per 
day 
Butter 
(teaspoon) 
         
Lite Butter e.g. 
Dawn  
Lite, Connacht 
Gold  
(teaspoon) 
         
Sunflower 
margarine  
e.g. Flora 
(teaspoon) 
         
Low-fat 
margarine (e.g.  
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Low-low) 
Cholesterol 
Lowering  
Spreads e.g. 
Flora Pro  
Active, Dairy 
Gold Heart  
(teaspoon) 
         
Cream & 
Vegetable Oil  
spread e.g. 
Golden  
Pasture, 
Kerrymaid,  
Dairy Gold – 
teaspoon 
         
Olive oil spread 
e.g.  
Golden Olive 
(teaspoon) 
         
 
FRUIT  
(1 Fruit or 
medium  
serving) 
Never 
or less 
than 
once 
per 
month 
1-3 per 
month 
Once a 
week 
2-4 
per 
week 
5-6 
per 
week 
Once 
a day 
2-3 
per 
day 
4-5 
per 
day 
6+ 
per 
day 
Apples          
Pears          
Oranges, 
Satsumas,  
Mandarins 
         
Grapefruit          
Bananas          
Grapes          
Melon          
Peaches, 
Plums,  
Apricot 
         
Strawberries,  
Raspberries, 
Kiwi fruit 
         
Tinned fruit          
Dried fruit e.g. 
raisins 
         
Frozen fruit          
 
VEGETABLES  
Fresh, frozen 
or tinned  
(Medium 
serving – 2  
tablespoons) 
Never 
or less 
than 
once 
per 
month 
1-3 per 
month 
Once a 
week 
2-4 
per 
week 
5-6 
per 
week 
Once 
a day 
2-3 
per 
day 
4-5 
per 
day 
6+ 
per 
day 
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Carrots          
Spinach          
Broccoli, Spring  
Greens, Kale 
         
Brussel Sprouts          
Cabbage          
Peas          
Green Beans, 
Broad  
Beans, Runner 
Beans 
         
Marrow, 
Courgettes 
         
Cauliflower          
Parsnips, 
Turnips 
         
Leeks          
Onions          
Garlic          
Mushrooms          
Sweet Peppers          
Beansprouts          
Green salad, 
Lettuce 
         
Cucumber, 
Celery 
         
Watercress          
Tomatoes          
Sweetcorn          
Beetroot          
Coleslaw          
Avocado          
Baked Beans          
Dried lentils, 
beans,  
peas 
         
Tofu, Soya 
Meat, TVP,  
Vegeburger 
         
 
SWEETS AND  
SNACKS 
(Medium  
serving) 
Never 
or less 
than 
once 
per 
month 
1-3 per 
month 
Once a 
week 
2-4 
per 
week 
5-6 
per 
week 
Once 
a day 
2-3 
per 
day 
4-5 
per 
day 
6+ 
per 
day 
Chocolate 
coated sweet  
biscuits e.g. 
digestive  
(one) 
         
Plain sweet 
biscuits e.g.  
Marietta, 
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digestives,  
rich tea (one) 
Cakes e.g. 
fruit, sponge 
         
Scones, 
flapjacks 
         
Buns, pastries 
e.g.  
croissants, 
doughnuts 
         
Fruit pies, 
tarts,  
crumbles 
         
Sponge 
puddings 
         
Milk puddings 
e.g. rice,  
custard, trifle 
         
Ice cream, 
choc ices,  
Frozen 
desserts 
         
Chocolates, 
singles or  
squares 
         
Sweets, 
toffees, mints 
         
Sugar added 
to tea  
coffee, cereal  
(teaspoon) 
         
Sugar 
substitute e.g.  
canderel 
added to tea  
coffee, cereal  
(teaspoon) 
         
Crisps or other 
packet  
snacks 
         
Peanuts or 
other nuts 
         
 
SOUPS, SAUCES 
AND  
SPREADS 
Never 
or less 
than 
once 
per 
month 
1-3 per 
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per 
week 
Once 
a day 
2-3 
per 
day 
4-5 
per 
day 
6+ 
per 
day 
Vegetable soups:  
Homemade/Fresh  
(1 bowl) 
         
Vegetable soups:  
Tinned/packet  
(1 bowl) 
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Meat or cream 
soups:  
Homemade/Fresh 
(1 bowl) 
         
Meat or cream 
soups:  
Tinned/packet  
(1 bowl) 
         
Sauces e.g. white  
sauce, cheese sauce,  
gravy (Tablespoon) 
         
Tomato based 
sauces  
e.g. pasta sauces 
         
Curry-type sauces          
Pickles, chutney  
(Tablespoon) 
         
Marmite, Bovril  
(Tablespoon) 
         
Jam, marmalade, 
honey,  
syrup (teaspoon) 
         
Peanut butter  
(teaspoon) 
         
 
DRINKS Never 
or less 
than 
once 
per 
month 
1-3 per 
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per 
week 
Once 
a day 
2-3 
per 
day 
4-5 
per 
day 
6+ 
per 
day 
Tea (cup)          
Coffee instant (cup)          
Coffee, 
decaffeinated (cup)  
         
Coffee whitener 
e.g.  
coffee-mate 
(teaspoon) 
         
Cocoa, Hot 
Chocolate  
(cup) 
         
Horlicks, Ovaltine 
(cup) 
         
Wine (glass)          
Beer, Larger or 
Cider  
(half pint) 
         
Alcopops e.g. 
Bacardi  
Breezer  
(bottle) 
         
Port, Sherry, 
Vermouth,  
Liqueurs (glass) 
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Spirits e.g. Gin,  
Whiskey (single  
measure) 
         
Low calorie or diet 
soft  
drink, fizzy (glass) 
         
Fizzy soft drinks 
e.g.  
Coca Cola (glass) 
         
Pure fruit drinks 
e.g.  
orange juice (small  
glass) 
         
Fruit squash (small  
glass) 
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Food Knowledge Questionnaire 
Here we are interested in finding out about your knowledge of food.  
 
(1) Advice from the Health Experts  
The first few questions are about what advice you think experts are giving us  
 
(a) Do you think health experts recommend that people should be eating more, the 
same amount, or less of these foods? (Fill in one box per food) 
 More Same Less Not sure 
Vegetables     
Sugary foods     
Meat     
Starchy foods     
Fatty foods     
High fibre foods     
Fruit     
Salty foods     
 
(b) How many servings of fruit and vegetables a day do you think experts are 
advising people to eat? (One serving could be, for example, an apple or a handful of 
chopped carrots)  
 
  
(c) Which fat do experts say is most important for people to cut down on? (Only fill 
one box) 
 Monounsaturated fat 
 Poly unsaturated fat 
 Saturated fat 
 Not sure 
 
(d) What version of dairy foods do experts say people should eat? (Only fill one box) 
 Full fat 
 Lower fat 
 Mixture of full fat and lower fat 
 Neither, dairy foods should be cut out 
 Not sure 
(2) Food Groups and Nutritional Content of Foods  
 
This section is concerned with food groups and the nutritional content of foods.  
(a) Do you think these foods are high or low in added sugar? (Fill in one box per 
food)  
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 High Low Not sure 
Bananas    
Unflavoured yogurt    
Ice-cream    
Orange juice    
Tomato ketchup    
Tinned fruit in 
natural juice 
   
 
(b) Do you think these foods are high or low in fat? (Fill in one box per food)  
 High Low Not sure 
Pasta (without 
sauce) 
   
Low fat spread    
Baked beans    
Lunch/sandwich 
meat (e.g. corned 
beef) 
   
Honey    
Meat pastry pie    
Nuts    
Bread    
Cottage cheese    
Polyunsaturated 
margarine 
   
 
(c) Do you think experts put these in the starchy foods group? (Fill in one box per 
food)  
 High Low Not sure 
Cheese    
Pasta    
Butter    
Nuts    
Rice    
Porridge    
 
(d) Do you think these foods are high or low in salt? (Fill in one box per food) 
 High Low Not sure 
Sausages    
Pasta    
Kippers    
Red meat    
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Frozen vegetables    
Cheese    
Tinned soup    
 
(e) Do you think these foods are high or low in protein? (Fill in one box per food) 
 High Low Not sure 
Chicken    
Cheese    
Fruit    
Baked beans    
Butter    
Cream    
 
(f) Do you think these foods are high or low in fibre/roughage? (Fill in one box per 
food) 
 High Low Not sure 
Cornflakes    
Bananas    
Eggs    
Red meat    
Broccoli    
Nuts    
Fish    
Baked potatoes with 
skins 
   
Chicken    
Baked beans    
 
(g) Do you think these fatty foods are high or low in saturated fat? (Fill in one box 
per food) 
 High Low Not sure 
Mackerel    
Whole milk    
Olive oil    
Red meat    
Broccoli    
Sunflower 
margarine 
   
Chocolate    
 
(h) Some foods contain a lot of fat but no cholesterol 
 Agree 
 Disagree 
 Not sure 
 
(i) Do you think experts call these a healthy alternative to red meat? (Fill in one box 
per food) 
 Yes No Not sure 
Liver pate    
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Lunch/sandwich 
meat (e.g. corned 
beef) 
   
Baked beans    
Nuts    
Low fat cheese    
Quiche    
 
(j) A glass of unsweetened fruit juice counts as a helping of fruit 
 Agree 
 Disagree 
 Not sure 
 
 (k) Saturated fats are mainly found in: (only fill one box) 
 Vegetable oils 
 Dairy products 
 Both 
 Not sure 
 
(l) Brown sugar is a healthy alternative to white sugar 
 Agree 
 Disagree 
 Not sure 
 
(m) There is more protein in a glass of whole milk than in a glass of skimmed milk 
 Agree 
 Disagree 
 Not sure 
 
(n) Polyunsaturated margarine contains less fat than butter 
 Agree 
 Disagree 
 Not sure 
 
(o) Which of these breads contain the most vitamins and minerals? (Only fill one 
box) 
 White 
 Brown 
 Wholegrain 
 Not sure 
 
(p) Which do you think is higher in calories: butter or regular margarine? (Only fill 
one box) 
 Butter 
 Regular margarine 
 Both the same 
 Not sure 
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(q) A type of oil which contains mostly monounsaturated fat is: (only fill one box) 
 Coconut oil 
 Sunflower oil 
 Olive oil 
 Palm oil 
 Not sure 
 
(r) There is more calcium in a glass of whole milk than a glass of skimmed milk 
 Agree 
 Disagree 
 Not sure 
 
(s) Which one of the following has the most calories for the same weight? (Only fill 
one box) 
 Sugar 
 Starchy foods 
 Fibre/roughage 
 Fat 
 Not sure 
 
(t) Harder fats contain more: (only fill one box) 
 Monounsaturated 
 Polyunsaturated 
 Saturates 
 Not sure 
 
(u) Polyunsaturated fats are mainly found in: (only fill one box) 
 Vegetable oils 
 Dairy products 
 Both 
 Not sure 
 
(3) Food Choice  
The next few items are about choosing foods.  
Please answer what is being asked and not whether you like or dislike the food!  
For example, suppose you were asked………………  
‘If a person wanted to cut down on fat, which cheese would be best to eat?’  
(a) Cheddar cheese  
(b) Camembert  
(c) Cream cheese  
(d) Cottage cheese  
If you didn’t like cottage cheese, but knew it was the right answer, you would still 
fill in the box for cottage cheese. 
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(a) What is the best choice for a low fat, high fibre snack? (Only fill one box) 
 Diet strawberry yoghurt 
 Raisins 
 Muesli bars 
 Wholemeal crackers and cheddar cheese 
 
(b) What is the best choice for a low fat, high fibre light meal? (Only fill one box) 
 Grilled chicken 
 Cheese with wholemeal toast 
 Beans on wholemeal toast 
 Quiche 
 
(c) Which kind of sandwich is healthier? (Only fill one box) 
 
 Two thick slices of bread with a thin slice of cheddar cheese filling  
 Two thin slices of bread with a thick slice of cheddar cheese filling  
 
(d) Many people eat spaghetti Bolognese (pasta with tomato and meat sauce). 
Which option is healthier? (Only fill one box) 
 A large amount of pasta with a little sauce on top  
 A small amount of pasta with a lot of sauce on top  
 
(e) If a person wanted to reduce the amount of fat in their diet, which would be the 
best choice? (Only fill one box) 
 Steak, grilled 
 Sausages, grilled 
 Turkey, grilled 
 Pork chop, grilled 
 
(f) If a person wanted to reduce the amount of fat in their diet, but didn’t want to 
give up chips, which one would be the best choice? (Only fill one box) 
 Thick cut chips 
 Thin cut chips 
 Crinkle cut chips 
 
(g) If a person felt like something sweet, but was trying to cut down on sugar, which 
would be the best choice? (Only fill one box) 
 Honey on toast 
 A cereal snack bar 
 Plain digestive biscuit 
 Banana with plain yoghurt 
 
(h) Which of these would be the healthiest pudding? (Only fill one box) 
 Baked apple 
 Strawberry yoghurt 
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 Wholemeal crackers with cheddar cheese 
 Carrot cake with cream cheese topping 
 
(i) Which cheese would be the best choice as a lower fat option? (Only fill one box) 
 Plain cream cheese 
 Edam 
 Cheddar 
 Stilton 
 
(j) If a person wanted to reduce the amount of salt in their diet, which would be the 
best choice? (Only fill one box) 
 Ready-made frozen shepherd’s pie  
 Gammon with pineapple  
 Mushroom omelette  
 Stir fry vegetables with soy sauce  
 
(k) Which one of these would be the right portion size for a serving of cheese? (Only 
fill one box) 
 1 match-box size portion 
 2 match-box portion 
 Palm of the hand 
 
(l) Which one of these would be the right portion size for a serving of peanut 
butter? (Only fill one box) 
(a) 1 teaspoon (5ml) 
(b) 2 teaspoons (10ml) 
(c) 3 teaspoons (15ml) 
 
 
(4) Diet and Disease  
This section is about the relationship between diet and health problems or 
diseases. 
 
(a) Are you aware of any major health problems or diseases that are related to a 
low intake of fruit and vegetables? 
 Yes 
 No 
 Not sure 
 
(b) If yes, what diseases or health problems do you think are related to a low intake 
of fruit and vegetables? 
____________________________________________________________________
_______ 
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(c) Are you aware of any major health problems or diseases that are related to a 
low intake of fibre? 
 Yes 
 No 
 Not sure 
 
 
(d) If yes, what diseases or health problems do you think are related to a low intake 
of fibre? 
 
 
 
(e) Are you aware of any major health problems or diseases that are related to how 
much sugar people eat? 
 Yes 
 No 
 Not sure 
 
(f) If yes, what diseases or health problems do you think are related to sugar? 
____________________________________________________________________ 
 
(g) Are you aware of any major health problems or diseases that are related to how 
much salt or sodium people eat?  
 Yes 
 No 
 Not sure 
 
(h) If yes, what diseases or health problems do you think are related to salt? 
 
(i) Are you aware of any major health problems or diseases that are related to the 
amount of fat people eat? 
 Yes 
 No 
 Not sure 
 
(j) If yes, what diseases or health problems do you think are related to fat? 
____________________________________________________________________ 
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(k) Do you think these help to reduce the chances of getting certain kinds of cancer? 
(Answer each one) 
 Yes No Not sure 
Eating more fibre    
Eating less sugar    
Eating less fruit    
Eating less salt    
Eating more fruit & 
vegetables 
   
Eating less 
preservatives/additives 
   
 
(l) Do you think these help prevent heart disease? (Answer each one) 
 Yes No Not sure 
Eating more fibre    
Eating less saturated 
food 
   
Eating less salt    
Eating more fruit & 
vegetables 
   
Eating less 
preservatives/additives 
   
 
(m) Which one of these is more likely to raise people’s blood cholesterol level? 
(Only fill one box)  
 Antioxidants 
 Polyunsaturated fats 
 Saturated fats 
 Cholesterol in the diet 
 Not sure 
 
(n) Have you heard of antioxidant vitamins?  
 Yes 
 No 
 
(o) If YES to question J46, do you think these vitamins are antioxidant vitamins? 
(Answer each one) 
 Yes No Not sure 
Vitamin A    
B complex vitamins    
Vitamin C    
Vitamin D    
Vitamin E    
Vitamin K    
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Appendix B: 
 
Supplementary Information for Chapter 3: 
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Figure 1: 
 
Supplementary Figure 1: Expression levels of different classes of HDACs: (A,B) 
Expression data from the BioGPS database showing the relative expression of (A) 
Class-I HDACs, HDAC 2, 3 and 8 and (B) Class-IIa HDACs, HDAC 4, 7 and 9 in the 
placenta (red) relative to multiple human tissues and fetal brain. 
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Figure 2:  
 
Description: DNMT Inhibitor on HSD11B2 regulation in the placenta (A) Expression 
data from the BioGPS database showing the relative expression of a DNMT1in the 
placenta (red) relative to multiple human tissues and fetal brain.  (B) Graphical 
representation of HSD11B2 expression in JEG-3 cells treated with 0-10mM of 
DNMT1 inhibitor 5-aza-2’-deoxycytidine (5-AZA) for 24h. (D) Representative 
photomicrographs of JEG-3 cells immunocytochemically stained for HSD11B2 after 
treatment with (0-10µM) 5-AZA for 24h.  (D, E) Graphical representation and of 
HSD11B2 expression in JEG-3 cells treated with 2mM Cort (D) or (E) 10ng/ml IL1b in 
the presence or absence of 10mM 5-AZAfor 24h. Data are expressed as 
mean ± SEM (*** p < 0.001 compared to control; one-way ANOVA with post-hoc 
Tukey’s test; N = 3). Scale bar = 50μm. 
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Appendix C: 
 
Supplementary Information for Chapter 4: 
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Table 1: Prenatal stress, anxiety and depression and other neonatal outcomes 
Perceived Stress Scale 
 OR (CI ; p-value) aOR (CI ; p-value) 
Birth centiles 0.429 (0.115 – 1.606 ; 0.209) 0.395 (0.104 – 1.501 ; 0.173) 
Neonatal Resuscitation 0.404 (0.109 – 1.501 ; 0.176) 0.460 (0.122 – 1.743 ; 0.253) 
NICU Admission 1.405 (0.225 – 8.774 ; 0.716) 1.572 (0.240 – 10.312 ; 0.637) 
Stat Trait Anxiety Inventory 
 OR (CI ; p-value) aOR (CI ; p-value) 
Birth centiles 1.279 (0.407 – 4.019 ; 0.673) 1.272 (0.396 – 4.080 ; 0.686) 
Neonatal Resuscitation 1.142 (0.368 – 3.544 ; 0.818) 1.206 (0.375 – 3.873 ; 0.753) 
NICU Admission 4.448 (0.708 – 27.954 ; 0.111) 1.109 (0.930 – 1.323 ; 0.250) 
Edinburgh Postnatal Depression Scale 
 OR (CI ; p-value) aOR (CI ; p-value) 
Birth centiles 0.650 (0.172 – 2.456 ; 0.525) 0.602 (0.152 – 2.382 ; 0.469) 
Neonatal Resuscitation 0.618 (0.164 – 2.324 ; 0.476) 0.654 (0.165 – 2.593 ; 0.546) 
NICU Admission 2.071 (0.329 – 13.032 ; 0.438) 1.857 (0.277 – 12.460 ; 0.524) 
Cumulative 
 OR (CI ; p-value) aOR (CI ; p-value) 
Birth centiles 0.363 (0.045 – 2.945 ; 0.342) 0.334 (0.039 – 2.855 ; 0.316) 
Neonatal Resuscitation 0.764 (0.158 – 3.689 ; 0.738) 0.795 (0.158 – 4.003 ; 0.781) 
NICU Admission 4.444 (0.685 – 28.828 ; 0.118) 1.007 (0.878 – 1.155 ; 0.919) 
Table 1: Relationship between scoring in the PSS, STAI, and/or EPDS with infants in 
the lower 10th birth centile, neonatal resuscitations and NICU Admissions. Binary 
logistic regression shows no significant difference between groups P>0.05. Adjusted 
for maternal age, BMI and social class. 
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Figure 1: Participants groupings based on Questionnaire Scorings 
 
Figure 1: Graphical representation of Perceived Stress Scale (A), State Trait Anxiety 
Inventory (B) and Edinburgh Postnatal Depression Scale (C) scores between women 
ranked in the low and high categories. Unpaired student t-test show a significant 
difference between groups P < 0.001 ***, N=121.  
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Table 2: Global sample means of measured variables 
Measure Population Low High 
 Mean ± SD (N) Mean ± SD (N) Mean ± SD (N) 
Perceived Stress Scale 15.88 ± 6.5 (121) 12.75 ± 4.5 (81) 23.65 ± 2.4 (40) 
State Trait Anxiety Inventory 6.17 ± 3.8 (121) 4.20 ± 2.1 (87) 11.21 ± 2.0 (34) 
Edinburgh Postnatal Depression Scale 9.07 ± 5.6 (121) 6.52 ± 3.7 (90) 16.48 ± 2.9 (31) 
Table 2: Global sample means of measured variables expressed as mean ± SD. High 
stress (PSS ≥ 20), low stress (PSS ≤ 19). High anxiety (STAI ≥ 9), low anxiety (STAI ≤ 
8). High probability of depression (EPDS ≥ 13), low probability of depression (EPDS ≤ 
12).   
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Figure 2: Intercorrelations of questionnaire scores 
 
Figure 2: Correlation matrices showing relationship between PSS, STAI and EPDS 
scores. Pearson correlation shows each questionnaire is significantly correlated. PSS 
and STAI (r = 0.521; P < 0.001 ***), PSS and EPDS (r = 0.724; P < 0.001 ***) and STAI 
and EPDS (r = 0.678; P > 0.001 ***). RStudio Graphics. 
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Table 3: Prenatal distress with number of newborn adversities 
Table 3: Odds ratios assessing the relationship between prenatal distress and 
number of newborn adversities. Newborns were grouped into number of adverse 
birth outcomes based on six parameters (a) Admission to the NICU (b) Newborn 
Resuscitation received (c) Delivered before 37 weeks gestation (d) 5 minute Apgar 
score ≤ 7 (e) Birth Temperature < 36.5°C and (f) Birth Centile ≤ 10 or ≥ 90. Ordinal 
logistic regression analysis revealed no significant effect (P > 0.05 *). Adjusted for 
maternal age, BMI and social class. 
  
Perceived Stress Scale 
 OR (CI ; p-value) aOR (CI ; p-value) 
1 adverse outcome 0.669 (-1.245 – 0.442; 0.351) 0.648 (-1.302 - 0.435; 0.328) 
2 adverse outcomes 0.341 (-3.276 – 1.122; 0.337) 0.335 (-3.310 – 1.124; 0.334) 
3 adverse outcomes 0.852 (-2.607 – 2.287; 0.898) 0.878 (-2.628 – 2.468; 0.474) 
Stat Trait Anxiety Inventory 
 OR (CI ; p-value) aOR (CI ; p-value) 
1 adverse outcome 0.914 (-0.974 – 0.794; 0.842) 0.860 (-1.076 – 0.773; 0.748) 
2 adverse outcomes 1.325 (-1.492 – 2.055; 0.756) 1.440 (-1.445 – 2.174; 0.693) 
3 adverse outcomes 1.325 (-2.174 – 2.736; 0.822) 0.809 (-2.769 – 2.346; 0.871) 
Edinburgh Postnatal Depression Scale 
 OR (CI ; p-value) aOR (CI ; p-value) 
1 adverse outcome 0.914 (-0.974 – 0.794; 0.842) 0.914 (-1.019 – 0.839; 0.849) 
2 adverse outcomes -- -- 
3 adverse outcomes 1.325 (-2.174 – 2.736; 0.822) 1.090 (-2.517 – 2.690; 0.948) 
Cumulative 
 OR (CI ; p-value) aOR (CI ; p-value) 
1 adverse outcome 1.025 (-1.056 – 1.105; 0.965) 0.986 (-1.148 – 1.120; 0.981) 
2 adverse outcomes -- -- 
3 adverse outcomes 2.818 (-1.449 – 3.521; 0.414) 1.610 (-2.143 – 3.094; 0.722) 
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Table 4: Linear Regression analysis of placental HSD11B2 mRNA expression with 
maternal distress, demographics and neonatal outcomes 
HSD11B2 R2 β-coefficient 95% CI p-value 
Birthweight 0.019 0.137 -0.783 – 1.547 0.505 
Placental weight 0.037 0.119 -0.144 – 0.382 0.360 
PWR 0.030 0.173 0.00 – 0.00 0.408 
Birthweight centiles 0.012 0.109 -0.068 – 0.116 0.597 
1 min Apgar 0.012 0.109 -0.002 – 0.003 0.597 
5 min Apgar 0.011 0.103 -0.001 – 0.002 0.617 
Birth Temperature 0.003 0.054 -0.001 – 0.001 0.794 
Head Circumference 0.023 0.153 -0.003 – 0.006 0.476 
Gravidity 0.000 -0.009 -0.009 – 0.009 0.964 
Maternal Age 0.004 -0.064 -0.647 – 0.472 0.472 
Maternal BMI 0.062 -0.248 -0.001 – 0.000 0.212 
Social Class 0.009 -0.095 -0.954 – 0.594 0.636 
PSS 0.137 -0.370 -0.051 – 0.001 0.058 
STAI 0.070 -0.265 -0.025 – 0.005 0.181 
EPDS 0.068 -0.260 -0.038 – 0.008 0.190 
Table 4: Placental HSD11B2 expression and continuous variables. Linear regression analysis. 
P > 0.05 
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Table 5: Linear Regression analysis of placental NR3C1 mRNA expression with 
maternal distress, demographics and neonatal outcomes 
NR3C1 R2 
 
β-coefficient 95% CI p-value 
Birthweight 0.083 -0.288 -1961 – 325.796 0.153 
Placental weight 0.159 -0.398 -790.258 - -2.667 0.049 
PWR 0.086 -0.293 -0.867 – 0.146 0.155 
Birthweight centiles 0.170 -0.412 -180 - -6.380 0.036 
1 min Apgar 0.004 -0.064 -2.870 – 2.111 0.756 
5 min Apgar 0.00 0.010 -1.714 – 1.794 0.962 
Birth Temperature 0.038 -0.195 -1.267 – 0.455 0.340 
Head Circumference 0.042 -0.206 -10.938 – 3.888 0.355 
Gravidity 0.003 -0.054 -9.854 – 7.583 0.791 
Maternal Age 000 0.015 -547.008 – 588.035 0.941 
Maternal BMI 0.023 0.151 -0.292 – 0.635 0.453 
Social Class 0.005 0.074 -644.397 – 955.528 0.715 
PSS 0.075 0.273 -8.437 – 45.959 0.168 
STAI 0.003 0.052 -13.496 – 17.405 0.797 
EPDS 0.007 0.084 -18.893 – 28.563 0.678 
Table 5: Placental NR3C1 expression and continuous variables. Linear regression analysis. 
Placental weight and birthweight centiles associated with NR3C1 levels. P < 0.05 * 
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Table 6: Linear Regression analysis of placental FKBP51 mRNA expression with 
maternal distress, demographics and neonatal outcomes 
FKBP51 R2 
 
β-coefficient 95% CI p-value 
Birthweight 0.033 -0.183 -2955.102 – 1147.112 0.372 
Placental weight 0.109 -0.330 -1010.482 – 106.235 0.107 
PWR 0.020 -0.140 -0.959 – 0.487 0.506 
Birthweight centiles 0.150 -0.387 -308.452 – 0.616 0.051 
1 min Apgar 0.011 0.107 -3.244 – 5.473 0.603 
5 min Apgar 0.002 0.05 -2.714 – 3.444 0.809 
Birth Temperature 0.015 -0.122 -1.985 – 1.086 0.551 
Head Circumference 0.049 -0.222 -14.815 – 4.733 0.296 
Gravidity 0.012 -0.122 -19.559 – 11.174 0.579 
Maternal Age 0.137 -0.370 -47.048 – 1.302 0.063 
Maternal BMI 0.185 0.430 3.069 – 42.498 0.025 
Social Class 0.023 0.153 -862.086 – 1893.458 0.448 
PSS 0.038 0.194 -25.554 – 72.702 0.332 
STAI 0.008 0.088 -21.420 – 33.170 0.661 
EPDS 0.045 0.212 -1.231 – 3.962 0.289 
Table 6: Placental FKBP5 expression and continuous variables. Linear regression analysis. 
Maternal BMI positively associated with FKBP5 levels. P < 0.05 *. 
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Figure 3: Placental Gene expression, gender and obstetric outcomes 
 
Figure 3: Expression of placental HSD11B2, NR3C1 and FKBP5 in relation newborn 
sex and obstetric outcomes. No significant differences between groups. Unpaired 
Student’s t-test. P < 0.005. Spontaneous (Spont), Induction (Induct), Spontaneous 
rupture of membranes (SROM), Artificial Rupture of membranes (AROM), 
Spontaneous vaginal delivery (SVD), Operative delivery (Opera) Vaginal delivery 
(Vagin) and C-Section delivery (C-Sect). 
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Supplementary Information for Chapter 6: 
 
  
 324 
 
Table 1: Descriptive statistics of continuous variables 
Measure Mean ± SD (N) Range 
Age 30.67 ± 4.4 (105) 19 - 41 
BMI 15wks gestation (kg/m2) 25.43 ± 3.8 (105) 18.1 - 39.0 
BMI 20wks gestation (kg/m2) 26.34 ± 3.6 (105) 18.9 – 39.7 
BMI 32wks gestation (kg/m2) 28.87 ± 3.9 (90) 20.0 – 41.7 
Gestational Age at Delivery 39.68 ± 1.3 (105) 34 - 42 
1 minute Apgar score 8.57 ± 1.1 (105) 3 - 10 
5 minute Apgar score 9.52 ± 0.6 (105) 6 - 10 
Birthweight (g) 3548.76 ± 477.5 (105) 2060 - 4980 
Birthweight Centiles 49.17 ± 27.1 (105) 1 – 100 
Maximum temperature in labour (®C) 37.06 ± 0.48 (86) 36.0 – 38.6 
Supplementary table 1: Descriptive statistics of maternal age, body mass index (BMI) and 
obstetric and neonatal outcomes of study cohort.  Data shown are cohort Mean ± Standard 
deviation (SD) and range.  
 
Table 2: Descriptive statistics of categorical variables 
Measure Frequency (N) 
Country of birth 
Europe 
South America 
Africa 
*Missing 
 
92.8 (103) 
0.9(1) 
0.9 (1) 
5.4 (6) 
Marital status 
Married 
Defacto 
Single 
*Missing 
 
56.8 (63) 
27.0 (30) 
10.8 (12) 
5.4 (6) 
Tertiary Education 
Graduated 
None 
Still attending  
*Missing 
 
67.6 (75) 
25.2 (28) 
1.8 (2) 
5.4 (6) 
Employment 
Employed 
Unemployed 
*Missing 
 
86.2 (96) 
8,1 (9) 
5.4 (6) 
Income  
< €21K 
 
8.1 (9) 
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€21K – €42K 
€43K – €63K 
> €64K  
*Missing 
13.5 (15) 
20.7 (23) 
49.5 (55) 
8.1 (9) 
Hx IBD 
No 
Yes  
*Missing 
 
91.9 (103) 
2.7 (3) 
5.4 (6) 
Hx Coeliac disease 
No 
Yes  
*Missing 
 
92.8 (103) 
1.8 (2) 
5.4 (6) 
Hx IBS 
No 
Yes  
*Missing 
 
85.6 (95) 
9.0 (10) 
5.4 (6) 
Hx Depression 
No 
Yes  
*Missing 
 
83.8 (93) 
10.8 (12) 
5.4 (6) 
Sex 
Male 
Female 
*Missing 
 
46.8 (52) 
47.7 (53) 
5.4 (6) 
Onset of delivery 
Spontaneous 
Induction 
Pre-labour caesarean 
PROM 
*Missing 
 
51.4 (57) 
24.3 (27) 
9.9 (11) 
9.0 (10) 
5.4 (6) 
Mode of delivery 
Unassisted vaginal 
Operative vaginal 
Caesarean in labour 
Pre-labour caesarean 
*Missing 
 
39.6 (44) 
32.4 (36) 
12.6 (14) 
9.9 (11) 
5.4 (6) 
Supplementary table 2: Table shows descriptive statistics of maternal demographics, 
pregnancy and neonatal outcomes for entire study cohort. Data shown are cohort 
frequencies. Abbreviations: History (Hx), Irritable Bowel Disease (IBD), Irritable Bowel 
Syndrome (IBS). 
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Figure 1: Mode of feeding in infants by second trimester maternla stress 
 
Supplementary Figure 1: Pie Charts showing the percentage of infant feeding practises 
grouped by maternal stress (Perceived Stress Scale, low < 13, high > 14) in the second 
trimester. (A) 1 week old low stress versus high stress; 29.4% v 41.6% bottle-fed, 55.8% v 
44.4% breast-fed, 14.7% v 13.8% mixed-fed. (B) 2 weeks old low stress versus high stress; 
28.5% v 47.3% bottle-fed, 54.2% v 39.4% breast-fed, 17.1% v 13.1% mixed-fed. (C) 3 weeks 
old low stress versus high stress; 27.2% v 48.6% bottle-fed, 54.5% v 37.8% breast-fed, 
18.1% v 13.5% mixed-fed. (D) 3 months old low stress versus high stress; 28.1% v 51.5% 
bottle-fed, 50% v 39.3% breast-fed, 21.8% v 9.0% mixed-fed. (E) 5 months old low stress 
versus high stress; 40.7% v 58.0% bottle-fed, 48.1% v 32.2% breast-fed, 11.1% v 9.6% 
mixed-fed. (F) Eating solids by 5 months old low stress versus high stress; 28.5% v 20% no, 
71.4% v 80% high. P > 0.05 Chi Square Test.  
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Table 3: Maternal gut in the 2nd trimester by 2nd trimester stress 
OTU Relative Abundance (%) p-value 
Maternal gut (2nd trimester) Low PSS High PSS  
Chao1 Index 405.0 356.5 t(44) = 2.01, p=0.049 
Simpson Index 0.96 0.96 t(44) = -0.26, p=0.792 
Shannon Index 5.7 5.7 t(44) = 0.23, p=0.815 
Phylogenetic diversity 20.4 18.9 t(44) = 1.42, p=0.160 
Observed Species 315.6 288.9 t(44) = 1.59, p=0.118 
Actinobacteria 4.5 4.4 W=276, p=0.800 
Bacteroidetes 21.8 21.4 W=231, p=0.478 
Firmicutes 69.8 69.7 W=280, p=0.735 
Proteobacteria 1.7 1.8 W=242, p=0.639 
Verrucomicrobia 1.3 2.1 W=215.5, p=0.290 
Bifidobacteriaceae 2.8 2.5 W=288, p=0.608 
Coriobacteriaceae 1.5 1.3 W=271.5, p=0.877 
Bacteroidaceae 11.3 12.7 W=191.5, p=0.113 
Porphyromonadaceae 3.8 3.0 W=248.5, p=0.741 
Prevotellaceae 2.6 2.2 W=314.5, p=0.270 
Rikenellaceae 3.3 3.2 W=263, p=0.991 
Christensenellaceae 2.0 1.3 W=318.5, p=0.235 
Clostridiaceae1 1.5 1.2 W=298.5, p=0.454 
Lachnospiraceae 34.2 35.3 W=233, p=0.506 
Peptostreptococcaceae 3.0 3.3 W=265, p=0.991 
Ruminococcaceae 21.8 18.7 W=357, p=0.041 
Erysipelotrichaceae 2.0 2.2 W=278, p=0.766 
Acidaminococcaceae 0.8 1.3 W=228, p=0.422 
Veillonellaceae 2.4 3.9 W=244, p=0.668 
Oxalobacteraceae 0.0 0.0 W=345, p=0.044 
Campylobacteraceae 0.0 0.0 W=220, p=0.050 
Verrucomicrobiaceae 1.3 2.0 W=214.5, p=0.280 
Bifidobacterium 2.8 2.5 W=288, p=0.608 
Bacteroides 11.3 12.7 W=191.5, p=0.113 
Barnesiella 1.2 1.1 W=249, p=0.749 
Prevotella 2.3 1.8 W=270, p=0.902 
Alistipes 3.1 3.2 W=255, p=0.853 
Christensenellaceae uncultured 2.0 1.2 W=323.5, p=0.194 
Clostridium sensu stricto1 1.5 1.2 W=298.5, p=0.454 
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Anaerostipes 1.3 2.0 W=231, p=0.474 
Eubacterium 0.0 0.0 W=220, p=0.050 
Blautia 4.4 4.8 W=203, p=0.183 
Coprococcus 1.0 1.1 W=254.5, p=0.843 
Lachnospiraceaen Icertae Sedis 10.2 11.9 W=216.5, p=0.301 
Pseudobutyrivibrio 3.0 2.9 W=297.5, p=0.468 
Roseburia 1.6 1.2 W=299, p=0.448 
Shuttleworthia 0.0 0.0 W=353.5, p=0.044 
Lachnospiraceae uncultured 11.3 10.0 W=295, p=0.506 
Peptostreptococcaceae Incertae Sedis 0.9 1.0 W=261.5, p=0.964 
Peptostreptococcaceae uncultured 2.0 2.3 W=273.5, p=0.843 
Faecalibacterium 6.1 4.8 W=312, p=0.296 
Ruminococcaceae Incertae Sedis 1.7 2.0 W=276, p=0.800 
Oscillibacter 0.0 0.0 W=353.5, p=0.047 
Ruminococcus 1.9 1.4 W=281.5, p=0.708 
Subdoligranulum 3.7 2.7 W=312, p=0.296 
Ruminococcaceae uncultured 7.9 7.3 W=279, p=0.752 
Dialister 2.2 2.8 W=270, p=0.903 
Campylobacter 0.0 0.0 W=220, p=0.050 
Akkermansia 1.3 2.0 W=214.5, p=0.280 
Supplementary table 3: Relative abundance of bacterial OTUs in the 2nd trimester maternal 
gut by maternal stress in the 2nd trimester. Listed are all OTUs with an abundance of 
greater than 1% and significant OTUs with an abundance of less than 1%. Low stress (PSS < 
13; N=22), high stress (PSS > 4; N=25). Unpaired students t-test and Mann-Whitney-
Wilcoxon test. Abbreviations: Operational taxonomic unit (OTU), Perceived Stress Scale 
(PSS). 
 
Table 4: Maternal gut in the 2nd trimester by 2nd trimester anxiety 
OTU Relative Abundance (%) p-value 
Maternal gut (2nd trimester) Low STAI High STAI  
Chao1 Index 382.5 372.6 t(44) = 0.37, p=0.712 
Simpson Index 0.9 0.9 t(44) = -1.00, p=0.319 
Shannon Index 5.6 5.8 t(44) = -1.03, p=0.307 
Phylogenetic diversity 19.7 19.3 t(44) = 0.25, p=0.802 
Observed Species 299.5 300.1 t(44) = -0.03, p=0.974 
Actinobacteria 4.3 4.6 W=250, p=0.766 
Bacteroidetes 23.2 20.2 W=274, p=0.836 
Firmicutes 68.3 71.2 W=232, p=0.492 
Proteobacteria 1.5 2.0 W=211, p=0.251 
 329 
 
Verrucomicrobia 2.1 1.4 W=313.5, p=0.280 
Bifidobacteriaceae 2.6 2.7 W=260, p=0.939 
Coriobacteriaceae 1.3 1.3 W=242, p=0.636 
Bacteroidaceae 12.2 12.1 W=220.5, p=0.344 
Porphyromonadaceae 3.5 3.3 W=212.5, p=0.262 
Prevotellaceae 3.4 1.2 W=341, p=0.091 
Rikenellaceae 3.4 3.1 W=246, p=0.719 
Bacteroidales247 0.4 0.1 W=348, p=0.030 
Christensenellaceae 1.8 1.5 W=260.5, p=0.947 
Clostridiaceae1 1.6 1.2 W=272.5, p=0.860 
Lachnospiraceae 33.5 35.9 W=216, p=0.299 
Peptostreptococcaceae 3.0 3.4 W=264, p=1 
Ruminococcaceae 20.4 19.8 W=272, p=0.870 
Erysipelotrichaceae 1.7 2.6 W=214.5, p=0.281 
Acidaminococcaceae 0.8 1.3 W=222, p=0.348 
Veillonellaceae 3.1 3.4 W=296, p=0.488 
Verrucomicrobiaceae 2.0 1.4 W=310.5, p=0.311 
Bifidobacterium 2.6 2.7 W=260, p=0.939 
Slackia 0.0 0.0 W=183, p=0.029 
Bacteroides 12.2 12.1 W=220.5, p=0.244 
Barnesiella 1.1 1.3 W=196.5, p=0.140 
Prevotella 3.0 1.1 W=317, p=0.242 
Alistipes 3.2 3.1 W=235, p=0.534 
Rikenellaceae RC9 gut group 0.1 0.0 W=331.5, p=0.025 
Christensenellaceae uncultured 1.7 1.4 W=261.5, p=0.964 
Clostridium sensu stricto1 1.6 1.2 W=272.5, p=0.860 
Anaerostipes 1.2 1.9 W=225.5, p=0.403 
Blautia 4.7 4.4 W=243, p=0.652 
Anaerotruncus 0.1 0.3 W=118.5, p=0.001 
Hydrogenoanaero bacterium 0.0 0.0 W=201.5, p=0.029 
Erysipelotrichaceae Incertae Sedis 0.4 1.5 W=164.5, p=0.029 
Coprococcus 1.0 1.1 W=245, p=0.684 
Lachnospiraceaen Icertae Sedis 10.2 11.7 W=213.5, p=0.271 
Pseudobutyrivibrio 3.0 3.0 W=270, p=0.903 
Roseburia 1.3 1.5 W=221.5, p=0.355 
Lachnospiraceae uncultured 10.6 10.7 W=255, p=0.853 
Peptostreptococcaceae Incertae Sedis 0.8 1.1 W=227, p=0.422 
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Peptostreptococcaceae uncultured 2.2 2.3 W=278, p=0.766 
Faecalibacterium 5.4 05.4 W=256, p=0.869 
Ruminococcaceae Incertae Sedis 2.0 1.7 W=268.5, p=0.929 
Ruminococcus 1.6 1.6 W=247.5, p=0.725 
Subdoligranulum 3.3 3.0 W=277, p=0.783 
Ruminococcaceae uncultured 7.6 7.6 W=261, p=0.956 
Dialister 2.2 3.0 W=295, p=0.501 
Akkermansia 2.0 1.4 W=310.5, p=0.311 
Supplementary table 4: Relative abundance of bacterial OTUs in the 2nd trimester maternal 
gut by maternal anxiety in the 2nd trimester. Listed are all OTUs with an abundance of 
greater than 1% and significant OTUs with an abundance of less than 1%. Low anxiety (STAI 
< 4; N=24), high anxiety (STAI > 5; N=22). Unpaired students t-test and Mann-Whitney-
Wilcoxon test. Abbreviations: Operational taxonomic unit (OTU), State Trait Anxiety 
Inventory (STAI). 
 
Table 5: Maternal gut in the 2nd trimester by 2nd trimester depressive symptoms 
OTU Relative Abundance (%) p-value 
Maternal gut (2nd trimester) Low EPDS High EPDS  
Chao1 Index 392.1 326.2 t(44) = 2.11, p=0.040 
Simpson Index 0.9 0.9 t(44) = 0.84, p=0.400 
Shannon Index 5.8 5.5 t(44) = 1.41, p=0.163 
Phylogenetic diversity 20.2 16.9 t(44) = 2.33, p=0.024 
Observed Species 310.3 262.2 t(44) = 2.13, p=0.038 
Euryarchaeota 0.1 0.0 W=240, p=0.040 
Actinobacteria 4.4 4.7 W=174, p=0.883 
Bacteroidetes 21.2 23.8 W=140, p=0.297 
Firmicutes 70.2 67.7 W=210, p=0.438 
Cyanobacteria 0.2 0.0 W=266.5, p=0.020 
Proteobacteria 1.6 2.3 W=127, p=0.164 
Tenericutes 0.0 0.0 W=244, p=0.081 
Verrucomicrobia 1.9 1.2 W=206, p=0.496 
Methanobacteriaceae 0.1 0.0 W=240, p=0.040 
Bifidobacteriaceae 2.7 2.5 W=186, p=0.885 
Coriobacteriaceae 1.4 1.1 W=193.5, p=0.729 
Bacteroidaceae 11.4 14.9 W=112, p=0.072 
Porphyromonadaceae 3.3 3.8 W=119, p=0.1071 
Prevotellaceae 2.6 1.5 W=172, p=0.841 
Rikenellaceae 3.2 3.4 W=173, p=0.864 
Christensenellaceae 1.8 1.0 W=235.5, p=0.143 
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Clostridiaceae1 1.5 0.8 W=221.5, p=0.274 
Lachnospiraceae 33.5 38.6 W=108, p=0.056 
Peptostreptococcaceae 3.5 2.0 W=215, p=0.363 
Ruminococcaceae 20.9 17.2 W=250, p=0.063 
Erysipelotrichaceae 2.4 1.3 W=234, p=0.154 
Acidaminococcaceae 1.0 1.2 W=179, p=0.989 
Veillonellaceae 3.0 4.2 W=148, p=0.401 
Oxalobacteraceae 0.0 0.0 W=250.5, p=0.034 
Verrucomicrobiaceae 1.9 2.7 W=203, p=0.548 
Methanobrevibacter 0.1 0.0 W=240, p=0.040 
Bifidobacterium 1.2 2.5 W=186, p=0.885 
Bacteroides 11.4 14.9 W=112, p=0.072 
Barnesiella 1.1 1.3 W=133.5, p=0.220 
Prevotella 2.3 1.3 W=161.5, p=0.628 
Alistipes 3.1 3.4 W=167, p=0.743 
Christensenella 0.1 0.0 W=262, p=0.029 
Christensenellaceae uncultured 1.7 0.9 W=231.5, p=0.174 
Clostridium sensu stricto1 1.5 0.8 W=221.5, p=0.274 
Anaerostipes 1.3 2.6 W=119.5, p=0.110 
Blautia 4.5 4.8 W=148, p=0.401 
Coprococcus 1.1 0.8 W=196.5, p=0.670 
Howardella 0.0 0.0 W=240, p=0.040 
Lachnospiraceaen Icertae Sedis 10.5 12.6 W=136, p=0.246 
Pseudobutyrivibrio 2.7 4.1 W=155, p=0.514 
Roseburia 1.4 1.3 W=171, p=0.820 
Lachnospiraceae uncultured 10.6 10.8 W=170, p=0.803 
Peptostreptococcaceae Incertae 
Sedis 
1.0 0.8 W=183, p=0.946 
Peptostreptococcaceae 
uncultured 
2.5 1.1 W=229, p=0.196 
Faecalibacterium 4.7 7.7 W=98, p=0.029 
Ruminococcaceae Incertae Sedis 2.1 1.0 W=228, p=0.205 
Ruminococcus 1.8 0.8 W=237.5, p=0.129 
Subdoligranulum 3.4 2.5 W=219.5, p=0.299 
Ruminococcaceae uncultured 8.4 4.8 W=265, p=0.022 
Dialister 2.4 3.1 W=178, p=0.968 
Oxalobacter 0.0 0.0 W=246, p=0.043 
Akkermansia 1.9 1.2 W=203, p=0.548 
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Supplementary table 5: Relative abundance of bacterial OTUs in the 2nd trimester maternal 
gut by maternal depressive symptoms in the 2nd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low depressive symptoms (EPDS < 8; N=36), high depressive symptoms (EPDS > 9; N=10). 
Unpaired students t-test and Mann-Whitney-Wilcoxon test. Abbreviations: Operational 
taxonomic unit (OTU), Edinburgh Postnatal Depression Scale (EPDS). 
 
Table 6: Maternal gut in the 2nd trimester by 2nd trimester cortisol 
OTU Relative Abundance (%) p-value 
Maternal gut (2nd trimester) Low CAR High CAR  
Chao1 Index 357.3 390.2 t(36) = -1.19, p=0.2391 
Simpson Index 0.9 0.9 t(36) = -0.82, p=0.414 
Shannon Index 5.6 5.8 t(36) = -1.61, p=0.115 
Phylogenetic diversity 18.5 20.3 t(36) = -1.41, p=0.165 
Observed Species 283.15 311.8 t(36) = -1.44, p=0.156 
Actinobacteria 3.4 3.9 W=194, p=0.693 
Bacteroidetes 21.9 22.1 W=169, p=0.761 
Firmicutes 70.6 70.3 W=193, p=0.717 
Proteobacteria 1.7 1.9 W=170, p=0.783 
Verrucomicrobia 1.7 1.0 W=189.5, p=0.792 
Bifidobacteriaceae 1.9 2.3 W=205, p=0.478 
Coriobacteriaceae 1.0 1.4 W=177, p=0.907 
Bacteroidaceae 14.3 11.2 W=205, p=0.478 
Porphyromonadaceae 3.0 2.9 W=180, p=1 
Prevotellaceae 1.3 3.9 W=164, p=0.649 
Rikenellaceae 2.7 3.6 W=121, p=0.087 
Christensenellaceae 1.2 1.8 W=138.5, p=0.230 
Clostridiaceae1 1.5 1.2 W=203, p=0.510 
Lachnospiraceae 35.2 36.0 W=171, p=0.806 
Peptostreptococcaceae 3.4 2.4 W=197, p=0.633 
Ruminococcaceae 20.5 20.4 W=185, p=0.896 
Erysipelotrichaceae 1.8 2.3 W=199.5, p=0.578 
Acidaminococcaceae 1.2 1.0 W=214, p=0.314 
Veillonellaceae 3.7 2.9 W=197, p=0.629 
Verrucomicrobiaceae 1.7 1.0 W=187.5, p=0.837 
Bifidobacterium 1.9 2.2 W=205, p=0.478 
Bacteroides 14.3 11.2 W=,205 p=0.478 
Barnesiella 1.4 0.9 W=196.5, p=0.639 
Odoribacter 0.0 0.0 W=109, p=0.039 
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Prevotella 1.0 3.5 W=156.5, p=0.493 
Alistipes 2.6 3.4 W=124, p=0.105 
Christensenellaceae uncultured 1.1 1.8 W=136, p=0.206 
Clostridium sensu stricto1 1.5 1.2 W=203, p=0.510 
Anaerostipes 1.3 1.6 W=159.5, p=0.558 
Blautia 4.3 5.2 W=146, p=0.327 
Coprococcus 1.1 1.4 W=161.5, p=0.598 
Lachnospiraceaen Icertae Sedis 11.7 10.4 W=215.5, p=0.306 
Pseudobutyrivibrio 3.4 3.6 W=171, p=0.803 
Roseburia 1.4 1.1 W=203, p=0.510 
Lachnospiraceae uncultured 10.5 11.1 W=158, p=0.534 
Peptostreptococcaceae 
uncultured 
2.4 1.6 W=177, p=0.941 
Faecalibacterium 5.9 6.2 W=162.5, p=0.619 
Ruminococcaceae Incertae Sedis 2.2 1.3 W=175.5, p=0.906 
Ruminococcus 1.9 2.1 W=149.5, p=0.380 
Subdoligranulum 3.6 2.6 W=228, p=0.166 
Ruminococcaceae uncultured 6.4 7.6 W=147, p=0.346 
Phascolarctobacterium 1.1 0.9 W=212, p=0.344 
Dialister 2.8 2.2 W=220, p=0.246 
Akkermansia 1.7 1.0 W=187.5, p=0.837 
Supplementary table 6: Relative abundance of bacterial OTUs in the 2nd trimester maternal 
gut by maternal cortisol in the 2nd trimester. Listed are all OTUs with an abundance of 
greater than 1% and significant OTUs with an abundance of less than 1%. Low cortisol (CAR 
< 545131; N=20), high cortisol (CAR > 545132; N=18). Unpaired students t-test and Mann-
Whitney-Wilcoxon test. Abbreviations: Operational taxonomic unit (OTU), Cortisol 
Awakening Response (CAR). 
 
Table 7: Maternal gut in the 3rd trimester by 2nd trimester stress 
OTU Relative Abundance (%) p-value 
Maternal gut (3rd trimester) Low PSS High PSS  
Chao1 Index 390.7 362.0 t(29) = 0.98, p=0.330 
Simpson Idnex 0.9 0.9 t(29) = -0.60, p=0.546 
Shannon Index 5.8 5.7 t(29) = 0.35, p=0.728 
Phylogenetic diversity 19.9 18.8 t(29) = 0.74, p=0.459 
Observed Species 306.1 287.4 t(29) = 0.85, p=0.401 
Actinobacteria 6 6 W=105, p=0.571 
Bacteroidetes 17 19 W=107, p=0.626 
Firmicutes 72 69 W=131, p=0.682 
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Proteobacteria 2 2 W=116, p=0.891 
Verrucomicrobia 2 3 W=117, p=0.921 
Bifidobacteriaceae 3 4 W=117, p=0.922 
Nocardiaceae 2 1 W=126, p=0.827 
Coriobacteriaceae 2 2 W=87, p=0.202 
Bacteroidaceae 11 12 W=102, p=0.494 
Porphyromonadaceae 3 3 W=117, p=0.922 
Prevotellaceae 0 2 W=93.5, p=0.301 
Rikenellaceae 3 2 W=129, p=0.740 
Christensenellaceae 3 2 W=145.5, p=0.323 
Clostridiaceae1 2 1 W=152.5, p=0.205 
Lachnospiraceae 34 36 W=108, p=0.653 
Peptostreptococcaceae 3 2 W=141, p=0.417 
Ruminococcaceae 22 20 W=137, p=0.514 
Erysipelotrichaceae 2 2 W=115, p=0.860 
Acidaminococcaceae 2 1 W=125.5, p=0.838 
Veillonellaceae 3 4 W=119, p=0.984 
Alcaligenaceae 1 1 W=116.5, p=0.905 
Verrucomicrobiaceae 2 3 W=116, p=0.889 
Bifidobacterium 3 4 W=118, p=0.953 
Rhodococcus 2 1 W=126, p=0.827 
Bacteroides 11 12 W=102, p=0.494 
Barnesiella 1 1 W=136, p=0.539 
Porphyromonadaceae uncultured 1 1 W=95.5, p=0.342 
Prevotella 0 3 W=77, p=0.082 
Alistipes 1 2 W=128, p=0.770 
Christensenellaceae uncultured 3 2 W=144, p=0.352 
Clostridium sensu stricto1 2 1 W=153, p=0.198 
Anaerostipes 1 1 W=104, p=0.545 
Blautia 5 5 W=102, p=0.489 
Coprococcus 1 1 W=122.5, p=0.937 
Lachnospiraceae Incertae Sedis 10 10 W=114, p=0.827 
Pseudobutyrivibrio 3 4 W=95, p=0.889 
Roseburia 2 2 W=116, p=0.889 
Lachnospiraceae uncultured 10 11 W=112, p=0.658 
Peptostreptococcaceae Incertae Sedis 1 1 W=133.5, p=0.607 
Peptostreptococcaceae uncultured 1 1 W=126, p=0.823 
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Faecalibacterium 6 7 W=117, p=0.921 
Ruminococcaceae Incertae Sedis 2 2 W=125, p=0.858 
Ruminococcus 2 1 W=128, p=0.766 
Subdoligranulum 4 4 W=130, p=0.711 
Ruminococcaceae uncultured 8 7 W=128, p=0.770 
Phascolarctobacterium 2 1 W=126.5, p=0.806 
Dialister 2 2 W=138, p=0.486 
Megamonas 1 2 W=94, p=0.250 
Akkermansia 2 3 W=116, p=0.889 
Turicibacter 0.4 0.0 W=178.5, p=0.021 
Supplementary table 7: Relative abundance of bacterial OTUs in the 3rd trimester maternal 
gut by maternal stress in the 2nd trimester. Listed are all OTUs with an abundance of greater 
than 1% and significant OTUs with an abundance of less than 1%. High stress (PSS < 13; 
N=16), low stress (PSS > 14; N=15). Unpaired students t-test and Mann-Whitney-Wilcoxon 
test. Abbreviations: Operational taxonomic unit (OTU), Perceived Stress Scale (PSS) 
 
Table 8: Maternal gut in the 3rd trimester by 2nd trimester anxiety 
OTU Relative Abundance (%) p-value 
Maternal gut (3rd trimester) Low STAI High STAI   
Chao1 Index 385.0 365.5 t(29) = 0.65, p=0.514 
Simpson Index 0.9 0.9 t(29) = 1.15, p=0.256 
Shannon Index 5.8 5.7 t(29) = 1.00, p=0.323 
Phylogenetic diversity 19.8 18.8 t(29) = 0.65, p=0.516  
Observed Species 300.8 291.9 t(29) = 0.39, p=0.693 
Actinobacteria 7 6 W=124, p=0.797 
Bacteroidetes 18 19 W=106, p=0.678 
Firmicutes 70 72 W=109, p=0.767 
Proteobacteria 2 2 W=129, p=0.650 
Verrucomicrobia 3 1 W=136, p=0.458 
Bifidobacteriaceae 4 2 W=153, p=0.157 
Nocardiaceae 1 2 W=114, p=0.920 
Coriobacteriaceae 2 1 W=140, p=0.373 
Bacteroidaceae 11 12 W=97, p=0.440 
Porphyromonadaceae 3 3 W=107, p=0.707 
Prevotellaceae 2 1 W=148.5, p=0.212 
Rikenellaceae 2 3 W=95, p=0.394 
Christensenellaceae 2 2 W=106.5, p=0.688 
Clostridiaceae1 2 1 W=140, p=0.367 
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Lachnospiraceae 33 37 W=93, p=0.352 
Peptostreptococcaceae 3 2 W=139, p=0.389 
Ruminococcaceae 20 22 W=95.5, p=0.400 
Erysipelotrichaceae 2 2 W=95, p=0.394 
Acidaminococcaceae 1 1 W=116.5, p=0.1 
Veillonellaceae 4 3 W=135.5, p=0.471 
Alcaligenaceae 1 1 W=114, p=0.920 
Verrucomicrobiaceae 3 1 W=137, p=0.434 
Bifidobacterium 4 2 W=153, p=0.157 
Rhodococcus 1 2 W=114, p=0.920 
Atopobium 0.0 0.0 W=155, p=0.050 
Bacteroides 11 12 W=97, p=0.440 
Barnesiella 1 1 W=100, p=0.508 
Porphyromonadaceae uncultured 1 1 W=100.5, p=0.521 
Paraprevotella 0.1 0.0 W=162, p=0.047 
Alistipes 2 3 W=94, p=0.373 
Bacteroidales uncultured 0.2 0.0 W=159.5, p=0.049 
Christensenellaceae uncultured 2 2 W=109.5, p=0.779 
Clostridium sensu stricto1 2 1 W=139.5, p=0.378 
Anaerostipes 1 2 W=95, p=0.394 
Blautia 4 5 W=95, p=0.389 
Coprococcus 1 1 W=122.5, p=0.841 
Lachnospiraceae Incertae Sedis 9 11 W=74, p=0.088 
Pseudobutyrivibrio 3 4 W=111, p=0.828 
Roseburia 2 2 W=122, p=0.857 
Lachnospiraceae uncultured 10 11 W=110, p=0.797 
Peptostreptococcaceae Incertae Sedis 1 1 W=132, p=0.561 
Peptostreptococcaceae uncultured 2 1 W=96, p=0.400 
Faecalibacterium 6 7 W=124, p=0.794 
Ruminococcaceae Incertae Sedis 2 2 W=133.5, p=0.521 
Ruminococcus 1 2 W=111, p=0.825 
Subdoligranulum 4 3 W=139, p=0.394 
Ruminococcaceae uncultured 6 8 W=99, p=0.489 
Phascolarctobacterium 1 1 W=117.5, p=1 
Dialister 2 1 W=155, p=0.131 
Megamonas 1 2 W=114, p=0.909 
Akkermansia 3 1 W=137, p=0.434 
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Escherichia Shigella 0.0 0.2 W=61.5, p=0.024 
Supplementary table 8: Relative abundance of bacterial OTUs in the 3rd trimester maternal 
gut by maternal anxiety in the 2nd trimester. Listed are all OTUs with an abundance of 
greater than 1% and significant OTUs with an abundance of less than 1%. High anxiety (STAI 
< 4; N=18), low anxiety (STAI > 5; N=13). Unpaired students t-test and Mann-Whitney-
Wilcoxon test. Abbreviations: Operational taxonomic unit (OTU), State Trait Anxiety 
Inventory (STAI). 
 
Table 9: Maternal gut in the 3rd trimester by 2nd trimester depressive symptoms 
OTU Relative Abundance (%) p-value 
Maternal gut (3rd trimester) Low EPDS  High EPDS  
Chao1 Index 377.4 374.9 t(29) = 0.07, p=0.939 
Simpson Index 0.9 0.9 t(29) = -0.47, p=0.636 
Shannon Index 5.8 5.7 t(29) = 0.40, p=0.684 
Phylogenetic diversity 19.6 18.8 t(29) = 0.51, p=0.612 
Observed Species 299.1 291.2 t(29) = 0.31, p=0.757 
Actinobacteria 6 6 W=70, p=0.338 
Bacteroidetes 19 15 W=103, p=0.642 
Firmicutes 69 75 W=67, p=0.274 
Proteobacteria 2 2 W=78, p=0.594 
Verrucomicrobia 3 2 W=109, p=0.456 
Bifidobacteriaceae 4 3 W=86, p=0.807 
Nocardiaceae 1 2 W=86, p=0.803 
Coriobacteriaceae 2 1 W=95, p=0.912 
Bacteroidaceae 11 11 W=91, p=0.982 
Porphyromonadaceae 3 2 W=102, p=0.674 
Prevotellaceae 2 0 W=110.5, p=0.414 
Rikenellaceae 3 2 W=102, p=0.674 
Christensenellaceae 2 1 W=92.5, p=1 
Clostridiaceae1 2 1 W=123.5, p=0.161 
Lachnospiraceae 33 41 W=54, p=0.090 
Peptostreptococcaceae 3 2 W=123, p=0.168 
Ruminococcaceae 21 22 W=77.5, p=0.527 
Erysipelotrichaceae 2 2 W=91, p=0.982 
Acidaminococcaceae 1 2 W=85, p=0.762 
Veillonellaceae 4 4 W=90.5, p=0.964 
Alcaligenaceae 1 1 W=70, p=0.331 
Verrucomicrobiaceae 3 2 W=109, p=0.456 
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Bifidobacterium 4 3 W=86, p=0.807 
Rhodococcus 1 2 W=86, p=0.803 
Bacteroides 11 11 W=91, p=0.982 
Barnesiella 1 1 W=76, p=0.483 
Porphyromonadaceae uncultured 1 1 W=110.5, p=0.416 
Alistipes 2 2 W=102, p=0.674 
Christensenellaceae uncultured 2 1 W=92.5, p=1 
Clostridium sensu stricto1 2 1 W=123, p=0.168 
Anaerostipes 1 2 W=84, p=0.740 
Blautia 4 6 W=46, p=0.039 
Coprococcus 1 2 W=80.5, p=0.619 
Lachnospiraceae Incertae Sedis 10 10 W=83, p=0.701 
Pseudobutyrivibrio 3 5 W=62, p=0.186 
Roseburia 2 2 W=73, p=0.403 
Lachnospiraceae uncultured 10 12 W=67, p=0.274 
Peptostreptococcaceae Incertae Sedis 1 1 W=108.5,  p=0.470 
Peptostreptococcaceae uncultured 2 1 W=135, p=0.054 
Faecalibacterium 6 7 W=89, p=0.910 
Ruminococcaceae Incertae Sedis 2 2 W=84, p=0.734 
Ruminococcus 2 2 W=112, p=0.378 
Subdoligranulum 4 4 W=82, p=0.674 
Ruminococcaceae uncultured 7 7 W=94, p=0.947 
Phascolarctobacterium 1 2 W=86, p=0.798 
Dialister 2 1 W=126, p=0.128 
Megamonas 1 2 W=70.5, p=0.279 
Akkermansia 3 2 W=109, p=0.456 
Parasutterella 0.3 0.8 W=124, p=0.012 
Supplementary table 9: Relative abundance of bacterial OTUs in the 3rd trimester maternal 
gut by maternal depressive symptoms in the 2nd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
High depressive (EPDS < 8; N=23), low depressive (EPDS > 9; N=8). Unpaired students t-test 
and Mann-Whitney-Wilcoxon test. Abbreviations: Operational taxonomic unit (OTU), 
Edinburgh Postnatal Depression Scale (EPDS). 
 
Table 10: Maternal gut in the 3rd trimester by 2nd trimester cortisol 
OTU Relative Abundance (%) p-value 
Maternal gut (3rd trimester) Low CAR High CAR  
Chao1 Index 364.7 410.6 t(26) = -1.53, p=0.136 
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Simpson Index 0.9 0.9 t(26) = 0.62, p=0.536 
Shannon Index 5.7 5.8 t(26) = -0.55, p=0.583 
Phylogenetic diversity 18.6 21.4 t(26) = -2.05, p=0.049 
Observed Species 284.6 327.3 t(26) = -1.95, p=0.061 
Actinobacteria 5.6 7.7 W=108, p=0.650 
Euryarchaeota 0.0 0.1 W=64, p=0.034 
Bacteroidetes 19.0 17.8 W=103, p=0.820 
Firmicutes 71.2 67.9 W=119, p=0.338 
Proteobacteria 2.2 1.5 W=131, p=0.130 
Verrucomicrobia 1.5 4.0 W=91, p=0.782 
Bifidobacteriaceae 3.0 3.8 W=117, p=0.387 
Nocardiaceae 1.1 1.9 W=88.5, p=0.695 
Coriobacteriaceae 1.4 1.9 W=90, p=0.751 
Bacteroidaceae 12.4 10.5 W=113, p=0.495 
Porphyromonadaceae 3.1 2.8 W=112, p=0.525 
Prevotellaceae 1.4 0.9 W=83, p=0.517 
Rikenellaceae 1.9 2.8 W=78, p=0.387 
Christensenellaceae 1.4 3.4 W=65.5, p=0.146 
Clostridiaceae1 0.8 2.5 W=77, p=0.356 
Lachnospiraceae 37.2 29.4 W=134, p=0.097 
Peptostreptococcaceae 1.5 3.7 W=59, p=0.079 
Ruminococcaceae 21.3 20.5 W=115, p=0.433 
Erysipelotrichaceae 1.3 2.3 W=52, p=0.036 
Acidaminococcaceae 1.5 1.6 W=78.5, p=0.386 
Veillonellaceae 4.5 1.9 W=118, p=0.356 
Alcaligenaceae 1.1 0.6 W=149, p=0.018 
Verrucomicrobiaceae 1.4 3.9 W91=, p=0.782 
Methanobrevibacter 0.0 0.1 W=64, p=0.034 
Bifidobacterium 3.0 3.8 W=117, p=0.387 
Rhodococcus 1.1 1.9 W=88.5, p=0.695 
Bacteroides 12.4 10.5 W=113, p=0.495 
Barnesiella 1.0 0.9 W=112.5, p=0.504 
Porphyromonadaceae uncultured 0.5 0.7 W=84.5, p=0.564 
Alistipes 1.9 2.8 W=78, p=0.387 
Bacteroidete uncultured 0.0 0.3 W=144.5, p=0.031 
Christensenellaceae uncultured 1.3 3.4 W=64, p=0.128 
Clostridium sensu stricto1 0.8 2.5 W=58, p=0.381 
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Anaerostipes 1.3 1.3 W=85, p=0.586 
Blautia 4.9 3.8 W=129, p=0.153 
Coprococcus 1.6 1.1 W=116.5, p=0.394 
Howardella 0.0 0.0 W=61, p=0.029 
Lachnospiraceae Incertae Sedis 9.8 9.2 W=107, p=0.678 
Pseudobutyrivibrio 4.6 2.5 W=131, p=0.130 
Roseburia 1.8 1.3 W=125.5, p=0.204 
Lachnospiraceae uncultured 11.4 8.7 W=127, p=0.184 
Peptostreptococcaceae Incertae Sedis 0.8 1.7 W=73.5, p=0.278 
Peptostreptococcaceae uncultured 0.7 2.0 W=47.5, p=0.022 
Faecalibacterium 7.6 5.3 W=133, p=0.107 
Ruminococcaceae Incertae Sedis 1.7 1.8 W=85, p=0.580 
Ruminococcus 1.8 1.1 W=100, p=0.926 
Subdoligranulum 3.5 3.5 W=103, p=0.820 
Ruminococcaceae uncultured 6.1 8.2 W=81, p=0.467 
Asteroleplasma 0.0 0.1 W=61, p=0.029 
Turicibacter 0.1 0.6 W=39, p=0.007 
Phascolarctobacterium 1.5 1.6 W=77.5, p=0.360 
Dialister 1.1 1.6 W=92, p=0.816 
Megamonas 2.8 0.0 W=124, p=0.173 
Enterobacter 0.0 0.1 W=65.5, p=0.042 
Tenericutes Mollicutes uncultured 0.0 0.0 W=53, p=0.032 
Akkermansia 1.4 3.9 W=91, p=0.782 
Supplementary table 10: Relative abundance of bacterial OTUs in the 3rd trimester 
maternal gut by maternal cortisol in the 2nd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low cortisol (CAR < 545131; N=15), high cortisol (CAR > 545132; N=13). Unpaired students 
t-test and Mann-Whitney-Wilcoxon test. Abbreviations: Operational taxonomic unit (OTU), 
Cortisol Awakening Response (CAR). 
 
Table 11: Maternal gut in the 3rd trimester by 3rd trimester stress 
OTU Relative Abundance (%) p-value 
Maternal gut (3rd trimester) Low PSS High PSS  
Chao1 Index 355.7 370.3 t(31) = -0.62, p=0.536 
Simpson Index 0.9 0.9 t(31) = -0.04, p=0.967 
Shannon Index 5.7 5.7 t(31) = -0.25, p=0.799 
Phylogenetic diversity 18.6 19.0 t(31) = -0.37, p=0.711 
Observed Species 283.1 295.0 t(31) = -0.61, p=0.544 
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Actinobacteria 7 5 W=128, p=0.816 
Bacteroidetes 18 22 W=106, p=0.306 
Firmicutes 71 67 W=165, p=0.290 
Proteobacteria 2 2 W=157, p=0.436 
Verrucomicrobia 2 3 W=133.5, p=0.971 
Bifidobacteriaceae 4 3 W=145, p=0.734 
Nocardiaceae 1 1 W=116.5, p=0.514 
Coriobacteriaceae 2 2 W=128, p=0.814 
Bacteroidaceae 11 14 W=100, p=0.215 
Porphyromonadaceae 4 4 W=104, p=0.274 
Prevotellaceae 1 2 W=146, p=0.702 
Rikenellaceae 2 3 W=83, p=0.061 
Christensenellaceae 2 2 W=119, p=0.575 
Clostridiaceae1 1 1 W=142, p=0.814 
Lachnospiraceae 37 36 W=145, p=0.734 
Peptostreptococcaceae 3 2 W=169, p=0.225 
Ruminococcaceae 19 19 W=132.5, p=0.942 
Erysipelotrichaceae 2 1 W=160, p=0.380 
Acidaminococcaceae 1 2 W=93.5=, p=0.126 
Veillonellaceae 4 2 W=181, p=0.099 
Alcaligenaceae 1 1 W=164, p=0.302 
Verrucomicrobiaceae 2 3 W=133.5, p=0.971 
Bifidobacterium 4 3 W=145, p=0.734 
Rhodococcus 1 1 W=116.5, p=0.514 
Bacteroides 11 14 W=100, p=0.215 
Barnesiella 1 1 W=106.5, p=0.311 
Porphyromonadaceae uncultured 2 1 W=107, p=0.319 
Alistipes 2 3 W=81.5, p=0.055 
Christensenellaceae uncultured 2 2 W=119, p=0.575 
Clostridium sensu stricto1 1 1 W=142.5, p=0.800 
Anaerostipes 2 2 W=118, p=0.555 
Blautia 5 5 W=159, p=0.395 
Coprococcus 1 1 W=136.5, p=0.971 
Lachnospiraceae Incertae Sedis 11 10 W=138, p=0.928 
Pseudobutyrivibrio 3 4 W=111, p=0.400 
Roseburia 2 2 W=134, p=0.985 
Lachnospiraceae uncultured 11 11 W=142, p=0.816 
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Peptostreptococcaceae Incertae Sedis 1 1 W=159, p=0.395 
Peptostreptococcaceae uncultured 1 1 W=157.5, p=0.110 
Faecalibacterium 6 6 W=141, p=0.842 
Ruminococcaceae Incertae Sedis 2 2 W=166, p=0.274 
Ruminococcus 2 1 W=157.5, p=0.426 
Subdoligranulum 3 3 W=137, p=0.957 
Ruminococcaceae uncultured 6 6 W=113, p=0.442 
Gelria 0.0 0.0 W=79, p=0.016 
Phascolarctobacterium 1 2 W=94.5, p=0.135 
Dialister 3 1 W=189, p=0.051 
Megamonas 1 1 W=172.5, p=0.031 
Escherichia Shigella 0.0 0.0 W=72, p=0.021 
Akkermansia 2 3 W=133.5, p=0.974 
Supplementary table 11: Relative abundance of bacterial OTUs in the 3rd trimester 
maternal gut by maternal stress in the 3rd trimester. Listed are all OTUs with an abundance 
of greater than 1% and significant OTUs with an abundance of less than 1%. Low stress (PSS 
< 11; N=18), high stress (PSS > 12; N=14). Unpaired students t-test and Mann-Whitney-
Wilcoxon test. Abbreviations: Operational taxonomic unit (OTU), Perceived Stress Scale 
(PSS). 
 
Table 12: Maternal gut in the 3rd trimester by 3rd trimester anxiety 
OTU Relative Abundance (%) p-value 
Maternal gut (3rd trimester) Low STAI High STAI  
Chao1 Index 365.1 362.5 t(31) = 0.08, p=0.936 
Simpson Index 0.9 0.9 t(31) = -0.11, p=0.906 
Shannon Index 5.7 5.7 t(31) = 0.27, p=0.782 
Phylogenetic diversity 19.2 18.4 t(31) = 0.49, p=0.621 
Observed Species 292.3 286.0 t(31) = 0.23, p=0.812 
Actinobacteria 7 6 W=125, p=0.709 
Bacteroidetes 17 22 W=106, p=0.292 
Firmicutes 69 68 W=140, p=0.901 
Proteobacteria 2 1 W=173, p=0.188 
Verrucomicrobia 4 2 W=155, p=0.504 
Bifidobacteriaceae 5 3 W=157, p=0.465 
Nocardiaceae 0 1 W=120, p=0.576 
Coriobacteriaceae 2 2 W=123.5, p=0.665 
Bacteroidaceae 11 13 W=104, p=0.260 
Porphyromonadaceae 3 5 W=111, p=0.382 
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Prevotellaceae 1 2 W=165, p=0.302 
Rikenellaceae 2 3 W=110, p=0.363 
Christensenellaceae 2 1 W=137, p=0.985 
Clostridiaceae1 2 1 W=171.5, p=0.207 
Lachnospiraceae 34 37 W=104, p=0.260 
Peptostreptococcaceae 3 2 W=182, p=0.101 
Ruminococcaceae 19 20 W=126.5, p=0.745 
Erysipelotrichaceae 2 2 W=128, p=0.789 
Acidaminococcaceae 1 1 W=122.5, p=0.628 
Veillonellaceae 4 2 W=165, p=0.304 
Alcaligenaceae 1 1 W=156.5, p=0.471 
Verrucomicrobiaceae 3 2 W=155, p=0.504 
Bifidobacterium 5 3 W=157, p=0.465 
Rhodococcus 0 1 W=120, p=0.576 
Bacteroides 11 13 W=104, p=0.260 
Barnesiella 1 1 W=116, p=0.482 
Porphyromonadaceae uncultured 1 2 W=120, p=0.576 
Alistipes 2 3 W=110, p=0.358 
Bacteroidales uncultured 0.3 0.0 W=188, p=0.026 
Christensenellaceae uncultured 2 1 W=136, p=1 
Clostridium sensu stricto1 2 1 W=171, p=0.213 
Anaerostipes 1 2 W=111, p=0.382 
Blautia 5 5 W=128, p=0.814 
Coprococcus 1 1 W=140.5, p=0.885 
Lachnospiraceae Incertae Sedis 10 11 W=93, p=0.125 
Pseudobutyrivibrio 3 4 W=100, p=0.203 
Roseburia 2 2 W=141, p=0.871 
Lachnospiraceae uncultured 10 11 W=117, p=0.510 
Peptostreptococcaceae Incertae Sedis 1 1 W=159, p=0.417 
Peptostreptococcaceae uncultured 2 1 W=190, p=0.053 
Faecalibacterium 6 6 W=128, p=0.787 
Ruminococcaceae Incertae Sedis 2 2 W=161, p=0.382 
Ruminococcus 2 1 W=152.2, p=0.564 
Subdoligranulum 3 3 W=149, p=0.656 
Ruminococcaceae uncultured 6 7 W=123, p=0.656 
Phascolarctobacterium 1 1 W=123.5, p=0.655 
Dialister 3 1 W=189, p=0.057 
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Megamonas 1 1 W=118.5, p=0.477 
Akkermansia 3 2 W=155, p=0.504 
Supplementary table 12: Relative abundance of bacterial OTUs in the 3rd trimester 
maternal gut by maternal anxiety in the 3rd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low anxiety (STAI < 4; N=16), high anxiety (STAI > 5; N=17). Unpaired students t-test and 
Mann-Whitney-Wilcoxon test. Abbreviations: Operational taxonomic unit (OTU), State Trait 
Anxiety Inventory (STAI). 
 
Table 13: Maternal gut in the 3rd trimester by 3rd trimester depressive symptoms 
OTU Relative Abundance (%) p-value 
Maternal gut (3rd trimester) Low EPDS High EPDS  
Chao1 Index 363.9 364.1 t(31) = -0.00, p=0.995 
Simpson Index 0.9 0.9 t(31) = 0.55, p=0.586 
Shannon Index 5.6 5.6 t(31) = 0.41, p=0.681 
Phylogenetic diversity 18.1 18.1 t(31) = 0.57, p=0.568 
Observed Species 287.5 287.5 t(31) = 0.10, p=0.920 
Actinobacteria 8 6 W=93, p=0.789 
Bacteroidetes 18 25 W=62, p=0.116 
Firmicutes 71 64 W=138, p=0.116 
Proteobacteria 2 2 W=97.5, p=0.933 
Verrucomicrobia 2 4 W=96.5, p=0.899 
Bifidobacteriaceae 4 4 W=93, p=0.789 
Nocardiaceae 1 1 W=59.5, p=0.092 
Coriobacteriaceae 2 1 W=141, p=0.088 
Bacteroidaceae 11 15 W=63, p=0.127 
Porphyromonadaceae 4 5 W=57, p=0.073 
Prevotellaceae 2 0 W=125.5, p=0.291 
Rikenellaceae 2 4 W=56, p=0.066 
Christensenellaceae 2 2 W=75, p=0.303 
Clostridiaceae1 1 1 W=126, p=0.284 
Lachnospiraceae 37 32 W=121, p=0.396 
Peptostreptococcaceae 2 2 W=119.5, p=0.424 
Ruminococcaceae 20 19 W=102.5, p=0.933 
Erysipelotrichaceae 2 2 W=103, p=0.918 
Acidaminococcaceae 1 2 W=72.5, p=0.241 
Veillonellaceae 4 3 W=115, p=0.542 
Alcaligenaceae 1 1 W=120.5, p=0.400 
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Verrucomicrobiaceae 2 4 W=96.5, p=0.899 
Bifidobacterium 4 4 W=93, p=0.789 
Rhodococcus 1 1 W=59.5, p=0.092 
Bacteroides 11 15 W=63, p=0.127 
Barnesiella 1 2 W=44, p=0.019 
Coprobacter 0.0 0.0 W=48.5, p=0.024 
Porphyromonadaceae uncultured 1 1 W=72, p=0.247 
Alistipes 2 4 W=55, p=0.061 
Christensenellaceae uncultured 2 2 W=74.5, p=0.293 
Clostridium sensu stricto1 1 1 W=125.2, p=0.293 
Anaerostipes 2 1 W=120, p=0.420 
Blautia 6 3 W=142, p=0.081 
Coprococcus 1 1 W=107, p=0.784 
Lachnospiraceae Incertae Sedis 11 11 W=89, p=0.659 
Pseudobutyrivibrio 3 4 W=94, p=0.820 
Roseburia 2 2 W=102, p=0.949 
Lachnospiraceae uncultured 11 9 W=117, p=0.495 
Peptostreptococcaceae Incertae Sedis 1 1 W=95.5, p=0.866 
Peptostreptococcaceae uncultured 1 1 W=134.5, p=0.153 
Faecalibacterium 6 6 W=106, p=0.817 
Ruminococcaceae Incertae Sedis 2 1 W=119, p=0.444 
Ruminococcus 2 1 W=143.5, p=0.070 
Subdoligranulum 3 3 W=90, p=0.695 
Ruminococcaceae uncultured 6 7 W=90, p=0.695 
Phascolarctobacterium 1 2 W=70.5, p=0.208 
Dialister 2 1 W=140, p=0.095 
Megamonas 1 2 W=127, p=0.196 
Akkermansia 2 4 W=96.5, p=0.899 
Supplementary table 13: Relative abundance of bacterial OTUs in the 3rd trimester 
maternal gut by maternal depressive symptoms in the 3rd trimester. Listed are all OTUs 
with an abundance of greater than 1% and significant OTUs with an abundance of less than 
1%. Low depressive symptoms (EPDS < 8; N=25), high depressive symptoms (EPDS > 9; 
N=8). Unpaired students t-test and Mann-Whitney-Wilcoxon test. Abbreviations: 
Operational taxonomic unit (OTU), Edinburgh Postnatal Depression Scale (EPDS). 
 
Table 14: Maternal gut in the 3rd trimester by 3rd trimester cortisol 
OTU Relative Abundance (%) p-value 
Maternal gut (3rd trimester) Low CAR High CAR  
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Chao1 Index 365.3 384.4 t(31) = -0.63, p=0.527 
Simpson Index 0.9 0.9 t(31) = -0.49, p=0.622 
Shannon Index 5.7 5.7 t(31) = -0.07, p=0.944 
Phylogenetic diversity 19.0 19.8 t(31) = -0.52, p=0.603 
Observed Species 290.5 306.5 t(31) = -0.69, p=0.493 
Actinobacteria 5.2 8.1 W=78, p=0.155 
Bacteroidetes 21.2 16.0 W=133, p=0.499 
Firmicutes 68.6 70.5 W=120, p=0.552 
Proteobacteria 1.8 1.9 W=96.5, p=0.480 
Verrucomicrobia 2.4 2.8 W=126.5, p=0.666 
Bifidobacteriaceae 2.7 4.3 W=91, p=0.363 
Nocardiaceae 1.1 1.8 W=77.5, p=0.146 
Coriobacteriaceae 1.3 1.8 W=103, p=0.652 
Bacteroidaceae 12.2 11.2 W=115, p=1 
Porphyromonadaceae 4.4 2.4 W=147, p=0.221 
Prevotellaceae 1.6 0.1 W=103.5, p=0.664 
Rikenellaceae 2.3 2.0 W=122, p=0.802 
Christensenellaceae 2.0 2.2 W=114, p=0.984 
Clostridiaceae1 0.9 2.0 W=137.5, p=0.388 
Lachnospiraceae 35.3 33.8 W=118, p=0.923 
Peptostreptococcaceae 1.7 3.4 W=91, p=0.363 
Ruminococcaceae 20.6 19.9 W=127, p=0.652 
Erysipelotrichaceae 1.5 2.4 W=88, p=0.304 
Acidaminococcaceae 1.4 1.6 W=103, p=0.642 
Veillonellaceae 3.2 3.1 W=114.5, p=1 
Alcaligenaceae 1.0 0.8 W=119, p=0.890 
Verrucomicrobiaceae 2.3 2.8 W125.5=, p=0.695 
Bifidobacterium 2.7 4.3 W=91, p=0.363 
Rhodococcus 1.1 1.8 W=77.5, p=0.146 
Olsenella 0.0 0.0 W=92, p=0.033 
Bacteroides 12.2 11.2 W=115, p=1 
Barnesiella 1.2 0.7 W=128.5, p=0.610 
Porphyromonadaceae uncultured 1.5 0.6 W=136, p=0.421 
Alistipes 2.3 2.0 W=122, p=0.799 
Christensenellaceae uncultured 1.9 2.1 W=113.5, p=0.968 
Clostridium sensu stricto1 0.9 2.0 W=138, p=0.378 
Parvimonas 0.0 0.0 W=79.5, p=0.041 
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Anaerostipes 1.6 1.7 W=95, p=0.451 
Blautia 4.9 4.1 W=121, p=0.829 
Coprococcus 1.2 1.6 W=109, p=0.829 
Lachnospiraceae Incertae Sedis 10.7 9.3 W=140, p=0.337 
Pseudobutyrivibrio 3.2 4.3 W=93, p=0.406 
Roseburia 1.6 1.5 W=119.5, p=0.875 
Lachnospiraceae uncultured 10.5 9.5 W=123, p=0.772 
Peptostreptococcaceae Incertae Sedis 0.7 1.8 W=94.5, p=0.433 
Peptostreptococcaceae uncultured 0.9 1.6 W=103, p=0.652 
Faecalibacterium 6.3 6.0 W=125, p=0.709 
Ruminococcaceae Incertae Sedis 1.6 1.9 W=91, p=0.363 
Ruminococcus 2.0 0.8 W=157, p=0.104 
Subdoligranulum 3.1 3.6 W=100, p=0.576 
Ruminococcaceae uncultured 7.1 7.0 W=118, p=0.923 
Phascolarctobacterium 1.4 1.6 W=102, p=0.613 
Dialister 1.7 1.0 W=145.5, p=0.237 
Megamonas 1.0 1.9 W=79.5, p=0.111 
Akkermansia 2.3 2.8 W=125.5, p=0.695 
Supplementary table 14: Relative abundance of bacterial OTUs in the 3rd trimester 
maternal gut by maternal cortisol in the 3rd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low cortisol (CAR < 562349; N=23), high cortisol (PCAR > 562350; N=10). Unpaired students 
t-test and Mann-Whitney-Wilcoxon test. Abbreviations: Operational taxonomic unit (OTU), 
Cortisol Awakening Response (CAR). 
 
Table 15: Maternal vaginal microbiome by 2nd trimester stress 
OTU Relative Abundance (%) p-value 
Vaginal Low PSS High PSS  
Chao1 Index 235.5 199.6 t(50) = 1.88, p=0.064 
Simpson Index 0.4 0.5 t(50) = -1.16, p=0.250 
Shannon Index 1.8 2.3 t(50) = -1.09, p=0.278 
Phylogenetic diversity 8.4 9.0 t(50) = -0.58, p=0.558 
Observed Species 163 139.9 t(50) = 1.09, p=0.280 
Actinobacteria 9.6 11.6 W=271, p=0.313 
Bacteroidetes 3.0 1.4 W=270.5, p=0.309 
Firmicutes 82.0 68.6 W=403, p=0.152 
Fusobacteria 0.5 1.5 W=317, p=0.876 
Proteobacteria 2.6 14.4 W=254, p=0.187 
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Otherphyla 0.7 1.3 W=366, p=0.455 
Bifidobacteriaceae 6.5 6.1 W=311, p=0.793 
Corynebacteriaceae 2.0 3.8 W=283, p=0.433 
Prevotellaceae 2.6 1.0 W=286.5, p=0.472 
Staphylococcaceae 1.8 1.4 W=313, p=0.822 
Lactobacillaceae 67.1 61.7 W=360, p=0.529 
Streptococcaceae 6.2 0.8 W=415, p=0.096 
ClostridialesFamilyXI 4.4 1.8 W=331.5, p=0.918 
Veillonellaceae 0.7 1.6 W=320, p=0.925 
Leptotrichiaceae 0.5 1.5 W=264, p=0.186 
Caulobacteraceae 0.2 1.9 W=266, p=0.270 
Sphingomonadaceae 0.5 3.4 W=246.5, p=0.143 
Moraxellaceae 0.6 3.3 W=240, p=0.112 
Pseudomonadaceae 0.4 2.0 W=249.5, p=0.159 
Otherfamily 0.7 1.3 W=366, p=0.455 
Gardnerella 6.4 5.6 W=301, p=0.653 
Corynebacterium 1.7 3.4 W=294, p=0.562 
Rhodcoccus 0.1 0.7 W=179, p=0.006 
Prevotella 2.6 1.0 W=286.5, p=0.472 
Staphylococcus 1.8 1.4 W=312, p=0.808 
Lactobacillus 67.1 61.7 W=360, p=0.529 
Streptococcus 6.2 0.8 W=215, p=0.096 
Anaerococcus 2.1 0.6 W=352, p=0.627 
Sneathia 0.5 1.5 W=264, p=0.186 
Brevundimonas 0.2 1.7 W=262, p=0.239 
Sphingobium 0.2 1.6 W=235.5, p=0.094 
Sphingomonas 0.3 1.8 W=256.5, p=0.201 
Acinetobacter 0.6 3.3 W=240, p=0.112 
Pseudomonas 0.4 2.0 W=249.5, p=0.159 
OtherGenus 0.7 1.3 W=366, p=0.455 
Supplementary table 15: Relative abundance of bacterial OTUs in the maternal vagina by 
maternal stress in the 2nd trimester. Listed are all OTUs with an abundance of greater than 
1% and significant OTUs with an abundance of less than 1%. Low stress (PSS < 13; N=21), 
high stress (PSS > 14; N=31). Unpaired students t-test and Mann-Whitney-Wilcoxon test. 
Abbreviations: Operational taxonomic unit (OTU), Perceived Stress Scale (PSS). 
 
Table 16: Maternal vaginal microbiome by 2nd trimester anxiety 
OTU Relative Abundance (%) p-value 
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Vaginal Low STAI20W High STAI20W  
Chao1 Index 217.2 227.4 t(50) = -0.34, p=0.730 
Simpson Index 0.5 0.4 t(50) = 0.67, p=0.501 
Shannon Index 2.2 1.8 t(50) = 0.78, p=0.438 
Phylogenetic diversity 9.0 8.6 t(50) = 0.36, p=0.716 
Observed Species 148.8 149.9 t(50) = -0.05, p=0.959 
Actinobacteria 10.1 11.8 W=277, p=0.370 
Bacteroidetes 2.0 2.1 W=311, p=0.794 
Firmicutes 72.9 75.6 W=340, p=0.795 
Fusobacteria 1.4 0.6 W=361, p=0.496 
Proteobacteria 11.3 7.2 W=360, p=0.529 
Otherphyla 1.4 0.5 W=299, p=0.627 
Bifidobacteriaceae 5.7 7.2 W=311.5, p=0.801 
Corynebacteriaceae 2.8 3.4 W=322.5, p=0.962 
Prevotellaceae 1.5 1.9 W=305.5, p=0.715 
Staphylococcaceae 2.1 0.8 W=380, p=0.313 
Lactobacillaceae 60.4 69.0 W=300, p=0.643 
Streptococcaceae 4.8 0.3 W=490.5, p=0.002 
ClostridialesFamilyXI 3.6 1.6 W=357.5, p=0.556 
Veillonellaceae 0.5 2.3 W=317, p=0.881 
Leptotrichiaceae 1.4 0.6 W=303.5, p=0.641 
Caulobacteraceae 1.5 0.8 W=369, p=0.422 
Sphingomonadaceae 2.6 1.7 W=369.5, p=0.417 
Moraxellaceae 2.6 1.6 W=345, p=0.723 
Pseudomonadaceae 1.6 1.0 W=361, p=0.513 
Otherfamily 1.4 0.5 W=299, p=0.627 
Gardnerella 5.1 7.0 W=286, p=0.466 
Corynebacterium 2.6 2.8 W=333.5, p=0.888 
Prevotella 1.5 1.9 W=305.5, p=0.715 
Staphylococcus 2.1 0.8 W=380, p=0.313 
Lactobacillus 60.4 69.0 W=300, p=0.643 
Streptococcus 4.8 0.3 W=490.5, p=0.002 
Anaerococcus 1.7 0.5 W=364, p=0.477 
Shuttleworthia 0.0 0.0 W=279, p=0.033 
Sneathia 1.4 0.6 W=303.5, p=0.641 
Brevundimonas 1.4 0.8 W=373.5, p=0.374 
Sphingobium 1.2 0.8 W=372, p=0.390 
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Sphingomonas 1.4 0.8 W=360, p=0.525 
Acinetobacter 2.6 1.5 W=344.5, p=0.730 
Pseudomonas 1.6 1.0 W=361, p=0.513 
OtherGenus 1.4 0.5 W=299, p=0.627 
Supplementary Table 16: Relative abundance of bacterial OTUs in the maternal vagina by 
maternal anxiety in the 2nd trimester. Listed are all OTUs with an abundance of greater 
than 1% and significant OTUs with an abundance of less than 1%. Low anxiety (PSS < 4; 
N=31), high anxiety (PSS > 5; N=21). Unpaired students t-test and Mann-Whitney-Wilcoxon 
test. Abbreviations: Operational taxonomic unit (OTU), State Trait Anxiety Inventory (STAI). 
 
Table 17: Maternal vaginal microbiome by 2nd trimester depressive symptoms 
OTU Relative Abundance (%) p-value 
Vaginal Low EPDS High EPDS  
Chao1 Index 219.6 226.6 t(50) = -0.20, p=0.835 
Simpson Index 0.4 0.4 t(50) = -0.16, p=0.866 
Shannon Index 2.0 2.2 t(50) = -0.23, p=0.811 
Phylogenetic diversity 8.4 9.9 t(50) = -1.28, p=0.203 
Observed Species 147.7 153.8 t(50) = -0.25, p=0.801 
Actinobacteria 9.2 15.5 W=172, p=0.086 
Bacteroidetes 2.2 1.7 W=201.5, p=0.276 
Firmicutes 76.9 65.6 W=334, p=0.091 
Fusobacteria 0.3 3.6 W=230.5, p=0.620 
Proteobacteria 9.3 10.7 W=204, p=0.304 
Otherphyla 1.3 0.3 W=293.5, p=0.403 
Bifidobacteriaceae 5.1 9.7 W=208.5, p=0.346 
Corynebacteriaceae 2.6 4.5 W=189.5, p=0.179 
Prevotellaceae 1.8 1.3 W=200.5, p=0.266 
Staphylococcaceae 2.0 0.4 W=252.5, p=0.991 
Lactobacillaceae 65.8 58.0 W=287, p=0.490 
Streptococcaceae 3.8 0.5 W=270.5, p=0.727 
ClostridialesFamilyXI 3.0 2.4 W=223, p=0.526 
Veillonellaceae 0.7 3.0 W=195, p=0.219 
Leptotrichiaceae 0.2 3.5 W=229, p=0.556 
Caulobacteraceae 1.2 1.3 W=216.5, p=0.440 
Sphingomonadaceae 2.1 2.5 W=212, p=0.386 
Moraxellaceae 2.2 2.3 W=200.5, p=0.267 
Pseudomonadaceae 1.3 1.5 W=208.5, p=0.346 
Otherfamily 1.3 0.3 W=293.5, p=0.403 
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Gardnerella 4.7 9.6 W=194.5, p=0.215 
Corynebacterium 2.4 3.6 W=205, p=0.309 
Atopobium 0.2 0.5 W=155, p=0.033 
Prevotella 1.8 1.3 W=200.5, p=0.266 
Staphylococcus 2.0 0.4 W=252.5, p=0.991 
Lactobacillus 65.8 58.0 W=287, p=0.490 
Streptococcus 3.8 0.5 W=270.5, p=0.727 
Anaerococcus 1.3 0.8 W=216, p=0.433 
Sneathia 0.2 3.5 W=229, p=0.556 
Brevundimonas 1.1 1.2 W=215.5, p=0.427 
Sphingobium 1.0 1.2 W=208, p=0.341 
Sphingomonas 1.1 1.3 W=219.5, p=0.478 
Acinetobacter 2.1 2.3 W=199.5, p=0.258 
Pseudomonas 1.3 1.5 W=208.5, p=0.346 
OtherGenus 1.3 0.3 W=293.5, p=0.403 
Supplementary Table 17: Relative abundance of bacterial OTUs in the maternal vagina by 
maternal depressive symptoms in the 2nd trimester. Listed are all OTUs with an abundance 
of greater than 1% and significant OTUs with an abundance of less than 1%. Low depressive 
(EPDs < 8; N=39), high depressive (EPDS > 9; N=13). Unpaired students t-test and Mann-
Whitney-Wilcoxon test. Abbreviations: Operational taxonomic unit (OTU), Edinburgh 
Postnatal Depression Scale (EPDS).  
 
Table 18: Maternal vaginal microbiome by 2nd trimester cortisol 
OTU Relative Abundance (%) p-value 
Vaginal Low CAR High CAR  
Chao1 Index 256.2 181.9 t(46) = 2.52, p=0.014 
Simpson Index 0.4 0.4 t(46) = 0.51, p=0.610 
Shannon Index 2.1 1.8 t(46) = 0.56, p=0.575 
Phylogenetic diversity 9.3 8.1 t(46) = 1.14, p=0.257 
Observed Species 170.5 124.2 t(46) = 2.11, p=0.039 
Actinobacteria 13.2 7.4 W=322, p=0.332 
Bacteroidetes 2.1 1.9 W=202, p=0.569 
Firmicutes 72.6 80.0 W=240, p=0.464 
Fusobacteria 0.1 0.6 W=275.5, p=1 
Proteobacteria 9.5 7.6 W=300, p=0.616 
Bifidobacteriaceae 7.8 3.8 W=266, p=0.849 
Corynebacteriaceae 4.1 2.0 W=330, p=0.254 
Prevotellaceae 1.6 1.7 W=284.5, p=0.857 
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Staphylococcaceae 1.4 1.4 W=317.5, p=0.381 
Lactobacillaceae 61.6 71..5 W=217, p=0.223 
Streptococcaceae 3.5 2.7 W=267, p=0.866 
ClostridialesFamilyXI 2.9 2.6 W=310, p=0.473 
Veillonellaceae 1.4 0.9 W=303, p=0.568 
Leptotrichiaceae 0.1 0.5 W=248.5, p=0.519 
Caulobacteraceae 1.2 1.0 W=286, p=0.832 
Sphingomonadaceae 2.2 1.8 W=298.5, p=0.635 
Moraxellaceae 2.3 1.7 W=301, p=0.598 
Pseudomonadaceae 1.4 1.0 W=307.5, p=0.506 
Gardnerella 7.6 3.1 W=260, p=0.751 
Corynebacterium 3.7 1.8 W=323.5, p=0.316 
Prevotella 1.6 1.7 W=284.5, p=0.857 
Staphylococcus 1.4 1.4 W=316.5, p=0.393 
Lactobacillus 61.6 71.5 W=217, p=0.223 
Streptococcus 3.5 2.7 W=267, p=0.866 
Anaerococcus 1.0 1.2 W=304.5, p=0.547 
Blautia 0.0 0.0 W=370.5, p=0.008 
Faecalibacterium 0.0 0.0 W=370, p=0.018 
Sneathia 0.1 0.5 W=248.5, p=0.519 
Brevundimonas 1.1 0.9 W=279, p=0.949 
Sphingobium 1.0 0.8 W=308.5, p=0.493 
Sphingomonas 1.1 0.9 W=290.5, p=0.759 
Acinetobacter 2.2 1.6 W=301.5, p=0.590 
Pseudomonas 1.4 1.0 W=307.5, p=0.506 
Supplementary Table 18: Relative abundance of bacterial OTUs in the maternal vagina by 
maternal cortisol in the 2nd trimester. Listed are all OTUs with an abundance of greater 
than 1% and significant OTUs with an abundance of less than 1%. Low cortisol (CAR < 
545131; N=29), high cortisol (CAR > 545132; N=19). Unpaired students t-test and Mann-
Whitney-Wilcoxon test. Abbreviations: Operational taxonomic unit (OTU), Cortisol 
Awakening Response (CAR).  
 
Table 19: Maternal vaginal microbiome by 3rd trimester stress 
OTU Relative Abundance (%) p-value 
Vaginal Low PSS High PSS  
Chao1 Index 267.7 198.9 t(41) = 1.96, p=0.055 
Simpson Index 0.4 0.5 t(41) = -0.85, p=0.398 
Shannon Index 2.2 2.4 t(41) = -0.33, p=0.738 
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Phylogenetic diversity 9.4 8.8 t(41) = 0.52, p=0.599 
Observed Species 181.9 137.6 t(41) = 1.73, p=0.091 
Actinobacteria 11.4 13.2 W=218, p=0.763 
Bacteroidetes 2.7 1.4 W=208.5, p=0.592 
Firmicutes 74.7 68.3 W=258, p=0.523 
Fusobacteria 0.0 0.1 W=251.5, p=0.612 
Proteobacteria 8.3 14.7 W=207, p=0.571 
Otherphyla 2.2 0.3 W=283, p=0.210 
Bifidobacteriaceae 7.4 6.9 W=277.5, p=0.263 
Corynebacteriaceae 2.8 5.2 W=211.5, p=0.643 
Prevotellaceae 2.2 1.0 W=197.5, p=0.422 
Staphylococcaceae 2.1 2.3 W=203, p=0.503 
Lactobacillaceae 59.0 59.0 W=234, p=0.952 
Streptococcaceae 5.7 1.6 W=261, p=0.473 
ClostridialesFamilyXI 5.5 1.9 W=247.5, p=0.697 
Veillonellaceae 0.5 1.8 W=229, p=0.970 
Leptotrichiaceae 0.0 0.1 W=259.5, p=0.439 
Caulobacteraceae 1.1 1.9 W=216, p=0.724 
Sphingomonadaceae 1.9 3.4 W=203.5, p=0.511 
Moraxellaceae 1.9 3.3 W=199, p=0.444 
Pseudomonadaceae 1.1 2.1 W=211.5, p=0.644 
Otherfamily 2.2 0.3 W=283, p=0.210 
Gardnerella 6.6 6.8 W=271, p=0.336 
Corynebacterium 2.5 4.6 W=223.5, p=0.864 
Prevotella 2.2 1.0 W=197.5, p=0.422 
Staphylococcus 2.1 2.3 W=203, p=0.503 
Lactobacillus 59.0 59.0 W=234, p=0.952 
Streptococcus 5.7 1.6 W=261, p=0.473 
Anaerococcus 2.3 0.7 W=245.5, p=0.733 
Sneathia 0.0 0.1 W=259.5, p=0.439 
Brevundimonas 1.0 1.7 W=214.5, p=0.697 
Sphingobium 0.9 1.6 W=215.5, p=0.715 
Sphingomonas 1.0 1.8 W=189.5, p=0.318 
Acinetobacter 1.9 3.3 W=200.5, p=0.466 
Pseudomonas 1.1 2.1 W=211.5, p=0.644 
OtherGenus 2.2 0.3 W=283, p=0.210 
Supplementary Table 19: Relative abundance of bacterial OTUs in the maternal vagina by 
maternal stress in the 3rd trimester. Listed are all OTUs with an abundance of greater than 
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1% and significant OTUs with an abundance of less than 1%. Low stress (PSS < 11; N=22), 
high stress (PSS > 12; N=21). Unpaired students t-test and Mann-Whitney-Wilcoxon test. 
Abbreviations: Operational taxonomic unit (OTU), Perceived Stress Scale (PSS). 
 
Table 20: Maternal vaginal microbiome by 3rd trimester anxiety 
OTU Relative Abundance (%) p-value 
Vaginal Low STAI High STAI  
Chao1 Index 240.6 228.4 t(41) = 0.33, p=0.740 
Simpson Index 0.5 0.4 t(41) = 0.71, p=0.477 
Shannon Index 2.5 2.1 t(41) = 0.83, p=0.407 
Phylogenetic diversity 9.4 8.8 t(41) = 0.49, p=0.626 
Observed Species 169.1 152.6 t(41) = 0.62, p=0.534 
Actinobacteria 11.2 13.2 W=233, p=0.952 
Bacteroidetes 2.9 1.4 W=239, p=0.836 
Firmicutes 72.1 70.8 W=245, p=0.726 
Fusobacteria 0.0 0.1 W=256, p=0.517 
Proteobacteria 10.8 11.9 W=195, p=0.404 
Otherphyla 2.1 0.5 W=255, p=0.550 
Bifidobacteriaceae 5.8 8.4 W=293.5, p=0.124 
Corynebacteriaceae 3.9 4.1 W=225.5, p=0.922 
Prevotellaceae 2.2 1.1 W=237, p=0.874 
Staphylococcaceae 2.6 1.8 W=225.5, p=0.922 
Lactobacillaceae 55.3 62.2 W=216, p=0.744 
Streptococcaceae 7.0 0.9 W=287.5, p=0.165 
ClostridialesFamilyXI 4.7 2.9 W=245.5, p=0.714 
Veillonellaceae 0.7 1.6 W=259.5, p=0.479 
Leptotrichiaceae 0.0 0.1 W=277.5, p=0.193 
Caulobacteraceae 1.4 1.6 W=207, p=0.583 
Sphingomonadaceae 2.6 2.8 W=189, p=0.324 
Moraxellaceae 2.6 2.7 W=181, p=0.237 
Pseudomonadaceae 1.5 1.7 W=190, p=0.336 
Otherfamily 2.1 0.5 W=255, p=0.550 
Bifidobacterium 0.8 0.0 W=321.5, p=0.026 
Gardnerella 4.9 8.3 W=281, p=0.218 
Corynebacterium 3.5 3.5 W=230, p=1 
Prevotella 2.2 1.1 W=237, p=0.874 
Staphylococcus 2.6 1.8 W=225.5, p=0.922 
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Lactobacillus 55.3 62.2 W=216, p=0.744 
Streptococcus 7.0 0.9 W=287.5, p=0.165 
Anaerococcus 2.1 1.0 W=234, p=0.931 
Sneathia 0.0 0.1 W=277.5, p=0.193 
Brevundimonas 1.3 1.4 W=206, p=0.566 
Sphingobium 1.2 1.3 W=190, p=0.336 
Sphingomonas 1.3 1.4 W=185, p=0.278 
Acinetobacter 2.5 2.6 W=182, p=0.247 
Pseudomonas 1.5 1.7 W=190, p=0.336 
OtherGenus 2.1 0.5 W=255, p=0.550 
Supplementary Table 20: Relative abundance of bacterial OTUs in the maternal vagina by 
maternal anxiety in the 3rd trimester. Listed are all OTUs with an abundance of greater than 
1% and significant OTUs with an abundance of less than 1%. Low anxiety (STAI < 4; N=20), 
high anxiety (STAI > 5; N=23). Unpaired students t-test and Mann-Whitney-Wilcoxon test. 
Abbreviations: Operational taxonomic unit (OTU), State Trait Anxiety Inventory (STAI). 
 
Table 21: Maternal vaginal microbiome by 3rd trimester depressive symptoms 
OTU Relative Abundance (%) p-value 
Vaginal Low EPDS High EPDS  
Chao1 Index 231.6 245.1 t(41) = -0.28, p=0.775 
Simpson Index 0.5 0.5 t(41) = -0.55, p=0.583 
Shannon Index 2.3 2.5 t(41) = -0.42, p=0.671 
Phylogenetic diversity 9.0 9.7 t(41) = -0.44, p=0.659 
Observed Species 158.0 170.1 t(41) = -0.35, p=0.724 
Actinobacteria 10.5 20.0 W=114, p=0.433 
Bacteroidetes 2.3 1.1 W=130, p=0.766 
Firmicutes 74.1 59.6 W=171, p=0.348 
Fusobacteria 0.0 0.3 W=139, p=0.987 
Proteobacteria 10.7 14.4 W=123, p=0.613 
Otherphyla 1.4 0.5 W=124.5, p=0.639 
Bifidobacteriaceae 5.8 13.0 W=142.5, p=0.950 
Corynebacteriaceae 3.6 5.7 W=114, p=0.425 
Prevotellaceae 1.8 0.6 W=123, p=0.606 
Staphylococcaceae 2.5 0.7 W=118.5, p=0.512 
Lactobacillaceae 60.4 53.0 W=149, p=0.794 
Streptococcaceae 4.2 1.9 W=121.5, p=0.574 
ClostridialesFamilyXI 4.0 2.8 W=127, p=0.696 
Veillonellaceae 1.4 0.3 W=129, p=0.742 
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Leptotrichiaceae 0.0 0.3 W=134, p=0.845 
Caulobacteraceae 1.4 1.8 W=127.5, p=0.707 
Sphingomonadaceae 2.5 3.4 W=123.5, p=0.617 
Moraxellaceae 2.5 3.2 W=124, p=0.628 
Pseudomonadaceae 1.5 2.0 W=131, p=0.790 
Otherfamily 1.4 0.5 W=124.5, p=0.639 
Gardnerella 5.3 12.9 W=135, p=0.888 
Corynebacterium 3.0 5.6 W=103.5, p=0.260 
Prevotella 1.8 0.6 W=123, p=0.606 
Staphylococcus 2.5 0.7 W=118.5, p=0.512 
Lactobacillus 60.4 53.0 W=149, p=0.794 
Streptococcus 4.2 1.9 W=121.5, p=0.574 
Anaerococcus 1.7 0.8 W=142, p=0.962 
Sneathia 0.0 0.3 W=134, p=0.845 
Brevundimonas 1.3 1.6 W=125, p=0.650 
Sphingobium 1.1 1.6 W=126.5, p=0.684 
Sphingomonas 1.3 1.8 W=121.5, p=0.574 
Acinetobacter 2.5 3.1 W=124, p=0.628 
Pseudomonas 1.5 2.0 W=131, p=0.790 
OtherGenus 1.4 0.5 W=124.5, p=0.639 
Supplementary Table 21: Relative abundance of bacterial OTUs in the maternal vagina by 
maternal depressive symptoms in the 3rd trimester. Listed are all OTUs with an abundance 
of greater than 1% and significant OTUs with an abundance of less than 1%. Low depressive 
symptoms (EPDS < 8; N=35), high depressive symptoms (EPDS > 9; N=8). Unpaired students 
t-test and Mann-Whitney-Wilcoxon test. Abbreviations: Operational taxonomic unit (OTU), 
Edinburgh Postnatal Depression Scale (EPDS). 
 
Table 22: Maternal vaginal microbiome by 3rd trimester cortisol 
OTU Relative Abundance (%) p-value 
Vaginal Low CAR High CAR  
Chao1 Index 245.5 203.1 t(37) = 1.04, p=0.301 
Simpson Index 0.4 0.5 t(37) =-0.52, p=0.604 
Shannon Index 2.1 2.4 t(37) =-0.48, p=0.627 
Phylogenetic diversity 8.7 9.0 t(37) =-0.20, p=0.835 
Observed Species 163.9 140.3 t(37) = 0.81, p=0.420 
Actinobacteria 9.0 16.8 W=162, p=0.717 
Bacteroidetes 2.6 0.9 W=182, p=0.849 
Firmicutes 78.5 66.5 W=194, p=0.592 
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Fusobacteria 0.4 0.1 W=207.5, p=0.325 
Proteobacteria 7.9 12.1 W=140, p=0.316 
Bifidobacteriaceae 4.4 10.3 W=155.5, p=0.577 
Corynebacteriaceae 3.6 5.2 W=169.5, p=0.883 
Prevotellaceae 2.1 0.5 W=197, p=0.528 
Staphylococcaceae 1.5 3.9 W=155.5, p=0.577 
Lactobacillaceae 64.2 53.8 W=182, p=0.851 
Streptococcaceae 4.5 3.3 W=165.5, p=0.792 
ClostridialesFamilyXI 3.9 4.1 W=184.5, p=0.792 
Veillonellaceae 2.2 0.2 W=196, p=0.548 
Leptotrichiaceae 0.4 0.1 W=202.5, p=0.373 
Caulobacteraceae 1.0 1.6 W=136, p=0.259 
Sphingomonadaceae 1.8 2.8 W=135.5, p=0.253 
Moraxellaceae 1.8 2.8 W=142, p=0.341 
Pseudomonadaceae 1.1 1.7 W=137.5, p=0.278 
Gardnerella 4.2 10.1 W=130.5, p=0.196 
Corynebacterium 0.5 0.4 W=164, p=0.758 
Prevotella 2.1 0.5 W=197, p=0.528 
Staphylococcus 1.5 3.9 W=155.5, p=0.577 
Lactobacillus 64.2 53.8 W=182, p=0.851 
Streptococcus 4.5 3.3 W=165.5, p=0.792 
Anaerococcus 1.5 1.9 W=175.5, p=1 
Sneathia 0.4 0.1 W=202.5, p=0.373 
Brevundimonas 0.9 1.5 W=132, p=0.212 
Sphingobium 0.8 1.3 W=135.5, p=0.253 
Sphingomonas 0.9 1.5 W=140, p=0312 
Acinetobacter 1.8 2.8 W=141.5, p=0.333 
Pseudomonas 1.1 1.7 W=137.5, p=0.278 
Supplementary table 22: Relative abundance of bacterial OTUs in the maternal vagina by 
maternal cortisol in the 3rd trimester. Listed are all OTUs with an abundance of greater 
than 1% and significant OTUs with an abundance of less than 1%. Low cortisol (CAR < 
562349; N=25), high cortisol (CAR > 562350; N=14). Unpaired students t-test and Mann-
Whitney-Wilcoxon test. Abbreviations: Operational taxonomic unit (OTU), Cortisol 
Awakening Response (CAR).  
 
Table 23: Infant gut at 1 week old by 2nd trimester stress 
OTU Relative Abundance (%) 
1 week old Low PSS High PSS p-value 
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Chao1 Index 79.7 76.4 t(39) = 0.52, p=0.599 
Simpson Index 0.6 0.7 t(39) = -0.65, p=0.514 
Shannon Index 2.3 2.4 t(39) = -0.31, p=0.757 
Phylogenetic diversity 4.1 3.9 t(39) = 0.90, p=0.372 
Observed Species 55.6 50.7 t(39) = 1.44, p=0.157 
Actinobacteria 49.4 46.3 W=217, p=0.846 
Bacteroidetes 16.4 9.1 W=223.5, p=0.714 
Firmicutes 31.9 41.0 W=153, p= 0.148 
Proteobacteria 2.0 3.4 W=247.5, p=0.320 
Bifidobacteriaceae 32.3 31.7 W=206, p=0.947 
Nocardiaceae 15.4 12.5 W=231.5, p=0.565 
Coriobacteriaceae 1.2 1.5 W=220.5,p= 0.770 
Bacteroidaceae 12.6 8.2 W=225, p=0.685 
Porphyromonadaceae 3.8 0.9 W=274.5, p=0.084 
Staphylococcaceae 5.7 4.7 W=211, p=0.969 
Enterococcaceae 1.9 2.5 W=249.5, p=0.293 
Lactobacillaceae 1.9 3.3 W=216.5, p=0.853 
Streptococcaceae 8.5 7.2 W=213, p=0.927 
Clostridiaceae1 5.9 8.7 W=176, p=0.395 
Lachnospiraceae 5.3 3.6 W=279, p=0.069 
Veillonellaceae 1.3 9.6 W=150.5, p=0.129 
Enterobacteriaceae 1.8 1.8 W=240.5, p=0.416 
Bifidobacterium 32.3 31.7 W=206, p=0.947 
Rhodococcus 15.4 12.5 W=231.5, p=0.565 
Collinsella 1.2 1.4 W=193, p=0.675 
Bacteroides 12.6 8.2 W=225, p=0.685 
Porphyromonadaceae uncultured 2.4 0.7 W=270, p=0.092 
Staphylococcus 5.7 4.7 W=211, p= 0.969 
Enterococcus 1.9 2.5 W=249.5, p=0.293 
Lactobacillus 1.9 3.3 W=216.5, p=0.853 
Streptococcus 8.5 7.2 W=213, p=0.927 
Clostridium sensu stricto 1 5.9 8.7 W=176, p=0.395 
Lachnospiraceae Incertae Sedis 5.1 3.4 W=278.5, p=0.070 
Veillonella 1.3 8.2 W=167.5, p=0.283 
Enterobacter 1.0 0.1 W=249.5, p=0.279 
Escherichia Shigella 0.6 1.7 W=238, p=0.453 
Supplementary table 23: Relative abundance of bacterial OTUs in the infant gut at 1 week 
old by maternal stress in the 2nd trimester. Listed are all OTUs with an abundance of greater 
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than 1% and significant OTUs with an abundance of less than 1%. Low stress (PSS < 13; 
Vaginal; N=19; C-Section; N=6), high stress (PSS > 14; Vaginal; N=22; C-Section; N=5). 
Unpaired students t-test and Mann-Whitney-Wilcoxon test. Abbreviations: Operational 
taxonomic unit (OTU), Perceived Stress Scale (PSS). 
 
Table 24: Infant gut at 1 week old by 2nd trimester anxiety 
OTU Relative Abundance (%) 
1 week old Low STAI High STAI p-value 
Chao1 Index 80.0 75.0 t(39) = 0.80, p=0.427 
Simpson Index 0.6 0.7 t(39) = -
0.99,p=0.325 
Shannon Index 2.2 2.5 t(39) =-
1.52, p=0.134 
Phylogenetic diversity 3.9 4.1 t(39) =-
0.72, p=0.470 
Observed Species 53.0 53.0 t(39) = 0.01, p=0.986 
Actinobacteria 57.3 34.1 W=310, p=0.004 
Bacteroidetes 8.2 18.6 W=169.5, p=0.368 
Firmicutes 33.0 42.2 W=150, p=0.158 
Proteobacteria 1.3 4.9 W=218.5, p=0.711 
Bifidobacteriaceae 36.8 25.1 W=265, p=0.109 
Nocardiaceae 18.8 6.9 W=297.5, p=0.013 
Propionibacteriaceae 0.0 0.0 W=185.5, p=0.402 
Coriobacteriaceae 1.4 1.2 W=195.5, p=0.830 
Bacteroidaceae 6.2 16.0 W=184, p=0.605 
Porphyromonadaceae 2.0 2.5 W=169.5, p=0.361 
Staphylococcaceae 6.0 4.1 W=196, p=0.844 
Enterococcaceae 1.2 3.8 W=139, p=0.086 
Lactobacillaceae 2.1 3.4 W=120, p=0.025 
Streptococcaceae 9.0 6.1 W=217.5, p=0.730 
Clostridiaceae1 5.8 9.7 W=180, p=0.533 
Clostridiales Family XI 0.0 0.0 W=112, p=0.010 
Lachnospiraceae 4.3 4.6 W=217.5, p=0.730 
Veillonellaceae 3.4 9.1 W=149.5, p=0.152 
Enterobacteriaceae 0.6 3.4 W=245.5, p=0.276 
Bifidobacterium 36.8 25.1 W=266, p=0.103 
Gardnerella 0.0 0.0 W=168, p=0.037 
Rhodococcus 18.8 6.9 W=297.5, p=0.013 
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Propionibacterium 0.0 0.0 W=185.5, p=0.402 
Collinsella 1.4 1.1 W=229, p=0.503 
Bacteroides 6.2 16.0 W=184, p=0.605 
Porphyromonadaceae uncultured 1.1 2.1 W=171, p=0.260 
Staphylococcus 6.0 4.1 W=196, p=0.844 
Enterococcus 1.2 3.8 W=139, p=0.086 
Lactobacillus 2.3 3.4 W=120, p=0.025 
Streptococcus 9.0 6.1 W=217.5, p=0.730 
Clostridium sensu stricto 1 5.8 9.7 W=180, p=0.533 
Anaerococcus 0.0 0.0 W=134, p=0.027 
Finegoldia 0.0 0.0 W=138, p=0.043 
Blautia 0.0 0.0 W=285, p=0.014 
Coprococcus 0.0 0.0 W=151, p=0.023 
Lachnospiraceae Incertae Sedis 3.9 4.6 W=202, p=0.968 
Faecalibacterium 0.0 0.0 W=154, p=0.032 
Veillonella 2.3 9.1 W=148, p=0.141 
Enterobacter 0.0 1.2 W=239.5, p=0.338 
Escherichia Shigella 0.6 1.9 W=274, p=0.064 
Supplementary table 24: Relative abundance of bacterial OTUs in the infant gut at 1 week 
old by maternal anxiety in the 2nd trimester. Listed are all OTUs with an abundance of 
greater than 1% and significant OTUs with an abundance of less than 1%. Low anxiety (STAI 
< 4; Vaginal; N=24; C-Section; N=4), high anxiety (PSS > 5; Vaginal; N=17; C-Section; N=7). 
Unpaired students t-test and Mann-Whitney-Wilcoxon test. Abbreviations: Operational 
taxonomic unit (OTU), State Trait Anxiety Inventory (STAI). 
 
Table 25: Infant gut at 1 week old by 2nd trimester depressive symptoms 
OTU Relative Abundance (%) 
1 week old Low EPDS High EPDS p-value 
Chao1 Index 80.6 67.2 t(39) = 
1.77, p=0.083 
Simpson Index 0.7 0.7 t(39) = 0.21, p=0.828 
Shannon Index 2.4 2.3 t(39) = 0.09, p=0.921 
Phylogenetic diversity 4.1 3.8 t(39) = 0.64, p=0.521 
Observed Species 54.6 46.5 t(39) = 
1.95, p=0.058 
Actinobacteria 50.7 35.4 W=176, p=0.155 
Bacteroidetes 11.9 15.3 W=130, p=0.960 
Firmicutes 34.5 46.3 W=100, p=0.306 
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Proteobacteria 2.7 2.9 W=163, p=0.315 
Bifidobacteriaceae 32.9 28.1 W=154, p=0.479 
Nocardiaceae 15.6 6.7 W=175, p=0.161 
Coriobacteriaceae 1.6 0.5 W=129, p=0.933 
Bacteroidaceae 9.7 12.7 W=175, p=0.680 
Porphyromonadaceae 2.1 2.5 W=139.5, p=0.815 
Staphylococcaceae 5.5 3.6 W=119, p=0.686 
Enterococcaceae 1.5 5.3 W=125, p=0.830 
Lactobacillaceae 3.3 0.0 W=130, p=0.960 
Streptococcaceae 8.4 5.4 W=153, p=0.500 
Clostridiaceae1 7.3 7.7 W=131.5, p=1 
Lachnospiraceae 3.7 7.5 W=151, p=0.542 
Veillonellaceae 3.3 15.8 W=68, p=0.036 
Enterobacteriaceae 2.1 0.3 W=183, p=0.095 
Campylobacteraceae 0.0 0.0 W=115.5, p=0.048 
Helicobacteraceae 0.0 0.0 W=115.5, p=0.048 
Oxalobacteraceae 0.0 0.0 W=131.5, p=1 
Bifidobacterium 32.9 28.1 W=155, p=0.610 
Rhodococcus 15.6 6.7 W=175, p=0.161 
Collinsella 1.5 0.4 W=130.5, p=0.972 
Bacteroides 9.7 12.7 W=145, p=0.680 
Porphyromonadaceae uncultured 1.4 2.1 W=148.5, p=0.575 
Staphylococcus 5.5 3.6 W=119, p=0.686 
Enterococcus 1.5 5.3 W=125, p=0.830 
Lactobacillus 3.3 0.0 W=140, p=0.508 
Streptococcus 8.4 5.4 W=153, p=0.500 
Clostridium sensu stricto 1 7.3 7.7 W=131.5, p=1 
Lachnospiraceae Incertae Sedis 3.4 7.4 W=151, p=0.542 
Veillonella 2.4 15.8 W=66, p=0.030 
Campylobacter 0.0 0.0 W=115.5, p=0.048 
Helicobacter 0.0 0.0 W=115.5, p=0.048 
Enterobacter 0.6 1.4 W=191.5, p=0.044 
Massilia 0.0 0.0 W=131.5, p=1 
Citrobacter 0.0 0.0 W=137, =0.809 
Escherichia Shigella 0.1 0.2 W=184.5, p=0.085 
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Trabulsiella 0.0 0.0 W=130, p=0.947 
Supplementary table 25: Relative abundance of bacterial OTUs in the infant gut at 1 week 
old by maternal depressive symptoms in the 2nd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low depressive (EPDS < 8; Vaginal; N=33; C-Section; N=9), high depressive (EPDS > 9; 
Vaginal; N=8; C-Section; N=2). Unpaired students t-test and Mann-Whitney-Wilcoxon test. 
Abbreviations: Operational taxonomic unit (OTU), Edinburgh Postnatal Depression Scale 
(EPDS). 
 
Table 26: Infant gut at 1 week old by 2nd trimester cortisol 
OTU Relative Abundance (%) 
1 week old Low CAR High CAR p-value 
Chao1 Index 70.4 80.7 t(34) =-1.66, p=0.104 
Simpson Index 0.6 0.7 t(34) =-0.43, p=0.664 
Shannon Index 2.3 2.3 t(34) =-0.07, p=0.938 
Phylogenetic diversity 4.0 4.0 t(34) = 0.02 p=0.979 
Observed Species 51.3 52.6 t(34) =-0.35, p=0.724 
Actinobacteria 43.5 45.8 W=155, p=0.839 
Bacteroidetes 12.6 11.9 W=161, p=0.987 
Firmicutes 41.3 38.3 W=164, p=0.962 
Proteobacteria 2.3 3.7 W=109.5, p=0.099 
Bifidobacteriaceae 23.0 35.2 W=126, p=0.261 
Nocardiaceae 17.8 9.8 W=181.5, p=0.547 
Coriobacteriaceae 1.9 0.6 W=207, p=0.150 
Bacteroidaceae 11.8 8.7 W=172.5, p=0.751 
Porphyromonadaceae 0.8 3.2 W=180, p=0.572 
Staphylococcaceae 5.3 6.1 W=143, p=0.562 
Enterococcaceae 4.2 0.9 W=198.5, p=0.253 
Lactobacillaceae 3.3 2.3 W=198, p=0.257 
Streptococcaceae 9.6 6.7 W=180, p=0.579 
Clostridiaceae1 7.8 9.0 W=168.5, p=0.849 
Lachnospiraceae 3.6 5.3 W=144, p=0.579 
Veillonellaceae 6.3 6.4 W=185.5, p=0.466 
Enterobacteriaceae 2.0 1.9 W=148.5, p=0.679 
Bifidobacterium 22.9 35.2 W=127.5, p=0.281 
Rhodococcus 17.8 9.8 W=181.5, p=0.547 
Collinsella 1.9 0.5 W=194, p=0.301 
Bacteroides 11.8 8.7 W=172.5, p=0.751 
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Porphyromonadaceae uncultured 0.5 2.0 W=201.5, p=0.186 
Staphylococcus 5.3 6.1 W=143, p=0.562 
Enterococcus 4.2 0.9 W=198.5, p=0.253 
Lactobacillus 3.3 2.3 W=198, p=0.257 
Streptococcus 9.6 6.7 W=180, p=0.579 
Clostridium sensu stricto 1 7.8 9.0 W=168.5, p=0.849 
Lachnospiraceae Incertae Sedis 3.3 5.1 W=166.5, p=0.889 
Veillonella 4.6 6.4 W=169.5, p=0.824 
Enterobacter 0.1 1.0 W=151.5, p=0.743 
Escherichia Shigella 1.9 0.6 W=152, p=0.761 
Supplementary table 26: Relative abundance of bacterial OTUs in the infant gut at 1 week 
old by maternal cortisol in the 2nd trimester. Listed are all OTUs with an abundance of 
greater than 1% and significant OTUs with an abundance of less than 1%. Low cortisol (CAR 
< 545131; Vaginal; N=18; C-Section; N=8), high cortisol (CAR > 545132; Vaginal; N=18; C-
Section; N=2). Unpaired students t-test and Mann-Whitney-Wilcoxon test. Abbreviations: 
Operational taxonomic unit (OTU), Cortisol Awakening Response (CAR). 
 
Table 27: Infant gut at 1 week old by 3rd trimester stress 
OTU Relative Abundance (%) 
1 week old Low PSS High PSS p-value 
Chao1 Index 83.1 76.0 t(41) = 1.08, p=0.283 
Simpson Index 0.7 0.7 t(41) = 0.27, p=0.784 
Shannon Index 2.5 2.4 t(41) = 0.43, p=0.668 
Phylogenetic diversity 4.2 3.8 t(41) = 
1.70, p=0.095 
Observed Species 55.6 50.0 t(41) = 
1.90, p=0.063 
Actinobacteria 54.7 39.6 W=302, p=0.086 
Bacteroidetes 10.5 16.4 W=187, p=0.290 
Firmicutes 33.7 37.9 W=220, p=0.800 
Proteobacteria 0.9 6.0 W=251, p=0.635 
Bifidobacteriaceae 34.0 28.9 W=247, p=0.706 
Nocardiaceae 18.1 9.3 W=294, p=0.128 
Coriobacteriaceae 2.3 0.6 W=288, p=0.164 
Bacteroidaceae 8.3 14.2 W=179.5, p=0.215 
Porphyromonadaceae 2.2 2.1 W=229.5, p=0.980 
Staphylococcaceae 6.1 4.2 W=220, p=0.800 
Enterococcaceae 1.7 3.4 W=238.5, p=0.864 
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Lactobacillaceae 1.6 3.3 W=192.5, p=0.349 
Streptococcaceae 10.0 7.1 W=230, p=0.990 
Clostridiaceae1 5.5 10.2 W=184, p=0.258 
Lachnospiraceae 4.6 4.8 W=275, p=0.290 
Veillonellaceae 2.3 3.5 W=213.5, p=0.679 
Caulobacteraceae 0.0 0.0 W=297, p=0.008 
Enterobacteriaceae 0.8 5.2 W=270.5, p=0.342 
Bifidobacterium 34.0 28.9 W=247, p=0.706 
Rhodococcus 18.1 9.3 W=294, p=0.128 
Atopobium 0.0 0.0 W=275, p=0.035 
Collinsella 2.2 0.5 W=291.5, p=0.132 
Bacteroides 8.3 14.2 W=179.5, p=0.215 
Porphyromonadaceae uncultured 1.1 1.8 W=203, p=0.477 
Staphylococcus 6.1 4.2 W=220, p=0.800 
Enterococcus 1.7 3.4 W=238.5, p=0.864 
Lactobacillus 1.6 3.3 W=192.5, p=0.349 
Streptococcus 10.0 7.1 W=230, p=0.990 
Clostridium sensu stricto 1 5.5 10.2 W=184, p=0.258 
Finegoldia 0.0 0.0 W=132.5, p=0.005 
Blautia 0.1 0.0 W=317.5, p=0.017 
Lachnospiraceae Incertae Sedis 4.0 4.5 W=254, p=0.583 
Lachnospiraceae uncultured 0.2 0.0 W=321.5, p=0.017 
Veillonella 2.2 3.4 W=219, p=0.779 
Brevundimonas 0.0 0.0 W=297, p=0.008 
Enterobacter 0.1 0.8 W=244.5, p=0.745 
Escherichia Shigella 0.6 1.7 W=282.5, p=0.212 
Supplementary table 27: Relative abundance of bacterial OTUs in the infant gut at 1 week 
old by maternal stress in the 3rd trimester. Listed are all OTUs with an abundance of greater 
than 1% and significant OTUs with an abundance of less than 1%. Low stress (PSS < 11; 
Vaginal; N=21; C-Section; N=4), high stress (PSS > 12; Vaginal; N=22; C-Section; N=5). 
Unpaired students t-test and Mann-Whitney-Wilcoxon test. Abbreviations: Operational 
taxonomic unit (OTU), Perceived Stress Scale (PSS). 
 
Table 28: Infant gut at 1 week old by 3rd trimester anxiety 
OTU Relative Abundance (%) 
1 week old Low STAI High STAI p-value 
Chao1 Index 83.6 74.7 t(41) = 1.38, p=0.173 
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Simpson Index 0.7 0.7 t(41) = 0.11, p=0.907 
Shannon Index 2.4 2.4 t(41) =-
0.16, p=0.868 
Phylogenetic diversity 4.1 3.8 t(41) = 1.55, p=0.127 
Observed Species 54.9 50.2 t(41) = 1.58, p=0.120 
Actinobacteria 53.1 39.9 W=294, p=0.122 
Bacteroidetes 14.4 12.5 W=250, p=0.634 
Firmicutes 31.4 40.9 W=178, p=0.212 
Proteobacteria 0.9 6.5 W=247, p=0.687 
Bifidobacteriaceae 33.7 28.7 W=254, p=0.567 
Nocardiaceae 17.0 9.7 W=289, p=0.154 
Coriobacteriaceae 2.1 0.7 W=281.5, p=0.208 
Bacteroidaceae 11.6 11.0 W=245.5, p=0.714 
Porphyromonadaceae 2.7 1.5 W=251, p=0.612 
Staphylococcaceae 6.5 3.6 W=251, p=0.621 
Enterococcaceae 2.1 3.1 W=278, p=0.245 
Lactobacillaceae 0.8 4.4 W=152.5, p=0.057 
Streptococcaceae 9.8 7.1 W=237.5, p=0.864 
Clostridiaceae1 4.6 11.7 W=143, p=0.035 
Lachnospiraceae 4.8 4.5 W=303.5, p=0.075 
Veillonellaceae 1.8 4.1 W=175.5, p=0.188 
Enterobacteriaceae 0.8 5.6 W=259, p=0.486 
Pasteurellaceae 0.0 0.0 W=308, p=0.037 
Bifidobacterium 33.7 28.7 W=254, p=0.567 
Rhodococcus 17.0 9.7 W=289, p=0.154 
Collinsella 2.0 0.6 W=292, p=0.122 
Bacteroides 11.6 11.0 W=245.5, p=0.714 
Porphyromonadaceae uncultured 1.7 1.1 W=217, p=0.746 
Staphylococcus 6.5 3.6 W=251, p=0.621 
Enterococcus 2.1 3.1 W=278, p=0.245 
Lactobacillus 0.8 4.4 W=152.5, p=0.057 
Streptococcus 9.8 7.1 W=237.5, p=0.864 
Clostridium sensu stricto 1 4.6 11.7 W=143, p=0.035 
Blautia 0.0 0.1 W=302, p=0.047 
Lachnospiraceae Incertae Sedis 4.1 4.4 W=295, p=0.115 
Peptostreptococcaceae Incertae Sedis 0.0 0.8 W=155.5, p=0.044 
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Veillonella 1.8 4.0 W=178.5, p=0.213 
Enterobacter 0.1 0.6 W=263.5, p=0.408 
Escherichia Shigella 0.9 1.7 W=282, p=0.206 
Trabulsiella 0.0 2.7 W=154.5, p=0.024 
Haemophilus 0.0 0.0 W=308, p=0.037 
Supplementary table 28: Relative abundance of bacterial OTUs in the infant gut at 1 week 
old by maternal anxiety in the 3rd trimester. Listed are all OTUs with an abundance of 
greater than 1% and significant OTUs with an abundance of less than 1%. Low anxiety (STAI 
< 4; Vaginal; N=23; C-Section; N=5), high anxiety (STAI > 5; Vaginal; N=20; C-Section; N=4). 
Unpaired students t-test and Mann-Whitney-Wilcoxon test. Abbreviations: Operational 
taxonomic unit (OTU), State Trait Anxiety Inventory. 
 
Table 29: Infant gut at 1 week old by 3rd trimester depressive symptoms 
OTU Relative Abundance (%) 
1 week old Low EPDS High EPDS p-value 
Chao1 Index 83.1 71.0 t(41) = 
1.75, p=0.086 
Simpson Index 0.7 0.6 t(41) = 0.83, p=0.410 
Shannon Index 2.5 2.3 t(41) = 0.91, p=0.365 
Phylogenetic diversity 4.1 3.6 t(41) = 
2.28, p=0.027 
Observed Species 54.7 48.2 t(41) = 
2.05, p=0.045 
Actinobacteria 50.1 39.7 W=241, p=0.232 
Bacteroidetes 14.7 10.7 W=224, p=0.450 
Firmicutes 33.8 40.5 W=166, p=0.456 
Proteobacteria 1.2 8.8 W=191, p=0.926 
Bifidobacteriaceae 32.9 27.9 W=211, p=0.681 
Nocardiaceae 14.7 11.2 W=218.5, p=0.542 
Coriobacteriaceae 1.9 0.4 W=243, p=0.203 
Bacteroidaceae 12.2 9.2 W=219.5, p=0.525 
Porphyromonadaceae 2.4 1.5 W=181.5, p=0.727 
Bacillales Family XI 0.0 0.0 W=273.5, p=0.031 
Staphylococcaceae 6.4 2.4 W=252, p=0.136 
Enterococcaceae 2.1 3.5 W=222.5, p=0.473 
Lactobacillaceae 2.6 2.3 W=158.5, p=0.334 
Streptococcaceae 9.8 5.6 W=242, p=0.218 
Clostridiaceae1 5.2 14.2 W=114.5, p=0.034 
Lachnospiraceae 4.3 5.7 W=247.5, p=0.168 
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Veillonellaceae 1.7 5.6 W=167, p=0.466 
Aeromonadaceae 0.0 0.1 W=165, p=0.032 
Enterobacteriaceae 0.7 8.5 W=198, p=0.947 
Bifidobacterium 32.9 27.9 W=211, p=0.681 
Rhodococcus 14.7 11.2 W=218.5, p=0.542 
Collinsella 1.8 0.3 W=261, p=0.074 
Bacteroides 12.2 9.2 W=219.5, p=0.525 
Porphyromonadaceae uncultured 1.6 1.0 W=159.5, p=0.324 
Gemella 0.0 0.0 W=273.5, p=0.031 
Staphylococcus 6.4 2.4 W=252, p=0.136 
Enterococcus 2.1 3.5 W=222.5, p=0.473 
Lactobacillus 2.6 2.3 W=158.5, p=0.334 
Streptococcus 9.8 5.6 W=242, p=0.218 
Clostridium sensu stricto 1 5.3 14.2 W=114.5, p=0.034 
Lachnospiraceae Incertae Sedis 3.6 5.7 W=231.5, p=0.340 
Lachnospiraceae uncultured 0.0 0.0 W=277, p=0.018 
Veillonella 1.7 5.6 W=161, p=0.374 
Aeromonas 0.0 0.1 W=165, p=0.032 
Enterobacter 0.1 1.4 W=202, p=0.859 
Escherichia Shigella 0.5 2.6 W=210.5, p=0.689 
Supplementary table 29: Relative abundance of bacterial OTUs in the infant gut at 1 week 
old by maternal depressive symptoms in the 3rd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low depressive (EPDS < 8; Vaginal; N=30; C-Section; N=7), high depressive (EPDS > 9; 
Vaginal; N=13; C-Section; N=2). Unpaired students t-test and Mann-Whitney-Wilcoxon test. 
Abbreviations: Operational taxonomic unit (OTU), Edinburgh Postnatal Depression Scale 
(EPDS). 
 
Table 30: Infant gut at 1 week old by 3rd trimester cortisol 
OTU Relative Abundance (%) 
1 week old Low CAR High CAR p-value 
Chao1 Index 83.1 76.2 t(35) = 0.93, p=0.357 
Simpson Index 0.7 0.7 t(35) = 0.36, p=0.717 
Shannon Index 2.4 2.3 t(35) = 0.53, p=0.597 
Phylogenetic diversity 4.0 3.8 t(35) = 0.82, p=0.415 
Observed Species 54.1 50.5 t(35) = 1.06, p=0.293 
Actinobacteria 43.7 56.4 W=124, p=0.184 
Bacteroidetes 16.4 10.6 W=186.5, p=0.580 
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Firmicutes 35.8 32.1 W=193, p=0.457 
Proteobacteria 3.9 0.6 W=215.5, p=0.149 
Bifidobacteriaceae 23.8 40.8 W=112, p=0.088 
Nocardiaceae 17.1 14.2 W=194.5, p=0.425 
Coriobacteriaceae 2.1 1.1 W=184, p=0.629 
Bacteroidaceae 13.9 9.1 W=182, p=0.678 
Porphyromonadaceae 2.4 1.5 W=213.5, p=0.163 
Staphylococcaceae 3.7 5.6 W=115, p=0.108 
Enterococcaceae 2.5 3.6 W=172, p=0.914 
Lactobacillaceae 3.9 0.6 W=192.5, p=0.458 
Streptococcaceae 7.3 7.5 W=160, p=0.820 
Clostridiaceae1 8.2 6.8 W=209, p=0.217 
Lachnospiraceae 5.0 4.0 W=210, p=0.203 
Veillonellaceae 3.8 3.0 W=196.5, p=0.390 
Sphingomonadales Ellin 6055 0.0 0.0 W=136.5, p=0.044 
Enterobacteriaceae 3.1 0.5 W=227.5, p=0.069 
Bifidobacterium 23.8 40.8 W=112, p=0.088 
Rhodococcus 17.1 14.2 W=194.5, p=0.425 
Collinsella 2.1 1.0 W=192, p=0.457 
Bacteroides 13.9 9.1 W=182, p=0.678 
Porphyromonadaceae uncultured 1.1 1.3 W=200.5, p=0.301 
Staphylococcus 3.7 5.6 W=115, p=0.108 
Enterococcus 2.5 3.6 W=172, p=0.914 
Lactobacillus 3.9 0.6 W=192.5, p=0.458 
Streptococcus 7.3 7.5 W=160, p=0.820 
Clostridium sensu stricto 1 8.2 6.8 W=209, p=0.217 
Lachnospiraceae Incertae Sedis 4.4 3.7 W=225, p=0.082 
Veillonella 2.3 3.0 W=180.5, p=0.712 
Sphingomonadales Ellin 6055 uncultured 0.0 0.0 W=136.5, p=0.044 
Enterobacter 1.0 0.0 W=220.5, p=0.100 
Escherichia Shigella 1.9 0.5 W=206, p=0.246 
Supplementary table 30: Relative abundance of bacterial OTUs in the infant gut at 1 week 
old by maternal cortisol in the 3rd trimester. Listed are all OTUs with an abundance of 
greater than 1% and significant OTUs with an abundance of less than 1%. Low cortisol (CAR 
< 562349; Vaginal; N=21; C-Section; N=7), high cortisol (CAR > 562350; Vaginal; N=16; C-
Section; N=7). Unpaired students t-test and Mann-Whitney-Wilcoxon test. Abbreviations: 
Operational taxonomic unit (OTU), Cortisol Awakening Response (CAR).  
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Table 31: Infant gut at 2 weeks old by 2nd trimester stress 
OTU Relative Abundance (%) 
2 weeks old Low PSS High PSS p-value 
Chao1 Index 83.3 80.1 t(36) = 0.43, p=0.663 
Simpson Index 0.7 0.7 t(36) =-
1.69, p=0.099 
Shannon Index 2.4 2.7 t(36) =-
1.51,p= 0.138 
Phylogenetic diversity 4.3 4.3 t(36) = 0.15,p= 0.874 
Observed Species 55.8 56.9 t(36) =-
0.29, p=0.768 
Actinobacteria 52.8 54.0 W=177, p=0.942 
Bacteroidetes 11.9 7.7 W=174.5, p=0.883 
Firmicutes 31.3 36.4 W=156, p=0.496 
Proteobacteria 3.8 1.7 W=205, p=0.478 
Bifidobacteriaceae 41.8 36.6 W=199, p=0.592 
Nocardiaceae 9.3 14.3 W=145.5, p=0.320 
Coriobacteriaceae 1.3 2.4 W=154.5, p=0.458 
Bacteroidaceae 10.7 5.8 W=177.5, p=0.953 
Porphyromonadaceae 1.1 1.8 W=196, p=0.636 
Staphylococcaceae 5.1 2.8 W=196, p=0.654 
Enterococcaceae 0.6 2.1 W=153, p=0.437 
Lactobacillaceae 1.7 1.2 W=171.5, p=0.814 
Streptococcaceae 6.3 4.9 W=196.5, p=0.639 
Clostridiaceae1 5.8 9.0 W=135, p=0.193 
Lachnospiraceae 5.0 5.5 W=169.5, p=0.769 
Veillonellaceae 5.9 7.9 W=128, p=0.131 
Enterobacteriaceae 3.3 1.7 W=174.5, p=0.883 
Pseudomonadaceae 0.0 0.0 W=239.5, p=0.044 
Xanthomonadaceae 0.0 0.0 W=220, p=0.029 
Bifidobacterium 41.8 36.6 W=199, p=0.592 
Rhodococcus 9.3 14.4 W=145.5, p=0.320 
Collinsella 1.1 2.3 W=155, p=0.446 
Bacteroides 10.7 5.8 W=177.5, p=0.953 
Staphylococcus 5.1 2.8 W=196, p=0.654 
Enterococcus 0.6 2.1 W=153, p=0.437 
Lactobacillus 1.7 1.2 W=171.5, p=0.814 
Streptococcus 6.3 4.9 W=196.5, p=0.639 
 370 
 
Clostridium sensu stricto 1 5.8 9.0 W=135, p=0.193 
Blautia 0.0 0.2 W=117, p=0.006 
Lachnospiraceae Incertae Sedis 4.9 2.6 W=184.5, p=0.906 
Dialister 0.0 0.0 W=240, p=0.006 
Veillonella 5.1 5.6 W=140, p=0.248 
Sphingomonas 0.0 0.0 W=220, p=0.030 
Enterobacter 2.0 0.3 W=152, p=0.416 
Pseudomonas 0.0 0.0 W=239.5, p=0.044 
Stenotrophomonas 0.0 0.0 W=220, p=0.029 
Supplementary table 31: Relative abundance of bacterial OTUs in the infant gut at 1 week 
old by maternal stress in the 2nd trimester. Listed are all OTUs with an abundance of greater 
than 1% and significant OTUs with an abundance of less than 1%. Low stress (PSS < 13; 
Vaginal; N=18; C-Section; N=8), high stress (PSS > 14; Vaginal; N=20; C-Section; N=4). 
Unpaired students t-test and Mann-Whitney-Wilcoxon test. Abbreviations: Operational 
taxonomic unit (OTU), Perceived Stress Scale (PSS). 
 
Table 32: Infant gut at 2 weeks old by 2nd trimester anxiety 
OTU Relative Abundance (%) 
2 weeks old Low STAI High STAI p-value 
Chao1 Index 79.5 85.8 t(36) =-
0.82, p=0.412 
Simpson Index 0.7 0.7 t(36) =-
0.82, p=0.417 
Shannon Index 2.5 2.7 t(36) =-0.70,p=0.482 
Phylogenetic diversity 4.3 4.3 t(36) =-0.18,p=0.853 
Observed Species 56.5 56.3 t(36) =0.06, p=0.952 
Actinobacteria 54.1 52.1 W=178, p=0.648 
Bacteroidetes 7.8 13.3 W=135.5, p=0.414 
Firmicutes 35.2 31.6 W=184, p=0.523 
Proteobacteria 2.7 2.8 W=148, p=0.670 
Bifidobacteriaceae 38.0 41.0 W=139, p=0.484 
Nocardiaceae 13.8 8.3 W=196.5, p=0.302 
Coriobacteriaceae 1.9 1.8 W=127.5, p=0.281 
Bacteroidaceae 6.1 12.1 W=128, p=0.295 
Porphyromonadaceae 1.6 1.1 W=153, p=0.773 
Staphylococcaceae 4.0 3.6 W=169, p=0.855 
Enterococcaceae 1.2 1.7 W=135.5, p=0.414 
Lactobacillaceae 0.4 3.4 W=131.5, p=0.345 
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Streptococcaceae 6.5 3.7 W=210.5, p=0.143 
Clostridiaceae1 7.7 7.2 W=175, p=0.711 
Lachnospiraceae 5.7 4.5 W=140, p=0.498 
Veillonellaceae 8.4 4.1 W=186.5, p=0.469 
Shewanellaceae 0.0 0.0 W= 118.5, p=0.022 
Enterobacteriaceae 2.3 2.7 W=137, p=0.441 
Bifidobacterium 38.0 41.0 W=139, p=0.484 
Rhodococcus 13.8 8.3 W=196.5, p=0.302 
Collinsella 1.8 1.6 W=134, p=0.359 
Bacteroides 6.1 12.1 W=128, p=0.295 
Staphylococcus 4.0 3.6 W=169, p=0.855 
Enterococcus 1.22 1.7 W=135.5, p=0.414 
Lactobacillus 0.4 3.4 W=131.5, p=0.345 
Streptococcus 6.5 3.7 W=210.5, p=0.143 
Clostridium sensu stricto 1 7.7 7.2 W=175, p=0.711 
Lachnospiraceae Incertae Sedis 3.5 4.1 W=140, p=0.497 
Veillonella 6.1 4.1 W=165.5, p=0.938 
Shewanella 0.0 0.0 W=118.5, p=0.022 
Enterobacter 1.1 1.1 W=111, p=0.113 
Supplementary table 32: Relative abundance of bacterial OTUs in the infant gut at 2 weeks 
old by maternal anxiety in the 2nd trimester. Listed are all OTUs with an abundance of 
greater than 1% and significant OTUs with an abundance of less than 1%. Low anxiety (STAI 
< 4; Vaginal; N=25; C-Section; N=6), high anxiety (STAI > 5; Vaginal; N=13; C-Section; N=6). 
Unpaired students t-test and Mann-Whitney-Wilcoxon test. Abbreviations: Operational 
taxonomic unit (OTU), State Trait Anxiety Inventory (STAI). 
 
Table 33: Infant gut at 2 weeks old by 2nd trimester depressive symptoms 
OTU Relative Abundance (%) 
2 weeks old Low EPDS High EPDS p-value 
Chao1 Index 82.6 78.5 t(36) = 0.48, p=0.628 
Simpson Index 0.5 0.7 t(36) =-
0.71, p=0.477 
Shannon Index 2.5 2.75 t(36) =-
0.74, p=0.462 
Phylogenetic diversity 4.3 4.4 t(36) =-
0.51, p=0.606 
Observed Species 56.0 57.8 t(36) =-
0.43, p=0.665 
Actinobacteria 56.9 42.2 W=184, p=0.068 
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Bacteroidetes 9.9 9.0 W=115, p=0.606 
Firmicutes 30.2 46.2 W=84, p=0.115 
Proteobacteria 2.8 2.4 W=127, p=0.919 
Bifidobacteriaceae 41.3 31.7 W=161, p=0.308 
Nocardiaceae 13.0 8.4 W=166.5, p=0.222 
Coriobacteriaceae 2.2 1.0 W=111.5, p=0.519 
Bacteroidaceae 8.2 8.1 W=108, p=0.449 
Porphyromonadaceae 1.6 0.9 W=119.5, p=0.707 
Staphylococcaceae 4.1 2.9 W=122, p=0.787 
Enterococcaceae 1.2 2.1 W=106.5, p=0.418 
Lactobacillaceae 1.8 0.3 W=136.5, p=0.849 
Streptococcaceae 6.0 4.1 W=156.5, p=0.381 
Clostridiaceae1 5.5 14.2 W=88.5, p=0.154 
Lachnospiraceae 5.3 5.2 W=147.5, p=0.570 
Veillonellaceae 5.4 11.9 W=86, p=0.130 
Enterobacteriaceae 2.5 2.3 W=119, p=0.633 
Bifidobacterium 41.3 31.7 W=161, p=0.308 
Rhodococcus 13.0 8.4 W=166.5, p=0.222 
Collinsella 2.0 0.7 W=112, p=0.511 
Bacteroides 8.2 8.1 W=108, p=0.449 
Staphylococcus 4.1 2.9 W=122, p=0.787 
Enterococcus 1.2 2.1 W=106.5, p=0.418 
Lactobacillus 1.8 0.3 W=136.5, p=0.849 
Streptococcus 6.0 4.1 W=156.5, p=0.381 
Clostridium sensu stricto 1 5.5 14.2 W=88.5, p=0.164 
Lachnospiraceae Incertae Sedis 4.1 2.3 W=150, p=0.513 
Megamonas 0.0 0.0 W=80.5, p=0.007 
Veillonella 3.9 10.3 W=95, p=0.229 
Enterobacter 1.3 0.5 W=83.5, p=0.106 
Supplementary table 33: Relative abundance of bacterial OTUs in the infant gut at 2 weeks 
old by maternal depressive symptoms in the 2nd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low depressive (EPDS < 8; Vaginal; N=29; C-Section; N=11), high depressive (EPDS > 9; 
Vaginal; N=9; C-Section; N=1). Unpaired students t-test and Mann-Whitney-Wilcoxon test. 
Abbreviations: Operational taxonomic unit (OTU), Edinburgh Postnatal; Depression Scale 
(EPDS).  
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Table 34: Infant gut at 2 weeks old by 2nd trimester cortisol 
OTU Relative Abundance (%) 
2 weeks old Low CAR High CAR p-value 
Chao1 Index 86.6 82.7 t(29) = 0.44, p=0.606 
Simpson Index 0.7 0.6 t(29) = 
2.29, p=0.028 
Shannon Index 2.8 2.3 t(29) = 2.63,p=0.013 
Phylogenetic diversity 4.6 4.2 t(29) = 1.42,p=0.164 
Observed Species 59.8 54.6 t(29) = 1.19, p=0.240 
Actinobacteria 44.3 55.5 W=76, p=0.091 
Bacteroidetes 16.5 7.2 W=170.5, p=0.042 
Firmicutes 36.8 35.1 W=117, p=0.953 
Proteobacteria 2.1 2.0 W=107, p=0.652 
Bifidobacteriaceae 31.6 41.4 W=93, p=0.916 
Nocardiaceae 9.2 13.6 W=86.5, p=0.204 
Coriobacteriaceae 2.7 0.0 W=199.5, p=0.001 
Bacteroidaceae 12.4 7.1 W=161, p=0.099 
Porphyromonadaceae 4.0 0.1 W=169.5, p=0.040 
Rikenellaceae 0.0 0.0 W=155.5, p=0.037 
Staphylococcaceae 3.3 3.8 W=105, p=0.797 
Enterococcaceae 1.7 1.4 W=132, p=0.619 
Lactobacillaceae 1.4 1.5 W=122, p=0.920 
Streptococcaceae 3.7 7.3 W=89, p=0.241 
Clostridiaceae1 7.9 7.7 W=96.5, p=0.382 
Lachnospiraceae 4.6 6.1 W=149, p=0.241 
Aeromonadaceae 0.0 0.0 W=118.5, p=1 
Veillonellaceae 11.1 5.3 W=144, p=0.330 
Enterobacteriaceae 1.6 1.6 W=113, p=0.827 
Bifidobacterium 31.6 41.4 W=93, p=0.316 
Rhodococcus 9.2 13.6 W=86.5, p=0.204 
Collinsella 2.6 0.0 W=180, p=0.008 
Bacteroides 12.4 7.1 W=161, p=0.099 
Parabacteroides 3.1 0.1 W=167, p=0.038 
Alistipes 0.0 0.0 W=155.5, p=0.037 
Staphylococcus 3.3 3.8 W=105, p=0.597 
Enterococcus 1.7 1.4 W=132, p=0.619 
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Lactobacillus 1.4 1.5 W=122, p=0.920 
Streptococcus 3.7 7.3 W=89, p=0.241 
Clostridium sensu stricto 1 7.9 7.7 W=96.5, p=0.382 
Lachnospiraceae Incertae Sedis 4.5 2.9 W=161.5, p=0.094 
Phascolarctobacterium 1.2 0.0 W=161.5, p=0.009 
Veillonella 8.9 4.4 W=142.5, p=0.361 
Aeromonas  0.0 0.0 W=118.5, p=1 
Enterobacter 0.3 0.8 W=144.5, p=0.315 
Supplementary table 34: Relative abundance of bacterial OTUs in the infant gut at 2 weeks 
old by maternal cortisol in the 2nd trimester. Listed are all OTUs with an abundance of 
greater than 1% and significant OTUs with an abundance of less than 1%. Good sleep 
quality (CAR < 545131; Vaginal; N=14; C-Section; N=8), poor sleep quality (CAR > 545132; 
Vaginal; N=17; C-Section; N=3). Unpaired students t-test and Mann-Whitney-Wilcox test. 
Abbreviations: Operational taxonomic unit (OTU), Cortisol Awakening Response (CAR).  
 
Table 35: Infant gut at 2 weeks old by 3rd trimester stress 
OTU Relative Abundance (%) 
2 weeks old Low PSS High PSS p-value 
Chao1 Index 86.6 76.6 t(33) = 1.23, p=0.224 
Simpson Index 0.7 0.7 t(33) =1.30, p=0.201 
Shannon Index 2.7 2.5 t(33) = 1.18,p=0.245 
Phylogenetic diversity 4.5 4.2 t(33) = 1.09,p=0.281 
Observed Species 59.6 54.7 t(33) = 1.23, p=0.226 
Actinobacteria 53.5 51.2 W=158, p=0.805 
Bacteroidetes 10.7 14.4 W=131, p=0.537 
Firmicutes 31.0 32.5 W=147, p=0.934 
Proteobacteria 4.7 1.8 W=171.5, p=0.483 
Bifidobacteriaceae 36.6 43.8 W=122, p=0.364 
Nocardiaceae 13.8 6.3 W=202.5, p=0.083 
Coriobacteriaceae 2.7 0.2 W=212.5, p=0.036 
Bacteroidaceae 9.7 13.3 W=133, p=0.582 
Porphyromonadaceae 0.8 1.1 W=138.5, p=0.707 
Staphylococcaceae 3.6 3.4 W=137, p=0.680 
Enterococcaceae 1.0 1.6 W=124.5, p=0.403 
Lactobacillaceae 1.1 2.5 W=113, p=0.222 
Streptococcaceae 5.1 5.6 W=178, p=0.364 
Clostridiaceae1 4.5 8.1 W=125, p=0.414 
Lachnospiraceae 7.6 5.6 W=190.5, p=0.182 
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Veillonellaceae 6.5 3.1 W=205, p=0.069 
Enterobacteriaceae 4.4 1.5 W=178.5, p=0.350 
Bifidobacterium 36.6 43.8 W=122, p=0.362 
Rhodococcus 13.8 6.3 W=202.5, p=0.083 
Collinsella 2.5 0.0 W=199.5, p=0.078 
Bacteroides 9.7 13.3 W=133, p=0.582 
Staphylococcus 3.6 3.4 W=137, p=0.680 
Enterococcus 1.0 1.6 W=124.5, p=0.403 
Lactobacillus 1.1 2.5 W=113, p=0.222 
Streptococcus 5.2 5.6 W=178, p=0.364 
Clostridium sensu stricto 1 4.5 8.1 W=125, p=0.414 
Finegoldia 0.0 0.8 W=83, p=0.020 
Lachnospiraceae Incertae Sedis 4.8 3.9 W=188.5, p=0.204 
Dialister 0.0 0.0 W=195, p=0.023 
Negativicoccus 0.0 0.0 W-110, p=0.044 
Veillonella 5.0 3.1 W=193.5, p=0.151 
Enterobacter 1.3 0.3 W=142.5, p=0.813 
Supplementary table 35: Relative abundance of bacterial OTUs in the infant gut at 2 weeks 
old by maternal pregnancy stress in the 3rd trimester. Listed are all OTUs with an abundance 
of greater than 1% and significant OTUs with an abundance of less than 1%. Low stress (PSS 
< 11; Vaginal; N=20; C-Section; N=6), high stress (PSS > 15; Vaginal; N=14; C-Section; N=5). 
Unpaired students t-test and Mann-Whitney-Wilcoxon test. Abbreviations: Operational 
taxonomic unit (OTU), Perceived Stress Scale (PSS). 
 
Table 36: Infant gut at 2 weeks old by 3rd trimester anxiety 
OTU Relative Abundance (%) 
2 weeks old Low STAI High STAI p-value 
Chao1 Index 86.9 73.2 t(33) = 1.68, p=0.101 
Simpson Index 0.7 0.7 t(33) =-0.52, p=0.606 
Shannon Index 2.6 2.7 t(33) =-0.61,p=0.541 
Phylogenetic diversity 4.4 4.3 t(33) = 0.58,p=0.559 
Observed Species 58.6 55.4 t(33) = 0.76, p=0.449 
Actinobacteria 54.1 49.4 W=160, p=0.460 
Bacteroidetes 11.5 13.7 W=122, p=0.590 
Firmicutes 30.3 34.0 W=131, p=0.823 
Proteobacteria 3.8 2.7 W=133.5, p=0.889 
Bifidobacteriaceae 39.1 40.9 W=132, p=0.850 
Nocardiaceae 12.4 7.1 W=177.5, p=0.175 
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Coriobacteriaceae 2.2 0.5 W=138.5, p=1 
Bacteroidaceae 10.7 12.3 W=121.5, p=0.577 
Porphyromonadaceae 0.7 1.3 W=106.5, p=0.269 
Staphylococcaceae 4.1 2.4 W=158, p=0.503 
Enterococcaceae 1.1 1.6 W=133.5, p=0.889 
Lactobacillaceae 0.8 3.4 W=83.5, p=0.059 
Streptococcaceae 5.5 5.1 W=165, p=0.362 
Clostridiaceae1 4.0 9.9 W=105, p=0.258 
Lachnospiraceae 7.7 5.0 W=151.5, p=0.651 
Veillonellaceae 5.7 3.8 W=165, p=0.356 
Shewanellaceae 0.0 0.0 W=100, p=0.031 
Enterobacteriaceae 3.5 2.6 W=120.5, p=0.554 
Pasteurellaceae 0.2 0.0 W=198.5, p=0.024 
Actinomyces 0.3 0.5 W=162.5, p=0.354 
Bifidobacterium 39.1 40.9 W=132, p=0.850 
Rhodococcus 12.4 7.1 W=177.5, p=0.175 
Collinsella 2.0 0.2 W=141.5, p=0.910 
Bacteroides 10.7 12.3 W=121.5, p=0.577 
Staphylococcus 4.1 2.4 W=158, p=0.503 
Enterococcus 1.1 1.6 W=133.5, p=0.889 
Lactobacillus 0.8 3.4 W=83.5, p=0.059 
Streptococcus 5.5 5.1 W=165, p=0.362 
Clostridium sensu stricto 1 4.0 9.9 W=105, p=0.258 
Lachnospiraceae Incertae Sedis 4.2 4.9 W=146.5, p=0.780 
Veillonella 4.4 3.7 W=157, p=0.520 
Shewanella 0.0 0.0 W=100, p=0.031 
Enterobacter 0.9 1.0 W=88.5, p=0.085 
Haemophilus 0.2 0.0 W=199, p=0.023 
Supplementary table 36: Relative abundance of bacterial OTUs in the infant gut at 2 weeks 
old by maternal pregnancy anxiety in the 3rd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low anxiety (STAI < 4; Vaginal; N=23; C-Section; N=5), high anxiety (STAI > 5; Vaginal; N=12; 
C-Section; N=6). Unpaired students t-test and Mann-Whitney-Wilcoxon test. Abbreviations: 
Operational taxonomic unit (OTU), State Trait Anxiety Inventory (STAI).
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Table 37: Infant gut at 2 weeks old by 3rd trimester depressive symptoms 
OTU Relative Abundance (%) 
2 weeks old Low EPDS High EPDS p-value 
Chao1 Index 86.7 67.0 t(33) = 2.20, p=0.034 
Simpson Index 0.7 0.7 t(33) =-0.50, p=0.616 
Shannon Index 2.6 2.7 t(33) =-0.21,p=0.834 
Phylogenetic diversity 4.5 4.0 t(33) = 1.68,p=0.101 
Observed Species 59.9 49.3 t(33) = 2.40, p=0.022 
Actinobacteria 55.4 42.6 W=146, p=0.143 
Bacteroidetes 12.4 11.9 W=112, p=0.890 
Firmicutes 28.2 43.2 W=59, p=0.055 
Proteobacteria 3.8 2.2 W=127.5, p=0.455 
Bifidobacteriaceae 40.3 37.7 W=117, p=0.743 
Nocardiaceae 12.6 3.8 W=167.5, p=0.020 
Propionibacteriaceae 0.1 0.0 W=152, p=0.037 
Coriobacteriaceae 2.1 0.0 W=148.5, p=0.111 
Bacteroidaceae 11.4 10.9 W=111.5, p=0.906 
Porphyromonadaceae 0.9 1.0 W=104.5, p=0.903 
Staphylococcaceae 3.9 2.1 W=127, p=0.475 
Enterococcaceae 1.0 2.3 W=103.5, p=0.874 
Lactobacillaceae 0.9 4.4 W=70, p=0.139 
Streptococcaceae 5.2 5.7 W=130, p=0.405 
Clostridiaceae1 3.5 14.5 W=73, p=0.175 
Lachnospiraceae 6.9 6.3 W=131.5, p=0.366 
Veillonellaceae 4.9 5.4 W=108, p=1 
Aeromonadaceae 0.0 0.0 W=64, p=0.014 
Shewanellaceae 0.0 0.0 W=77, p=0.048 
Enterobacteriaceae 3.5 2.1 W=119.5, p=0.665 
Pasteurellaceae 0.1 0.0 W=165, p=0.016 
Bifidobacterium 40.3 37.7 W=117, p=0.743 
Rhodococcus 12.6 3.8 W=167.5, p=0.020 
Collinsella 1.8 0.0 W=133.5, p=0.340 
Bacteroides 11.4 10.9 W=111.5, p=0.906 
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Staphylococcus 3.9 2.1 W=127, p=0.475 
Enterococcus 1.0 2.3 W=103.5, p=0.874 
Lactobacillus 0.9 4.4 W=70, p=0.139 
Streptococcus 5.2 5.7 W=130, p=0.405 
Clostridium sensu stricto 1 3.5 14.5 W=73, p=0.175 
Lachnospiraceae Incertae Sedis 3.9 6.3 W=124.5, p=0.529 
Veillonella 3.8 5.4 W=97.5, p=0.694 
Aeromonas 0.0 0.0 W=77, p=0.048 
Shewanell 0.0 0.0 W=77, p=0.048 
Enterobacter 1.0 0.5 W=82, p=0.311 
Haemophilus 0.1 0.0 W=165, p=0.016 
Supplementary table 37: Relative abundance of bacterial OTUs in the infant gut at 2 
weeks old by maternal pregnancy depressive symptoms in the 3rd trimester. Listed are all 
OTUs with an abundance of greater than 1% and significant OTUs with an abundance of 
less than 1%. Low depressive (EPDS < 8; Vaginal; N=27; C-Section; N=9), high depressive 
(EPDS > 9; Vaginal; N=8; C-Section; N=2). Unpaired students t-test and Mann-Whitney-
Wilcoxon test. Abbreviations: Operational taxonomic unit (OTU), Edinburgh Postnatal 
Depression Scale (EPDS).  
 
Table 38: Infant gut at 2 weeks old by 3rd trimester cortisol 
OTU Relative Abundance (%) 
2 weeks old Low CAR High CAR p-value 
Chao1 Index 85.9 76.0 t(33) = 1.22, p=0.228 
Simpson Index 0.7 0.7 t(33) = 1.12, p=0.267 
Shannon Index 2.7 2.4 t(33) = 1.36,p=0.180 
Phylogenetic diversity 4.4 4.0 t(33) = 1.31,p=0.196 
Observed Species 58.3 52.4 t(33) = 1.66, p=0.104 
Actinobacteria 46.6 55.2 W=122, p=0.318 
Bacteroidetes 17.9 9.3 W=167, p=0.655 
Firmicutes 33.5 33.5 W=159, p=0.857 
Proteobacteria 1.7 1.8 W=164.5, p=0.716 
Bifidobacteriaceae 29.2 44.9 W=96, p=0.061 
Nocardiaceae 12.8 8.4 W=192, p=0.203 
Coriobacteriaceae 4.3 1.0 W=222.5, p=0.020 
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Bacteroidaceae 16.0 8.7 W=166.5, p=0.667 
Porphyromonadaceae 1.8 0.5 W=200.5, p=0.110 
Staphylococcaceae 2.9 4.8 W=104, p=0.110 
Enterococcaceae 1.0 1.7 W=147, p=0.855 
Lactobacillaceae 3.1 0.5 W=196.5, p=0.153 
Streptococcaceae 5.4 7.4 W=129, p=0.442 
Clostridiaceae1 7.5 6.0 W=174, p=0.498 
Lachnospiraceae 5.2 5.7 W=179.5, p=0.390 
Acidaminococcaceae 1.1 0.1 W=215.5, P=0.007 
Veillonellaceae 6.1 6.2 W=151.5, p=0.973 
Enterobacteriaceae 1.1 1.6 W=177, p=0.437 
Bifidobacterium 29.2 44.9 W=96, p=0.061 
Rhodococcus 12.8 8.4 W=192, p=0.203 
Collinsella 4.2 0.9 W=188, p=0.225 
Bacteroides 16.0 8.7 W=166.5, p=0.667 
Staphylococcus 2.9 4.8 W=104, p=0.110 
Enterococcus 1.0 1.7 W=147, p=0.855 
Lactobacillus 3.1 0.5 W=196.5, p=0.153 
Streptococcus 5.4 7.4 W=129, p=0.442 
Clostridium sensu stricto 1 7.5 6.0 W=174, p=0.498 
Coprococcus 0.0 0.0 W=189, p=0.033 
Lachnospiraceae Incertae Sedis 3.6 4.1 W=190.5, p=0.221 
Phascolarctobacterium 1.1 0.1 W=215.5, p=0.007 
Veillonella 4.3 6.2 W=140.5, p=0.691 
Enterobacter 0.4 0.5 W=177.5, p=0.421 
Supplementary table 38: Relative abundance of bacterial OTUs in the infant gut at 2 
weeks old by maternal cortisol in the 3rd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low cortisol (CAR < 562349; Vaginal; N=17; C-Section; N=5), high cortisol (CAR > 562350; 
Vaginal; N=18; C-Section; N=6). Unpaired students t-test and Mann-Whitney-Wilcoxon 
test. Abbreviations: Operational taxonomic unit (OTU), Cortisol Awakening Response 
(CAR).  
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Table 39: Infant gut at 3 weeks old by 2nd trimester stress 
OTU Relative Abundance (%) 
3 weeks old Low PSS High PSS p-value 
Chao1 Index 83.8 86.3 t(42) =-0.32, p=0.746 
Simpson Index 0.7 0.8 t(42) =-2.56, p=0.013 
Shannon Index 2.6 2.9 t(42) =-1.86,p=0.069 
Phylogenetic diversity 4.4 4.4 t(42) = 0.01,p=0.988 
Observed Species 60.6 59.3 t(42) = 0.40, p=0.689 
Actinobacteria 51.4 41.9 W=299, p=0.182 
Bacteroidetes 13.6 8.2 W=305.5, p=0.135 
Firmicutes 31.8 45.4 W=149, p=0.029 
Proteobacteria 3.1 4.3 W=235, p=0.887 
Bifidobacteriaceae 39.1 26.3 W=315, p=0.086 
Nocardiaceae 10.4 13.2 W=223, p=0.672 
Coriobacteriaceae 1.6 1.8 W=255.5, p=0.749 
Bacteroidaceae 11.5 7.1 W=326, p=0.048 
Porphyromonadaceae 2.1 1.0 W=347.7, p=0.012 
Staphylococcaceae 2.5 1.2 W=250, p=0.850 
Enterococcaceae 1.0 2.3 W=204, p=0.383 
Lactobacillaceae 3.5 1.6 W=286, p=0.300 
Streptococcaceae 7.5 4.5 W=272, p=0.484 
Clostridiaceae1 6.5 14.2 W=159.5, p=0.055 
Lachnospiraceae 5.1 9.7 W=203.5, p=0.378 
Veillonellaceae 4.6 10.1 W=144, p=0.021 
Enterobacteriaceae 2.7 3.5 W=234, p=0.869 
Bifidobacterium 39.0 26.3 W=315, p=0.086 
Rhodococcus 10.3 13.2 W=223, p=0.672 
Collinsella 1.4 1.7 W=217, p=0.558 
Bacteroides 11.5 7.1 W=326, p=0.048 
Parabacteroides 1.0 1.0 W=337.5, p=0.020 
Porphyromonadaceae uncultured 1.0 0.0 W=345, p=0.007 
Staphylococcus 2.5 1.2 W=250, p=0.850 
Enterococcus 1.0 2.3 W=204, p=0.383 
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Lactobacillus 3.5 1.6 W=286, p=0.300 
Streptococcus 7.5 4.5 W=272, p=0.484 
Clostridiumsensustricto1 6.4 14.2 W=157, p=0.048 
LachnospiraceaeIncertaeSedis 5.1 6.6 W=243.5, p=0.971 
Lachnospiraceaeuncultured 0.0 2.2 W=225.5, p=0.698 
Veillonella 3.6 9.2 W=157, p=0.048 
Sphingomonas 0.0 0.0 W=218, p=0.497 
Enterobacter 1.44 0.97 W=221.5, p=0.643 
EscherichiaShigella 0.8 2.3 W=240.5, p=0.990 
Supplementary table 39: Relative abundance of bacterial OTUs in the infant gut at 3 
weeks old by maternal stress in the 2nd trimester. Listed are all OTUs with an abundance 
of greater than 1% and significant OTUs with an abundance of less than 1%. Low stress 
(PSS < 13; Vaginal; N=23; C-Section; N=7), high stress (PSS > 14; Vaginal; N=21; C-
Section; N=5). Unpaired students t-test and Mann-Whitney-Wilcoxon test. 
Abbreviations: Operational taxonomic unit (OTU), Perceived Stress Scale (PSS). 
 
Table 40: Infant gut at 3 weeks old by 2nd trimester anxiety 
OTU Relative Abundance (%) 
3 weeks old Low STAI High STAI p-value 
Chao1 Index 82.7 90.5 t(42) =-0.95, p=0.344 
Simpson Index 0.7 0.7 t(42) =-0.69, p=0.492 
Shannon Index 2.7 2.8 t(42) =-0.25,p=0.797 
Phylogenetic diversity 4.4 4.6 t(42) =-0.93,p=0.357 
Observed Species 59.5 61.3 t(42) =-0.51, p=0.606 
Actinobacteria 48.7 42.5 W=241, p=0.320 
Bacteroidetes 8.5 17.1 W=117.5, p=0.545 
Firmicutes 39.1 36.4 W=205, p=0.939 
Proteobacteria 3.5 3.8 W=182, p=0.625 
Bifidobacteriaceae 33.7 31.1 W=198, p=0.939 
Nocardiaceae 12.6 9.5 W=249.5, p=0.221 
Coriobacteriaceae 1.9 1.1 W=199.5, p=0.969 
Bacteroidaceae 6.9 15.3 W=167.5, p=0.388 
Porphyromonadaceae 1.5 1.7 W=221.5, p=0.612 
Rikenellaceae 0.0 0.0 W=170.5, p=0.029 
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Staphylococcaceae 1.8 2.1 W=212.5, p=0.787 
Enterococcaceae 1.6 1.8 W=189, p=0.757 
Lactobacillaceae 2.4 3.0 W=176.5, p=0.527 
Streptococcaceae 6.4 5.4 W=217, p=0.703 
Clostridiaceae1 10.2 9.9 W=215, p=0.738 
Clostridiales Family XIII 0.0 0.0 W=170.5, p=0.029 
Lachnospiraceae 7.1 7.7 W=171, p=0.440 
Ruminococcaceae 0.2 0.4 W=203, p=0.977 
Veillonellaceae 8.1 5.1 W=246, p=0.261 
Enterobacteriaceae 2.9 3.3 W=191, p=0.797 
Bifidobacterium 33.7 31.1 W=198, p=0.939 
Scardovia 0.0 0.0 W=170.5, p=0.029 
Corynebacteriaceae uncultured 0.0 0.0 W=146.5, p=0.010 
Rhodococcus 12.6 9.5 W=249.5, p=0.221 
Collinsella 1.8 0.9 W=194.5, p=0.862 
Alistipes 0.0 0.0 W=170.5, p=0.029 
Bacteroides 6.9 15.3 W=167.5, p=0.388 
Staphylococcus 1.8 2.1 W=212.5, p=0.787 
Enterococcus 1.6 1.8 W=189, p=0.757 
Lactobacillus 2.4 3.0 W=176.5, p=0.527 
Streptococcus 6.4 5.4 W=217, p=0.703 
Clostridiumsensustricto1 10.2 9.9 W=213.5, p=0.767 
Cellulosilyticum 0.0 0.0 W=170.5, p=0.029 
LachnospiraceaeIncertaeSedis 5.6 6.2 W=179.5, p=0.580 
Stomatobaculum 0.0 0.0 W=170.5, p=0.029 
Lachnospiraceaeuncultured 0.9 1.3 W=158.5, p=0.245 
Veillonella 6.7 5.1 W=219.5, p=0.652 
Enterobacter 1.2 1.0 W=182, p=0.621 
EscherichiaShigella 1.4 2.1 W=223, p=0.588 
Supplementary table 40: Relative abundance of bacterial OTUs in the infant gut at 3 
weeks old by maternal anxiety in the 2nd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low anxiety (STAI < 4; Vaginal; N=31; C-Section; N=5), high anxiety (STAI > 5; Vaginal; 
 383 
 
 
N=13; C-Section; N=7). Unpaired students t-test and Mann-Whitney-Wilcoxon test. 
Abbreviations: Operational taxonomic unit (OTU), State Trait Anxiety Inventory (STAI).  
 
Table 41: Infant gut at 3 weeks old by 2nd trimester depressive symptoms 
OTU Relative Abundance (%) 
3 weeks old Low EPDS High EPDS p-value 
Chao1 Index 86.4 78.5 t(42) = 0.81, p=0.422 
Simpson Index 0.7 0.7 t(42) =-0.63, p=0.525 
Shannon Index 2.7 2.8 t(42) =-0.44,p=0.660 
Phylogenetic diversity 4.4 4.7 t(42) =-0.90,p=0.371 
Observed Species 59.9 60.5 t(42) =-0.13, p=0.892 
Actinobacteria 48.9 37.7 W=187, p=0.200 
Bacteroidetes 10.1 15.4 W=123.5, p=0.542 
Firmicutes 37.7 41.1 W=129, p=0.665 
Proteobacteria 3.2 5.7 W=105.5, p=0.247 
Bifidobacteriaceae 34.3 27.0 W=163, p=0.580 
Nocardiaceae 12.3 9.1 W=168.5, p=0.465 
Coriobacteriaceae 1.9 0.6 W=129.5, p=0.668 
Bacteroidaceae 8.1 15.0 W=112.5, p=0.345 
Porphyromonadaceae 1.9 0.1 W=167, p=0.489 
Candidate division TM7 uncultured 0.0 0.0 W=98, P=0.011 
Staphylococcaceae 2.0 1.3 W=129, p=0.659 
Enterococcaceae 1.3 3.0 W=80, p=0.052 
Lactobacillaceae 3.1 0.1 W=204, p=0.069 
Streptococcaceae 6.5 4.0 W=164, p=0.559 
Clostridiaceae1 9.5 12.8 W=151.5, p=0.831 
Lachnospiraceae 6.6 10.6 W=128, p=0.637 
Veillonellaceae 7.2 7.3 W=123, p=0.539 
Enterobacteriaceae 2.7 4.8 W=134, p=0.772 
Trueperella 0.0 0.0 W=126, P=0.039 
Bifidobacterium 34.3 27.0 W=163, p=0.580 
Rhodococcus 12.3 9.1 W=168.5, p=0.465 
Collinsella 1.8 0.4 W=133, p=0.740 
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Slackia 0.0 0.0 W=126, P=0.039 
Bacteroides 8.1 15.0 W=112.5, p=0.345 
Paraprevotella 0.0 0.2 W=126, P=0.039 
Staphylococcus 2.0 1.3 W=129, p=0.659 
Enterococcus 1.3 3.0 W=80, p=0.052 
Lactobacillus 3.1 0.1 W=204, p=0.069 
Streptococcus 6.5 4.0 W=164, p=0.559 
Clostridiumsensustricto1 9.5 12.8 W=150, p=0.867 
Mogibacterium 0.0 0.0 W=126, P=0.039 
Blautia 0.0 0.6 W=102.5, P=0.049 
LachnospiraceaeIncertaeSedis 5.3 7.9 W=133, p=0.464 
Pseudobutyrivibrio 0.0 0.0 W=126,  P=0.039 
Lachnospiraceaeuncultured 1.1 0.7 W=131.5, p=0.698 
Veillonella 6.1 7.0 W=119, p=0.455 
Neisseria 0.0 0.0 W=126, P=0.039 
Enterobacter 1.2 1.0 W=118.5, p=0.442 
EscherichiaShigella 1.2 3.1 W169.5=, p=0.446 
Supplementary table 41: Relative abundance of bacterial OTUs in the infant gut at 3 
weeks old by maternal depressive symptoms in the 2nd trimester. Listed are all OTUs with 
an abundance of greater than 1% and significant OTUs with an abundance of less than 
1%. Low depressive (EPDS < 8; Vaginal; N=36; C-Section; N=12), high depressive (EPDS > 
9; Vaginal; N=8; C-Section; N=0). Unpaired students t-test and Mann-Whitney-Wilcoxon 
test. Abbreviations: Operational taxonomic unit (OTU), Edinburgh Postnatal; Depression 
Scale (EPDS).  
 
Table 42: Infant gut at 3 weeks old by 2nd trimester cortisol 
OTU Relative Abundance (%) 
3 weeks old Low CAR High CAR p-value 
Chao1 Index 81.3 89.0 t(36) =-0.95, p=0.347 
Simpson Index 0.7 0.7 t(36) = 1.13, p=0.262 
Shannon Index 2.8 2.7 t(36) = 0.94, p=0.348 
Phylogenetic diversity 4.4 4.5 t(36) =-0.23,p=0.815 
Observed Species 59.0 62.2 t(36) =-0.90, p=0.369 
Actinobacteria 40.9 51.8 W=132,  p=0.162 
 385 
 
 
Bacteroidetes 11.2 8.9 W=187, p=0.860 
Firmicutes 44.4 34.9 W=209, p=0.418 
Proteobacteria 3.3 4.2 W=192, p=0.748 
Bifidobacteriaceae 24.8 39.8 W=122, p=0.090 
Nocardiaceae 12.8 11.3 W=183, p=0.953 
Coriobacteriaceae 2.7 0.1 W=243, p=0.069 
Bacteroidaceae 8.7 7.7 W=179, p=0.976 
Porphyromonadaceae 2.3 1.1 W=178,5, p=0.964 
Staphylococcaceae 2.0 2.1 W=147, p=0.335 
Enterococcaceae 2.4 1.0 W=149, p=0.046 
Lactobacillaceae 2.6 3.1 W=137, p=0.207 
Streptococcaceae 6.5 6.4 W=187, p=0.862 
Clostridiaceae1 13.1 10.2 W=170.5, p=0.781 
Lachnospiraceae 9.9 5.6 W=246, p=0.057 
Acidaminococcaceae 0.0 0.0 W=228, p=0.042 
Veillonellaceae 7.0 5.4 W=195, p=0.686 
Enterobacteriaceae 2.7 3.5 W=187, p=0.860 
Bifidobacterium 24.8 39.8 W=122, p=0.090 
Rhodococcus 12.8 11.3 W=183, p=0.953 
Collinsella 2.5 0.0 W=222.5, p=0.212 
Bacteroides 8.7 7.7 W=179, p=0.976 
Staphylococcus 2.0 2.1 W=147, p=0.335 
Enterococcus 2.4 1.0 W=249, p=0.046 
Lactobacillus 1.6 3.1 W=137, p=0.207 
Streptococcus 6.5 6.4 W=187, p=0.862 
Clostridiumsensustricto1 13.1 10.2 W=173, p=0.838 
LachnospiraceaeIncertaeSedis 8.9 3.4 W=253, p=0.035 
Lachnospiraceaeuncultured 0.8 1.3 W=,200 p=0.559 
Peptostreptococcus 0.0 0.0 W=142.5, p=0.039 
Phascolarctobacterium 0.3 0.0 W=228, p=0.042 
Veillonella 6.1 5.3 W=185, p=0.908 
Bilophila 0.0 0.0 W=218.5, p=0.039 
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Enterobacter 0.7 1.5 W=183, p=0.953 
EscherichiaShigella 1.6 1.8 W=160.5, p=0.568 
Supplementary table 42: Relative abundance of bacterial OTUs in the infant gut at 3 
weeks old by maternal cortisol in the 2nd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low cortisol (CAR < 545131; Vaginal; N=19; C-Section; N=7), high cortisol (CAR > 545132; 
Vaginal; N=19; C-Section; N=4). Unpaired students t-test and Mann-Whitney-Wilcoxon 
test. Abbreviations: Operational taxonomic unit (OTU), Cortisol Awakening Response 
(CAR).  
 
Table 43: Infant gut at 3 weeks old by 3rd trimester stress 
OTU Relative Abundance (%) 
3 weeks old Low PSS High PSS p-value 
Chao1 Index 77.2 87.0 t(38) =-1.25, p=0.218 
Simpson Index 0.7 0.7 t(38) =-0.45, p=0.653 
Shannon Index 2.7 2.7 t(38) =-0.00,p=0.996 
Phylogenetic diversity 4.5 4.3 t(38) = 0.57,p=0.570 
Observed Species 59.9 58.5 t(38) = 0.44, p=0.660 
Actinobacteria 51.9 39.0 W=266, p=0.076 
Bacteroidetes 8.7 13.9 W=184.5, p=0.684 
Firmicutes 37.1 42.0 W=175, p=0.511 
Proteobacteria 2.1 4.8 W=167.5, p=0.386 
Bifidobacteriaceae 33.1 30.8 W=203, p=0.946 
Corynebacteriaceae 0.0 0.0 W=228.5, p=0.437 
Nocardiaceae 16.5 6.1 W=282, p=0.027 
Coriobacteriaceae 1.9 1.0 W=238.5, p=0.301 
Bacteroidaceae 7.1 12.9 W=178, p=0.560 
Porphyromonadaceae 1.4 0.9 W=216, p=0.673 
Staphylococcaceae 3.0 1.8 W=218, p=0.635 
Enterococcaceae 1.3 1.5 W=175.5, p=0.514 
Lactobacillaceae 1.7 2.8 W=164.5, p=0.342 
Streptococcaceae 7.9 5.3 W=217, p=0.658 
Clostridiaceae1 8.7 12.4 W=208, p=0.839 
Lachnospiraceae 5.9 10.1 W=170, p=0.424 
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Veillonellaceae 6.7 6.5 W=216, p=0.678 
Enterobacteriaceae 1.9 3.8 W=180, p=0.597 
Bifidobacterium 33.1 30.8 W=203, p=0.946 
Corynebacterium 0.0 0.0 W=243, p=0.233 
Rhodococcus 16.5 6.1 W=282, p=0.027 
Collinsella 1.6 1.0 W=232, p=0.377 
Bacteroides 7.1 12.9 W=178, p=0.560 
Staphylococcus 3.0 1.8 W=218, p=0.635 
Enterococcus 1.3 1.5 W=175.5, p=0.514 
Lactobacillus 1.7 2.8 W=164.5, p=0.342 
Streptococcus 7.9 5.3 W=217, p=0.658 
Clostridiumsensustricto1 8.6 12.4 W=205.5, p=0.892 
LachnospiraceaeIncertaeSedis 3.9 8.2 W=168, p=0.393 
Lachnospiraceaeuncultured 1.2 0.8 W=182.5, p=0.625 
Dialister 0.0 0.0 W=260, P=0.009 
Veillonella 5.3 6.5 W=198, p=0.967 
Enterobacter 0.4 1.6 W=137.5, p=0.090 
EscherichiaShigella 1.4 1.8 W=242.5, p=0.255 
Supplementary table 43: Relative abundance of bacterial OTUs in the infant gut at 3 
weeks old by maternal stress in the 3rd trimester. Listed are all OTUs with an abundance 
of greater than 1% and significant OTUs with an abundance of less than 1%. Low stress 
(PSS < 13; Vaginal; N=20; C-Section; N=5), high stress (PSS > 14; Vaginal; N=20; C-
Section; N=5). Unpaired students t-test and Mann-Whitney-Wilcoxon test. 
Abbreviations: Operational taxonomic unit (OTU), Perceived Stress Scale (PSS) 
 
Table 44: Infant gut at 3 weeks old by 3rd trimester anxiety 
OTU Relative Abundance (%) 
3 weeks old Low STAI High STAI p-value 
Chao1 Index 82.3 81.9 t(38) = 0.05, p=0.955 
Simpson Index 0.7 0.7 t(38) =-0.94, p=0.353 
Shannon Index 2.7 2.8 t(38) =-0.46,p=0.647 
Phylogenetic diversity 4.4 4.4 t(38) =-0.16,p=0.870 
Observed Species 60.8 57.2 t(38) = 1.12, p=0269 
Actinobacteria 50.6 39.1 W=259, p=0.100 
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Bacteroidetes 9.5 13.5 W=203, p=0.902 
Firmicutes 36.2 43.6 W=171, p=0.475 
Proteobacteria 3.4 3.6 W=201, p=0.945 
Bifidobacteriaceae 34.4 29.0 W=210, p=0.757 
Corynebacteriaceae 0.0 0.0 W=285.5, 0.015 
Nocardiaceae 14.2 7.7 W=265, p=0.070 
Coriobacteriaceae 1.2 1.8 W=209.5, p=0.763 
Bacteroidaceae 7.8 12.8 W=194, p=0.924 
Porphyromonadaceae 1.7 0.5 W=231.5, p=0.366 
Staphylococcaceae 3.4 1.2 W=224.5, p=0.479 
Enterococcaceae 1.6 1.3 W=203, p=0.902 
Lactobacillaceae 1.6 3.1 W=138.5, p=0.107 
Streptococcaceae 7.3 5.8 W=225, p=0.475 
Clostridiaceae1 9.0 12.4 W=186.5, p=0.764 
Lachnospiraceae 6.4 10.0 W=150.5, p=0.201 
Veillonellaceae 5.7 7.7 W=147, p=0.171 
Enterobacteriaceae 3.3 2.4 W=239, p=0.270 
Bifidobacterium 34.4 29.0 W=210, p=0.757 
Corynebacterium 0.0 0.0 W=298.5, p=0.004 
Rhodococcus 14.2 7.7 W=265, p=0.070 
Collinsella 1.0 1.7 W=178.5, p=0.592 
Bacteroides 7.8 12.8 W=194, p=0.924 
Staphylococcus 3.4 1.2 W=224.5, p=0.479 
Enterococcus 1.6 1.3 W=203, p=0.902 
Lactobacillus 1.6 3.1 W=138.5, p=0.107 
Streptococcus 7.3 5.8 W=225, p=0.475 
Clostridiumsensustricto1 9.0 12.4 W=184, p=0.713 
LachnospiraceaeIncertaeSedis 3.7 8.9 W=142, p=0.131 
Lachnospiraceaeuncultured 1.1 0.9 W=156, p=0.230 
Veillonella 4.5 7.7 W=128, p=0.058 
Enterobacter 1.3 0.5 W=190.5, p=0.847 
EscherichiaShigella 1.7 1.5 W=280, p=0.026 
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Supplementary table 44: Relative abundance of bacterial OTUs in the infant gut at 3 
weeks old by maternal anxiety in the 3rd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low anxiety (STAI < 4; Vaginal; N=22; C-Section; N=6), high anxiety (STAI > 5; Vaginal; 
N=18; C-Section; N=4). Unpaired students t-test and Mann-Whitney-Wilcoxon test. 
Abbreviations: Operational taxonomic unit (OTU), State Trait Anxiety Inventory (STAI).  
 
Table 45: Infant gut at 3 weeks old by 3rd trimester depressive symptoms 
OTU Relative Abundance (%) 
3 weeks old Low EPDS High EPDS p-value 
Chao1 Index 83.3 79.3 t(38) = 0.43, p=0.664 
Simpson Index 0.7 0.7 t(38) =-0.44, p=0.657 
Shannon Index 2.7 2.8 t(38) =-0.21,p=0.830 
Phylogenetic diversity 4.5 4.2 t(38) = 0.85,p=0.395 
Observed Species 60.4 55.9 t(38) = 1.26, p=0.211 
Actinobacteria 49.2 35.6 W=221, p=0.064 
Bacteroidetes 8.8 17.8 W=127, p=0.332 
Firmicutes 38.6 42.0 W=145, p=0.676 
Proteobacteria 3.1 4.4 W=149, p=0.762 
Bifidobacteriaceae 33.2 28.6 W=171, p=0.742 
Corynebacteriaceae 0.0 0.0 W=226, p=0.040 
Nocardiaceae 14.0 4.3 W=222.5, p=0.058 
Coriobacteriaceae 1.2 2.1 W=159.5, p=1 
Bacteroidaceae 7.6 16.5 W=119.5, p=0.231 
Porphyromonadaceae 1.2 1.0 W=126, p=0.314 
Staphylococcaceae 2.9 1.2 W=171, p=0.738 
Enterococcaceae 1.3 1.7 W=137.5, p=0.513 
Lactobacillaceae 2.2 2.3 W=168.5, p=0.796 
Streptococcaceae 7.5 4.4 W=202, p=0.206 
Clostridiaceae1 9.0 14.8 W=164, p=0.903 
Lachnospiraceae 7.7 9.0 W=150, p=0.785 
Veillonellaceae 6.5 6.9 W=130, p=0.385 
Enterobacteriaceae 2.6 3.4 W=190, p=0.363 
Bifidobacterium 33.2 28.6 W=171, p=0.742 
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Corynebacterium 0.0 0.0 W=235.5, p=0.017 
Rhodococcus 14.0 4.3 W=222.5, p=0.058 
Collinsella 1.0 2.0 W=156, p=0.925 
Bacteroides 7.6 16.5 W=119.5, p=0.231 
Coprobacter 0.0 0.0 W=130.5, p=0.022 
Staphylococcus 2.9 1.2 W=171, p=0.738 
Enterococcus 1.3 1.7 W=137.5, p=0.513 
Lactobacillus 2.2 2.3 W=168.5, p=0.796 
Streptococcus 7.5 4.4 W=202, p=0.206 
Clostridiumsensustricto1 8.9 14.8 W=163, p=0.927 
LachnospiraceaeIncertaeSedis 5.0 8.9 W=133.5, p=0.439 
Lachnospiraceaeuncultured 1.4 0.0 W=149, p=0.747 
Veillonella 5.6 6.9 W=117, p=0.203 
Enterobacter 1.0 0.8 W=179, p=0.560 
EscherichiaShigella 1.4 2.1 W=233, p=0.026 
Supplementary table 45: Relative abundance of bacterial OTUs in the infant gut at 3 
weeks old by maternal depressive symptoms in the 3rd trimester. Listed are all OTUs with 
an abundance of greater than 1% and significant OTUs with an abundance of less than 
1%. Low depressive (EPDS < 8; Vaginal; N=29; C-Section; N=9), high depressive (EPDS > 
9; Vaginal; N=11; C-Section; N=1). Unpaired students t-test and Mann-Whitney-
Wilcoxon test. Abbreviations: Operational taxonomic unit (OTU), Edinburgh Postnatal 
Depression Scale (EPDS).  
 
Table 46: Infant gut at 3 weeks old by 3rd trimester cortisol 
OTU Relative Abundance (%) 
3 weeks old Low CAR High CAR p-value 
Chao1 Index 79.3 90.3 t(35) =-1.29, p=0.202 
Simpson Index 0.7 0.7 t(35) =-0.62, p=0.535 
Shannon Index 2.7 2.9 t(35) =-0.83,p=0.407 
Phylogenetic diversity 4.2 4.5 t(35) =-0.87,p=0.384 
Observed Species 56.3 61.2 t(35) = 1.02, p=0.313 
Actinobacteria 48.7 44.3 W=191, p=0.557 
Bacteroidetes 7.5 14.0 W=149, p=0.513 
Firmicutes 41.7 35.7 W=197, p=0.443 
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Proteobacteria 1.9 5.8 W=135, p=0.284 
Bifidobacteriaceae 29.7 34.7 W=159, p=0.729 
Nocardiaceae 13.6 8.5 W=205.5, p=0.301 
Coriobacteriaceae 4.7 0.3 W=156.5, p=0.669 
Bacteroidaceae 6.5 12.0 W=141, p=0.369 
Porphyromonadaceae 0.9 1.9 W=187, p=0.634 
Staphylococcaceae 2.6 2.5 W=147.5, p=0.484 
Enterococcaceae 1.8 1.2 W=197, p=0.437 
Lactobacillaceae 3.2 1.1 W=185.5, p=0.669 
Streptococcaceae 5.3 7.3 W=141, p=0.374 
Clostridiaceae1 14.4 8.5 W=190, p=0.573 
Lachnospiraceae 7.3 6.6 W=178, p=0.843 
Veillonellaceae 5.2 7.4 W=143.5, p=0.411 
Enterobacteriaceae 1.0 5.3 W=146, p=0.456 
Bifidobacterium 29.7 34.7 W=159, p=0.729 
Rhodococcus 13.6 8.5 W=205.5, p=0.301 
Collinsella 4.6 0.2 W=163.5, p=0.828 
Bacteroides 6.5 12.0 W=141, p=0.369 
Staphylococcus 2.6 2.5 W=147.5, p=0.484 
Enterococcus 1.8 1.2 W=197, p=0.437 
Lactobacillus 3.2 1.1 W=185.5, p=0.669 
Lactococcus 0.0 0.0 W=225, p=0.010 
Streptococcus 5.3 7.3 W=141, p=0.374 
Clostridiumsensustricto1 14.4 8.5 W=191, p=0.553 
LachnospiraceaeIncertaeSedis 5.6 5.2 W=187, p=0.637 
Lachnospiraceaeuncultured 0.5 1.4 W=152, p=0.552 
Megamonas 0.0 0.0 W=153.5, p=0.034 
Veillonella 4.3 7.4 W=125, p=0.166 
Enterobacter 0.4 1.8 W=127, p=0.181 
EscherichiaShigella 0.5 2.9 W=171.5, p=1 
Supplementary table 46: Relative abundance of bacterial OTUs in the infant gut at 3 
weeks old by maternal cortisol in the 3rd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low cortisol (CAR < 562349; Vaginal; N=19; C-Section; N=5), high cortisol (CAR > 562350; 
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Vaginal; N=18; C-Section; N=6). Unpaired students t-test and Mann-Whitney-Wilcoxon 
test. Abbreviations: Operational taxonomic unit (OTU), Cortisol Awakening Response 
(CAR).  
 
Table 47: Infant gut at 3 months old by 2nd trimester stress 
OTU Relative Abundance (%) 
3 months old Low PSS High PSS p-value 
Chao1 Index 76.5 92.9 t(30) =-2.36, p=0.024 
Simpson Index 0.7 0.8 t(30) =-2.23, p=0.032 
Shannon Index 2.6 3.2 t(30) =-2.31,p=0.028 
Phylogenetic diversity 4.7 5.1 t(30) =-1.17,p=0.250 
Observed Species 60.0 67.0 t(30) =-1.49, p=0.313 
Actinobacteria 58.3 39.5 W=180, p=0.051 
Bacteroidetes 11.2 10.3 W=139, p=0.692 
Candidate division TM7 0.0 0.0 W=86, P=0.030 
Firmicutes 27.6 47.3 W=66, p=0.018 
Proteobacteria 1.2 2.6 W=105.5, p=0.406 
Bifidobacteriaceae 52.4 30.1 W=184, p=0.036 
Nocardiaceae 3.5 7.6 W=100, p=0.304 
Coriobacteriaceae 2.1 1.2 W=145.5, p=0.520 
Bacteroidaceae 9.1 8.8 W=142, p=0.615 
Porphyromonadaceae 2.0 1.5 W=135.5, p=0.787 
Candidate division TM7 uncultured 0.0 0.0 W=86, P=0.030 
Enterococcaceae 0.7 1.6 W=144, p=0.558 
Lactobacillaceae 2.3 0.5 W=203, p=0.004 
Streptococcaceae 2.1 1.9 W=104, p=0.375 
Clostridiaceae1 1.5 7.7 W=103.5, p=0.365 
Lachnospiraceae 10.6 20.1 W=89, p=0.148 
Erysipelotrichaceae 0.2 4.6 W=55.5, p=0.005 
Veillonellaceae 8.5 7.4 W=156, p=0.300 
Enterobacteriaceae 1.0 2.3 W=105, p=0.396 
Actinobaculum 0.0 0.0 W=88, P=0.018 
Bifidobacterium 52.4 30.1 W=184, p=0.036 
 393 
 
 
Rhodococcus 3.5 7.6 W=100, p=0.304 
Collinsella 1.8 1.0 W=138, p=0.701 
Bacteroides 9.1 8.8 W=142, p=0.615 
Prevotella 0.0 0.0 W=135, p=0.698 
Carnobacterium 0.0 0.0 W=74, P=0.023 
Enterococcus 0.7 1.6 W=144, p=0.558 
Lactobacillus 2.3 0.5 W=203, p=0.004 
Streptococcus 2.1 1.9 W=104, p=0.375 
Clostridiumsensustricto1 1.5 7.7 W=103.5, p=0.365 
Anaerococcus 0.0 0.1 W=79.5, p=0.027 
Blautia 1.5 5.1 W=94.5, p=0.210 
Coprococcus 0.0 0.3 W=96, p=0.038 
LachnospiraceaeIncertaeSedis 8.6 12.0 W=100, p=0.163 
Lachnospiraceaeuncultured 0.0 1.4 W=74.5, p=0.043 
Flavonifractor 0.0 0.5 W-80, p=0.034 
Erysipelotrichaceae Incertae Sedis 0.2 4.6 W=67, p=0.017 
Veillonella 8.5 6.5 W=169, p=0.126 
Enterobacter 0.4 0.6 W=111, p=0.531 
Supplementary table 47: Relative abundance of bacterial OTUs in the infant gut at 3 
months old by maternal stress in the 2nd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low stress (PSS < 13; Vaginal; N=16; C-Section; N=7), high stress (PSS > 14; Vaginal; 
N=26; C-Section; N=3). Unpaired students t-test and Mann-Whitney-Wilcoxon test. 
Abbreviations: Operational taxonomic unit (OTU), Perceived Stress Scale (PSS). 
 
Table 48: Infant gut at 3 months old by 2nd trimester anxiety 
OTU Relative Abundance (%) 
3 months old Low STAI High STAI p-value 
Chao1 Index 85.6 82.4 t(30) = 0.39, p=0.696 
Simpson Index 0.7 0.7 t(30) =-0.81, p=0.420 
Shannon Index 2.8 3.0 t(30) =-0.79,p=0.434 
Phylogenetic diversity 5.0 4.7 t(30) = 0.66,p=0.510 
Observed Species 63.9 62.4 t(30) = 0.28, p=0.779 
Actinobacteria 50.2 45.6 W=113, p=0.711 
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Bacteroidetes 12.3 6.8 W=123, p=0.425 
Candidate division TM7 0.0 0.0 W=87.5, p=0.369 
Firmicutes 34.4 45.0 W=79, p=0.320 
Proteobacteria 1.7 2.4 W=81, p=0.356 
Bifidobacteriaceae 42.2 38.8 W=106.5, p=0.916 
Nocardiaceae 6.3 3.5 W=151, p=0.047 
Propionibacteriaceae 0.0 0.0 W=100.5, p=0.835 
Coriobacteriaceae 1.1 2.9 W=68, p=0.141 
Bacteroidaceae 10.1 6.0 W=118, p=0.564 
Porphyromonadaceae 2.1 0.8 W=125, p=0.368 
Candidate division TM7 uncultured 0.0 0.0 W=87.5, p=0.369 
Enterococcaceae 0.9 1.8 W=62.5, p=0.088 
Lactobacillaceae 1.1 2.2 W=108.5, p=0.849 
Streptococcaceae 2.4 1.0 W=132, p=0.240 
Clostridiaceae1 3.4 7.7 W=52, p=0.032 
Lachnospiraceae 15.2 15.9 W=96, p=0.773 
Peptostreptococcaceae 0.5 1.2 W=54, p=0.037 
Erysipelotrichaceae 0.6 7.0 W=90.5, p=0.591 
Veillonellaceae 8.5 6.4 W=110.5, p=0.785 
Enterobacteriaceae 1.4 2.3 W=74.5, p=0.232 
Bifidobacterium 42.2 38.8 W=106.5, p=0.916 
Rhodococcus 6.3 3.5 W=151, p=0.047 
Collinsella 1.0 2.5 W=113, p=0.686 
Eggerthella 0.1 0.4 W=56.5, p=0.041 
Bacteroides 10.1 6.0 W=118, p=0.564 
Enterococcus 0.9 1.8 W=62.5, p=0.088 
Lactobacillus 1.1 2.2 W=108.5, p=0.849 
Streptococcus 2.4 1.0 W=132, p=0.240 
Clostridiumsensustricto1 3.4 7.7 W=52, p=0.032 
Blautia 2.1 6.5 W=79, p=0.311 
Coprococcus 0.0 0.4 W=73, p=0.028 
LachnospiraceaeIncertaeSedis 11.2 8.0 W=106, p=0.934 
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Lachnospiraceaeuncultured 0.8 0.4 W=103.5, p=1 
Ruminococcus 0.1 0.0 W=144, p=0.034 
Erysipelotrichaceae Incertae Sedis 0.6 7.0 W=94, p=0.693 
Veillonella 8.0 6.4 W=103.5, p=1 
Enterobacter 0.4 0.8 W=70.5, p=0.170 
Supplementary table 48: Relative abundance of bacterial OTUs in the infant gut at 3 
months old by maternal anxiety in the 2nd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low anxiety (STAI < 4; Vaginal; N=23; C-Section; N=4), high anxiety (STAI > 5; Vaginal; 
N=9; C-Section; N=6). Unpaired students t-test and Mann-Whitney-Wilcoxon test. 
Abbreviations: Operational taxonomic unit (OTU), State Trait Anxiety Inventory (STAI).  
 
Table 49: Infant gut at 3 months old by 2nd trimester depressive symptoms 
OTU Relative Abundance (%) 
3 months old Low EPDS High EPDS p-value 
Chao1 Index 83.4 91.9 t(30) =-0.82, p=0.413 
Simpson Index 0.7 0.7 t(30) = 0.59, p=0.554 
Shannon Index 2.9 2.8 t(30) = 0.34,p=0.735 
Phylogenetic diversity 4.9 5.0 t(30) =-0.11,p=0.910 
Observed Species 63.3 64.6 t(30) =-0.19, p=0.850 
Actinobacteria 50.1 42.2 W=72, p=0.840 
Bacteroidetes 11.5 6.8 W=73, p=0.795 
Firmicutes 35.5 47.9 W=50, p=0.389 
Proteobacteria 1.7 2.9 W=45.5, p=0.264 
Bifidobacteriaceae 41.8 38.7 W=69.5, p=0.937 
Nocardiaceae 6.2 2.2 W=88, p=0.309 
Coriobacteriaceae 1.8 0.6 W=46.5, p=0.286 
Bacteroidaceae 9.3 6.8 W=68, p=1 
Porphyromonadaceae 2.1 0.0 W=94.5, p=0.159 
Enterococcaceae 0.9 2.6 W=47, p=0.298 
Lactobacillaceae 1.7 0.1 W=94.5, p=0.166 
Streptococcaceae 1.8 3.4 W=66, p=0.958 
Clostridiaceae1 4.8 3.7 W=69, p=0.958 
Lachnospiraceae 15.8 12.9 W=79, p=0.579 
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Erysipelotrichaceae 0.5 12.5 W=43, p=0.202 
Veillonellaceae 7.5 10.4 W=56.5, p=0.585 
Neisseriaceae 0.0 0.0 W=54, p=0.025 
Moraxellaceae 0.0 0.0 W=27.5, p=0.013 
Xanthomonadaceae 0.0 0.0 W=54, p=0.025 
Enterobacteriaceae 1.4 2.7 W=50, p=0.377 
Bifidobacterium 41.8 38.7 W=69.5, p=0.937 
Scardovia 0.0 0.0 W=54, p=0.025 
Corynebacterium 0.0 0.0 W=30.5, p=0.021 
Rhodococcus 6.2 2.2 W=88, p=0.309 
Collinsella 1.7 0.0 W=75.5, p=0.676 
Coriobacteriaceae uncultured 0.0 0.0 W=54, p=0.025 
Bacteroides 9.3 6.8 W=68, p=1 
Enterococcus 0.9 2.6 W=47, p=0.298 
Lactobacillus 1.7 0.1 W=94.5, p=0.166 
Streptococcus 1.8 3.4 W=66, p=0.958 
Clostridiumsensustricto1 4.8 3.7 W=69, p=0.958 
Blautia 3.1 4.4 W=60.5, p=0.734 
Coprococcus 0.0 0.8 W=43.5, p=0.033 
LachnospiraceaeIncertaeSedis 10.9 6.9 W=83, p=0.448 
Marvinbryantia 0.0 0.0 W=54, p=0.025 
Lachnospiraceaeuncultured 0.7 0.5 W=46.5, p=0.282 
Erysipelotrichaceae Incertae Sedis 0.5 12.5 W=52, p=0.415 
Turicibacter 0.0 0.0 W=54, p=0.025 
Veillonella 7.0 10.4 W=54.5, p=0.516 
Neisseria 0.0 0.0 W=54, p=0.025 
Enterobacter 0.5 0.7 W=59.5, p=0.695 
Stenotrophomonas 0.0 0.0 W=54, p=0.025 
Supplementary table 49: Relative abundance of bacterial OTUs in the infant gut at 3 
months old by maternal depressive symptoms in the 2nd trimester. Listed are all OTUs 
with an abundance of greater than 1% and significant OTUs with an abundance of less 
than 1%. Low depressive (EPDS < 8; Vaginal; N=27; C-Section; N=10), high depressive 
(EPDS > 9; Vaginal; N=5; C-Section; N=0). Unpaired students t-test and Mann-Whitney-
Wilcoxon test. Abbreviations: Operational taxonomic unit (OTU), Edinburgh Postnatal 
Depression Scale (EPDS).  
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Table 50: Infant gut at 3 months old by 2nd trimester cortisol 
OTU Relative Abundance (%) 
3 months old Low CAR High CAR p-value 
Chao1 Index 89.3 80.5 t(26) = 1.02, p=0.313 
Simpson Index 0.7 0.7 t(26) = 0.46, p=0.646 
Shannon Index 2.9 2.9 t(26) =-0.02,p=0.978 
Phylogenetic diversity 5.2 4.9 t(26) = 0.81,p=0.424 
Observed Species 66.8 62.1 t(26) = 0.88, p=0.384 
Actinobacteria 51.4 47.8 W=107, p=0.631 
Bacteroidetes 9.1 10.3 W=112, p=0.443 
Firmicutes 37.6 38.2 W=102, p=0.801 
Proteobacteria 1.1 2.6 W=62, p=0.119 
Bifidobacteriaceae 39.8 44.2 W=89, p=0.762 
Nocardiaceae 6.9 2.8 W=111, p=0.507 
Coriobacteriaceae 4.3 0.3 W=148.5, p=0.015 
Bacteroidaceae 7.9 8.2 W=120, p=0.280 
Porphyromonadaceae 1.2 2.1 W=98, p=0.943 
Enterococcaceae 1.2 1.1 W=83.5, p=0.577 
Lactobacillaceae 1.1 1.9 W=70.5, p=0.241 
Streptococcaceae 2.2 2.3 W=86, p=0.659 
Clostridiaceae1 5.1 5.0 W=81, p=0.500 
Lachnospiraceae 12.5 16.9 W=93, p=0.909 
Erysipelotrichaceae 3.7 2.1 W=107, p=0.614 
Veillonellaceae 10.0 5.9 W=124, p=0.205 
Enterobacteriaceae 0.9 2.2 W=66.5, p=0.177 
Bifidobacterium 39.8 44.2 W=89, p=0.762 
Rhodococcus 6.9 2.8 W=111, p=0.507 
Collinsella 4.0 0.1 W=142, p=0.027 
Bacteroides 7.9 8.2 W=120, p=0.280 
Enterococcus 1.2 1.2 W=83.5, p=0.577 
Lactobacillus 1.1 1.9 W=70.5, p=0.241 
Streptococcus 2.2 2.3 W=86, p=0.659 
Clostridiumsensustricto1 5.1 5.0 W=81, p=0.500 
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Blautia 4.3 3.7 W=83, p=0.559 
LachnospiraceaeIncertaeSedis 7.3 11.0 W=86, p=0.664 
Lachnospiraceaeuncultured 0.4 0.8 W=103, p=0.760 
Erysipelotrichaceae Incertae Sedis 3.7 2.1 W=106, p=0.641 
Veillonella 8.9 5.9 W=109, p=0.567 
Enterobacter 0.3 0.6 W=71.5, p=0.262 
Supplementary table 50: Relative abundance of bacterial OTUs in the infant gut at 3 
months old by maternal cortisol in the 2nd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low cortisol (CAR < 545131; Vaginal; N=12; C-Section; N=6), high cortisol (CAR > 545132; 
Vaginal; N=16; C-Section; N=3). Unpaired students t-test and Mann-Whitney-Wilcoxon 
test. Abbreviations: Operational taxonomic unit (OTU), Cortisol Awakening Response 
(CAR).  
 
Table 51: Infant gut at 3 months old by 3rd trimester stress 
OTU Relative Abundance (%) 
3 months old Low PSS High PSS p-value 
Chao1 Index 90.5 82.8 t(28) = 0.72, p=0.472 
Simpson Index 0.7 0.7 t(28) = 0.81, p=0.423 
Shannon Index 2.9 2.7 t(28) = 0.78,p=0.48 
Phylogenetic diversity 4.8 4.8 t(28) = 0.10,p=0.913 
Observed Species 63.2 58.6 t(28) = 0.93, p=0.357 
Actinobacteria 47.2 51.8 W=93, p=0.482 
Bacteroidetes 13.1 9.6 W=109.5, p=0.983 
Firmicutes 35.5 34.1 W=112, p=0.967 
Proteobacteria 3.0 3.2 W=89.5, p=0.390 
Bifidobacteriaceae 37.7 46.5 W=93, p=0.476 
Nocardiaceae 7.1 3.6 W=171, p=0.010 
Coriobacteriaceae 2.0 1.3 W=136.5, p=0.284 
Bacteroidaceae 11.0 8.5 W=111, p=1 
Porphyromonadaceae 2.0 1.1 W=114.5, p=0.881 
Enterococcaceae 0.2 2.2 W=64.5, p=0.055 
Lactobacillaceae 1.0 1.6 W=84.5, p=0.282 
Streptococcaceae 2.2 3.3 W=102, p=0.741 
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Clostridiaceae1 5.8 4.5 W=112, p=0.966 
Lachnospiraceae 15.1 9.8 W=127, p=0.508 
Erysipelotrichaceae 0.4 3.5 W=98.5, p=0.610 
Veillonellaceae 8.7 6.4 W=137, p=0.276 
Enterobacteriaceae 2.7 2.9 W=99, p=0.645 
Bifidobacterium 37.7 46.5 W=93, p=0.476 
Rhodococcus 7.1 3.6 W=171, p=0.010 
Collinsella 1.8 1.1 W=136, p=0.262 
Bacteroides 11.0 8.5 W=111, p=1 
Enterococcus 0.2 2.2 W=64.5, p=0.055 
Lactobacillus 1.0 1.6 W=84.5, p=0.282 
Streptococcus 2.2 3.3 W=102, p=0.741 
Clostridiumsensustricto1 5.8 4.5 W=112, p=0.966 
Blautia 3.4 0.9 W=113.5, p=0.915 
LachnospiraceaeIncertaeSedis 9.5 8.4 W=125, p=0.563 
Lachnospiraceaeuncultured 0.9 0.2 W=117, p=0.797 
Peptostreptococcus 0.0 0.0 W=85, p=0.044 
Erysipelotrichaceae Incertae Sedis 0.4 3.5 W=116.5, p=0.801 
Megamonas 0.0 0.0 W=85, p=0.044 
Megasphaera 0.0 0.0 W=149.5, p=0.021 
Veillonella 8.7 6.4 W=137, p=0.276 
Enterobacter 1.3 1.6 W=96.5, p=0.570 
Supplementary table 51: Relative abundance of bacterial OTUs in the infant gut at 3 
months old by maternal stress in the 3rd trimester. Listed are all OTUs with an abundance 
of greater than 1% and significant OTUs with an abundance of less than 1%. Low stress 
(PSS < 11; Vaginal; N=17; C-Section; N=4), high stress (PSS > 12; Vaginal; N=13; C-
Section; N=4). Unpaired students t-test and Mann-Whitney-Wilcoxon test. 
Abbreviations: Operational taxonomic unit (OTU), Perceived Stress Scale (PSS). 
 
Table 52: Infant gut at 3 months old by 3rd trimester anxiety 
OTU Relative Abundance (%) 
3 months old Low STAI High STAI p-value 
Chao1 Index 86.6 88.4 t(28) =-0.16, p=0.871 
Simpson Index 0.7 0.7 t(28) =-0.38, p=0.704 
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Shannon Index 2.8 2.8 t(28) =-0.14,p=0.884 
Phylogenetic diversity 4.8 5.0 t(28) =-0.54,p=0.587 
Observed Species 61.4 61.0 t(28) = 0.08, p=0.932 
Actinobacteria 48.2 51.1 W=94, p=0.812 
Bacteroidetes 12.3 10.2 W=90.5, p=0.692 
Firmicutes 34.7 35.3 W=89, p=0.649 
Proteobacteria 3.7 1.9 W=104.5, p=0.860 
Bifidobacteriaceae 40.3 44.0 W=98, p=0.947 
Nocardiaceae 5.8 5.2 W=113, p=0.588 
Coriobacteriaceae 1.8 1.5 W=102.5, p=0.929 
Bacteroidaceae 10.2 9.3 W=89, p=0.649 
Porphyromonadaceae 2.1 0.8 W=106.5, p=0.787 
Enterococcaceae 0.8 1.5 W=72.5, p=0.233 
Lactobacillaceae 1.1 1.5 W=90.5, p=0.690 
Streptococcaceae 3.1 1.9 W=126, p=0.267 
Clostridiaceae1 5.0 5.7 W=99, p=0.982 
Lachnospiraceae 13.4 11.7 W=99, p=0.982 
Erysipelotrichaceae 0.3 4.6 W=63, p=0.088 
Veillonellaceae 8.4 6.3 W=121, p=0.367 
Enterobacteriaceae 3.4 1.6 W=107, p=0.774 
Trueperella 0.0 0.0 W=80, p=0.047 
Bifidobacterium 40.3 44.0 W=98, p=0.947 
Rhodococcus 5.8 5.2 W=113, p=0.588 
Collinsella 1.6 1.2 W=138, p=0.077 
Bacteroides 10.2 9.3 W=89, p=0.649 
Enterococcus 0.8 1.5 W=72.5, p=0.233 
Lactobacillus 1.1 1.5 W=90.5, p=0.690 
Streptococcus 3.1 1.9 W=126, p=0.267 
Clostridiumsensustricto1 5.0 5.7 W=99, p=0.982 
Anaerococcus 0.1 0.0 W=50, p=0.011 
Blautia 2.8 1.2 W=100.5, p=1 
LachnospiraceaeIncertaeSedis 8.7 9.7 W=98, p=0.948 
Lachnospiraceaeuncultured 0.7 0.2 W=96.5, p=0.892 
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Erysipelotrichaceae Incertae Sedis 0.3 4.6 W=70.5, p=0.164 
Veillonella 8.4 6.3 W=121, p=0.367 
Enterobacter 1.9 0.7 W=120, p=0.388 
Supplementary table 52: Relative abundance of bacterial OTUs in the infant gut at 3 
months old by maternal anxiety in the 3rd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low anxiety (STAI < 4; Vaginal; N=20; C-Section; N=5), high anxiety (STAI > 5; Vaginal; 
N=10; C-Section; N=3). Unpaired students t-test and Mann-Whitney-Wilcoxon test. 
Abbreviations: Operational taxonomic unit (OTU), State Trait Anxiety Inventory (STAI).  
 
Table 53: Infant gut at 3 months old by 3rd trimester depressive symptoms 
OTU Relative Abundance (%) 
3 months old Low EPDS High EPDS p-value 
Chao1 Index 88.4 84.4 t(28) = 0.34, p=0.735 
Simpson Index 0.7 0.7 t(28) = 0.82, p=0.415 
Shannon Index 2.9 2.6 t(28) = 1.03,p=0.311 
Phylogenetic diversity 4.8 4.8 t(28) = 0.12,p=0.899 
Observed Species 62.9 57.4 t(28) = 1.03, p=0.307 
Actinobacteria 46.8 54.9 W=72, p=0.325 
Bacteroidetes 11.9 10.7 W=85.5, p=0.700 
Firmicutes 36.7 30.8 W=104, p=0.689 
Proteobacteria 3.6 1.9 W=95.5, p=0.981 
Bifidobacteriaceae 39.0 47.5 W=79, p=0.497 
Nocardiaceae 5.6 5.5 W=109, p=0.533 
Coriobacteriaceae 1.7 1.7 W=94.5, p=1 
Bacteroidaceae 9.7 10.3 W=76, p=0.422 
Porphyromonadaceae 2.2 0.4 W=112.5, p=0.419 
Enterococcaceae 0.7 1.9 W=62, p=0.145 
Lactobacillaceae 1.2 1.5 W=95.5, p=0.981 
Streptococcaceae 2.9 2.1 W=111, p=0.476 
Clostridiaceae1 6.4 2.4 W=121, p=0.239 
Lachnospiraceae 14.8 8.2 W=111, p=0.476 
Erysipelotrichaceae 0.5 4.7 W=86.5, p=0.719 
Veillonellaceae 7.4 8.4 W=94, p=1 
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Enterobacteriaceae 3.3 1.7 W=100.5, p=0.803 
Bifidobacterium 39.0 47.5 W=79, p=0.497 
Rhodococcus 5.6 5.5 W=109, p=0.533 
Collinsella 1.5 1.4 W=115, p=0.332 
Bacteroides 9.7 10.3 W=76, p=0.422 
Enterococcus 0.7 1.9 W=62, p=0.145 
Lactobacillus 1.2 1.5 W=95.5, p=0.981 
Streptococcus 2.9 2.1 W=111, p=0.476 
Clostridiumsensustricto1 6.4 2.4 W=121, p=0.239 
Blautia 2.8 1.2 W=120, p=0.252 
LachnospiraceaeIncertaeSedis 10.2 6.2 W=112, p=0.448 
Lachnospiraceaeuncultured 0.7 0.2 W=104.5, p=0.659 
Erysipelotrichaceae Incertae Sedis 0.5 4.7 W=93, p=0.960 
Veillonella 7.4 8.3 W=94, p=1 
Enterobacter 1.8 0.7 W=116, p=0.339 
Supplementary table 53: Relative abundance of bacterial OTUs in the infant gut at 3 
months old by maternal depressive symptoms in the 3rd trimester. Listed are all OTUs 
with an abundance of greater than 1% and significant OTUs with an abundance of less 
than 1%. Low depressive (EPDS < 8; Vaginal; N=21; C-Section; N=7), high depressive 
(EPDS > 9; Vaginal; N=9; C-Section; N=1). Unpaired students t-test and Mann-Whitney-
Wilcoxon test. Abbreviations: Operational taxonomic unit (OTU), Edinburgh Postnatal 
Depression Scale (EPDS).  
 
Table 54: Infant gut at 3 months old by 3rd trimester cortisol 
OTU Relative Abundance (%) 
3 months old Low CAR High CAR p-value 
Chao1 Index 84.0 100.1 t(30) =-1.72, p=0.094 
Simpson Index 0.7 0.7 t(30) = 1.44, p=0.158 
Shannon Index 3.0 2.7 t(30) = 0.92,p=0.362 
Phylogenetic diversity 5.1 4.9 t(30) = 0.56,p=0.578 
Observed Species 64.5 63.6 t(30) = 0.17, p=0.858 
Actinobacteria 47.1 57.3 W=70, p=0.040 
Bacteroidetes 12.9 7.8 W=154, p=0.249 
Firmicutes 36.2 31.8 W=155, p=0.238 
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Proteobacteria 1.9 2.8 W=105, p=0.489 
Bifidobacteriaceae 36.8 50.8 W=69, p=0.036 
Nocardiaceae 5.5 4.3 W=147, p=0.382 
Coriobacteriaceae 4.4 1.6 W=146, p=0.398 
Bacteroidaceae 10.3 6.9 W=146, p=0.404 
Porphyromonadaceae 2.5 0.9 W=159.5, p=0.167 
Enterococcaceae 0.4 1.9 W=120.5, p=0.923 
Lactobacillaceae 1.5 1.1 W=143, p=0.462 
Streptococcaceae 2.0 3.8 W=86, p=0.157 
Clostridiaceae1 5.6 1.7 W=140.5, p=0.526 
Lachnospiraceae 15.0 11.5 W=165, p=0.116 
Erysipelotrichaceae 0.3 3.7 W=112.5, p=0.673 
Veillonellaceae 9.5 5.2 W=162, p=0.144 
Enterobacteriaceae 1.6 2.6 W=106, p=0.514 
Actinomyces 0.1 0.2 W=69.5, p=0.038 
Bifidobacterium 36.8 50.8 W=69, p=0.036 
Rhodococcus 5.5 4.3 W=147, p=0.382 
Collinsella 4.2 1.3 W=132, p=0.752 
Bacteroides 10.3 6.9 W=146, p=0.404 
Odoribacter 0.2 0.0 W=169, p=0.016 
Enterococcus 0.4 1.9 W=120.5, p=0.923 
Lactobacillus 1.5 1.1 W=143, p=0.462 
Streptococcus 2.0 3.8 W=86, p=0.157 
Clostridiumsensustricto1 5.6 1.7 W=140.5, p=0.526 
Blautia 3.4 2.5 W=130, p=0.816 
LachnospiraceaeIncertaeSedis 10.5 6.8 W=161, p=0.157 
Lachnospiraceaeuncultured 0.5 0.9 W=108, p=0.557 
Erysipelotrichaceae Incertae Sedis 0.3 3.7 W=127.5, p=0.885 
Veillonella 8.8 5.1 W=153, p=0.265 
Enterobacter 1.0 0.8 W=115, p=0.758 
Supplementary table 54: Relative abundance of bacterial OTUs in the infant gut at 3 
months old by maternal cortisol in the 3rd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low cortisol (CAR < 562349; Vaginal; N=19; C-Section; N=5), high cortisol (CAR > 552350; 
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Vaginal; N=13; C-Section; N=4). Unpaired students t-test and Mann-Whitney-Wilcoxon 
test. Abbreviations: Operational taxonomic unit (OTU), Cortisol Awakening Response 
(CAR).  
 
Table 55: Infant gut at 5 months old by 2nd trimester stress 
OTU Relative Abundance (%) 
5 months old Low PSS High PSS p-value 
Chao1 Index 87.5 115.4 t(20) =-1.92, p=0.069 
Simpson Index 0.6 0.8 t(20) =-3.02, p=0.006 
Shannon Index 2.4 3.3 t(20) =-2.60,p=0.016 
Phylogenetic diversity 5.2 6.3 t(20) =-2.13,p=0.045 
Observed Species 64.1 83.5 t(20) =-2.28, p=0.033 
Actinobacteria 59.2 44.8 W=66, p=0.203 
Bacteroidetes 12.4 13.8 W=48.5, p=1 
Firmicutes 28.0 39.3 W=34, p=0.329 
Proteobacteria 0.1 0.8 W=21.5, p=0.055 
Bifidobacteriaceae 52.4 34.1 W=71, p=0.098 
Nocardiaceae 3.4 9.2 W=40, p=0.590 
Coriobacteriaceae 2.2 1.3 W=57, p=0.530 
Bacteroidaceae 11.4 11.3 W=50.5, p=0.882 
Porphyromonadaceae 1.0 1.3 W=50.5, p=0.882 
Lactobacillaceae 2.9 0.5 W=78, p=0.027 
Streptococcaceae 3.7 1.1 W=52.5, p=0.768 
Clostridiaceae1 0.1 2.3 W=17, p=0.024 
Lachnospiraceae 9.1 17.4 W=34, p=0.329 
Ruminococcaceae 0.2 1.3 W=16, p=0.020 
Erysipelotrichaceae 0.2 3.8 W=24.5, p=0.089 
Veillonellaceae 10.2 9.4 W=51, p=0.857 
Bifidobacterium 53.4 34.1 W=71, p=0.098 
Rhodococcus 3.4 9.2 W=40, p=0.590 
Collinsella 1.9 1.1 W=58, p=0.477 
Bacteroides 11.4 11.3 W=50.5, p=0.882 
Lactobacillus 2.9 0.5 W=78, p=0.027 
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Streptococcus 3.7 1.1 W=48.5, p=1 
Clostridiumsensustricto1 0.1 2.3 W=17, p=0.024 
Blautia 1.0 4.4 W=40, p=0.578 
LachnospiraceaeIncertaeSedis 7.4 9.6 W=41, p=0.640 
Lachnospiraceaeuncultured 0.5 1.5 W=23.5, p=0.076 
Ruminococcaceae Incertae Sedis 0.0 0.1 W=18, p=0.027 
ErysipelotrichaceaeIncertaeSedis 0.2 3.8 W=24, p=0.080 
Citrobacter 0.0 0.0 W=15, p=0.009 
Enterobacter 0.0 0.1 W=17, p=0.023 
Megasphaera 0.0 3.0 W=44, p=0.754 
Veillonella 1.2 6.4 W=60, p=0.407 
Supplementary table 55: Relative abundance of bacterial OTUs in the infant gut at 5 
months old by maternal stress in the 2nd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low stress (PSS < 13; Vaginal; N=6; C-Section; N=1), high stress (PSS > 16; Vaginal; N=13; 
C-Section; N=2). Unpaired students t-test and Mann-Whitney-Wilcoxon test. 
Abbreviations: Operational taxonomic unit (OTU), Perceived Stress Scale (PSS). 
 
Table 56: Infant gut at 5 months old by 2nd trimester anxiety 
OTU Relative Abundance (%) 
5 months old Low STAI High STAI p-value 
Chao1 Index 103.8 118.3 t(20) =-0.94, p=0.358 
Simpson Index 0.7 0.8 t(20) =-0.57, p=0.569 
Shannon Index 2.9 3.3 t(20) =-0.84,p=0.410 
Phylogenetic diversity 6.0 6.1 t(20) =-0.18,p=0.851 
Observed Species 77.3 80.6 t(20) =-0.34, p=0.732 
Actinobacteria 51.9 40.1 W=60, p=0.407 
Bacteroidetes 14.1 11.5 W=50.5, p=0.882 
Firmicutes 32.7 45.7 W=31, p=0.230 
Proteobacteria 0.5 1.0 W=20.5, p=0.184 
Bifidobacteriaceae 42.0 32.4 W=57, p=0.541 
Nocardiaceae 8.3 5.8 W=40, p=0.590 
Coriobacteriaceae 1.5 1.8 W=47, p=0.970 
Bacteroidaceae 13.2 6.3 W=59, p=0.438 
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Porphyromonadaceae 0.9 2.0 W=39, p=0.528 
Lactobacillaceae 1.3 0.7 W=55, p=0.626 
Streptococcaceae 1.9 1.7 W=55.5, p=0.605 
Clostridiaceae1 0.7 4.3 W=21, p=0.050 
Lachnospiraceae 13.8 18.6 W=37, p=0.449 
Erysipelotrichaceae 3.0 2.5 W=38.5, p=0.505 
Veillonellaceae 7.9 14.3 W=29, p=0.177 
Bifidobacterium 42.0 32.4 W=57, p=0.541 
Rhodococcus 8.3 5.8 W=40, p=0.590 
Collinsella 1.3 1.6 W=47.5, p=1 
Bacteroides 13.2 6.3 W=59, p=0.438 
Lactobacillus 1.3 0.7 W=55, p=0.626 
Streptococcus 1.8 1.7 W=52.5, p=0.768 
Clostridiumsensustricto1 0.7 4.3 W=22, p=0.060 
Blautia 2.0 7.4 W=45, p=0.852 
LachnospiraceaeIncertaeSedis 9.8 6.8 W=45, p=0.857 
Lachnospiraceaeuncultured 1.2 1.1 W=41, p=0.630 
ErysipelotrichaceaeIncertaeSedis 2.9 2.4 W=37.5, p=0.456 
Megasphaera 1.0 5.1 W=35, p=0.264 
Veillonella 6.8 9.1 W=39, p=0.541 
Sutterella 0.0 0.0 W=21, p=0.007 
Escherichia Shigella 0.1 0.5 W=18.5, p=0.032 
Supplementary table 56: Relative abundance of bacterial OTUs in the infant gut at 5 
months old by maternal anxiety in the 2nd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low anxiety (STAI < 4; Vaginal; N=16; C-Section; N=1), high anxiety (STAI > 5; Vaginal; 
N=6; C-Section; N=2). Unpaired students t-test and Mann-Whitney-Wilcoxon test. 
Abbreviations: Operational taxonomic unit (OTU), State Trait Anxiety Inventory (STAI).  
  
Table 57: Infant gut at 5 months old by 2nd trimester depressive symptoms 
OTU Relative Abundance (%) 
5 months old Low EPDS High EPDS p-value 
Chao1 Index 107.3 110.1 t(20) =-0.15, p=0.878 
Simpson Index 0.7 0.8 t(20) =-0.35, p=0.723 
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Shannon Index 3.0 3.0 t(20) = 0.00,p=0.996 
Phylogenetic diversity 6.1 5.5 t(20) = 0.87,p=0.392 
Observed Species 80.2 69.2 t(20) = 1.02, p=0.316 
Actinobacteria 49.3 45.7 W=38, p=0.902 
Bacteroidetes 14.3 9.6 W=44, p=0.523 
Firmicutes 35.2 41.0 W=32, p=0.774 
Proteobacteria 0.5 1.4 W=14, p=0.067 
Bifidobacteriaceae 39.4 39.0 W=38, p=0.902 
Nocardiaceae 8.1 5.3 W=41, p=0.712 
Propionibacteriaceae 0.0 0.0 W=27, p=0.045 
Coriobacteriaceae 1.6 1.2 W=24, p=0.327 
Bacteroidaceae 12.2 7.3 W=37.5, p=0.932 
Porphyromonadaceae 1.0 2.0 W=46, p=0.415 
Candidate division TM7 Unknown 0.0 0.0 W=27, p=0.045 
Lactobacillaceae 1.3 0.5 W=48, p=0.319 
Streptococcaceae 2.0 1.0 W=53.5, p=0.147 
Clostridiaceae1 1.8 1.3 W=29, p=0.579 
Lachnospiraceae 14.3 18.8 W=36, p=1 
Erysipelotrichaceae 2.7 3.3 W=30.5, p=0.669 
Veillonellaceae 8.9 12.7 W=32, p=0.774 
Shewanellaceae 0.0 0.0 W=27, p=0.045 
Bifidobacterium 39.4 39.0 W=38, p=0.902 
Rhodococcus 8.1 5.3 W=41, p=0.712 
Propionimicrobium 0.0 0.0 W=27, p=0.045 
Collinsella 1.4 1.0 W=35, p=0.965 
Bacteroides 12.2 7.3 W=37.5, p=0.932 
Carnobacterium 0.0 0.0 W=12, p=0.036 
Lactobacillus 1.3 0.5 W=48, p=0.319 
Streptococcus 2.0 1.0 W=51, p=0.216 
Clostridiumsensustricto1 1.8 1.2 W=30, p=0.639 
Eubacterium 0.0 0.0 W=27, p=0.045 
Blautia 1.8 10.9 W=31, p=0.699 
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LachnospiraceaeIncertaeSedis 9.6 6.1 W=42, p=0.652 
Lachnospiraceaeuncultured 1.3 1.0 W=33, p=0.831 
ErysipelotrichaceaeIncertaeSedis 2.7 3.3 W=29.5, p=0.605 
Megasphaera 0.9 7.7 W=24.5, p=0.257 
Veillonella 8.0 4.9 W=45, p=0.484 
Shewanella 0.0 0.0 W=27, p=0.045 
Proteus 0.0 0.0 W=27, p=0.045 
Supplementary table 57: Relative abundance of bacterial OTUs in the infant gut at 5 
months old by maternal depressive symptoms in the 2nd trimester. Listed are all OTUs 
with an abundance of greater than 1% and significant OTUs with an abundance of less 
than 1%. Low depressive (EPDS < 8; Vaginal; N=18; C-Section; N=3), high depressive 
(EPDS > 9; Vaginal; N=4; C-Section; N=0). Unpaired students t-test and Mann-Whitney-
Wilcoxon test. Abbreviations: Operational taxonomic unit (OTU), Edinburgh Postnatal 
Depression Scale (EPDS).  
 
Table 58: Infant gut at 5 months old by 2nd trimester cortisol 
OTU Relative Abundance (%) 
5 months old Low CAR High CAR p-value 
Chao1 Index 121.9 100.9 t(19) = 1.52, p=0.141 
Simpson Index 0.8 0.7 t(19) = 1.35, p=0.191 
Shannon Index 3.2 2.8 t(19) = 1.12,p=0.274 
Phylogenetic diversity 6.5 5.9 t(19) = 1.22,p=0.236 
Observed Species 84.6 75.0 t(19) = 1.12, p=0.274 
Actinobacteria 50.8 45.2 W=56, p=0.917 
Bacteroidetes 13.6 12.9 W=63.5, p=0.522 
Firmicutes 33.6 40.4 W=51, p=0.862 
Proteobacteria 0.9 0.6 W=68.5, p=0.319 
Bifidobacteriaceae 42.6 36.2 W=61, p=0.651 
Nocardiaceae 5.0 80.5.3 W=31, p=0.111 
Coriobacteriaceae 3.0 0.5 W=82.5, p=0.046 
Bacteroidaceae 11.4 12.5 W=63, p=0.545 
Porphyromonadaceae 2.0 0.4 W=66, p=0.409 
Lactobacillaceae 0.3 1.8 W=31, p=0.103 
Streptococcaceae 1.3 2.3 W=43.5, p=0.477 
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Clostridiaceae1 2.3 1.2 W=38.5, p=0.286 
Lachnospiraceae 11.9 19.5 W=54, p=1 
Erysipelotrichaceae 1.0 4.5 W=49.5, p=0.776 
Veillonellaceae 14.0 6.7 W=82, p=0.049 
Sphingomonadaceae 0.0 0.0 W=72, p=0.040 
Bifidobacterium 42.6 36.2 W=61, p=0.651 
Rhodococcus 5.0 8.3 W=31, p=0.111 
Collinsella 2.9 0.2 W=92, p=0.006 
Bacteroides 11.4 12.5 W=63, p=0.545 
Porphyromonadaceae uncultured 0.9 0.0 W=81.5, p=0.042 
Lactobacillus 0.3 1.8 W=31, p=0.103 
Streptococcus 1.3 2.2 W=46.5, p=0.618 
Clostridiumsensustricto1 2.3 1.1 W=37.5, p=0.255 
Blautia 2.4 5.3 W=57.5, p=0.830 
LachnospiraceaeIncertaeSedis 6.7 11.6 W=53, p=0.972 
Lachnospiraceaeuncultured 0.7 1.5 W=56, p=0.914 
ErysipelotrichaceaeIncertaeSedis 1.0 4.5 W=50.5, p=0.830 
Megasphaera 5.3 0.0 W=70.5, p=0.175 
Veillonella 8.6 6.7 W=60, p=0.702 
Supplementary table 58: Relative abundance of bacterial OTUs in the infant gut at 5 
months old by maternal cortisol in the 2nd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low cortisol (CAR < 545131; Vaginal; N=9; C-Section; N=3), high cortisol (CAR > 545132; 
Vaginal; N=12; C-Section; N=0). Unpaired students t-test and Mann-Whitney-Wilcoxon 
test. Abbreviations: Operational taxonomic unit (OTU), Cortisol Awakening Response 
(CAR).  
 
Table 59: Infant gut at 5 months old by 3rd trimester stress 
OTU Relative Abundance (%) 
5 months old Low PSS High PSS p-value 
Chao1 Index 96.8 105.3 t(19) =-0.57, p=0.572 
Simpson Index 0.7 0.8 t(19) =-0.65, p=0.522 
Shannon Index 3.0 3.0 t(19) =-0.03,p=0.971 
Phylogenetic diversity 5.9 5.9 t(19) = 0.00,p=0.993 
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Observed Species 76.7 74.9 t(19) = 0.18, p=0.857 
Actinobacteria 52.0 47.6 W=62, p=0.500 
Bacteroidetes 11.5 15.8 W=43, p=0.546 
Firmicutes 34.8 34.2 W=50, p=0.915 
Proteobacteria 0.3 1.5 W=26, p=0.063 
Bifidobacteriaceae 42.5 38.5 W=62, p=0.500 
Nocardiaceae 7.3 7.6 W=60, p=0.595 
Coriobacteriaceae 2.0 1.3 W=63.5, p=0.425 
Bacteroidaceae 10.4 14.5 W=41, p=0.446 
Porphyromonadaceae 1.0 1.2 W=59.5, p=0.609 
Lactobacillaceae 0.9 0.9 W=55, p=0.854 
Streptococcaceae 2.6 1.8 W=57.5, p=0.717 
Clostridiaceae1 0.7 2.1 W=54.5, p=0.884 
Lachnospiraceae 18.8 9.2 W=65, p=0.373 
Erysipelotrichaceae 2.2 3.8 W=52, p=1 
Veillonellaceae 5.2 12.3 W=31, p=0.140 
Bifidobacterium 42.5 38.5 W=62, p=0.500 
Rhodococcus 7.3 7.6 W=60, p=0.595 
Collinsella 1.7 1.2 W=56, p=0.795 
Bacteroides 10.4 14.5 W=41, p=0.446 
Lactobacillus 0.9 0.9 W=55, p=0.854 
Streptococcus 2.6 1.8 W=57.5, p=0.717 
Clostridiumsensustricto1 0.7 2.1 W=55.5, p=0.772 
Peptoniphilus 0.0 0.0 W=74.5, p=0.031 
Blautia 3.2 0.6 W=57, p=0.741 
LachnospiraceaeIncertaeSedis 12.5 6.7 W=61, p=0.546 
Lachnospiraceaeuncultured 1.7 0.3 W=64.5, p=0.382 
ErysipelotrichaceaeIncertaeSedis 2.2 3.8 W=54, p=0.912 
Phascolarctobacterium 0.0 0.1 W=28, p=0.032 
Megasphaera 0.0 2.4 W=41.5, p=0.387 
Veillonella 5.1 9.9 W=36, p=0.268 
Supplementary table 59: Relative abundance of bacterial OTUs in the infant gut at 5 
months old by maternal stress in the 3rd trimester. Listed are all OTUs with an abundance 
of greater than 1% and significant OTUs with an abundance of less than 1%. Low stress 
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(PSS < 11; Vaginal; N=8; C-Section; N=2), high stress (PSS > 12; Vaginal; N=13; C-Section; 
N=0). Unpaired students t-test and Mann-Whitney-Wilcoxon test. Abbreviations: 
Operational taxonomic unit (OTU), Perceived Stress Scale (PSS). 
 
Table 60: Infant gut at 5 months old by 3rd trimester anxiety 
OTU Relative Abundance (%) 
5 months old Low STAI High STAI p-value 
Chao1 Index 96.4 108.3 t(19) =-0.82, p=0.420 
Simpson Index 0.7 0.8 t(19) =-1.55, p=0.136 
Shannon Index 2.8 3.2 t(19) =-1.28,p=0.213 
Phylogenetic diversity 5.8 6.0 t(19) =-0.28,p=0.779 
Observed Species 73.8 77.6 t(19) =-0.39, p=0.700 
Actinobacteria 47.1 51.8 W=53, p=0.917 
Bacteroidetes 15.0 13.2 W=56, p=0.972 
Firmicutes 35.9 32.8 W=56, p=0.972 
Proteobacteria 1.0 1.1 W=30, p=0.084 
Bifidobacteriaceae 39.9 40.1 W=61, p=0.704 
Nocardiaceae 6.0 9.1 W=53, p=0.917 
Coriobacteriaceae 0.9 2.3 W=42.5, p=0.397 
Bacteroidaceae 14.5 11.2 W=61, p=0.698 
Porphyromonadaceae 0.4 1.9 W=42, p=0.374 
Lactobacillaceae 0.8 1.0 W=57.5, p=0.886 
Streptococcaceae 3.2 0.9 W=76.5, p=0.139 
Clostridiaceae1 0.5 2.8 W=34, p=0.148 
Lachnospiraceae 14.9 10.6 W=34, p=0.148 
Erysipelotrichaceae 2.9 3.6 W=51, p=0.804 
Acidaminococcaceae 0.0 0.2 W=31, p=0.037 
Veillonellaceae 9.2 10.0 W=56, p=0.972 
Bifidobacterium 39.9 40.1 W=61, p=0.704 
Rhodococcus 6.0 9.1 W=53, p=0.917 
Collinsella 0.6 2.2 W=35, p=0.160 
Bacteroides 14.5 11.2 W=61, p=0.698 
Lactobacillus 0.8 1.0 W=57.5, p=0.886 
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Streptococcus 3.2 0.9 W=76.5, p=0.139 
Clostridiumsensustricto1 0.5 2.8 W=36, p=0.192 
Blautia 2.3 0.8 W=62.5, p=0.617 
LachnospiraceaeIncertaeSedis 10.3 7.3 W=52, p=0.863 
Lachnospiraceaeuncultured 1.2 0.4 W=58.5, p=0.831 
ErysipelotrichaceaeIncertaeSedis 2.9 3.6 W=49, p=0.695 
Megasphaera 0.0 3.1 W=42, p=0.293 
Veillonella 9.2 6.8 W=66, p=0.467 
Sutterella 0.0 0.0 W=33, p=0.027 
Supplementary table 60: Relative abundance of bacterial OTUs in the infant gut at 5 
months old by maternal anxiety in the 3rd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
Low anxiety (STAI < 4; Vaginal; N=11; C-Section; N=2), high anxiety (STAI > 5; Vaginal; 
N=10; C-Section; N=0). Unpaired students t-test and Mann-Whitney-Wilcoxon test. 
Abbreviations: Operational taxonomic unit (OTU), State Trait Anxiety Inventory (STAI).  
 
Table 61: Infant gut at 5 months old by 3rd trimester depressive symptoms 
OTU Relative Abundance (%) 
5 months old Low EPDS High EPDS p-value 
Chao1 Index 107.0 86.4 t(30) = 1.24, p=0.227 
Simpson Index 0.7 0.7 t(30) = 0.63, p=0.534 
Shannon Index 3.1 2.7 t(30) = 1.20,p=0.244 
Phylogenetic diversity 6.1 5.3 t(30) = 1.16,p=0.257 
Observed Species 79.3 63.8 t(30) = 1.43, p=0.168 
Actinobacteria 44.8 63.7 W=23, p=0.179 
Bacteroidetes 14.5 13.0 W=44, p=0.779 
Firmicutes 38.2 22.2 W=57, p=0.179 
Proteobacteria 1.1 0.7 W=43, p=0.841 
Bifidobacteriaceae 34.9 56.4 W=19, p=0.091 
Nocardiaceae 8.3 4.9 W=57, p=0.179 
Coriobacteriaceae 1.3 2.3 W=27, p=0.301 
Bacteroidaceae 13.4 11.5 W=43.5, p=0.804 
Porphyromonadaceae 1.0 1.5 W=33, p=0.588 
Lactobacillaceae 0.7 1.6 W=25, p=0.225 
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Streptococcaceae 2.5 1.0 W=51.5, p=0.363 
Clostridiaceae1 2.0 0.2 W=58, p=0.148 
Lachnospiraceae 15.0 5.7 W=58, p=0.153 
Erysipelotrichaceae 4.2 0.1 W=69, p=0.018 
Veillonellaceae 9.3 10.5 W=40, p=1 
Bifidobacterium 34.9 56.4 W=19, p=0.091 
Rhodococcus 8.3 4.9 W=57, p=0.179 
Collinsella 1.2 2.1 W=30, p=0.423 
Bacteroides 13.4 11.5 W=43.5, p=0.804 
Lactobacillus 0.7 1.6 W=25, p=0.225 
Streptococcus 2.5 1.0 W=51.5, p=0.363 
Clostridiumsensustricto1 2.0 0.2 W=58, p=0.148 
Blautia 2.1 0.0 W=58, p=0.143 
LachnospiraceaeIncertaeSedis 10.0 5.5 W=52, p=0.353 
Lachnospiraceaeuncultured 1.1 0.0 W=57, p=0.170 
ErysipelotrichaceaeIncertaeSedis 4.2 0.1 W=68.5, p=0.019 
Megasphaera 1.9 0.0 W=34, p=0.588 
Veillonella 7.3 10.5 W=35, p=0.719 
Supplementary table 61: Relative abundance of bacterial OTUs in the infant gut at 5 
months old by maternal depressive symptoms in the 3rd trimester. Listed are all OTUs 
with an abundance of greater than 1% and significant OTUs with an abundance of less 
than 1%. Low depressive (EPDS < 8; Vaginal; N=16; C-Section; N=2), high depressive 
(EPDS > 9; Vaginal; N=5; C-Section; N=0). Unpaired students t-test and Mann-Whitney-
Wilcoxon test. Abbreviations: Operational taxonomic unit (OTU), Edinburgh Postnatal 
Depression Scale (EPDS).  
 
Table 62: Infant gut at 5 months old by 3rd trimester cortisol 
OTU Relative Abundance (%) 
5 months old Low CAR High CAR p-value 
Chao1 Index 103.2 102.3 t(21) = 0.05, p=0.954 
Simpson Index 0.7 0.7 t(21) =-0.50, p=0.617 
Shannon Index 2.9 3.1 t(21) =-0.59,p=0.559 
Phylogenetic diversity 5.8 5.8 t(21) = 0.36,p=0.970 
Observed Species 73.0 75.5 t(21) =-0.27, p=0.786 
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Actinobacteria 49.8 53.5 W=55, p=0.643 
Bacteroidetes 12.7 14.3 W=66.5, p=0.850 
Firmicutes 35.9 29.6 W=84, p=0.201 
Proteobacteria 1.3 0.5 W=79, p=0.328 
Bifidobacteriaceae 40.0 45.2 W=53, p=0.557 
Nocardiaceae 6.8 7.0 W=58, p=0.781 
Coriobacteriaceae 2.9 1.0 W=83, p=0.219 
Bacteroidaceae 11.2 13.7 W=63.5, p=1 
Porphyromonadaceae 1.4 0.4 W=75, p=0.565 
Lactobacillaceae 0.8 0.6 W=56.5, p=0.699 
Streptococcaceae 2.5 1.8 W=46.45, p=0.313 
Clostridiaceae1 1.9 0.7 W=44.5, p=0.256 
Lachnospiraceae 11.0 14.1 W=74, p=0.516 
Erysipelotrichaceae 3.4 1.4 W=71.5, p=0.613 
Veillonellaceae 13.5 6.6 W=92, p=0.072 
Bifidobacterium 39.9 45.2 W=53, p=0.557 
Rhodococcus 6.8 7.0 W=58, p=0.781 
Collinsella 2.7 0.9 W=89, p=0.102 
Bacteroides 11.2 13.7 W=63.5, p=1 
Lactobacillus 0.8 0.6 W=56.5, p=0.699 
Streptococcus 2.5 1.8 W=46, p=0.305 
Clostridiumsensustricto1 1.9 0.7 W=44.5, p=0.256 
Blautia 1.0 2.1 W=70, p=0.679 
LachnospiraceaeIncertaeSedis 8.3 9.5 W=71, p=0.643 
Oribacterium 0.0 0.0 W=42, p=0.026 
Lachnospiraceaeuncultured 0.3 1.3 W=51.5, p=0.485 
Peptostreptococcus 0.0 0.0 W=38.5, p=0.035 
ErysipelotrichaceaeIncertaeSedis 3.4 1.4 W=72, p=0.589 
Megasphaera 3.4 0.0 W=72.5, p=0.519 
Veillonella 10.0 6.5 W=76, p=0.438 
Supplementary table 62: Relative abundance of bacterial OTUs in the infant gut at 5 
months old by maternal cortisol in the 3rd trimester. Listed are all OTUs with an 
abundance of greater than 1% and significant OTUs with an abundance of less than 1%. 
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Good sleep quality (CAR < 562349; Vaginal; N=14; C-Section; N=2), poor sleep quality 
(CAR > 562350; Vaginal; N=9; C-Section; N=1). Unpaired students t-test and Mann-
Whitney-Wilcoxon test. Abbreviations: Operational taxonomic unit (OTU), Cortisol 
Awakening Response (CAR).  
 
